Šw‰ď•ń
ƒgƒbƒv‚Ö
–ß‚é

(Šw‰ď)

2019

‘ć226‰ń“ú–{“ŕ‰ČŠw‰ď‹ß‹E’n•ű‰ď
‘ĺă@12ŒŽ21“ú

ƒAƒUƒVƒ`ƒWƒ“‚đ“Š—^’†‚ÉMycobacterium abscessus‚É‚ć‚é”dŽíŤ”ńŒ‹ŠjŤRŽ_‹ŰÇ‚đ”­Ç‚ľ‚˝œ‘ˆŮŒ`ŹÇŒóŒQ
’F@ŽŽqA’ç@”ü“ŢŽqA’†ŽÉ—m•ăA‹g“c‘SGA‹g‘ş‘ě˜NA—с@—ÇŽ÷A’†”ö—˛•śAŽRŞF‹v

 

61th ASH (American Society of Hematology)
‚n‚’‚Œ‚‚Ž‚„‚@12ŒŽ7“úE10“ú
4492
Pretransplant Risk Factors for Calcineurin Inhibitor-Induced Encephalopathy and Limbic Encephalitis Following Allogeneic Hematopoietic Cell Transplantation
Tanizawa N, Koh H, Okamura H, Shiro K, Nanno S, Nishimoto M, Hirose A, Nakamae M, Nakashima Y, Nakane T, Hino M, Nakamae H
2030
Impact of Donor KIR and HLA Genotypes on Clinical Outcomes According to Pre-Transplant Remission Status after HLA-Haploidentical Transplantation with Post-Transplantation Cyclophosphamide
Ido K, Koh H, Okamura H, Koh S, Nanno S, Nishimoto M, Hirose A, Nakamae M, Nakashima Y, Nakane T, Hino M, Nakamae H
4159
Phase 2 Study of Bosutinib in Japanese Patients with Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia
Takahashi N, Matsumura I, Fujisawa S, Ishizawa K, Ono T, Sakaida E, Sekiguchi N, Tanetsugu Y, Fukuhara K, Ohkura M, Koide Y, Hino M
4587
Prospective Evaluation of Alternative Donor from Unrelated Volunteer Donor and Cord Blood in Adult Acute Leukemia and Myelodysplastic Syndrome: No Difference between Unrelated Donor and Cord Blood
Terakura S, Nishida T, Sawa M, Kato T, Miyao K, Ozawa Y, Goto T, Kohno A, Ozeki K, Onishi Y, Fukuhara N, Fujii N, Yokoyama H, Kasai M, Iida H, Kanemura N, Endo T, Ago H, Onizuka M, Iyama S, Nawa Y, Nakamae M, Nagata Y, Kurahashi S, Tomiya Y, Yanagisawa A, Suzuki R, Kuwatsuka Y, Atsuta Y, Miyamura K, Murata M

 

‘ć81‰ń“ú–{ŒŒ‰tŠw‰ď@

“Œ‹ž@10ŒŽ11“ú-13“ú
OS1-7C-1
Real-world outcomes of ixazomib: a multicenter retrospective analysis from Kansai Myeloma Forum
Teruhito Takakuwa(KMF), Ryosuke Yamamura, Kensuke Ohta, Hitomi Kaneko, Kazunori Imada, Aya Nakaya, Shinichi Fuchida, Hirohiko Shibayama, Mitsuhiro Matsuda, Yutaka Shimazu, Yoko Adachi, Satoru Kosugi, Hitoji Uchiyama, Hirokazu Tanaka, Hitoshi Hanamoto, Yuji Shimura, Junya Kanda, Yoshiyuki Onda, Nobuhiko Uoshima, Hideo Yagi, Satoshi Yoshihara, Masayuki Hino, Chihiro Shimazaki, Akifumi Takaori, Junya Kuroda, Itaru Matsumura, Yuzuru Kanakura, Shosaku Nomura
OS1-13C-1
Development of personalized survival prediction curves in allogeneic HCT using machine learning
Hiroshi Okamura, Mika Nakamae, Makoto Moriguchi, Yusuke Okayama, Nao Tanizawa, Yumi Tagaito, Tetsuya Hayashi, Kazuki Sakatoku, Kentaro Ido, Naonori Harada, Satoru Nanno, Yasuhiro Nakashima, Hideo Koh, Takahiko Nakane, Asao Hirose, Kohei Yabusaki, Masayuki Hino, Hirohisa Nakamae
OS2-9D-1
Retrospective multi-centers study of AYA-MM

‚`ya Nakaya(KMF), Takae Kohara, Hirohiko Shibayama, Yoshiyuki Onda, Junya Kanda, Hitomi Kaneko, Kazunori Imada, Toru Kida, Satoru Kosugi, Jun Ishikawa, Ryosuke Yamamura, Yutaka Shimazu, Hirokazu Tanaka, Shinichi Fuchida, Yuji Shimura, Miki Kiyota, Katsuya Wada, Nobuhiko Uoshima, Hideo Yagi, Satoshi Yoshihara, Kensuke Ohta, Chihiro Shimazaki, Masayuki Hino, Akifumi Takaori, Junya Kuroda, Itaru Matsumura, Yuzuru Kanakura, Shosaku Nomura
OS3-14B-3
Phase I study of bortezomib-added GVHD prophylaxis for allo-HCT from HLA mismatched unrelated donor

Takahiko Nakane, Hiroshi Okamura, Yumi Tagaito, Shiro Koh, Yousuke Makuuchi, Satoru Nanno, Takuro Yoshimura, Asao Hirose, Mika Nakamae, Yasuhiro Nakashima, Hideo Koh, Masayuki Hino, Hirohisa Nakamae
OS2-7C-2
Aggressive ATL prospective cohort study: CB and haploidentical transplantation may be feasible

Ayumu Ito, Nobuaki Nakano, Takashi Tanaka, Shigeo Fuji, Junya Makiyama, Yoshitaka Inoue, Ilseung Choi, Hirohisa Nakamae, Koji Nagafuji, Ken Takase, Shinichiro Machida, Tsutomu Takahashi, Yasushi Sawayama, Tomohiko Kamimura, Koji Kato, Toshiro Kawakita, Masao Ogata, Rika Sakai, Souichi Shiratori, Yoshihiro Inamoto, Kaoru Uchimaru, Atae Utsunomiya, Takahiro Fukuda
OS2-14D-1
Impact of pre-transplant donor-specific anti-HLA antibodies in cord blood transplantation

Shigeo Fuji, Kumi Oshima, Kazuteru Ohashi, Masashi Sawa, Takeshi Saito, Tetsuya Eto, Masatsugu Tanaka, Makoto Onizuka, Hirohisa Nakamae, Souichi Shiratori, Yukiyasu Ozawa, Michihiro Hidaka, Tokiko Nagamura, Hidenori Tanaka, Takahiro Fukuda, Tatsuo Ichinohe, Yoshiko Atsuta, Masao Ogata

OS3-8A-2
Unit selection for umbilical cord blood transplantation for adults with AML in complete remission

Masamitsu Yanada, Takaaki Konuma, Yachiyo Kuwatsuka, Tadakazu Kondo, Takahito Kawata, Satoshi Takahashi, Naoyuki Uchida, Shigesaburo Miyakoshi, Masatsugu Tanaka, Yukiyasu Ozawa, Masashi Sawa, Hirohisa Nakamae, Nobuyuki Aotsuka, Junya Kanda, Minoko Takanashi, Yoshinobu Kanda, Yoshiko Atsuta, Shingo Yano

OS2-7A-4
Clinicopathological analysis of HIV associated lymphoma at Osaka City General Hospital

Minako Tsutsumii‘ĺăŽs—§‘‡ˆă—ĂƒZƒ“ƒ^[j
, Takafumi Nakao, Yosuke Nakaya, Masahiro Yoshida, Takuro Yoshimura, Yoshiki Hayashi, Takeshi Inoue, Takahisa Yamane

OS2-7B-1
Importance of diagnosis-to-treatment interval in newly diagnosed Japanese patients with DLBCL

Masahiro Yoshidai‘ĺăŽs—§‘‡ˆă—ĂƒZƒ“ƒ^[j, Yosuke Nakaya, Minako Tsutsumi, Takuro Yoshimura, Yoshiki Hayashi, Takafumi Nakao, Takahisa Yamane
OS1-15C-5
Clinical decision analysis with machine learning in relapse and refractory multiple myeloma

Shiro Kohiś’ˇ‰ď•{’†•a‰@j, Kumiyo Nakai, Yusuke Kizawa, Hiroyoshi Ichihara, Shoji Ine, Atsuko Mugitani
OS1-15D-5
Retrospective analysis of the safety and efficacy of thalidomide for myeloma in single institution
Yumi Kimurai‘ĺă•{Ďś‰ď’†’Ă•a‰@j,Teruhito Takakuwa, Moe Nomura, Ippei Otomaru, Taku Araki, Akiko Miura, Yotaro Fujitani, Ryosuke Yamamura
OS1-15D-6
A single-institute experience of pomalidomide for relapsed and refractory multiple myeloma patients

Teruhito Takakuwai‘ĺă•{Ďś‰ď’†’Ă•a‰@j, Taku Araki, Moe Nomura, Yumi Kimura, Ippei Otomaru, Akiko Miura, Yotaro Fujitani, Ryosuke Yamamura
OS3-12C-3
Clinicopathologic prognostic factors of gastrointestinal CMV disease after allogeneic HCT

Masatomo Kuno, Takashi Tanaka, Akiko Maeshima, Hirokazu Taniguchi, Kinuko Tajima, Wataru Takeda, Tsuneaki Hirakawa, Ayumu Ito, Yoshihiro Inamoto, Saiko Kurosawa, Sung-Won Kim, Takahiro Fukuda

PS3-23-3
Case of successful treatment of cryptococcal meningitis by voriconazole complicated by ATL

Kiryang Kohi‘ĺă“S“š•a‰@j, Dai Momose, Shiro Koh, Masahiro Manabe, Yasuyoshi Sugano, Masayuki Hino

PS2-16-8
‚qetrospective study of ibrutinib therapy for patients with CLL / SLL and MCL
Mirei Horiuchii‘ĺăŽs—§‘‡ˆă—ĂƒZƒ“ƒ^[j, Takafumi Nakao, Hirohisa Nakamae, Manabu Hirai, Hiroyoshi Ichihara, Kensuke Ohta, Dai Momose, Akiko Miura, Takahisa Yamane
PS2-14-1
Effective treatment of acute B-lymphoblastic leukemia with PDGFRB-EBF1 fusion treated by imatinib
Mirei Horiuchii‘ĺăŽs—§‘‡ˆă—ĂƒZƒ“ƒ^[j, Masahiro Yoshida, Minako Tsutsumi, Yosuke Nakaya, Takuro Yoshimura, Yoshiki Hayashi, Takafumi Nakao, Kai Yamasaki, Takane Aoyama, Takahisa Yamane
PS2-18-3
Delayed diagnosis of Epstein-Barr virus-positive mucocutaneous ulcer: a case report

Takuro Yoshimurai‘ĺăŽs—§‘‡ˆă—ĂƒZƒ“ƒ^[j, Minako Tsutsumi, Yosuke Nakaya, Naoko Tatsumi, Masahiro Yoshida, Yoshiki Hayashi, Takafumi Nakao, Takahisa Yamane
PS3-11-1
 HHV-8 positive multicentric Castleman disease featuring germinotropic plasmablastic proliferation
Yosuke Nakayai‘ĺăŽs—§‘‡ˆă—ĂƒZƒ“ƒ^[j, Minako Tsutsumi, Masahiro Yoshida, Takuro Yoshimura, Yoshiki Hayashi, Takafumi Nakao, Takeshi Inoue, Takahisa Yamane

PS2-23-8
Elotuzumab therapy combined with lenalidomide and dexamethasone for patients with multiple myeloma

Moe Nomurai‘ĺă•{Ďś‰ď’†’Ă•a‰@j, Teruhito Takakuwa, Yumi Kimura, Ippei Otomaru, Akiko Miura, Taku Araki, Yotaro Fujitani, Ryosuke Yamamura

PS2-24-5
Retrospective analysis of carfilzomib combination therapy for multiple myeloma at our hospital

Ippei Otomarui‘ĺă•{Ďś‰ď’†’Ă•a‰@j, Teruhito Takakuwa, Moe Nomura, Yumi Kimura, Akiko Miura, Taku Araki, Yotaro Fujitani, Ryosuke Yamamura
PS3-2-6
Comparison of first-line with second-line treatment of anagrelide for essential thrombocythemia

Teruhito Takakuwai‘ĺă•{Ďś‰ď’†’Ă•a‰@j, Moe Nomura, Yumi Kimura, Ippei Otomaru, Akiko Miura, Taku Araki, Yotaro Fujitani, Ryosuke Yamamura
PS2-13-2
Analysis of treatment selection and prognosis of high-risk myelodysplastic syndrome patients

Yusuke Kizawaiś’ˇ‰ď•{’†•a‰@j, Shiro Koh, Soichiro Nakako, Mitsuharu Hashimura, Hiroyoshi Ichihara, Shoji Ine, Atsuko Mugitani
PS2-9-1
Report of 2 CML patients who discontinued TKI and have achieved pregnancy and childbirth

Kumiyo Nakaiiś’ˇ‰ď•{’†•a‰@j, Shoji Ine, Yusuke Kizawa, Shiro Koh, Hiroyoshi Ichihara, Atsuko Mugitani

 

‘ć225‰ń“ú–{“ŕ‰ČŠw‰ď‹ß‹E’n•ű‰ď
‘ĺă@9ŒŽ21“ú

Œ´”­Ťƒ}ƒNƒƒOƒƒuƒŠƒ“ŒŒÇ‚ĚŒo‰ß’†‚ÉŒă“VŤŒŒ—F•a‚`‚đ”­Ç‚ľ‚˝‚P—á
–Ř‘ş—F”üA’†“ˆN”ŽA‰ŞŽR—T‰îA‰Ş‘ş_ŽjC“ě–ě@’qC’†ŞF•FAN@G’jC’†‘O”Ž‹vC“ú–ě‰ë”VA”őŒă^“o

 

“ú–{ŒŸ¸ŒŒ‰tŠw‰ď
“ޗǁ@7ŒŽ6“ú-7“ú
ŒŒ‰t“ŕ‰ČˆăŽt‚ɑ΂ˇ‚é×–E•Ş—Ţ‹łˆç‚ɂ‚˘‚āAŒŸ¸Žş‚ĚŽć‚č‘g‚݁[‘ć1•ü[
’r–{@ĘAĄˆäd—ǁA•“c^ˆęA‹v•Ű“c@_A’†‘O”ü‰ŔA“ú–ě‰ë”V
‚s×–EƒŠƒ“ƒp‰č‹…ŤƒŠƒ“ƒpŽî‚É”­Ç‚ľ‚˝ˆÚAŒăƒŠƒ“ƒp‘BŤŽžŠł
Ąˆäd—ǁA’r–{@ĘA•“c^ˆęA‹v•Ű“c@_A’†‘O”ü‰ŔA“ú–ě‰ë”V

‘˝”­Ťœ‘Žî‚É‚¨‚Ż‚é×–EŒ`‘Ô•Ş—Ţ‚Ć—\Œă‚Ć‚ĚŠÖ˜AŤ‚ĚŒŸ“˘
•ŸŽR’qŽqAr–Ř‘ńA‚ŒK‹PlA‹v“疞䝁AŠC]“cˆÇ“ށA’†‘şPmA[“cŒb—˜“ށAŽR‘ş—ş‰î

 

‘ć111‰ń‹ß‹EŒŒ‰tŠw’n•ű‰ď

‘ĺă@6ŒŽ‚Q‚X“ú

‹äB‚Ĺ”­Ç‚ľ‚˝ƒAƒOƒŒƒbƒVƒuNK ×–E”’ŒŒ•a‚Ě1—á
XŒű@TA’†“ˆN”ŽA‰Ş‘ş_ŽjA“ě–ě@’qAN@G’j@’†ŞF•FA’†‘O”Ž‹vA“ú–ě‰ë”VA‘ĺŕV­•F

ƒ_ƒTƒ`ƒjƒu•s‘Ď—e‚Ĺ‚ ‚Á‚˝‚ށAƒCƒ}ƒ`ƒjƒu‚É‚ć‚莞ŠłƒRƒ“ƒgƒ[ƒ‹‚ľ“ž‚˝‚—îƒtƒBƒ‰ƒfƒ‹
‰ŞŽR—T‰îi‘ĺă•{Ďś‰ď’†’Ă•a‰@jA‚ŒK‹PlA‰łŠŰˆę•˝A–x“ŕ”ü—߁AŽO‰YWŽqAr–؁@‘ńA“Ą’J—m‘ž˜NAŽR‘ş—ş‰î

ľżu‰‰
–Ťœ‘Ť”’ŒŒ•aŽĄ—Ă‚ĚĹVî•ńEĹ‘Oü
’†‘O”Ž‹v

 

‘ć224‰ń“ú–{“ŕ‰ČŠw‰ď‹ß‹E’n•ű‰ď
‘ĺă@6ŒŽ1“ú

ä`‘ŃŒŒˆÚAŒăA‚q‚rƒEƒCƒ‹ƒX”x‰Š‚ɑ΂ľ‚ăŠƒoƒrƒŠƒ““Š—^‚đs‚¤‚ŕ’vŽ€“I‚Č“]‹A‚đ’H‚Á‚˝ with MRC‚Ě1—á
‰ŞŽR—T‰îAN@G’jC‰Ş‘ş_ŽjC“ě–ě@’qC’†“ˆN”ŽA’†ŞF•FA’†‘O”Ž‹vC“ú–ě‰ë”V

 

“ú–{—AŒŒ×–EŽĄ—ĂŠw‰ď
ŒF–{@5ŒŽ23“ú-25“ú

“–‰@‚Ě—AŒŒ•”‚Ć‘˘ŒŒ×–EˆÚAƒR[ƒfƒBƒl[ƒ^[i‚g‚b‚s‚bj‚ĹŽć‚č‘g‚ŢˆÚAŠÖ˜A‹Ć–ą
˜@—Ö—ş‰îA‰Ž“c—´ĆAź–{—F‹IA“Ą–ěŒbŽOA”~–{—R—˘A“cŽçş”ŽA‰Í“c‘Ľ•śA“ú–ě‰ë”V

 

“ú–{ˆăŠwŒŸ¸Šw‰ď
ŽRŒű@5ŒŽ18“ú-19“ú

“–‰@‚É‚¨‚Ż‚錌Ź”—AŒŒ•s‰žÇ—á‚ĚŒă•űŽw“EŒŸ“˘
ŠC]“cˆÇ“ށA•ŸŽR@’qŽqAűüŒK@‹PlA‹v“ç@–žäťA’†‘ş@PmA[“c@Œb—˜“Ţ AŽR‘ş@—ş‰î

 

‘ć41‰ń“ú–{‘˘ŒŒ×–EˆÚAŠw‰ď‘‰ď
‘ĺă@3ŒŽ7“úE9“ú
O4-2
”ńŠ°‰đŠúAML‚ĚˆÚA‘O––˝ŒŒWT1mRNAƒŒƒxƒ‹‚É”ä—á‚ľ“ŻŽí‘˘ŒŒŠ˛×–EˆÚAŒă‚ĚŽ€–SƒŠƒXƒN‚Ş‘‰Á‚ˇ‚é

ˆäŒËŒ’‘ž˜YA’†‘O”ü‰ŔAN@G’jA‰Ş‘ş_ŽjA“ě–ě@’qAź–{ŒőFA‹´–{—R“żA•‰ŞNMAœAŁ’ŠśA’†“ˆN”ŽA’†ŞF•FA“ú–ě‰ë”VA’†‘O”Ž‹v

O16-1
HLAˆę’vŒŒ‰–”‚Í”ńŒŒ‰ƒhƒi[‚Š‚ç‚Ě“ŻŽíˆÚA‚É‚¨‚Ż‚éPTC‚™‹y‚ŃTac‚đ—p‚˘‚˝GVHD—\–h-—Տ°‘ć2‘ŠŽŽŒą’†ŠÔ‰đÍ-

’†ŞF•FA’†‘O”Ž‹vA“ě–ě@’qA‰Ş‘ş_ŽjAź–{ŒőFA–‹“ŕ—z‰îA’ˇč÷ŽœA“cŠ_“ŕ—D”üA—с@“NĆAŒ´“cŽŒ›AˆäŒËŒ’‘ž˜YAŽđ“żˆęŠóA’JŕV@’źA‰ŞŽR—T‰îAXŒű@TAœAŁ’ŠśA’†‘O”ü‰ŔA’†“ˆN”ŽAN@G’jA•‰ŞNMA“ú–ě‰ë”V

O19-4
SOSf’f‚É‚¨‚Ż‚éŒo’ź’°–ĺ–ŹƒVƒ“ƒ`ƒOƒ‰ƒtƒB[‚ĆƒVƒAƒgƒ‹Šî€‚Ě”äŠrŒŸ“˘
‰Ş‘ş_ŽjAN@G’jA‚ŒK‹PlAˆäŒËŒ’‘ž˜YA–‹“ŕ—z‰îAˆäŞČ“ńA“ě–ě@’qA’†“ˆN”ŽA’†ŞF•FAéŒă“ÄŽuAŽR–{@WA‰HŽş‰ë•vA‹g“c~ŽjAŹ’JW•˝A‰Í粏÷ŽĄA“ŒŽRŽ –žA‰–ŒŠ@iA‘ĺŕV­•FA“ú–ě‰ë”VA’†‘O”Ž‹v
O25-3
“ŻŽí‘˘ŒŒŠ˛×–EˆÚAŒăStenotrophomonas maltophiliaŠ´őÇ‚Ě“Á’Ľ‚¨‚ć‚Ń”­ÇŠÖ˜AˆöŽq‚ĚŒŸ“˘
œAŁ’ŠśAN@G’jA’†‘O”ü‰ŔA’†ŞF•FA’†“ˆN”ŽA•‰ŞNMAŽR“cNˆęAŠ|‰Ž@OA“ú–ě‰ë”VA’†‘O”Ž‹v

O31-5
HCTC‚Ě‹Ć–ą‚ÉŠÖ‚ˇ‚éƒAƒ“ƒP[ƒg‚đ’Ę‚ś‚˝’nˆć‚ĚŒťó‚Ě”cˆŹ‚Ɖۑč‚ĚŒŸ“˘
”~–{—R—˘A“c’†—˘•cA•Ÿ“c—˛_A“ú–ě‰ë”V

O36-5
“–‰@‚É‚¨‚Ż‚é‘˝”­Ťœ‘Žî‚ɑ΂ˇ‚鎊‰Ć‘˘ŒŒŠ˛×–EˆÚA‚ĚŽĄ—ÐŹŃ

–Ř‘ş—F”üA‚ŒK‹PlAr–؁@‘ńA‰łŠŰˆę•˝AŽO‰YWŽqA“Ą’J —m‘ž˜NA‘ž“cŒ’‰îAŽR‘ş—ş‰î
O37-3
“ŻŽí‘˘ŒŒŠ˛×–EˆÚA‘O‚ĚŒŒ´beta-2 microgloburin‚Í‘Sś‘ś—Ś‚Ě—\Œă—\‘ރ}[ƒJ[‚Ć‚Č‚č“ž‚é
Œ´“cŽŒ›A’†ŞF•FA’†‘O”ü‰ŔA“cŠ_“ŕ—D”üA—с@“NĆAˆäŒËŒ’‘ž˜YA–‹“ŕ—z‰îA‰Ş‘ş_ŽjA“ě–ě@’qAź–{ŒőFA•‰ŞNMAœAŁ’ŠśA’†“ˆN”ŽAN@G’jA“ú–ě‰ë”VA’†‘O”Ž‹v
P3-5
“ŻŽí‘˘ŒŒ×–EˆÚAŒă“ŤƒEƒCƒ‹ƒXŠ´őÇ‚ɑ΂ˇ‚é–ƉuƒOƒƒuƒŠƒ“‘ĺ—Ę—Ă–@‚Ě—LŒřŤEˆŔ‘SŤ‚ĚŒŸ“˘

ˆäŒËŒ’‘ž˜YA’†ŞF•FA‰Ş‘ş_ŽjA“ě–ě@’qAź–{ŒőFAœAŁ’ŠśA’†‘O”ü‰ŔA’†“ˆN”ŽAN@G’jA“ú–ě‰ë”VA’†‘O”Ž‹v
P12-2
ŠO‰Č“IŘœ‚ĆŽŠ‰Č‘˘ŒŒŠ˛×–EˆÚA‚É‚ć‚芰‰đ‚ÉŽŠ‚Á‚˝Langerhans×–E“÷Žî
’†”ö—˛•śA•š‰Ž”ż—I—˘A’ç@”üŘŽqA’†ŽÉ—m•ăA–x“ŕ”ü—߁A‹g“c‘SGA‹g‘ş‘ě˜NA—с@—ÇŽ÷AŽRŞF‹v
P37-2
œ‘ƒoƒ“ƒNĚŽćŽó‚Ż“ü‚ę‰Â”Ű“ü—̓VƒXƒeƒ€‚Ě“ü—Íó‹ľ‚ĆĄŒă‚̉ۑč

“c’†—˘•cA”~–{—R—˘Aœ‘ƒoƒ“ƒN‹ß‹EŽ––ą‹ÇA•Ÿ“c—˛_A“ú–ě‰ë”V
ŠĹP7-5
ƒNƒŠ[ƒ“ƒ‹[ƒ€–ʉŒŔŠÉ˜a‚ŞŠłŽŇ‚̐S—ó‹ľ‚É‚ŕ‚˝‚炡Œř‰Ę

Ş—ˆ^•ŕA‹g’JŽŔ‰ÄA”ź“c‚ł‚â‚ŠA“Ą“c“Ţ•äA“cŒ´łŒbAŽs‘ş—R‹I”TA‰L’rƒŽqA’ß“c—Œb
ƒCƒuƒjƒ“ƒOƒZƒ~ƒi[
–{‘ԐŤŒŒŹ”ÂŒŒÇ‚É‚¨‚Ż‚é×–EŒ¸­—Ă–@‚ĚˆĘ’u‚Ă‚Ż
’†‘O”Ž‹v

ƒCƒuƒjƒ“ƒOƒZƒ~ƒi[
‘˘ŒŒŠ˛×–EˆÚAƒhƒi[‚ĚˆŔ‘SŤ‚ɂ‚˘‚ā`œ‘‹y‚ŃG-CSF‚đ—p‚˘‚˝––˝ŒŒŠ˛×–EĚŽć‚ɂ‚˘‚ā`
“ú–ě‰ë”V

 

‘ć223‰ń“ŕ‰ČŠw‰ď‹ß‹E’n•ű‰ď
‹ž“s@3ŒŽ2“ú
ƒŠƒ“ƒpß•a•Ď‚đ”F‚ß‚¸‘˝”­œ•a•Ď‚Őf’f‚ł‚ę‚˝RichiterÇŒóŒQ‚Ě1—á
’JŕV@’źA•‰ŞNMAŒ´“cŽŒ›A‰Ş‘ş_ŽjA“ě–ě@’qA’†“ˆN”ŽAN@G’jA’†ŞF•FA’†‘O”Ž‹vA“ú–ě‰ë”V

Á‰ťŠÇúE‚É‚ć‚čf’f‚ÉŽŠ‚Á‚˝ŒĘ”­Ťœ‘“÷Žî
ˆ°“c‹˝–˛i‘ĺăŽs—§‘‡ˆă—ĂƒZƒ“ƒ^[jA’†”ö—˛•śA’ç@”üŘŽqA’†ŽÉ—m•ăA•š‰Ž”ż—I—˘A–x“ŕ”ü—߁A‹g“c‘SGA‹g‘ş‘ě˜NA—с@—ÇŽ÷AŽRŞF‹v

 

‘ć33‰ń“ú–{‚Ş‚ńŠĹŒěŠw‰ď
•Ÿ‰Ş@2ŒŽ24“ú

ƒ‰ƒ“ƒ`ƒIƒ“ƒZƒ~ƒi[
–Ťœ‘Ť”’ŒŒ•a`ƒAƒhƒqƒAƒ‰ƒ“ƒXŒüă‚đ–ÚŽw‚ľ‚ā`
“ú–ě‰ë”V

•ž–ňƒAƒhƒqƒAƒ‰ƒ“ƒXŒüă‚Ě‚˝‚ß‚Ě–ňÜŽt‚ĚŽć‚č‘g‚Ý
‚‹´Ž”V

ŠłŽŇŽŠg‚Ş•a‚˘‚ĆŽĄ—Ă‚ÉŒü‚Ť‡‚˘‘ą‚Ż‚é‚˝‚ß‚ĚŠĹŒěŽt‚ĚŽć‚č‘g‚Ý
’ß“c—Œb

 

2018

‘ć222‰ń“ú–{“ŕ‰ČŠw‰ď‹ß‹E’n•ű‰ď
‘ĺă@12ŒŽ15“ú
śŠU‹łˆçu‰‰‰ď
‘˘ŒŒŠ˛×–EˆÚA‚Ć’nˆć˜AŒg
“ú–ě‰ë”V

äNă÷“ŕŽîᎂɂć‚é”A˜H•ÂÇ‚𐜂ś‚˝‚Ń‚Ü‚ńŤ‘ĺ×–EŒ^B×–EŤƒŠƒ“ƒpŽî
•Ä–{–˘—ˆC•‰ŞNMC‰Ş‘ş_ŽjC“ě–ě@’qC’†‘O”Ž‹vC“ú–ě‰ë”V

 

60th ASH (American Society of Hematology)
Atlanta@12ŒŽ9“úE12“ú
2087
Noninvasive diagnostic approach by per rectal portal scintigraphy for sinusoidal obstruction syndrome after allogeneic hematopoietic cell transplantation
Okamura H, Koh H, Ido K, Makuuchi Y, Takakuwa T, Ine S, Nanno S, Nakashima Y, Nakane T, Jogo A, Yamamoto A, Hamuro M, Yoshida A, Kotani K, Higashiyama S, Kawabe J, Shiomi S, Ohsawa M, Hino M, Nakamae H
4664
Pre-transplant Serum Beta-2 Microglobulin Level is**a Potential Novel Prognostic Marker for **Overall Survival after Allogeneic Hematopoietic Stem Cell Transplantation
Harada H, Nakane T, Nakamae M, Okamura H, Nanno S, Nishimoto M, Takeoka Y, Hirose A, Nakashima Y, Koh H, Hino M, Nakamae H
4665
The Proportional Association between WT1 mRNA level in Peripheral Blood before Allogeneic Hematopoietic Cell Transplantation and Risk of Mortality in Acute Myeloid Leukemia Not in Remission
Ido K, Nakamae M, Koh H, Okamura H, Nanno S, Nishimoto M, Hashimoto Y, Takeoka Y, Hirose A, Nakashima Y, Nakane T, Hino M, Nakamae H

3
Long-Term Efficacy and Safety (5 Years) in RESPONSE, a Phase 3 Study Comparing Ruxolitinib (rux) with Best Available Therapy (BAT) in Hydroxyurea (HU)-Resistant/Intolerant Patients (pts) with Polycythemia Vera (PV)

Kiladjian JJ, Zachée P, Hino M, Pane F
, Masszi T, Harrison CN, Mesa RA, Miller CB, Passamonti F, Durrant S, Griesshammer M, Kirito K, Besses C, Moiraghi B, Rumi E, Rosti V, Blau IW, Francillard N, Dong T, Wroclawska M, Vannucchi AM, Verstovsek S

 

‘ć65‰ń“ú–{—Տ°ŒŸ¸ˆăŠw‰ď

“Œ‹ž@11ŒŽ15“ú-18“ú
ŽŠŒČ–ƉuÇó‚đ’悡‚錌‰tŽžŠł‚É‚¨‚Ż‚éB×–EŤ–ƉuˆŮí‚ĚŒŸ“˘
•“cáÁˆęA’†‘O”ü‰ŔAœAŁ’ŠśA’†ŞF•FA’†‘O”Ž‹vA“ú–ě‰ë”V
–Ťœ‘Ť”’ŒŒ•aŠłŽŇ‚̐SŒŒŠÇŒn‡•šÇ‚ɑ΂ˇ‚éABI/CAVIAčň•”ƒGƒR[ŒŸ¸‚ĚˆÓ‹`‚ÉŠÖ‚ˇ‚é•ďŠ‡“IŒŸ“˘
’†‘O”ü‰ŔA’†‘O”Ž‹vA‹´–{[A‹gě~ˆęA“Ą‰Şˆę–çA“ú–ě‰ë”V

 

‘ć110‰ń‹ß‹EŒŒ‰tŠw’n•ű‰ď
“ޗǁ@11ŒŽ10“ú
‹CŠÇH“šá‘‡•š‚Ě–˘•Ş‰ť‘ĺ×–EƒŠƒ“ƒpŽî‚ɑ΂ľAŽŠ‰Ć‘˘ŒŒŠ˛×–EˆÚAŒă‚ÉŠO‰Č“IÄŒšp‚đŽ{s‚ľ‚˝ˆę—á
—с@“NĆA“ě–ě@’qA’†“ˆN”ŽA’†‘O”Ž‹vA“ú–ě‰ë”VA’†@—şŽqA“ĄŒ´—LŽjAŒY•”@Œ›A—›@žÄ’ŒA‰Ş–{K”ü
RichterÇŒóŒQ‚ɑ΂ľIbrutinib“ŕ•ž‚đŽ{s‚ľ‚˝2Ç—á‚ĚŒŸ“˘
’ç@Ť–çiś’ˇ‰ď•{’†•a‰@jAŽsŒ´O‘PAˆäŞČƒjAŠěŕV—S‰îAN@Žj˜NA’†ˆä‹vŽŔ‘ăAęm’JˆŔ’ĂŽq
SƒAƒ~ƒƒCƒh[ƒVƒX‡•š‚Ş‹^‚í‚ę‚˝‘˝”­Ťœ‘Žî‚Ěˆę—á
’†ˆä‹vŽŔ‘ăiś’ˇ‰ď•{’†•a‰@jAN@Žj˜NAŠěŕV—S‰îAŽsŒ´O‘PAˆäŞČƒjAęm’JˆŔ’ĂŽq
Ž•“÷‚É”’ŒŒ•a“÷Žî‚đŒ`Ź‚ľ‚˝‹}Ť‘Oœ‘‹…Ť”’ŒŒ•a‚Ěˆę—á
’ç@”üŘŽqi‘ĺăŽs—§‘‡ˆă—ĂƒZƒ“ƒ^[jA‹g“c‘SGA’†ŽÉ—m•ăA•šŒŠ”ż—I—˘A‹g‘ş‘ě˜NA—с@—ÇŽ÷A’†”ö—˛•śAŽRŞF‹v
HTLV-1ŠÖ˜AŇ‘ÇiHAMj‚ɍ‡•š‚ľ‚˝Hodgkin-like Adult T-cell lymphoma‚Ěˆę—á
’†ŽÉ—m•ăi‘ĺăŽs—§‘‡ˆă—ĂƒZƒ“ƒ^[jA‹g“c‘SGA’ç@”üŘŽqA•šŒŠ”ż—I—˘A–x“ŕ”ü—߁A‹g‘ş‘ě˜NA—с@—ÇŽ÷A’†”ö—˛•śAŽRŞF‹v
‰ťŠw—Ă–@‚É—\–h“I‘o“ŕ’ŽË‚đ•š—p‚ľ‚˝äSŒ´”­‚Ń‚Ü‚ńŤ‘ĺ×–EŒ^B×–EƒŠƒ“ƒpŽî‚ĚˆęÇ—á
’F@ŽŽqi‹ž“s‘ć2Ô\Žš•a‰@jA‰Ş–{–ž–çAŹX—F‹IŽqA’ç@N•FA˛X–ؓށXA‹›“ˆL•F

 

‘ć80‰ń“ú–{ŒŒ‰tŠw‰ď@

‘ĺă@10ŒŽ12“ú-14“ú
OS1-10D-5
“–‰@‚É‚¨‚Ż‚é‘˝”­Ťœ‘ŽîŠłŽŇ‚ɑ΂ˇ‚éƒ_ƒ‰ƒcƒ€ƒ}ƒu‚ĚŽg—pŒoŒą

‚ŒK‹Pli‘ĺă•{Ďś‰ď’†’Ă•a‰@jAr–Ř‘ńA‰łŠŰˆę•˝Aź‰Yˆť”TAŽO‰YWŽqA“Ą’J—m‘ž˜NAŽR‘ş—ş‰îA‘ž“cŒ’‰î
OS1-14D-4
‘˘ŒŒŠíŽžŠłŠłŽŇ‚É‚¨‚Ż‚éƒvƒƒoƒCƒIƒeƒBƒNƒX‚̉e‹ż‚ÉŠÖ‚ˇ‚鎟˘‘ăƒV[ƒNƒGƒ“ƒT[‰đÍ
“Ą’J@—m‘ž˜Ni‘ĺă•{Ďś‰ď’†’Ă•a‰@jCˆęŠŰ@’q”üCˆî‘ş@^—R”üCŒĂŕV@‘•cCŒ´“c@ŠxC‰˝@•űC‚ŒK@‹PlCr–؁@‘ńCŽO‰Y@WŽqCŽR‘ş@—ş‰îC‘ž“c@Œ’‰î
OS1-5A-5
Ĺ–˘•Ş‰ťŒ^‹}Ťœ‘Ť”’ŒŒ•a‚ɑ΂ˇ‚é“ŻŽí‘˘ŒŒŠ˛×–EˆÚA‚ÉŠÖ‚ˇ‚錟“˘
ŽRč@‘AÂ–؁@~AX@rˆęAŒ´“c‰î“lAŕV@łŽjA“ŕ“c’ź”VA‘ĺ‹´ˆę‹@A•Ÿ“c—˛_AN@Žj˜NA‹ŕX•˝˜aAŹěŒ[‹ąA‰œ‘şœA˜aAˆęŒË’C•vA_“c‘PLA“c’†~ŽiA”M“c—RŽqA–ö“cłŒőA–î–ěTŒá
OS1-‚WA-3
ć“VŤ—nŒŒŤ•nŒŒf’f‚É‚¨‚Ż‚é–Ô—…“Iˆâ“`ŽqŒŸ¸‚Ě—L—pŤ

‘„ŕV‘ĺŽ÷AÂ–Ř‹MŽqAŹ‘q_”üA‰Ş–{D—YAěă‚OAŽRŞF‹vAŽR–{rŽŠA›–ě@m
OS1-10A-5
ÇŒóŤœ‘Žî1414—á‚ĚŒă•űŽ‹“I‰đÍFŠÖźœ‘ŽîƒtƒH[ƒ‰ƒ€‚Š‚ç‚̍ŐV•ń
“c’†G˜aA‹ÚŕVŒ›‘ž˜YA’†’J@ˆťA‹ŕŽqmbA‘ž“cŒ’‰îAŹ™@’qA”Ş–ŘG’jA‰Ô–{@mA•Ł“c^ˆęAŽu‘ş—EŽiAŽÄŽR_•FAŹŒ´ŽŒbA’†’J‰pmAć|“c~–çA‹›“ˆL•FA˜a“cŸ–çA‰G–ě—˛”ŽAźˆä—˜[A“ŕŽRl“ńAź“cŒőOA‘Ť—§—zŽqA‚ÜWŽjA•“cƒ–çA’J˜e‰ëŽjA“‡čçqA“ú–ě‰ë”VAĄ“c˜a“TA–ě‘şšěA‹ŕ‘q@÷Aź‘ş@“ž
OS1-10B-‚U
RRMMŠłŽŇ‚ɑ΂ˇ‚éKRD—Ă–@‚¨‚ć‚ŃKD—Ă–@‚ĚŒă•űŽ‹“I‰đÍiŠÖźœ‘ŽîƒtƒH[ƒ‰ƒ€j
‰ś“c‰ŔKAć|“c~–çA‹ŕŽqmbAŽÄŽR_•FAŽu‘ş—EŽiA‘ž“cŒ’‰îA“c’†G˜aA•Ł“c^ˆęA’†’J@ˆťA‹›“ˆL•FAŹ™@’qAź“cŒőOA‘Ť—§—zŽqA”Ş–ŘG’jA“ŕŽRl“ńAV“°^‹IAĄ“c˜a“TA“ú–ě‰ë”VA–ě‘şšěA“‡čçqA•“cƒ–çA‹ŕ‘q@÷A‚ÜWŽjAź‘ş@“ž

OS1-‚TD-‚U
ƒTƒŠƒhƒ}ƒCƒh’P“ĆŽĄ—Ă‚đŽ{s‚ľ‚˝ÇŒóŤœ‘Žî230—á‚ĚŒă•űŽ‹“I‰đÍiŠÖźœ‘ŽîƒtƒH[ƒ‰ƒ€j
‹ŕŽqmbAŽÄŽR_•FA”Ş–ŘG’jAć|“c~–çA’†’J@ˆťAŹ™@’qA–Ř“c@‹œA“c’†G˜aAŽu‘ş—EŽiA•Ł“c^ˆęA‘Ť—§—zŽqA˜a“cŸ–çA´“cŽŔŠóA‹›“ˆL•FA‘ž“cŒ’‰îAŹŒ´ŽŒbAŕ_“cí‹`AŹ—ѐłsA“ŕŽRl“ńA‰G–ě—˛”ŽA•“cƒ–çAĄ“c˜a“TA‚ÜWŽjA“‡čçqA‹ŕ‘q@÷A“ú–ě‰ë”VA–ě‘şšěAź‘ş@“ž

PS1-3-3
‚U”ԐőF‘Ě‚ĚƒgƒŠƒ\ƒ~[‚𔺂Á‚˝‹}Ť’P‹…Ť”’ŒŒ•a
ŠÔ•”ŒŤŠ°i‘ĺă“S“š•a‰@jAó“c—ćŽqA”‹Œ´—SŽŠA•SŁ@‘ĺA›–ěˆŔŠěAáÁč@•A‚@‹N—Ç
PS1-6-2
–{‘ԐŤŒŒŹ”ÂŒŒÇŠłŽŇ‚ĚƒŠƒXƒN‘w•Ę
‹´–{—R“żi’šŽćŒ§—§’†‰›•a‰@jA’†‘O”Ž‹vA“c’†FKAŹ‘ş—T”üA–x“ŕ”ü—߁A‹g‘ş‘ě˜NA‚ŒK‹PlA”ž’JˆŔ’ĂŽqAœAŁ’ŠśA’†‘O”ü‰ŔAN@G’jA“ú–ě‰ë”V
PS1-13-4
‘ĚŠOŽŽ–ŒŒ^lH”xiECMOjŽg—p‰ş‚ɉťŠw—Ă–@‚đs‚˘A‹~–˝‚ľ“ž‚˝HIVŠÖ˜AS‘ŸŒ´”­ˆŤŤƒŠƒ“ƒpŽî‚Ěˆę—á
•š‰Ž”ż—I—˘i‘ĺăŽs—§‘‡ˆă—ĂƒZƒ“ƒ^[jA‹g‘ş‘ě˜NA’ç@”üŘŽqA’†ŽÉ—m•ăA–x“ŕ”ü—߁A‹g“c‘SGA—с@—ÇŽ÷A’†”ö—˛•śAŽRŞF‹v
PS1-15-5
ƒXƒeƒƒCƒh“Š—^Œă‚ÉäB”j—ô‚đ‚Ť‚˝‚ľA“Ž–ŹÇđp‚É‚ć‚č‹~–˝‚ľ‚Ś‚˝ŒŒŠÇ“ŕˆŤŤƒŠƒ“ƒpŽîiAITLj ŠłŽŇ‚Ěˆę—á
ź‰Yˆť”Ti‘ĺă•{Ďś‰ď’†’Ă•a‰@jA‚ŒK‹PlA‰łŠŰˆę•˝AŽO‰YWŽqAr–Ř‘ńA“Ą’J—m‘ž˜NAŽR‘ş—ş‰îAź“c“TŽjA‘ž“cŒ’‰î
PS1-17-1
Œ`Žż×–EŽî‚ĚŒă•űŽ‹“I‘˝Ž{Ý‹¤“ŻŒ¤‹†iŠÖźœ‘ŽîƒtƒH[ƒ‰ƒ€j
’†’J@ˆťA“c’†G˜aA”Ş–ŘG’jA‘ž“cŒ’‰îAŽÄŽR_•FAć|“c~–çAV“°^‹IAŽu‘ş—EŽiAŹ™@’qA–Ř“c@‹œA‹ŕŽqmbAĄ“c˜a“TA‰G–ě—˛”ŽAź“cŒőOA”Ń“cłlA‘Ť—§—zŽqA•Ł“c^ˆęA‹›“ˆL•FA“ŕŽRl“ńA‚‹´—LjęAźˆä—˜[A˜a“cŸ–çA´“cŽŔŠóA“‡čçqA“ú–ě‰ë”VA•“cƒ–çA‹ŕ‘q@÷A‚ÜWŽjA–ě‘şšěAź‘ş@“ž
OS2-8B-6
Äś•s—ǐŤ•nŒŒ‚ɑ΂ˇ‚éƒtƒ‹ƒ_ƒ‰ƒrƒ“Aƒƒ‹ƒtƒ@ƒ‰ƒ“ATBI ‚SGy‘Oˆ’u‚É‚ć‚éä`‘ŃŒŒˆÚA
N@G’jA‹g‘ş‘ě˜NA“cŠ_“ŕ—D”üA—с@“NĆAŒ´“cŽŒ›A‰Ş‘ş_ŽjA“ě–ě@’qAœAŁ’ŠśA’†‘O”ü‰ŔA’†“ˆN”ŽA’†ŞF•FA“ú–ě‰ë”VA’†‘O”Ž‹v

OS2-11C-2
Ä”­E“ALLŠłŽŇ‚đ‘ÎŰ‚Ć‚ľ‚ɃCƒmƒcƒYƒ}ƒuƒIƒ]ƒKƒ}ƒCƒVƒ“‚đ“Š—^‚ľ‚˝‘ć‚R‘ŠŽŽŒą‚É‚¨‚Ż‚éƒAƒWƒAl‚ĚŒ‹‰Ę
“ú–ě‰ë”VA“ŕ“crŽ÷A‘吟@NAChul Won JungAYeow Tee GohA˛“Ą@Œ‰AMing Chung Wang
AŹ–ě’mânAź‰i@“sAM.Luisa PaccagnellaABarbara SleightAErik VandendriesA“Ąˆä—z‰îA“Ą“‡’źm

PS2-19-4
¸‘ƒŒ´”­PTCL, NOS‚Ěˆę—á
“cŠ_“ŕ—D”üA’†“ˆN”ŽA‰Ş‘ş_ŽjA“ě–ě@’qAN@G’jA’†ŞF•FA’†‘O”Ž‹vA“ú–ě‰ë”V
PS2-25-1
ƒJƒ‹ƒtƒBƒ‹ƒ]ƒ~ƒu“Š—^Œă‚É‹}ŤS•s‘S‚ÉŽŠ‚Á‚˝IgAŒ^‘˝”­Ťœ‘Ží‚Ěˆę—á
‰łŠŰˆę•˝i‘ĺă•{Ďś‰ď’†’Ă•a‰@jA‚ŒK‹PlAź‰Yˆť”TAŽO‰YWŽqAr–Ř‘ńA“Ą’J—m‘ž˜NAŽR‘ş—ş‰îA‘ž“cŒ’‰î
PS2-25-3
KMF‚É“o˜^‚ł‚ę‚˝ƒ{ƒ‹ƒeƒ]ƒ~ƒu‚ĆIMiDs—źÜ‚É’ďRŤ‚ĚÄ”­œ‘Žî‚Ě—\Œă‰đÍ
“ĄŒ´—ş‰îA“c’†G˜aA‹ÚŕVŒ›‘ž˜YA‹ŕŽqmbAŽu‘ş—EŽiA‘ž“cŒ’‰îA•Ł“c^ˆęA’†’J@ˆťAć|“c~–çA”Ş–ŘG’jA˜a“cŸ–çAŹ™@’qA‹›“ˆL•FAŽÄŽR_•FAŹŒ´ŽŒbA’†’J‰pmA“ŕŽRl“ńA‘Ť—§—zŽqA”Ń“cłlAŕ_“cí‹`Aź“cŒőOA‚ÜWŽjA–ě‘şšěA“‡čçqA“ú–ě‰ë”VA•“cƒ–çA’J˜e‰ëŽjAĄ“c˜a“TA‹ŕ‘q@÷Aź‘ş@“ž
PS2-26-2
‰ß”SâfÇŒóŒQ‚𔺂¤Žá”N”­Ç‚ĚIgMŒ^‘˝”­Ťœ‘Žî
‹g‘ş‘ě˜Ni‘ĺăŽs—§‘‡ˆă—ĂƒZƒ“ƒ^[jA—с@—ÇŽ÷A’ç@”üŘŽqA’†ŽÉ—m•ăA•š‰Ž”ż—I—˘A‹g“c‘SGA’†”ö—˛•śAŽRŞF‹v

PS2-33-5
“–ŒŒ‰t“ŕ‰Č‚É‚¨‚Ż‚éÝ‘îˆă—Ă‹@ŠÖ‚Ö‚ĚĐ‰î
ŽsŒ´O‘Piś’ˇ‰ď•{’†•a‰@jAˆäŞČ“ńAŠěŕV—C‰îAN@Žj˜NA‘ž“c’‰MAŒĂě‰Ŕ‰›A’†ˆä‹vŽŔ‘ăAÂŽR‘׍FA”ž’JˆŔ’ĂŽq

OS3-8A-6
ƒ‚ƒKƒ€ƒŠƒYƒ}ƒu•š—p‰ťŠw—Ă–@‚É‚ÄŠŽ‘SŠ°‰đ“ž’BŒă‚ÉŒŒŠÇ“ŕ‘ĺ×–EŒ^B×–EƒŠƒ“ƒpŽî‚đ”­Ç‚ľ‚˝ATL‚Ě1Ç—á
•SŁ@‘ĺi‘ĺă“S“š•a‰@jAŠÔ•”ŒŤŠ°A›–ěˆŔŠěA‚@‹N—Ç
OS3-8B-3
“–Ž{Ý‚Ĺ‚Ě ‚—îŽŇ–˘ŽĄ—ĂATL‚ɑ΂ˇ‚郂ƒKƒ€ƒŠƒYƒ}ƒu•š—pCHOP—Ă–@‚ĚŒă•űŽ‹“IŒŸ“˘

‚@‹N—ǁi‘ĺă“S“š•a‰@jA•SŁ@‘ĺAŠÔ•”ŒŤŠ°A›–ěˆŔŠěA“ú–ě‰ë”V
OS3-13B-1
œ‘ƒoƒ“ƒN‚đ‰î‚ľ‚˝ƒR[ƒfƒBƒl[ƒgŠúŠÔ’Zk‚ÉŒü‚Ż‚˝ŠJŽnƒhƒi[l”‘‰Ái‚Tl->‚P‚Oljƒgƒ‰ƒCƒAƒ‹

•˝ěŒoWA’A”nŒŚŽqA‘ĺ‹´ˆęŽ÷A–L“ˆâM“żA‘吟@NAŹŕVK‘ׁA‰Á“Ą„“ńA“ú–ě‰ë”VA‘O“c‰ĂMA“ˆ“c@–žA‹{–{•q_A”’“yŠî–žAŽRŒűŒö•˝A•Ÿ“c—˛_
PS3-5-3
­—Ę’ZŠúŠÔ‚ĚƒAƒŒƒ€ƒcƒYƒ}ƒu‚Ş‘tŒ÷‚ľ‚˝AT×–E‘ĺč÷—ąƒŠƒ“ƒpŤ”’ŒŒ•a‚É”ş‚¤Ô‰č‹…á”

•‰ŞNMAN@G’jAŽđ“żˆęŠóA“Ą’J —m‘ž˜NA–î–쑸Œ[A–ö‘ňFŽŸA“ú–ě‰ë”V
PS3-8-2
œ‘ˆŮŒ`ŹÇŒóŒQ‚Š‚ç‚̐i“W‚ƍl‚Ś‚ç‚ę‚˝AŇ‘d–ŒŠO‚ÉŽîᎌ`Ź
‚ľ‚˝Ô‰č‹…“÷Žî
’†ŽÉ—m•ăi‘ĺăŽs—§‘‡ˆă—ĂƒZƒ“ƒ^[jA—с@—ÇŽ÷AŽRăp@“OA’ç@”üŘŽqAA•š‰Ž”ż—I—˘A–x“ŕ”ü—߁A‹g‘ş‘ě˜NA’†”ö—˛•śAˆäă@Œ’AŽRŞF‹v
PS3-19-1
f’f‚Š‚玥—Ă‚Ü‚Ĺ‚ĚŠúŠÔ‚Ş’Z‚˘‚Ů‚Ç‚—îDLBCLŠłŽŇ‚Ě—\Œă‚Í•s—Ç‚Ĺ‚ ‚é

‹g“c‘SGi‘ĺăŽs—§‘‡ˆă—ĂƒZƒ“ƒ^[jA’†ŽÉ—m•ăA’ç@”üŘŽqAA•š‰Ž”ż—I—˘A–x“ŕ”ü—߁A‹g‘ş‘ě˜NA—с@—ÇŽ÷A’†”ö—˛•śAŽRŞF‹v
PS3-24-8
“–‰@‚É‚¨‚Ż‚éŽŔ—Տ°‚Ĺ‚ĚƒCƒLƒTƒ]ƒ~ƒu‚ĚˆŔ‘SŤ‚Ć—LŒřŤ
‚ŒK‹Pli‘ĺă•{Ďś‰ď’†’Ă•a‰@jA‰łŠŰˆę•˝Aź‰Yˆť”TAŽO‰YWŽqAr–Ř‘ńA“Ą’J—m‘ž˜NA•‰ŞNMAŽR‘ş—ş‰îA‘ž“cŒ’‰î
 

 

‘ć221‰ń“ú–{“ŕ‰ČŠw‰ď‹ß‹E’n•ű‰ď
‘ĺă@9ŒŽ22“ú

Œ‹ŠjŤ• –Œ‰Š‚̐f’f‚É“ďa‚ľ‚˝• …‚𔺂¤–Ťœ‘Ť”’ŒŒ•a‚Ě1—á
XŒű@TC—с@“NĆC‰Ş‘ş_ŽjC“ě–ě@’qCN@G’jC’†ŞF•FC’†‘O”Ž‹vCŽR“cNˆę, Š|‰Ž@O,“ú–ě‰ë”V

 

‘ć58‰ń@“ú–{—Տ°‰ťŠw‰ď”NŽŸŠwpW‰ď
–źŒĂ‰Ž@8ŒŽ24“ú-26“ú

‚Š´“xHBsRŒ´‘Ş’č‚É‚¨‚Ż‚éƒRƒ“ƒ^ƒ~ƒl[ƒVƒ‡ƒ“ƒŠƒXƒN‚ĚŒŸ“˘
•‘ş˜aĆ, ěŒ´GŒb, ă–ěM–í, ‘ę‘ňŒb’ĂŽq, ’†‘O”ü‰Ŕ, “Ą‰Şˆę–ç, “ú–ě‰ë”V

 

‘ć19‰ń“ú–{ŒŸ¸ŒŒ‰tŠw‰ď
é‹Ę@7ŒŽ21“ú-22“ú

‹łˆçu‰‰
ˆăŠwŒ¤‹†EŠwpŠˆ“Ž‚É‚¨‚Ż‚éŒÂlî•ń‚Ěˆľ‚˘•ű

’†‘O”ü‰Ŕ

 

‘ć220‰ń“ú–{“ŕ‰ČŠw‰ď‹ß‹E’n•ű‰ď
‘ĺă@6ŒŽ16“ú
’á—p—ĘƒGƒgƒ|ƒVƒh‹y‚ŃƒXƒeƒƒCƒh“ŕ•ž—Ă–@‚Ş—LŒř‚Ĺ‚ ‚Á‚˝‰č‹…Œ`Žż×–E—lŽ÷ó×–EŽîᇁiBPDCNj‚Ě1—á
‰łŠŰˆę•˝Ar–؁@‘ńA‚ŒK‹PlAŽO‰YWŽqA“Ą’J —m‘ž˜N‚AŽR‘ş—ş‰îA‘ž“cŒ’‰î
‘˝‘ŸŠí‚É‚¨‚Ż‚é’vŽ€“I‚ȉŠÇ‚𔺂Á‚˝œ‘ˆŮŒ`ŹÇŒóŒQ‚Ě1—á
–Ř‘ş—F”üA–‹“ŕ—z‰îA•‰ŞNMA“ě–ě@’qA’†“ˆN”ŽA’†ŞF•FA’†‘O”Ž‹vA“ú–ě‰ë”VAŒK]—DŽqA‘ĺŕV­•F

 

‘ć109‰ń‹ß‹EŒŒ‰tŠw’n•ű‰ď
_ŒË@6ŒŽ9“ú
Œo‹CŠÇŽx”x–EśŒŸ‚É‚ć‚é•a—Šw“If’f‚É‚ć‚莥—Ă‚ľ“ž‚˝”xZ‚𔺂¤‹}Ť’P‹…Ť”’ŒŒ•a
Œ´“cŽŒ›A’†ŞF•FA‰Ş‘ş_ŽjA“ě–ě@’qA’†“ˆN”ŽAN@G’jA’†‘O”Ž‹vA“ú–ě‰ë”V

 

‘ć219‰ń“ú–{“ŕ‰ČŠw‰ď‹ß‹E’n•ű‰ď
‘ĺă@3ŒŽ3“ú
“ŻŽí‘˘ŒŒŠ˛×–EˆÚAŒă‚ɐś‚ś‚˝Aspergillus felis‚É‚ć‚éNPŤ”xƒAƒXƒyƒ‹ƒMƒ‹ƒXÇ‚Ě1—á
ˆäŒËŒ’‘ž˜YA‰Ş‘ş_ŽjA“ě–ě@’qA’†“ˆN”ŽA’†ŞF•FA’†‘O”Ž‹vA“ú–ě‰ë”VAŽR“ü˜aŽuAŽR“cNˆęAŠ|‰Ž@O

 

‘ć40‰ń“ú–{‘˘ŒŒ×–EˆÚAŠw‰ď‘‰ď
ŽD–y@2ŒŽ1“úE3“ú
O2-9-2(4)
“ŻŽíˆÚAŒă‚̐[ÝŤ^‹ŰÇ‚Ě”­Ç—\‘ރ}[ƒJ[‚Ć‚ľ‚Ä‚Ěƒgƒ‰ƒ“ƒXƒtƒFƒŠƒ“–O˜a

“ě–ě@’q
O2-3-2(2)
ˆÚAŒă‘ĺ—ĘƒVƒNƒƒtƒHƒXƒtƒ@ƒ~ƒh‚Í“ŻŽíˆÚA‚Ěƒ}ƒEƒXƒ‚ƒfƒ‹‚É‚¨‚˘‚ÄGVHD‚đ—}§‚ľAGVLŒř‰Ę‚đŒ¸Žă‚ł‚š‚é
–‹“ŕ—z‰î
O2-7-1(2)
“ŻŽí‘˘ŒŒŠ˛×–EˆÚAŒăŠłŽŇ‚ĚIgGƒTƒuƒNƒ‰ƒX‚Ć–ŤŠúŠ´őÇ‚ĚŠÖ˜AŤ‚̉đÍ
N@Žj˜N
P2-8(4)
‘ŠúŠm’čf’f‚Énested PCR–@‚Ş—L—p‚Ĺ‚ ‚Á‚˝AHLA”ź‡’v“ŻŽí‘˘ŒŒŠ˛×–EˆÚAŒă‚ɐś‚ś‚˝ƒgƒLƒ\ƒvƒ‰ƒYƒ}”]‰Š‚Ěˆę—á
űüŒK‹Pl

2017

59th ASH (American Society of Hematology)
Atlanta@12ŒŽ9“úE12“ú
1963
Pre-Transplant Transferrin Saturation Levels As a Predictive Marker for Invasive Fungal Disease Following Allogeneic Hematopoietic Stem Cell Transplantation
Nanno S, Koh H, Nishimoto M, Nakane T, Nakashima Y, Takeoka Y, Nakamae M, Hirose A, Hino M, Nakamae H
4448
Post-Transplant Cyclophosphamide Contributes to Impaired Graft-Versus-Leukemia Effects and Regulates Graft-Versus-Host Disease in the Murine Stem Cell Transplant Model
Makuuchi Y, Nakashima Y, Koh H, Nakane T, Nakamae H, Hino M
322
Results from the 208-Week (4-Year) Follow-up of RESPONSE Trial, a Phase 3 Study Comparing Ruxolitinib (Rux) with Best Available Therapy (BAT) for the Treatment of Polycythemia Vera (PV)
Kiladjian J-J, Verstovsek S, Griesshammer M, Masszi T, Durrant S, Passamonti F, Harrison CN, Pane F, Zachee P, Kirito K, Besses C, Hino M, Varela AI, Miller CB,  Rumi E, Rosti V, Blau IW, Mesa RA, Dong T, Francillard N, Laughlin M, Vannucchi AM

 

‘ć218‰ń“ú–{“ŕ‰ČŠw‰ď‹ß‹E’n•ű‰ď
_ŒË@12ŒŽ2“ú

“ŻŽí‘˘ŒŒŠ˛×–EˆÚAŒăAMicroascus spp.‚É‚ć‚é”x‰Š‚đ—ˆ‚ľ‚˝1—á
—с@“NĆAź–{ŒőFA“ě–ě@’qA’†“ˆN”ŽA’†ŞF•FA“ú–ě‰ë”VA’†‘O”Ž‹vA“Ą–{Š°Ž÷AŽR“cNˆęA
Š|‰Ž@O

‹}Ťœ‘Ť”’ŒŒ•a‚ɑ΂ˇ‚é’nŒĹ‚ß—Ă–@’†‚ɍ‡•š‚ľ‚˝Citrobacter braakii”sŒŒÇ
Ł”ö‰pLi‘ĺă“S“š•a‰@jAŠÔ•”ŒŤŠ°A•SŁ@‘ĺA›–ěˆŔŠěA‚@‹N—ǁA•ű—DA“ŕ“c‘ě–í

 

‘ć108‰ń‹ß‹EŒŒ‰tŠw’n•ű‰ď
‘ĺă@11ŒŽ18“ú
’°ŠÔ–ŒŽîᎂŔ­Ç‚ľ‚˝ŒŔ‹ÇŠúßŠOŤNK/T×–EƒŠƒ“ƒpŽîA•@Œ^iENKLj‚Ě‚P—á
ě“Y–ƒˆßiˆăŠw•”6”NśjA“cŠ_“ŕ—D”üA“ě–ě@’qAź–{ŒőFA•‰ŞNMA’†“ˆN”ŽA’†ŞF•FAN@G’jA’†‘O”Ž‹vA“ú–ě‰ë”V

 

‘ć60‰ń“ú–{—Տ°ŒŸ¸ˆăŠw‰ď‹ß‹EŽx•”‘‰ď
‹ž“s@10ŒŽ28“ú
ƒAƒNƒZƒX@ƒTƒCƒgƒƒKƒƒEƒCƒ‹ƒXR‘ĚŽŽ–ň‚É‚Š‚ń‚ˇ‚éŠî‘b“IŒŸ“˘
Šâ–{^Œ‹ŽqAĄˆäd—ǁAěŒ´GŒbA‘ĺ‰YˆťŽqA“Ą‰Şˆę–çA“ú–ě‰ë”V

 

‘ć79‰ń“ú–{ŒŒ‰tŠw‰ď

“Œ‹ž@10ŒŽ20“ú-22“ú
OS1-4C-1
^Ť‘˝ŒŒÇ‚¨‚ć‚Ń–{‘ԐŤŒŒŹ”ÂŒŒÇ‚É‚¨‚Ż‚éƒTƒCƒgƒJƒCƒ“ƒvƒƒtƒ@ƒCƒ‹‚Ě•ŞÍ
‚ŒK‹PlA’†‘O”ü‰ŔA“ě–ě@’qAź–{ŒőFA’†“ˆN”ŽAN@G’jA’†ŞF•FA•‰ŞNMA“ú–ě‰ë”VA’†‘O”ü‰Ŕ
OS2-9B-4
”­ěŤ–éŠÔŒŒF‘f”AÇŠłŽŇ‚É‚¨‚Ż‚銈ŤŽ_‘f‚ĆŒŒđÇ.
N@Žj˜NAN@G’jA“y‰Žł•FA•ĐŽR‹MŽqAź–{ŒőFA’†ŞF•FAœAŁ’ŠśA’†‘O”ü‰ŔAÂŽR‘׍FA•˝ˆä@ŠwA”ž’JˆŔ’ĂŽqA’†‘O”Ž‹vA“ú–ě‰ë”V
PS2-44-2
ƒNƒ‰ƒhƒŠƒrƒ“‚Ş‘tŒř‚ľ‚˝Hairy cell leukemia-Japanese variant‚Ěˆę—á
’†ŞF•FA‰Ş‘ş_ŽjAâˆä“c‹IŽqA“Ąˆäˆę‹MA’†“ˆN”ŽAN@G’jA’†‘O”Ž‹vA‘ĺŕV­•FA“ú–ě‰ë”V
PS2-25-1
“–Ž{Ý‚É‚¨‚Ż‚鐏lT×–E”’ŒŒ•a/ƒŠƒ“ƒpŽî17—á‚ɑ΂ˇ‚郂ƒKƒ€ƒŠƒYƒ}ƒu‚ĚŽĄ—ĂŒř‰Ę‚ĚŒŸ“˘
‚@‹N—ǁi‘ĺă“S“š•a‰@jAŠâ‰iłŽqA•SŁ@‘ĺAŠÔ•”ŒŤŠ°A›–ěˆŔŠěA“ú–ě‰ë”V
PS2-2-3
S?‰t’™—Ż4”NŒă‚ɐf’f‚ł‚ę‚˝S‘ŸŒ´”­ˆŤŤƒŠƒ“ƒpŽî
–x“ŕ”ü—߁i‘ĺăŽs—§‘‡ˆă—ĂƒZƒ“ƒ^[jA’†”ö—˛•śA’ç@”üŘŽqA’†ŽÉ—m•ăA•š‰Ž”ż—I—˘A‹g‘ş‘ě˜NA—с@—ÇŽ÷A‹ŕ“‡@LA”‹Œ´Œ‰’ʁA•Ÿ“‡—TŽqAˆäă@Œ’AŽRŞF‹v
OS3-10A-1
“ú–{lDLBCLŠłŽŇ‚É‚¨‚Ż‚éƒIƒrƒkƒcƒYƒ}ƒu‚Ě—LŒřŤ‚¨‚ć‚ŃˆŔ‘SŤFGOYAŽŽŒą•”•ŞW’c‰đÍ
—Š@W–çA’†‘O”Ž‹vA“ŕ“crŽ÷A–L“ˆâM“żA’†˘ŒĂ’mşAˆÉ“¤’ÍG“ńA”Š@´•FA–k–ěrsAÔŽi_ˆęA’ߌŠ@ŽőA‹ŕ‘q@÷A’†“‡G–žAă“c‹ą“TA’ˇ“ĄGŽiA‘ĺ—ä@ŒŞA”ň“ŕŒŤłA—é‹{~ŽiAÎ“c—zŽĄA’Ł@‚–žA“c‘şGlAÎě—˛”VAă“c‰p“TA‹v—́@—mA’C–¤—zˆę
OS3-10A-5
“ú–{lÄ”­E“Ť––˝ŤT×–EƒŠƒ“ƒpŽîŠłŽŇ‚đ‘ÎŰ‚Ć‚ľ‚˝ƒvƒ‰ƒ‰ƒgƒŒƒLƒT[ƒg‚Ě‘ć1/2‘Š—Տ°ŽŽŒą
“ż‰i—˛”VA”ň“ŕŒŤłA‰iˆäG˜aA‘O“c‰ĂMA’†ŞF•FA‰şŽR@’BA’‡—˘’ŠŽüAŽđˆäƒŠƒJAÎě—˛”VAˆÉ“¤’ÍG“ńAă“c—´ŽO
OS2-4B-5
ŠÖźƒ~ƒGƒ[ƒ}ƒtƒH[ƒ‰ƒ€‚É“o˜^‚ł‚ę‚˝‘˝”­Ťœ‘ŽîŠłŽŇ‚ɑ΂ˇ‚éKRD—Ă–@‚ĚŽĄ—ĂŒř‰Ę‚ĚŒă•űŽ‹“I‰đÍ
‰ś“c‰ŔKAć|“c~–çA‹ŕŽqmbAŽÄŽR_•FAŽu‘ş—EŽiA‘ž“cŒ’‰îA“c’†G˜aA•Ł“c^ˆęAź“cŒőOA’†’J@ˆťA“ŕŽRlmA‹›“ˆL•FAŹ™@’qAĄ“c˜a“TA“ú–ě‰ë”VA–ě‘şšěA“‡čçqA•“cƒ–çA‹ŕ‘q@÷A‚Üi‹ß“ĄjjWŽjAź‘ş@“ž
OS3-‚P‚TA-1
KMF‚É“o˜^‚ł‚ę‚˝‘˝”­Ťœ‘ŽîŠłŽŇ‚É‚¨‚Ż‚銲×–EĚŽć•s—Ç‚ĚŒă•űŽ‹“I‰đÍ
•Ł“c^ˆęA‹ŕŽqmbAŽÄŽR_•FAŽu‘ş—EŽiA‘ž“cŒ’‰îA’†’J@ˆťAŹ™@’qAAć|“c~–çA”Ş–ŘG’jA“c’†G˜aA“ŕŽRlmAă’Ň—R—˘A‰G–ěF”ŽAV“°^‹IA‘Ť—§—zŽqA‰Í“c‰p—˘Aź“cŒőOA‹›“ˆL•FAÎě@~AĄ“c˜a“TA‹ŕ‘q@÷A•“cƒ–çA“ú–ě‰ë”VA–ě‘şšěA‚Üi‹ß“ĄjjWŽjA“‡čçqAź‘ş@“ž

OS3-‚P‚TA-5
ÇŒóŤ‘˝”­Ťœ‘Žî‚ɑ΂ˇ‚鎊‰Ć––˝ŒŒŠ˛×–EˆÚAŒă‚Ě’nŒĹ‚ß—Ă–@‚¨‚ć‚ŃˆŰŽ—Ă–@‚Ě—L—pŤ
’†’J@ˆťA‹ŕŽqmbAŽÄŽR_•FAŽu‘ş—EŽiAć|“c~–çAV“°^‹IA‘ž“cŒ’‰îAŹ™@’qA•Ł“c^ˆęA”Ş–ŘG’jA“c’†G˜aAă’Ň—R—˘A‰G–ěF”ŽA‹›“ˆL•FA‰Í“c‰p—˘A‘Ť—§—zŽqA“ŕŽRlmAźˆä—˜ŒőAź“cŒőOAÎě@~Aŕ_“cí‹`A‚‹´—LjęAĄ“c˜a“TA“‡čçqA“ú–ě‰ë”VA•“cƒ–çA‹ŕ‘q@÷A‚Üi‹ß“ĄjjWŽjA–ě‘şšěAź‘ş@“ž

OS3-‚P‚TB-3
ƒvƒ‰ƒg[‚ÍŠůŽĄ—Ă‘˝”­Ťœ‘Žî‚ɑ΂ˇ‚郌ƒiƒŠƒhƒ~ƒhŽĄ—Ă‚Ě—\ŒăˆöŽq‚Ĺ‚ ‚é
‘ž“cŒ’‰îAr–؁@‘ńA’†’J@ˆťA‹ŕŽqmbA•Ł“c^ˆęAŽu‘ş—EŽiA”Ş–ŘG’jAŽÄŽR_•FAć|“c~–çA“ŕŽRlmAŹ™@’qA“c’†G˜aA‰Í“c‰p—˘A‹›“ˆL•FAÎě@~AŹŒ´ŽŒbA‰G–ěF”ŽAV“°^‹IA‚‹´—˛KA´…‹`•śA’†’J‰pmAĄ“c˜a“TA‹ŕ‘q@÷A•“cƒ–çA“ú–ě‰ë”VA–ě‘şšěA‚Üi‹ß“ĄjjWŽjA“‡čçqAź‘ş@“ž
OS3-‚P‚TB-5
’´‚—î(80ÎˆČăjÇŒóŤ‘˝”­Ťœ‘Žî‚ɑ΂ˇ‚鎥—ÐŹŃFKMF‚É‚¨‚Ż‚éŒă•űŽ‹“I‰đÍ
Žu‘ş—EŽiA‹ŕŽqmbA’†’J@ˆťAŹ™@’qA•Ł“c^ˆęA“c’†G˜aA‘ž“cŒ’‰îAŽÄŽR_•FA‹›“ˆL•FAć|“c~–çA”Ş–ŘG’jAźˆä—˜ŒőAă’Ň—R—˘Aź“cŒőOA‘Ť—§—zŽqA‰G–ěF”ŽA‰Í“c‰p—˘A“ŕŽRlmAěă@ŠwAŹŒ´ŽŒbAĄ“c˜a“TA“‡čçqA“ú–ě‰ë”VA‹ŕ‘q@÷A‚Üi‹ß“ĄjjWŽjA–ě‘şšěA•“cƒ–çAź‘ş@“ž

 

‘ć49‰ń“ú–{—Տ°ŒŸ¸ŽŠ“Ž‰ťŠw‰ď
‰Ą•l@9ŒŽ21“ú-23“ú
”Ä—pŽŠ“Ž•ŞÍ‘•’u—p‘Ş’čŽŽ–ňuƒiƒmƒsƒAIL-2Rv‚ĚŠî‘b“IŒŸ“˘
ěŒűç”T, ă–ěM–í, ‘ĺ‰YˆťŽq, ‰œˆä–őŽq, “Ą‰Şˆę–ç, ’†‘O”ü‰Ŕ, “ú–ě‰ë”V

 

‘ć217‰ń“ú–{“ŕ‰ČŠw‰ď‹ß‹E’n•ű‰ď
‘ĺă@9ŒŽ16“ú
’°ƒŠƒ“ƒpŠÇŠg’ŁÇ‚ĚŒo‰ß’†‚É”­Ç‚ľ‚˝‚Ń‚Ü‚ńŤ‘ĺ×–EŒ^B×–EŤƒŠƒ“ƒpŽî
’†ˆä‹vŽŔ‘ăA•‰ŞNMA’†ŞF•FA“ě–ě@’qAź–{ŒőFA“ú–ě‰ë”VAŽRă”Žˆę

 

‘ć18‰ń“ú–{ŒŸ¸ŒŒ‰tŠw‰ď
ŽD–y@7ŒŽ22-23“ú
ŽY‰ČDICŠÖ˜A2Ç—á‚É‚¨‚Ż‚é‹ĂŒĹEü—n•ŞŽqƒ}[ƒJ[‚Ć2ŽĐFDPED-ƒ_ƒCƒ}[‚̐„ˆÚ
“Ąˆäˆę‹M, Ąˆäd—Ç, ‹v•Ű“c _, “Ą‰Şˆę–ç, ă“cD, Ź‹{ŽR –L, “ŕ“cŒ[Žq,ŽO™‘ě–ç, ’†‘O”ü‰Ŕ, “ú–ě‰ë”V
œ‘“h–••W–{‚ւ̖ƉuőF‚ĚŽŽ‚Ý
ˆŔ”öŤK, ŽsŒ´O‘P, ‹Tˆäš–덁, ŒI–{—íŽq, ‹g‰ŞŒŤ“ń, Ź”¨ —Á, ’Jě ’, ęm’JˆŔ’ĂŽq

 

‘ć107‰ń‹ß‹EŒŒ‰tŠw’n•ű‰ď
‹ž“s@6ŒŽ17“ú
ˆÚA‘OƒTƒCƒgƒƒKƒƒEƒCƒ‹ƒXIgG‰AŤ‚đ’ć‚ľ‚˝ƒTƒCƒgƒƒKƒƒEƒCƒ‹ƒXö•šŠ´őƒŒƒVƒsƒGƒ“ƒg
ˆäŒËŒ’‘ž˜Yiś’ˇ‰ď•{’†•a‰@jAN@Žj˜NAŽsŒ´O‘PAÂŽR‘׍FA”ž’JˆŔ’ĂŽqA’†‘O”Ž‹vA“ú–ě‰ë”VA’J@Œc•F

 

‘ć39‰ń“ú–{‘˘ŒŒ×–EˆÚAŠw‰ď‘‰ď
ź]@3ŒŽ2“úE4“ú
P6-3
ƒ`ƒƒVƒ“ƒLƒi[ƒ[‘jŠQ–ňŽž‘ă‚ĚƒtƒBƒ‰ƒfƒ‹ƒtƒBƒAőF‘Ě—zŤ‹}ŤƒŠƒ“ƒpŤ”’ŒŒ•a‚ɑ΂ˇ‚é“ŻŽí‘˘ŒŒŠ˛×–EˆÚA‚Ě—LŒřŤ
ˆäŒËŒ’‘ž˜Yiś’ˇ‰ď•{’†•a‰@jAN@Žj˜NAŽsŒ´O‘PAÂŽR‘׍FA”ž’JˆŔ’ĂŽq
P14-2
Źl“ŻŽí‘˘ŒŒŠ˛×–EˆÚAŠłŽŇ‚ĚƒAƒfƒmƒEƒCƒ‹ƒXoŒŒŤäNă÷‰Š‚ɑ΂ˇ‚éƒVƒhƒtƒHƒrƒ‹ŽĄ—Ă‚ĚŒă•űŽ‹“IŒ¤‹†
‹g‘ş‘ě˜NAź–{ŒőFA’†ŞF•FAN@G’jA’†“ˆN”ŽA•‰ŞNMA’†‘O”ü‰ŔAœAŁ’ŠśA“ú–ě‰ë”VA’†‘O”Ž‹v
P16-4
‘ŠúŠm’čf’f‚Énested PCR–@‚Ş—L—p‚Ĺ‚ ‚Á‚˝AHLA”ź‡’v“ŻŽí‘˘ŒŒŠ˛×–EˆÚAŒă‚ɐś‚ś‚˝ƒgƒLƒ\ƒvƒ‰ƒYƒ}”]‰Š‚Ěˆę—á
–‹“ŕ—z‰îAź–{ŒőFA—с@—ÇŽ÷A‹v–ě‰ë’qA•FâŒšŽ™A˛“Ą“NśAŽR“cNˆęA’†“ˆN”ŽAN@G’jA’†ŞF•FA–ě˜CŁˆę”üA‹ŕŽqKOAŠ|‰Ž@OA“ú–ě‰ë”VA’†‘O”Ž‹v
P12-6
‘ŠúŠm’čf’f‚Énested PCR–@‚Ş—L—p‚Ĺ‚ ‚Á‚˝AHLA”ź‡’v“ŻŽí‘˘ŒŒŠ˛×–EˆÚAŒă‚ɐś‚ś‚˝ƒgƒLƒ\ƒvƒ‰ƒYƒ}”]‰Š‚Ěˆę—á
–x“ŕ”ü—߁i‘ĺăŽs—§‘‡ˆă—ĂƒZƒ“ƒ^[jA—с@—ÇŽ÷A’ç@”üŘŽqA•š‰Ž”ż—I—˘A”‹Œ´Œ‰’ʁA‹ŕ“‡@LA’†”ö—˛•śAˆäă@Œ’AŽRŞF‹v
P4-6
‚í‚Ş‘‚É‚¨‚Ż‚錌‰ŽŇŠÔ––˝ŒŒŠ˛×–E“€Œ‹‚ĚŽŔ‘Ô‚Ě”cˆŹ‚Ě‚˝‚ß‚ĚƒAƒ“ƒP[ƒg’˛¸
Ź—с@•A‘ĺ‹´ˆę‹PAŒ´Œű‹žŽqA‰œŽR”üŽ÷A“ú–ě‰ë”VA“c’†~ŽiAă“c‹ą“TAź“c“O–çA”M“c—RŽqA‚—œ”ü”TŽqA”Ń“c”ü“ŢŽqAŽşˆäˆę’jA–î•”WłA‹{‘şkˆę

 

BMT tandem meeting 2017
Orlando@2ŒŽ22“úE26“ú
P
Cidofovir treatment for adenovirus-associated hemorrhagic cystitis in adult recipients of allogeneic hematopoietic stem cell transplantation: a retrospective comparative study
Yoshimura T, Nishimono M, Nakane T, Koh H, Nakashima Y, Takeoka Y, Nakamae M, Hirose A, Hino M, Nakamae H

 

5rd International Symposium of Training Plan for Oncology Professionals

‘ĺăA3ŒŽ12“ú
Immunoprofile changes during dasatinib treatment in patients with chronic myeloid leukemia: a prospective observational study.
Kuno M

“ú—Ő‹Z‹ß‹EŽx•”ŒŒ‰tŒ¤C‰ď
‘ĺă@2ŒŽ4“ú-5“ú
“ŻŒŒ‰tŽžŠł(‘˘ŒŒŠ˛×–EˆÚA‚đŠÜ‚Ţ)‚Ěƒf[ƒ^‚ĚŒŠ•űEl‚Ś•ű
’†‘O@”ü‰Ŕ

2016

58th ASH (American Society of Hematology)

San Diego, Dec 3-6, 2016

Combination of Frailty Status and Comorbidity Score Improves the Prediction of Survival in Patients with Myelodysplastic Syndrome Due to Good Predictive Capability for Infection-Related Mortality
Sakatoku K, Takeoka Y, Araki T, Yamamura R, Nakane T, Nakamae H, Hino M, Ohta K

Safety and Efficacy of a Switch to Nilotinib in Patients with CML-CP Showing MMR to Imatinib: Results of a Multicenter Phase II Trial (NILSw Trial)
Shibayama H, Kawaguchi T, Kuroda J, Nakamae H, Matsumura I, Miyamoto T, Ishikawa J, Kamimura T, Fukushima K, Imamura Y, Eto T, Sunami K, Shimokawa M, Akashi K, Kanakura Y

Discontinuation of Nilotinib in Patients with Chronic Myeloid Leukemia Who Have Maintained Deep Molecular Responses for at Least 2 Years: A Multicenter Phase 2 Stop Nilotinib (Nilst) Trial
Kadowaki N, Kawaguchi T, Kuroda J, Nakamae H, Matsumura I, Miyamoto T, Ishikawa J, Nagafuji K, Imamura Y, Yamazaki H, Shimokawa M, Akashi K, Kanakura Y

 

‘ć214‰ń“ŕ‰ČŠw‰ď‹ß‹E’n•ű‰ď
‘ĺă@12ŒŽ3“ú
52
ˆę‰ßŤ‚ĚŽŠ‘RŠ°‰đ‚đ”F‚ß‚˝ŒŒŠÇ“ŕ‘ĺ×–EƒŠƒ“ƒpŽî
ŠěŕV—S‰îA’ˇč÷ŽœAź–{ŒőFA“ě–ě@’qAN@G’jA’†“ˆN”ŽA’†ŞF•FA’†‘O”Ž‹vA“ú–ě‰ë”V

 

“ú–{—Տ°ŒŸ¸ˆăŠw‰ď‘ć61‰ń‹ß‹EŽx•”—á‰ď
‘ĺă@11ŒŽ12“ú
‹łˆçu‰‰
“ŻŽí‘˘ŒŒŠ˛×–EˆÚA‚ĚŠî‘b‚Ć—Ő°ŒŸ¸‚ĚŠÖ‚í‚č

’†‘O”ü‰Ŕ
ƒVƒ“ƒ|ƒWƒEƒ€
‘˘ŒŒŠ˛×–EˆÚA‚É‚¨‚Ż‚é—Տ°ŒŸ¸‚Ě–đŠ„@ŒÄ‹z‹@”\ŒŸ¸
’†ŞF•FEŽR‰ş^—Žq
ƒVƒ“ƒ|ƒWƒEƒ€
‘˘ŒŒŠ˛×–EˆÚA‚É‚¨‚Ż‚é—Տ°ŒŸ¸‚Ě–đŠ„@SƒGƒR[ŒŸ¸
ź–{ŒőFE‹gě~ˆę

 

‘ć106‰ń‹ß‹EŒŒ‰tŠw’n•ű‰ď
‘ĺă@10ŒŽ29“ú
33
őF‘Ě11qŒ‡Ž¸‚𔺂¤–ŤƒŠƒ“ƒpŤ”’ŒŒ•a‚ɃCƒuƒ‹ƒ`ƒjƒu‚Ş‘tŒř‚ľ‚˝1—á
•SŁ@‘ĺiJR‘ĺă“S“š•a‰@jAŠÔ•”ŒŤŠ°A›–ěˆŔŠěA‚@‹N—Ç
41
AIH‚Ć”ńŠ´őŤ”x‰Š‚𔺂¤MDS‚É“ŻŽí‘˘ŒŒŠ˛×–EˆÚA‚đŽ{s‚ľ‚˝1—á
‰YăŽŔ‹GA‰Ş‘ş_ŽjAź–{ŒőFA“ě–ě@’qA•‰ŞNMA’†“ˆN”ŽAN@G’jA’†ŞF•FA’†‘O”Ž‹vB“ú–ě‰ë”V

 

‘ć78‰ń“ú–{ŒŒ‰tŠw‰ď

‰Ą•l@10ŒŽ13“ú-15“ú
OS-1-133
Comparison between presepsin and other biomarkers for diagnosing hematological diseases

Koh H, Nanno S, Katayama T, Hirose A, Nakamae M, Hino M, Nakamae H
PS-2-235
Case report: Paraneoplastic immune thrombocytopenic purpura concurrent with colon cancer.

Koh S, Nakane T, Koga Y, Nishimoto M, Hayashi Y, Tauchi Y, Nagahara H, Koh H, Nakashima Y, Nakamae H, Hirakawa K, Hino M
PS-2-85
Dose escalation of dasatinib for the treatment of two cases of CML with severe arrhythmia

Makuuchi Y, Nishimoto M, Kuno M, Nagasaki J, Hayashi Y, Nakashima Y, Koh H, Nakane T, Nakamae H, Hino M
PS-1-172
Follicular lymphoma harboring recurrent but rare t(3;9)(q27;p13): a case report

Manabe MiJR‘ĺă“S“š•a‰@j, Kito
K, Momosa D, Sugano Y, Ishida E, Koh KR
PS-1-227
­—Ę‚Ěƒ{ƒ‹ƒeƒ]ƒ~ƒuĽƒfƒLƒTƒƒTƒ]ƒ“‚đ—p‚˘‚˝ˆŰŽ—Ă–@‚ĚŒă•űŽ‹“IŒ¤‹†

r–؁@‘ńi‘ĺă•{Ďś‰ď’†’Ă•a‰@jAŽR‘ş—ş‰îAŽđ“żˆęŠóA“Ą’J —m‘ž˜NA•‰ŞNMA“ú–ě‰ë”VA‘ž“cŒ’‰î
PS-2-179
Mogamulizumab-combinated chemotherapy in untreated elderly ATLL: report of 3 cases in our institution.

Koh KRiJR‘ĺă“S“š•a‰@j,
Momosa D, Manabe M, Sugano Y, Hino M
PS-2-247
Acquired factor V inhibitor with bleeding symptoms documented after the start of prasgrel.

Sakatoku Ki‘ĺă•{Ďś‰ď’†’Ă•a‰@j, Takeoka Y, Araki T, Miura A, Fujitani Y, Yamamura R, Ohta K
PS-2-67
Mediastinal germ cell tumor associated with myelodysplastic syndrome

Kanashima Hi‘ĺăŽs—§‘‡ˆă—ĂƒZƒ“ƒ^[j, Tsutsumi M, Fuseya H, Horiuchi M, Hayashi Y, Hagihara K, Nakao T, Akiyoshi K, Inoue T, Yamane T

PL-3
Crinical features and prognosis of unselected patients with AML and RAEB-2: JALSG CS07 study
Miyazaki Y, Sakura T, Yanada M, Takase K, Imai K, Dobashi N, Aoyama Y, Sawa M, Itonaga H, Usuki K,Honda S, Ohtake S, Kiyoi H, Ohnishi K, Kobayashi Y, Naoe T

OS-2-30
Identification of multiple myeloma-specific antigens asa immunotherapeutic target
s
Hosen N, Hasegawa K, Aoyama Y, Ichihara H, Mugitani A, Nakao T, Yamane T, Manabe M, Tsuboi A, Nakata J, Nishida S, Oka Y, Oji Y, Hino M, Kumanogoh A, Sugiyama H
PS-2-47
Clinical impact of body-mass index on the outcome of Japanese patients with acute myeloid leukemia.

Harada K, Doki N, Hagino T, Miyawaki S, Ohtake S, Kiyoi H, Miyazaki Y, Fujita H, Usui N, Okumura H, Miyamura K, Nakaseko C, Fujieda A, Nagai T, Yamane T, Sakamaki H, Ohshima K, Naoe T, Ohno R, Ohashi K
OS-3-71
Kansai Myeloma Forum‚É“o˜^‚ł‚ę‚˝MGUS‚Ć–łÇŒóŤœ‘Žî644—á‚Ě—Ő°Œo‰ß‚̉đÍ.

‘ž“cŒ’‰îAŽR‘ş—ş‰îA“c’†G˜aAŽÄŽR_•FAŹŒ´ŽŒbA’†’J@ˆťAŹ™@’qA–Ř“c@‹œAŕ_“c^ˆęAV“°^‹IAŹ—ѐłsA•“cƒ–çA‹ŕŽqmbA‹›“ˆL•FAă’Ň—R—˘Aź“cŒőOA‚‹´—˛KAŕ_“cí‹`A’†’J‰pmAĄ“c˜a“TA“‡čçqA’J˜e‰ëŽjA–ě‘şšěA“ú–ě‰ë”VAź‘ş@“žA‹ŕ‘q@÷A‚Üi‹ß“ĄjWŽj
OS-3-72
Retrospective analysis of 1200 symptomatic multiple myeloma cases registered in Kansai Myeloma Forum.

Kobayashi M, Kanda J, Shindo M, Kaneko H, Imada K, Tanaka H, Kosugi S, Kida T, Ohta K, Kuroda J, Shibayama H, Kohara T, Nakaya A, Fuchida S, Kamitsuji Y, Uoshima N, Yagi H, Adachi Y, Kawata E, Uchiyama H, Hamada T, Takahashi T, Matsuda M, Iida M, Shimazaki C, Matsumura I, Hino M, Taniwaki M, Kanakura Y, Nomura S, Takaori-Kondo A
OS-3-80
Retrospective multicenter study of primary plasma cell leukemia.

Nakaya A, Tanaka H, Kaneko H, Kosugi S, Kida T, Ohta K, Kamitsuji Y, Shibayama H, Kohara T, Kobayashi H, Shindo M, Fuchida S, Takahashi R, Kanda J, Uoshima N, Yagi H, Adachi Y, Kawata E, Uchiyama H, Hamada T, Takahashi T, Matsuda M, Iida M, Imada K, Shimazaki C, Matsumura I, Hino M, Taniwaki M, Kanakura Y, Nomura S, Takaori-Kondo A

 

‘ć48‰ń“ú–{—Տ°ŒŸ¸ŽŠ“Ž‰ťŠw‰ď
‰Ą•l@9ŒŽ22“ú-24“ú
ŒŸ‘Ě”Ŕ‘—ƒVƒXƒeƒ€\’z‹y‚ŃŒŸ¸‹@ŠíXV‚É‚ć‚é‰ü‘P‚Ć‚ť‚ĚŒř‰Ę
ź‹g G, “ú–ě‰ë”V, ’†‘O”ü‰Ŕ, “Ą‰Şˆę–ç, ŽR‰ş ˜j, Ąˆäd—Ç, ěŒ´Gœ¨
ƒVƒNƒƒXƒ|ƒŠƒ“‘Ş’č‚É‚¨‚Ż‚錋‰Ę‚Ě˜¨—Ł‚ɂ‚˘‚Ä
ěŒ´Gœ¨A‘ĺ‰YˆťŽqAź‹g@GAŠâ–{^Œ‹ŽqAĄˆäd—ǁAŽR‰ş@˜jA“Ą‰Şˆę–çA•E–ě‘×”ŽA’†‘O”ü‰ŔA“ú–ě‰ë”V

 

‘ć65‰ń“ú–{ˆăŠwŒŸ¸Šw‰ď
_ŒË@9ŒŽ1“ú-4“ú
ƒA[ƒLƒeƒNƒgi2000SR‚É‚ć‚éPIVKA-II‘Ş’čŽŽ–ň‚ĚŠî‘b“IŒŸ“˘
‘ĺ‰YˆťŽqAĄˆäd—ǁAěŒ´Gœ¨A•E–ě‘×”ŽA“ú–ě‰ë”VA’†‘O”ü‰Ŕ
2-45
ŽŠŒČ–ƉuÇó‚đ’悡‚錌‰tŽžŠł‚É‚¨‚Ż‚éB×–EŤ–ƉuˆŮí‚ĚŒŸŘ‚Ě‚˝‚ß‚ĚŠî‘b“IŒŸ“˘
•“c^ˆęC’†‘O”ü‰ŔA’†‘O”Ž‹vC“ú–ě‰ë”V
6-8
CD6‚đ—p‚˘‚˝Treg‰đÍƒpƒlƒ‹‚Ě—L—pŤ‚ɂ‚˘‚Ä
“ĄŒ´–qŽqA“Ąˆäˆę‹MA’r–{@ĘAĄˆäd—ǁA颖ě‘×”ŽA’†‘O”ü‰ŔA’†‘O”Ž‹vC“ú–ě‰ë”V

 

‘ć17‰ń“ú–{ŒŸ¸ŒŒ‰tŠw‰ď
•Ÿ‰Ş@8ŒŽ6“ú-7“ú
148
×–E“œ‰ŮÜPerFix-ncˆ—‚É‚ć‚é×–E•\–ʍRŒ´‚ւ̉e‹ż
“Ąˆäˆę‹MC“ĄŒ´–qŽqC’r–{@ĘAĄˆäd—ǁA‹v•Ű“c@_A陖ě‘×”ŽA’†‘O”ü‰ŔA’†‘O”Ž‹vC“ú–ě‰ë”V

 

21th Congress of EHA (European Hematology Association)
Copenhargen@6ŒŽ9“úE12“ú
ePoster
The alteration of immunoprofile during dasatinib treatment in a patients with chronic myeloid leukemia: a prospective observational study
Kuno M, Nakamae H, Katayama T, Nishimoto M, Hayashi Y, Hirose A, Nakamae M, Nakashima Y, Koh H, Nakane T, HIno M

 

‘ć212‰ń“ú–{“ŕ‰ČŠw‰ď‹ß‹E’n•ű‰ď
‘ĺă@6ŒŽ25“ú
14
–{‘ԐŤƒNƒŠƒIƒOƒƒuƒŠƒ“ŒŒÇ‚ɃXƒeƒƒCƒh‚ĆƒŠƒcƒLƒVƒ}ƒu‚Ě•š—p—Ă–@‚Ş—LŒř‚Ĺ‚ ‚Á‚˝Ç—á
’F@ŽŽqi‰ŠúŒ¤CˆăjC‹g‘ş‘ě˜NC’†‘O”Ž‹vC“ú–ě‰ë”VA—с@‘ĺ•ă, “c’†N”VAŽsě‰Ŕ—_

 

‘ć105‰ń‹ß‹EŒŒ‰tŠw’n•ű‰ď
‘ĺă@6ŒŽ18“ú
2
S‘Ÿƒy[ƒXƒ[ƒJ[‚đ—Ż’u‚ľ‰ťŠw—Ă–@‚đŽ{s‚ľ‚˝S‘ŸŒ´”­DLBCL‚Ě1—á
–‹“ŕ—z‰îAź–{ŒőFA‹v–ě‰ë’qA—с@—ÇŽ÷A’†‘O”Ž‹vA“ú–ě‰ë”VA•â@ˆşAÎˆä@‰p
37
der(6)t(1;6)(q11;p21.3)‚𔺂˘œ‘üˆŰ‰ť‚̐is‚đ”F‚ß‚˝MDS RARS-T
’ˇč÷Žœiś’ˇ‰ď•{’†•a‰@jAˆäŒËŒ’‘ž˜YAŽsŒ´O‘PAÂŽR‘׍FA‘ž“c’‰MA”ž’JˆŔ’ĂŽq

 

‘ć38‰ń“ú–{‘˘ŒŒ×–EˆÚAŠw‰ď‘‰ď
–źŒĂ‰Ž@3ŒŽ3“úE5“ú
WS2-1
ˆÚAŒăƒVƒNƒƒtƒHƒXƒtƒ@ƒ~ƒh‘ĺ—Ę—Ă–@‚É”ş‚¤“ŐŤ‚Ě•]‰ż‚Ć‚ť‚Ě‘Îô
ź–{ŒőF
O28-1
ˆÚA‘OŽŠ—Ľ_Œo‹@”\’ቺ‚Í“ŻŽí‘˘ŒŒ×–EˆÚA—\Œă‚ɑ΂ˇ‚é‹­—Í‚Č—\‘ވöŽq‚Ĺ‚ ‚é
’†ŞF•FA’†‘O”ü‰ŔAN@G’jAź–{ŒőFA—с@—ÇŽ÷A’†“ˆN”ŽA“ú–ě‰ë”VA’†‘O”Ž‹v
O18-3
Fludarabine/Busulfan‚đ—p‚˘‚˝ˆŤŤƒŠƒ“ƒpŽî‚ɑ΂ˇ‚é“ŻŽí‘˘ŒŒŠ˛×–EˆÚA‘Oˆ’u
N@Žj˜NAź–{ŒőFA‹v–ě‰ë’qA–‹“ŕ—z‰îA‚ŒK‹PlA‰Ş‘ş_ŽjA‹g‘ş‘ě˜NA“ě–ě@’qA—с@—ÇŽ÷AN@G’jA’†“ˆN”ŽA’†ŞF•FAœAŁ’ŠśA’†‘O”ü‰ŔA“ú–ě‰ë”VA’†‘O”Ž‹v
ŠĹP4-1
ŠłŽŇĽ‰Ć‘°—p‚̑މ@Žx‰‡ƒ}ƒbƒv‚đŽg—p‚ľ‚˝Žć‚č‘g‚Ý
‚–ŘŠG—A‰L’rƒŽqA‰Í–ěŒjŽqA“cŒ´łŒbA‹{č—œšAŒ´“c‰Ę•ŕA[]ŽěŠó
LS17
PostCY‘ĺ—Ę—Ă–@‚đ—p‚˘‚˝ƒnƒvƒˆÚA‚̍ĄŒă‚̉”\Ť`ˆÚAŒă“ŻŽí–Ɖu”˝‰žA–ƉuÄ\’z‚̍lˆÄ‚đŠÜ‚߁`
’†‘O”Ž‹v

 

BMT tandem meeting 2016
Hawaii@2ŒŽ18“úE22“ú
321
Prognostic Impact of the Subcutaneous Adipose Tissue Loss on Survival Outcome in Patients with Multiple Myeloma
Sakatoku K,Takeoka Y, Miura A, Yamamura R, Araki T, Seura H, Okamura T, Hino M, Ohta K
612
Potential Value of Low-Dose ATG Treatment for Steroid-Resistant Acute GVHD
Murata M, Ikegame K, Ogawa H, Nakamae H, Ikeda T, Nishida T, Inoue M, Eto T, Ichinohe T, Atsuta Y, Teshima T, Morishita Y

 

2015”N

57th ASH (American Society of Hematology)

Orland, Dec 11-14, 2015

Pre-Transplant Autonomic Nervous System Malfunction Is a Powerful Predictor for Survival after Allogeneic Hematopoietic Cell Transplantation
Nakane T, NakamaeM, Koh H, Nishimoto M, Hayashi Y, Hirose A, Nakashima Y, Hino M, Nakamae H

Azacitidine (AZA) Combination Therapy with Low-Dose AraC for Aggressive Type MDS, Overt AML, and AML Patients
Hirai M, Inoue A, Hashimura M, Aimoto M, Sakamoto E

 

‘ć25‰ń“ú–{ˆă—Ă–ňŠw‰ď”N‰ď

‰Ą•lA11ŒŽ21“ú|23“ú
“ŻŽí‘˘ŒŒŠ˛×–EˆÚA‚É‚¨‚Ż‚éƒJƒXƒ|ƒtƒ@ƒ“ƒMƒ“‚ĆƒJƒ‹ƒVƒjƒ…[ƒŠƒ“‘jŠQÜ•š—pŽž‚Ě–ň•¨‘ŠŒÝě—p‚¨‚ć‚ŃˆŔ‘SŤ‚ÉŠÖ‚ˇ‚錟“˘
úş˜a–Ú“ÄŽjAź–{ŒőFA‚‹´ł–çA’†‘şˆŔFANG’jA’†‘O”Ž‹vAźě•ŽiA“ú–ě‰ë”VA‰iŽRŸ–ç

 

‘ć104‰ń‹ß‹EŒŒ‰tŠw’n•ű‰ď

‹ž“sA11ŒŽ7“ú
DLBCL’ˇŠúŠ°‰đŒă‚É”­Ç‚ľ‚˝BCL2ABCL6AMYC“]Ŕ—zŤ‚ĚIntermediate BL/DLBCL
‹î‘qŒ[‘žiM6ŠwśjA‚ŒK‹PlAź–{ŒőFA‰Ş‘ş_ŽjA—с@—ÇŽ÷A’†“ˆN”ŽAN@G’jA’†ŞF•FA’†‘O”Ž‹vA“ú–ě‰ë”VAŒK]—DŽqA‘ĺŕV­•F
‹}Ťœ‘Ť”’ŒŒ•a‚ɑ΂ˇ‚錌Ź”—AŒŒ’†‚Ɍċz‹‡”—‚đ’ć‚ľ‚ÄŽ€–S‚ÉŽŠ‚Á‚˝‚PÇ—á
ˆäŒËŒ’‘ž˜Yiś’ˇ‰ď•{’†•a‰@jA’ˇčőŽœAŽsŒ´O‘PAÂŽR‘׍FA”ž’JˆŔ’ĂŽq
‰Â‹tŤ‚ĚdasatinibŠÖ˜A”x“Ž–ŹŤ‚ŒŒˆłÇ‚đ”­Ç‚ľ‚˝–Ťœ‘Ť”’ŒŒ•a
’ˇčőŽœiś’ˇ‰ď•{’†•a‰@jAˆäŒËŒ’‘ž˜YAŽsŒ´O‘PAÂŽR‘׍FA”ž’JˆŔ’ĂŽqA–ě–{—z‘žAŽ†XŒö—Y

 

‘ć62‰ń“ú–{—Տ°ŒŸ¸ˆăŠw‰ď

’ˇ—ǐěA11ŒŽ19“ú|22“ú
”A’žŸÔŒŸ¸‚É‚¨‚˘‚ătƒ@ƒuƒŠ[•a‚Ɛf’f‚ľ“ž‚˝‚PÇ—á
‘ę‘ňŒb’ĂŽqA’†‘O”ü‰ŔA“ú–ě‰ë”VA•E–ě‘×”Ž

 

‘ć53‰ń“ú–{ŠŕŽĄ—ĂŠw‰ď

‹ž“sA10ŒŽ29“ú|31“ú
ˆÝ‚Ş‚ń‚ĚƒQƒmƒ€‰đÍ ˆÝŠŕ‚̐i“W‚É‹y‚Ú‚ˇœ‘—R—ˆŠÔŽż×–E‚ĚŠÖ—^‚ĚŒŸ“˘
Š}“‡ —T–ž, ”Ş‘ă ł˜a, ’†‘O ”Ž‹v, –kŽR ‹IB, ‘“c „, –؉ş tl, ŸNˆä Žé, –Lě ‹MO, ‹v•Ű ŽŽm, “c’† _–ž, ˜ZŽÔ ˆęĆ, ‘ĺ•˝ ‰ëˆę, ’†Ş F•F, “ú–ě ‰ë”V, •˝ě Oš

 

‘ć74‰ń“ú–{ŠŕŠw‰ď

–źŒĂ‰ŽA10ŒŽ8“ú|10“ú
Bone Marrow Derived Mesenchymal Stem Cells Are Attracted into the Gastric Cancer Microenvironment
Š}“‡ —T–ž, ”Ş‘ă ł˜a, ‘“c „, –؉ş tl, Xč ŽěŽŔ, •Ÿ‰Ş ’BŹ,, ’†Ş F•F, ’†‘O ”Ž‹v, “ú–ě ‰ë”V, ‘ĺ•˝ ‰ëˆę, •˝ě Oš

 

‘ć47‰ń“ú–{—Տ°ŒŸ¸ŽŠ“Ž‰ťŠw‰ď
‰Ą•lA10ŒŽ8“ú|10“ú

ˆŮí”˝‰ž‚đ”F‚ß‚˝‚ƒqƒAƒ‹ƒƒ“Ž_ŒŒÇ‚Ěˆę—á

ă–ě M–í, ‰œˆä –őŽq, ‹v•Ű“c _, •E–ě ‘×”Ž, “ú–ě ‰ë”V

 

‘ć77‰ń“ú–{ŒŒ‰tŠw‰ď
ÎěŒ§—§‰šŠy“°A‹ŕ‘ňA10ŒŽ16“ú|10ŒŽ18“ú
SY1-4
HLA haplo-identical allogeneic hematopoietic cell transplantation using reduced dose post-transplantation cyclophosphamide (PT/CY)

Nakamae H
OS-2-98
Comparison of presepsin and procalcitonin as biomarkers to detect infection in febrile neutropenia
Koh H, Aimoto M, Katayama T, Hirose A, Nakamae M, Hino M, Nakamae H
OS-1-172
Two cases of primary cardiac lymphoma in our institute

Hagihara Ki‘ĺăŽs—§‘‡ˆă—ĂƒZƒ“ƒ^[j, Nakao T, Yoshida M, Ueda H, Horiuchi M, Kanashima H, Yamane T
OS-2-11
Ruxolitinib is effective and safe in Japanese polycythenia vera (PV) patients with splenomegaly
Kirito KiŽĄŒąj, Suzuki K, Miyamura K, Takeuchi M, Handa H, Okamoto S, Dany H, Yamauchi K, Amagasaki T, Ito K, Masayuki H
OS-2-48
Dose early treatment improve the outcome of patients with transplant-ineligible symptomatic myeloma?.
Nakaya AiKMFj, Yagi H, Kaneko H, Kosugi S, Kida T, Adachi Y, Shibayama H, Kohara T, Kamitsuji Y, Fuchida S, Uoshima N, Kawata E, Kamitsuji Y, Iida M, Matsuda M, Takahashi T, Hamada T, Uchiyama H, Kuroda J, Takahashi T, Urase F, Ohta K, Hamada T, Miyamoto K, Kobayashi M, ShindoM, Tanaka H, Tsudo M, Shimazaki C, Matsumura I, Hino M, Taniwaki M, Kanakura Y, Nomura S, Takaori-Kondo A
OS-2-49
Retrospective analysis of MM patients with dual refractory to bortezomib and IMiDs in KMF registry
Kohara TiKMFj, Shibayama H, Nakatani E, Kaneko H, Fuchida S, Yagi H, Kuroda J, Kobayashi M, Shindo M, Ohta K, Kosugi S, Kida T, Tanaka H, Nakaya A, Adachi Y, Uchiyama H, Kawata E, Kamitsuji Y, Iida M, Matsuda M, Takahashi T, Hamada T, Nomura S, Shimazaki C, Tsudo M,, Hino M, Matsumura I, Taniwaki M, Kanakura Y, Takaori-Kondo A
OS-3-39
Second primary malignacies among patients with myeloma-related-diseases in KMF database
Kosugi SiKMFj, Shibayama H, Kida T, Nakatani E, Ohta K, Kaneko H, Yagi H, Tanaka H, Fuchida S, Nakaya A, Kobayashi M, Kuroda J, Kamitsuji Y, Uoshima N, Adachi Y, Tsudo M, Shimazaki C, Nomura S, Hino M, Matsumura I, Taniwaki M, Kanakura Y, Takaori-Kondo A
PS-1-195
A rare case of nonleukemic myeloid sarcoma with expression of B-cell markers.
Takakuwa T, Nakane T, Kuwae Y, Nishimoto M, Hayashi Y, Nakashima Y, Koh H, Nakamae H, Ohsawa M, Hino M
PS-1-243
Prognostic significance of WT1 mRNA expression level at diagnosis in elderly MDS patients
Nagasaki Jiś’ˇ‰ď•{’†•a‰@j, Ido K, Okita J, Manabe M, aoyama Y, Mugitani A
PS-1-310
Encephalomyelitis associated with chronic GVHD after allogeneic bone marrow transplantation
Ueda Hi‘ĺăŽs—§‘‡ˆă—ĂƒZƒ“ƒ^[j, Kanashima H, Horiuchi M, Hagihara K, Nakao T, Yamane T, Morihata H
PS-2-60
A rare chromosomal abnormality of t(3;8)(q25;q24) appeared during treatment for AML: a case report
Manabe Mi‘ĺă“S“š•a‰@j, Wada K, Momose D, Sugano Y, Hino M, Yamane T, Ishida E, Koh KR
PS-2-306
Long-term treatment with lenalidomide for multiple myeloma in our institutey
Mugitani Aiś’ˇ‰ď•{’†•a‰@j, Ido K, Nagasaki J, Aoyama Y, Ohta T, Furukawa Y
PS-2-338
ÇŒóŤœ‘Žî969Ç—á‚É‚¨‚Ż‚étáŠQ‚ĚŒă•űŽ‹“I‰đÍ
‹ŕŽqmbiKMFj, ”Ş–ŘG’j, ŹŒ´Ž“ž, ŽÄŽR_•F, “c’†G˜a, •Ł“c^ˆę, –Ř“c@‹œ, Ź™@’q, •“cƒ–ç, ‘ž“cŒ’‰î, V“°^‹I, Ź—ѐłs, ă’Ň—R—˘, ’†’J@ˆť, ‘Ť—§—zŽq, ‰Í“c‰p—˘, “ŕŽRl“ń, ‹›“ˆL•F, ‰YŁ•ś–ž, ‚‹´—˛K, ‚‹´—Lję, ”Ń“cłl, ź‘ş@“ž, “ú–ě‰ë”V, ‹ŕ‘q@÷, “‡čçq, ’J˜e‰ëŽj, –ě‘şšě, ’Ę“°@–ž, ‚ÜWŽj@

 

‘ć13‰ń“ú–{—Տ°Žîᇊw‰ď
ƒƒCƒgƒ“ŽD–yAŽD–yA7ŒŽ16“ú|18“ú

P1-2-15
IgG4ŠÖ˜AŽžŠł‚Ć‚ĚŠÓ•Ę‚đ—v‚ľ‚˝IgG4—zŤMALTƒŠƒ“ƒpŽî‚Ěˆę—á

‹v–ě‰ë’qA’†ŞF•FA–{ŠÔŒ\ˆę˜YA˜a“c’źŽ÷AN@Žj˜NA‹g‘ş‘ě˜NAź–{ŒőFA’†‘O”Ž‹vAXˆä‰pˆęA“ú–ě ‰ë”V

P3-8-15
Žá”N”­ÇPTCL-NOS‚ɑ΂ľ‚ÄŽŠ‰ĆˆÚAŒăupfront‚Ĺ“ŻŽíœ‘ˆÚA‚đŽ{s‚ľ‚˝Ç—á

‹g‘ş‘ě˜NA’†Ş F•FA–‹“ŕ—z‰îA‹v–ě‰ë’qA‚ŒK‹PlA‰Ş‘ş_ŽjAN@Žj˜NA“ě–ě@’qAź–{ŒőFA“ú–ě‰ë”V

P3-1-63
Neutrophil-to-lymphocyte ratio and treatment outcome in NSCLC patients received EGFR-TKI as first or second-line therapy

^ çéŽőAŒ´“c”Ž‰ëA‹{’n—•FA’|“ŕ—é‰ŔAŽR‰ŞV”ށA“ú–ě‰ë”V

 

‘ć16‰ń“ú–{ŒŸ¸ŒŒ‰tŠw‰ď
–źŒĂ‰Ž‘Ű‰ď‹cęA–źŒĂ‰ŽA7ŒŽ11“ú|12“ú

(ƒ‰ƒ“ƒ`ƒIƒ“ƒZƒ~ƒi[1j‘ŰŠî€‚ÉŠî‚Ă‚˘‚˝ŒŸ¸‚Ć–Ťœ‘Ť”’ŒŒ•a‚̍ŐVŽĄ—Ð헪
“ú–ě‰ë”V

2Ží—Ţ‚ĚŽŽ–ň‚Ě‘g‚ݍ‡‚í‚š‚É‚ć‚éFDP/D-ƒ_ƒCƒ}[”ä‚Ć‹ĂŒĹĽü—n•ŞŽqƒ}[ƒJ[‚Ć‚ĚŠÖŒW
“Ąˆäˆę‹MA“ĄŒ´–qŽqA’r–{@ĘAŽR‰ş@˜jA‹v•Ű“c@_A•E–ě‘×”ŽA“ú–ě‰ë”V

 

‘ć103‰ń‹ß‹EŒŒ‰tŠw’n•ű‰ď

‹ž“sA6ŒŽ20“ú
B×–EŤƒ}[ƒJ[—zŤ‚đŽŚ‚ľ‚˝ŒÇ—§Ťč÷—ą‹…“÷Žî
]č–ƒˆßŽqA‚ŒK‹PlAź–{ŒőFA’†ŞF•FA‰Ş‘ş_ŽjA—с@—ÇŽ÷A’†“ˆN”ŽAN@G’jA’†‘O”Ž‹vA“ú–ě‰ë”VAŒK]—DŽqA‘ĺŕV­•F

 

20th Congress of EHA (European Hematology Association)

Vienna, June 11-14, 2015

E1389
Plasma levels of presepsin (soluble CD14-subtype) as a novel prognostic marker for hemophagocytic syndrome
Nanno S, Koh H, Katayama T, Hashiba M, Sato A, Makuuchi Y, Nagasaki J, Yoshimura T, Okamura H, Nishimoto M, Hirose A, Nakamae M, Nakane T, Hino M, Nakamae H

E1167
A comparison of oral levofloxacin and cefepime in patients with low-risk febrile neutropenia by the Japan febrile neutropenia study group
Yoshida I, Tamura K, Oze I, Takahashi T, Hino M, Hatanaka K, Nakao Y, Narumi H, Itoh T,Ohyashiki K, Tanimoto M, Urabe A, Kanamaru A, Masaoka T
PB1805
Diagnostic value of plasma levels of presepsin (soluble CD14-subtype) for febrile neutropenia in patients with hematologic malignancies
Koh H, Katayama T, Hashiba M, Sato A, Kuno M, Makuuchi Y, Takakuwa T, Okamura H, Hirose A, Nakamae M, Hino M, Nakamae H

 

‘ć64‰ń“ú–{ˆăŠwŒŸ¸Šw‰ď
•Ÿ‰ŞA5ŒŽ16“ú|17“ú

”’ŒŒ‹…”’á’lˆć‚É‚¨‚Ż‚éXN-1000‚ĚƒŠƒT[ƒ`€–Ú‚Ě—L—pŤ‚ɂ‚˘‚Ä

“ĄŒ´ –qŽq, ’r–{ Ę, “Ąˆä ˆę‹M, ‹v•Ű“c _, •E–ě ‘×”Ž, ’†‘O ”ü‰Ŕ, “ú–ě ‰ë”V

CLEIA–@‚É‚ć‚éƒTƒCƒgƒƒKƒƒEƒCƒ‹ƒXR‘Ě‘Ş’čŽŽ–ň‚ĚŠî‘b“IŒŸ“˘

ěŒ´ Gœ¨, Ąˆä d—Ç, •E–ě ‘×”Ž, “ú–ě ‰ë”V

 

41th EBMT (European Society for Blood and Marrow Transplantation)

Istanbul, TurkeyAMarch 22-25
Drug interaction and safety profiles of concomitant use of caspofungin and tacrolimus in allogeneic hematopoietic stem cell transplant recipients.
Nishimoto M, Koh H, Tokuwame A, Makuuchi Y, Kuno M, Takakuwa T, Okamura H, Koh S, Yoshimura T, Nanno S, Hayashi Y, Nakamae M, Hirose A, Nakashima Y, Nakane T, Hino M, Nakamae H

 

ASCPT (American Society of Clinical Pharmacology and Therapeutics)

New Orleans, March 3-7
Panobinostat PK/PD in combination with bortezomib and dexamethasone in patients with relapsed and relapsed/refractory multiple myeloma (RRMM)
Mu S, Tajima T, Corrado C, Sunami K, Suzuki K, Hino M, Kuroda Y, Shibayama H, Lin R, Waldron E, Binlich F

 

‘ć37‰ń“ú–{‘˘ŒŒ×–EˆÚAŠw‰ď‘‰ď
_ŒË@3ŒŽ6“úE8“ú
O13-1
“ŻŽí‘˘ŒŒŠ˛×–EˆÚA‘O‚Ě––˝‹C“š•ÂÇƒ}[ƒJ[V50/V25’l‚́AˆÚAŒă‚̐ś‘ś—\‘ވöŽq‚Ć‚ľ‚Ẳż’l‚ލ‚‚˘Žw•W‚Ĺ‚ ‚é
’†‘O”ü‰ŔAŽR‰ş^—ŽqA’†‘O”Ž‹vA’†ŞF•FAN@G’jA’†“ˆN”ŽAœAŁ’ŠśA—с@—ÇŽ÷Aź–{ŒőFA“ú–ě‰ë”V
O18-1
“ŻŽí‘˘ŒŒŠ˛×–EˆÚAŒă‚Ě×‹ŰŠ´ő—\–h‚Ć‚ľ‚Ä‚Ě”ń‹zŽűŤ‚Ć‹zŽűŤR‹Ű–ň‚Ě”äŠr
N@Žj˜NA’†‘O”Ž‹vAŽR“cNˆęAź–{ŒőFA—с@—ÇŽ÷AN@G’jA’†“ˆN”ŽA’†ŞF•FAœAŁ’ŠśA’†‘O”ü‰ŔAŠ|‰Ž@OA“ú–ě‰ë”V
O28-2
œ‘ƒoƒ“ƒNƒhƒi[‚Ě•Ą”‰ńœ‘’ń‹Ÿ‚ÉŠÖ‚ˇ‚錟“˘Fƒhƒi[‚Ě•‰’S‚ĆˆÚAŠłŽŇ‚̐ś’…—Ś‚ւ̉e‹ż
ÜŒ´Ÿ–¤AŒáű¸_ŒúA‰œŽR”üŽ÷A—Ž‡—şˆęAŕV@łŽjA“c–ěč—˛“ńA‹Ęˆä‰ŔŽqA–L“ˆâM“żA’†”öN•vA“ú–ě‰ë”VA‹{č‘׎iA_“c‘PLA‹ŕX•˝˜a
O7-5
ŹŽ™‚¨‚ć‚ѐŹl‚É‚¨‚Ż‚éˆÚAŒă”ńŠ´őŤpŒă”x‡•šÇ‚ÉŠÖ‚ˇ‚錤‹†|“ńŽŸ’˛¸‰đÍŒ‹‰Ę•ńi20-18FGVHDˆČŠO‚̍‡•šÇWGj
‹S’ː^mAŹěŒ[‹ąA•Ÿ“c—˛_A“ú‚“šOA‹ŕX•˝˜aA‰Ş“cŒbŽqAˆäă‰ë”üA‰Á“Ą„“ńAX“‡‘×—YAâŠŞ@šćA—é–Ř—Ľ˜NA”M“c—RŽqA“ú–ě‰ë”VA“ĄˆäLŽĄA’‡@ŞGŽ÷
P7-6
ś‘̐tˆÚAŒă‚ĚMDS(RAEB-2)‚ɑ΂ľA”ńŒŒ‰œ‘ˆÚA‚đŽ{s‚ľ‚˝˘ŠE‰‚ĚÇ—á
’†“ˆN”ŽA’†ŞF•FA‹g‘ş‘ě˜NA‹v–ě‰ë’qA–‹“ŕ—z‰îA‚ŒK‹PlA‰Ş‘ş_ŽjAN@Žj˜NA“ě–ě@’qAź–{ŒőFA—с@—ÇŽ÷AœAŁ’ŠśA’†‘O”ü‰ŔAN@G’jA’†”ö‹gFA’†‘O”Ž‹vA“ú–ě‰ë”V
P10-6
ˆÚAŒă‘ĺ—ĘƒVƒNƒƒtƒHƒXƒtƒ@ƒ~ƒh‚đ—p‚˘‚˝HLA”ź‡’v“ŻŽí‘˘ŒŒŠ˛×–EˆÚAŒă–ŤŠú‚ɍL”͂ȉĄ’fŤŇ‘‰Š‚đ’ć‚ľ‚˝Ä”­Ť‹}ŤŽUÝŤ”]Ň‘‰Š‚Ěˆę—á
–‹“ŕ—z‰îAź–{ŒőFA’†‘O”Ž‹vA—с@—ÇŽ÷AN@G’jA‹v–ě‰ë’qA’†“ˆN”ŽAŽR–{Œ\ˆęA‚‹´—˜KA’†ŞF•FA“ú–ě‰ë”V
P20-1
‚—îŽŇ‚É‚¨‚Ż‚鍂ƒŠƒXƒNœ‘ˆŮŒ`ŹÇŒóŒQ‚¨‚ć‚Ń‹}Ťœ‘Ť”’ŒŒ•a‚ɑ΂ˇ‚é“ŻŽí‘˘ŒŒŠ˛×–EˆÚA‚Ě–đŠ„
‘ĺ–k~–çiś’ˇ‰ď•{’†•a‰@jA’ˇč÷ŽœAŒĂ‰ę—TŽ÷AŠÔ•”ŒŤŠ°AÂŽR‘׍FA”ž’JˆŔ’ĂŽq
P33-6
œ‘ƒoƒ“ƒNƒhƒi[ĚŽć‚ɑ΂ˇ‚鑢ŒŒŠ˛×–EˆÚAƒR[ƒfƒBƒl[ƒ^[‚Ě–đŠ„
”~–{—R—˘A“ú–ě‰ë”VA’†ŞF•FA’†“ˆN”ŽAź–{ŒőFA’†‘O”ü‰ŔAœAŁ’Šś
ŠĹP6-7
‘˘ŒŒŠ˛×–EˆÚA„i‹’“_•a‰@‚ĚŠˆ“Ž•ń
ă–ě^—RŽqAŠâŒŠ–žŽqAŽR–ě–őŽqA‹{–{’qŽqA‰L’rƒŽqA“ú–ě‰ë”V
ŠĹP7-1
‘މ@Žx‰‡‚Ě•W€‰ť`‘މ@Žx‰‡ƒ}ƒbƒv‚đŠˆ—p‚ľ‚ā`
ź‰Y—TŽqAě‘ş—R‰ÄA–ěâmŽŔA’J@~ŽqA‹{–{’qŽqA‰L’rƒŽq
ƒCƒuƒjƒ“ƒOƒZƒ~ƒi[
ƒhƒi[‚ĚˆŔ‘SŤ
“ú–ě‰ë”V

 

3rd International Symposium of Training Plan for Oncology Professionals

‘ĺăA2ŒŽ7“ú
Diagnostic value of serum ferritin and risk factors for hemohpagositic syndrome following allogeneic hematopoietic stem cell transplantations
Nanno S

 

2014”N

56th American Society of Hematology
San FranciscoADec 6-9
1145
Effectiveness of Antibacterial Prophylaxis with Non-Absorbable Polymyxin B Compared to Levofloxacin after Allogeneic Hematopoietic Stem Cell Transplantation

Koh S, Nakamae H, Yamada K, Nishimoto M, Hayashi Y, Koh H, Nakashima Y, Nakane T, Hirose A,  Nakamae M, Kakeya H, Hino M

1208
The V50/V25 Ratio, a Marker of Small Airway Disease, Is Highly Predictive of Survival after Allogeneic Hematopoietic Cell Transplantation

Nakamae M, Nakamae H, Yamashita M, Nishimoto M, Hayashi Y, Koh H, Nakane T, Nakashima Y, Hirose A, Hino M

3256
A Detailed Analysis of Myelodysplastic Syndrome Complicated By Autoimmune or Inflammatory Disorders: A Possible Efficacy of Low-Dose Lenalidomide

Takeoka Yi‘ĺă•{Ďś‰ď’†’Ă•a‰@j, Miura A, Nakamura K, Nakamura J, Yamamura R, Araki T, Nakamae H, Hino M, Ohta K

3260
Azacitidine (AZA) Combination Therapy with Low-Dose AraC Is Well Tolerated and Highly Effective for MDS with Overt Leukemia

Hirai MiŽl“V‰¤Ž›•a‰@j, Aimoto M, Inoue A, Hashimura M, Sakamoto E, Nakamae H, Hino M

4441
A Retrospective Study of Elderly Patients with Diffuse Large B-Cell Lymphoma (DLBCL): Clinical Significance of Treatment Intensity and Comprehensive Geriatric Assessment (CGA)

Yoshida Mi‘ĺăŽs—§‘‡ˆă—ĂƒZƒ“ƒ^[j, Horiuchi M, Ueda H, Hagihara K, Kanashima H, Nakao T, Yamane T

1815[‹¤“ŻŒ¤‹†]
Final Results From SENSOR: Switch to Nilotinib After Molecular Suboptimal Response (SoR) to Frontline Imatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP)

Tanimoto M, Miyamura K, Miyamoto T, Yamamoto K, Taniwaki M, Kimura S, Ohyashiki K, Kawaguchi T, Matsumura I, Hata T, Tsurumi H, Saito S, Hino M, Tadokoro S, Meguro K, Hyodo H,  Yamamoto M, Kubo K, Tsukada J,  Kondo M, Aoki M, Okada H, Yanada M

805[‹¤“ŻŒ¤‹†]
Odk-1201, One-Step RT-qPCR Major BCR-ABL/ABL mRNA Kit for the International Scale, with High Sensitivity to Detect Deeper MR

Matsumura I, Nakamae H, Yoshida C, Fletcher L, Branford S, Koga D, Sogabe T, Kanakura Y, Naoe T

2547[‹¤“ŻŒ¤‹†]
Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Acute Myeloid Leukemia Transformed from Ph-Negative Myeloproliferative Neoplasm: A Study from the Adult AML Working Group of the Japan Society for Hematopoietic Cell Transplantation (JSHCT)

Takagi S, Masuoka K, Uchida N, Kurokawa M, Nakamae H, Tsudo M, Iwato K, Ichinohe T, Atsuta Y, Takami A

2580[‹¤“ŻŒ¤‹†]
Allogeneic Peripheral Blood Stem Cell Transplantation Using Reduced-Intensity Conditioning Regimen with Fludarabine and Busulfan from HLA-Matched Related Donor for Elderly Adult T-Cell Leukemia/Lymphoma: Results of Multicenter Phase II Study (ATL-NST-3)

Tanosaki R, Choi I, Shimokawa M, Utsunomiya A, Tokunaga M, Nakano N, Fukuda T, Nakamae H, Takemoto S, Kusumoto S, Tomoyose T, Sueoka E, Shiratsuchi M, Suehiro Y, Yamanaka T, Okamura J, Uike N

4541[‹¤“ŻŒ¤‹†]
Efficacy and Safety of Nilotinib (NIL) vs Imatinib (IM) in Patients (pts) With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Long-Term Follow-Up (f/u) of ENESTnd 

Larson AR, Kim D-W, Issaragrilsil S, le Coutre P, Llacer PDE, Etienne G, Clark ER, Flinn I, Nakamae H, Hochhaus A, Saglio G, Kantarjian MH, Donohue B, Deng W, Menssen DH, Hughes PT

 

‘ć206‰ń“ú–{“ú–{“ŕ‰ČŠw‰ď‹ß‹E’n•ű‰ď

‹ž“sA12ŒŽ6“ú
cladribine‚Ş‘tŒ÷‚ľ‚˝hairy cell leukemia‚Ě‚P—á
‘ĺ–k~–çiś’ˇ‰ď•{’†•a‰@j,’ˇč÷ŽœCŒĂ‰ę—T‹KCŠÔ•”ŒŤŠ°CÂŽR‘׍FCęm’JˆŔ’ĂŽq

 

‘ć61‰ń“ú–{—Տ°ŒŸ¸ˆăŠw‰ď

•Ÿ‰Ş‘Ű‰ď‹cęA11ŒŽ22“ú-25“ú
ƒOƒ‹ƒRƒwƒ‚ƒOƒƒrƒ“^ƒOƒ‹ƒR[ƒX•ŞÍ‘•’uAH-8290‚ĚŠî‘b“IŒŸ“˘
Ąˆäd—ǁCěŒ´GŒbC•E–ě‘×”ŽC“ú–ě‰ë”V
Multi-color flow cytometry‚đ—p‚˘‚˝Œ’íl‚Ě––˝ŒŒ–Ɖu’S“–×–E”ä—Ś
“Ąˆäˆę‹MC“ĄŒ´–qŽqAŽR‰ş@˜jC‹v•Ű“c@_A•E–ě‘×”ŽC’†‘O”ü‰ŔA’†‘O”Ž‹vA“ú–ě‰ë”V
‘˘ŒŒŠ˛×–EˆÚAŠłŽŇ‚É‚¨‚Ż‚éŒÄ‹z‹@”\‚̐„ˆÚ‚â—\Œă‚Ć‚ĚŠÖ˜A
ŽR‰ş^—ŽqC–Ř‘şMŒMA’†‘O”ü‰ŔC’†‘O”Ž‹vA•E–ě‘×”ŽA“ú–ě‰ë”V
ƒCƒ“ƒXƒŠƒ“ťÜ‚ĆƒCƒ“ƒXƒŠƒ“‘Ş’čŽŽ–ň‚ĚŒđˇ”˝‰žŤ‚ĚŒŸ“˘
ěŒ´GŒbCĄˆäd—ǁA•E–ě‘×”ŽC’†‘O”ü‰ŔA“ú–ě‰ë”V

 

‘ć101‰ń‹ß‹EŒŒ‰tŠw’n•ű‰ď
ƒeƒCƒWƒ“ƒz[ƒ‹A‘ĺăA11ŒŽ8“ú

HLA”ź‡’vˆÚAŒăÄ”­Žž‚ÉŠĚ’_“šŒny‘fă¸‚đ’ć‚ľAƒfƒtƒFƒ‰ƒVƒƒNƒX‚ŞDLST‚Ĺ—zŤ‚Ć‚Č‚Á‚˝Ç—á
‹g‘ş‘ě˜NA’†‘O”Ž‹vA‰Ş‘ş_ŽjAN@Žj˜NAź–{ŒőFAN@G’jA“ú–ě‰ë”VA‚“c‚ł‚ä‚čA”‹Œ´~Ži

ƒCƒ“ƒtƒ‹ƒGƒ“ƒUƒƒNƒ`ƒ“ÚŽíŒă‚ÉITP‚đ”­Ç‚ľ‚˝‚RÇ—á
’ˇč÷ŽœAŠÔ•”ŒŤŠ°A‘ĺ–k~–çAŒĂ‰ę—T‹KAÂŽR‘׍FA‹v‘şŠx‰›A”ž’JˆŔ’ĂŽq

 

‘ć76‰ń“ú–{ŒŒ‰tŠw‰ď
‘ĺă‘Ű‰ď‹cęA‘ĺăA10ŒŽ31“ú|11ŒŽ2“ú
OS-3-85
Promising outcomes from intra-arterial steroid infusion for severe gut- graft versus-host disease
Nishimoto M, Koh H, Nakamae H, Hirose A, Nakamae M, Nakane T, Hayashi Y, Okamura H, Yoshimura T, Koh S, Nanno S, Nakashima Y, Takeshita T, Yamamoto A, Sakai Y, Nishida N, Matsuoka T, Miki Y, Hino M
OS-3-169
Usefulness of per rectal portal scintigraphy to diagnose the cause of liver dysfunction in all-HSCT
Okamura H, Koh H, Takakuwa T, Nanno S, Nishimoto M, Hayashi Y, Nakashima Y, Nakane T, Hirose A, Nakamae M, Nakamae H, Hino M
OS-1-108
Retrospective comparison of 3 BTZ-based therapies (BD, CBD, and MPB) and MP in elderly MM patients

Fuchida SiKMFj, Nakatani E, Kuroda J, Kaneko H, Tanaka H, Yagi H, Uoshima N, Kosugi S, Ohta K, Kohara T, Miyamoto K, Ishii K, Kida T, Shibayama H, Matsumura Y, Uchiyama H, Kawata E, Adachi Y, Iida M, Kamitsuji Y, Shindo M, Kobayashi M, Nomura S, Takaori-Kondo A, Matsumura I, Tsudo M, Hino M, Taniwaki M, Shimazaki C, Kanakura Y
OS-1-109
Novel agents for the elderly patients with multiple myeloma: Analysis in Kansai Myeloma Forum
Yagi HiKMFj, Hamamoto H, Tsubaki K, Fuchida S, Kosugi S, Kuroda J, Uoshima N, Kaneko H, Ohta K, Miyamoto K, Tanaka H, Ishii K, Adachi Y, Kohara T, Matsumura Y, Kida T, Shibayama H, Nakagawa M, Iida M, Kawata E, Takahashi T, Uchiyama H, Nomura S, Matsumura I, Hino M, Tsudo M, Shimazaki C, Taniwaki M, Takaori-Kondo A, Kanakura Y
OS-1-110
The effects of consolidation and maintenance therapies for symptomtic MM patients after auto HSCT.
Shibatama HiKMFj, Nakatani E, Kuroda J, Fuchida S, Kaneko H, Ohta K, Kohara T, Kosugi S, Adachi Y, Yagi H, Kobayashi M, Miyamoto K, Tanaka H, Uoshima N, Kida T, Ishii K, Kamitsuji Y, Hamada T, Takahashi T, Uchiyama H, Kawata E, Matsuda M, Nomura S, Matsumura I, Hino M, Tsudo M, Shimazaki C, Taniwaki M, Takaori-Kondo A, Kanakura Y
OS-1-113
ISS is a predictive factor of SCT effect for symptomatic myeloma patients under age 65
Kaneko MiKMFj, Nakatani E, Shibatama H, Kohara T, Kobayashi M, Miyamoto K, Shindo M, Fuchida S, Tanaka H, Kuroda J, Yagi H, Kosugi S, N, Kida T, Uoshima N, Matsumura Y, Kamitsuji Y, Adachi Y, Ohta K, Ishii K, Uchiyama H, Takahashi T, Iida M, Takaori-Kondo A, Shimazaki C, Matsumura I, Taniwaki M, Nomura S, Hino M, Tsudo M, Kanakura Y
OS-2-33
Retrospective multicenter study of ocular adnexal mucosa-associated lymphoid tissue lymphoma
Saitoh NiOLSGj, Shibayama H, Kohara T, Hashida N, Nishida K, Maeda Y, Inoue N, Ueda S, Sohma T, Iwasaki Y, Sugahara H, Hashimoto K, Azenishi Y, Arima N, Terada Y, Morii E, Sugiyama H, Matsumura I, Nomura S, Ogawa H, Hino M, Kanakura Y
OS-2-130
Update of a phase 1/2 study of ponatinib in Japanese patients with Philadelphia positive leukemia
Tojo AiŽĄŒąj, Kyo T, Yamamoto K, Takahashi N, Nakamae H, Kobayashi Y, Tauchi T, Okamoto S, Miyamura K, Iwasaki H, Hatake K, Matsumura I, Usui N, Yanase K, Hu S, Tuner C, Naoe T, Ohyashiki K
PS-1-324
Adult case of anti-neutrophil antibody-positive agranulocytosis
Koh,S, Koh H, Kuroda M, Kubo Y, Inaba M, Kuno M, Makuuchi Y, Okamura H, Yoshimura T, Nanno S, Nishimoto M, Nakashima Y, Nakamae H, Ueda M, Hino M
PS-1-221
‰ťŠw—Ă–@‚ĆMogamulizumab‚Ş‘tŒ÷‚ľ‚˝‰E‰şŽˆ–ƒáƒ‚𔺂¤Œă• –ŒATL‚ĚˆęÇ—á
‚@‹N—ǁi‘ĺă“S“š•a‰@jA•SŁ@‘ĺA›–ěˆŔŠěAš –{“Ţ’ĂŽqA‘ĺ–ě_ŽiAÎ“c‰p˜aA’†ŞF•FA˜a“cŸ–çAź‰Ş‰ë—YA“ú–ě‰ë”V
PS-1-222
Mogamulizumab treatment for Adult T-cell leukemia/ lymphoma: Report of 6 cases in our institution
Koh KRi‘ĺă“S“š•a‰@j, Momose D, Sugano Y, Wada K, Hino M
PS-1-257
B-cell acute lymphoblastic leukemia developed after chemotherapy without alkylating agents for MM
Ueda Hi‘ĺăŽs—§‘‡ˆă—ĂƒZƒ“ƒ^[j, Horiuchi M, Yoshida M, , Hagihara K, Kanashima H, Nakao T, Yamane T
PS-1-257
ŽčŽwć’[‚̉󎀂ɂĔ­Ç‚ľ‚˝‚PŒ^iƒ‚ƒmƒNƒ[ƒiƒ‹jƒNƒŠƒIƒOƒƒuƒŠƒ“ŒŒÇ
r–؁@‘ńi‘ĺă•{Ďś‰ď’†’Ă•a‰@jA•‰ŞNMAŽR‘ş—ş‰îAŽO‰YWŽqA“Ą’J —m‘ž˜NA’†‘şƒŽqA’†‘şPm
PS-2-96
A case of chronic myelomonocytic leukemia concomitant with monoclonal gammopathy
Harada Ni•{’†•a‰@j, Okita J, Manabe M, Aoyama Y, Kumura T, Mugitani A
PS-2-133
Double hit lymphoma treated by up-front autologous stem cell transplantation: A case report
Nagasaki Ji•{’†•a‰@j, Okita J, Harada N, Koga Y, Manabe M, Aoyama Y, Kumura T, Mugitani A
PS-2-166
Results of Devic therapy in six patients with central nervous system lymphoma in a single institute
Yoshida Mi‘ĺăŽs—§‘‡ˆă—ĂƒZƒ“ƒ^[j, Horiuchi M, Ueda H, Hagihara K, Kanashima H, Nakao T, Yamane T
PS-2-178
A case of angioimmunoblastic T cell lymphoma presenting with IgM monoclonal gammopathy
Okita Ji•{’†•a‰@j, Nagasaki J, Harada N, Manabe M, Aoyama Y, Kumura T, Mugitani A
PS-2-204
Bilateral hearing loss after bortezomib therapy in a multiole myeloma patient
Mugitani Ai•{’†•a‰@j, Okita J, Nagasaki J, Manabe M, Aoyama Y, Ohta T, Furukawa Y
PS-2-205
‘˝”­Ťœ‘Žî‚ɑ΂ˇ‚éBortezomib+lenalidomideŽĄ—ĂŒăŽž‰ż––˝ŒŒŠ˛×–EˆÚA‚ĚŒă•űŽ‹“IŒŸ“˘
Ź‘q˜aŠOA•‰ŞNMA˛“Ą@ŒŞA’†”ö—˛•śAŹ—ѐ^ˆęAŽRŞF‹vA–Ř‘ş•ś•FA‘ž“cŒ’‰îA’r“c‰FŽŸ
PS-2-295
Acute colonic pseudo-obstruction following allogeneic stem cell transplantation: A case report
Aoyama Yi•{’†•a‰@j, Manabe M, Nagasaki J, Ohkita J, Koga Y, Kumura T, Ohta T, Furukawa Y, Mugitani A
ŒöŠJƒVƒ“ƒ|ƒWƒEƒ€
ŒŒ‰tŽžŠłŽĄ—Ă‚ĚĹ‘Oü
“ú–ě‰ë”V

 

‘ć15‰ń“ú–{ŒŸ¸ŒŒ‰tŠw‰ď
ĺ‘䍑ŰƒZƒ“ƒ^[Aĺ‘äA7ŒŽ20“ú|21“ú

(‹łˆçu‰‰4jAPL‚Ě—Ő°‚ƍŐVŽĄ—Ă
“ú–ě‰ë”V

ATLL‚Š‚玥—ĂŠÖ˜A”’ŒŒ•aiM4)‚đ”­Ç‚ľ‚˝Ç—á
“ĄŒ´–qŽqA“Ąˆäˆę‹MA’r–{@ĘAĄˆäd—ǁAŽR‰ş@˜jA‹v•Ű“c@_A•E–ě‘×”ŽA’†‘O”ü‰ŔA“ú–ě‰ë”V

 

‘ć24‰ń“ú–{ƒTƒCƒgƒƒgƒŠ[Šw‰ď
ŠÖźˆă‰Č‘ĺŠwA–‡•űA6ŒŽ28“ú|29“ú

10ƒJƒ‰[ƒtƒ[ƒTƒCƒgƒƒgƒŠ[‚É‚ć‚鐳íœ‘×–E‚Ě•\–ʍRŒ´‰đÍ
“ĄŒ´ –qŽq, “Ąˆä ˆę‹M, ’r–{ Ę, ŽR‰ş ˜j, ‹v•Ű“c _, •E–ě ‘×”Ž, ’†‘O ”ü‰Ŕ, ’†‘O ”Ž‹v, “ú–ě ‰ë”V

 

‘ć68‰ń“ú–{Œđ’ĘˆăŠw‰ď
JR”Ž‘˝ƒVƒeƒBA”Ž‘˝A6ŒŽ7“ú|8“ú

“ŤALK‰AŤ–˘•Ş‰ť‘ĺ×–EŒ^ƒŠƒ“ƒpŽî‚ÉABVd‚Ş’˜Œř‚ľ‚˝ˆę—á
›–ě ˆŔŠě(JR‘ĺă“S“š•a‰@), Î“c ‰p˜a, ˜a“c Ÿ–ç, ‚ ‹N—Ç, •SŁ ‘ĺ, “ú–ě ‰ë”V

 

‘ć63‰ń“ú–{ˆăŠwŒŸ¸Šw‰ď
Žé˜hƒƒbƒZAVŠƒA5ŒŽ17“ú-18“ú

ƒGƒNƒ‹[ƒVƒXŽŽ–ňƒ^ƒNƒƒŠƒ€ƒX‚ĚŠî‘b“IŒŸ“˘
Ąˆä d—ǁAěŒ´ Gœ¨, ‰Fm ˜aŤ, •E–ě ‘×”Ž, “ú–ě ‰ë”V

ŒŒ’†ƒVƒNƒƒXƒ|ƒŠƒ“‘Ş’č‚Ě3–@‚É‚ć‚錟“˘
ěŒ´ Gœ¨, Ąˆä d—Ç, ‰Fm ˜aŤ, •E–ě ‘×”Ž, “ú–ě ‰ë”V
uƒA[ƒLƒeƒNƒgEhigh sensitiveƒgƒƒ|ƒjƒ“I STv‚ĚŠî‘b“IŒŸ“˘
‰Fm ˜aŤ, Ąˆä d—Ç, ěŒ´ Gœ¨, •E–ě ‘×”Ž, “ú–ě ‰ë”V

 

‘ć134”N‰ď“ú–{–ňŠw‰ď
ƒzƒeƒ‹“úqŒF–{AŒF–{A3ŒŽ27“ú|30“ú

’ŽË—pƒuƒXƒ‹ƒtƒ@ƒ““Š—^Žž‚Ěázš”­ě—\–h‚ɑ΂ˇ‚éƒoƒ‹ƒvƒŽ_ƒiƒgƒŠƒEƒ€‚Ě—LŒřŤ‚¨‚ć‚ŃˆŔ‘SŤ‚ÉŠÖ‚ˇ‚錟“˘
“ż˜a–Ú “ÄŽj, ‚‹´ ł–ç, Œőě NŽq, N G’j, ’†‘O ”Ž‹v, źě •Ži, “ú–ě ‰ë”V, ‰iŽR Ÿ–ç

 

‘ć12‰ń“ú–{—Տ°Žîᇊw‰ď
•Ÿ‰Ş‘Ű‰ď‹cęA•Ÿ‰ŞA7ŒŽ17“ú|19“ú

Empirical voriconazole therapy for febrile neutropenia in Japanese patients: The 5th Febrile Neutropenia Study

N G’jA“ú–ě ‰ë”VA‘ž“c Œ’‰îA‹g“c –ŤA’J–{ Œő‰šA‘剎•~ ˆę”nA‰Y•” ť•vA“c‘ş ˜a•vA‹ŕŠŰ ş‹vAł‰Ş “O

Cefozopran, meropenem, or imipenem-cilastatin versus cefepime as empirical therapy in high-risk febrile neutropenia

’†Ş F•FA“c‘ş ˜a•vA‹Ę’u rŽĄA‹g“c Œ÷A•Ÿ“‡ r—mA’J–{ Œő‰šA‘剎•~ ˆę”nA‰Y•” ť•vAł‰Ş “OA‹ŕŠŰ ş‹v

MGUSA–łÇŒóŤœ‘Žî‚Ě—Ő°Œo‰ß:KMF‚É“o˜^‚ł‚ę‚˝206—á‚ĚŒă•űŽ‹‰đÍ

‘ž“c Œ’‰îAŹ™ ’qAŹ—Ń łsA•“c ƒ–çA“c’† G˜aA•Ł“c ^ˆęAŽÄŽR _•FA‹›“ˆ L•FA’†’J ‰pmA‹ŕ‘q ÷

The effectiveness of salvage chemotherapy with S-1 for pretreated NSCLC patients: single center retrospective study
^ çéŽőiĎś‰ď–ě]•a‰@jA‹{’n —•FAŽR‰Ş V”ށA“°‘O ŽeA“ú–ě ‰ë”V

Role of Allogeneic Hematopoietic Stem-Cell Transplantation in Older Patients With AML or High risk MDS
ÂŽR ‘׍Fiś’ˇ‰ď•{’†•a‰@jAŠÔ•” ŒŤŠ°A‹v‘ş Šx‰›AŒ´“c ŽŒ›A’ˇč ÷ŽœA‘ĺ–k ~–çA”ž’J ˆŔ’ĂŽq

Diffuse large B-cell lymphoma during azathioprine therapy for autoimmune hepatitis: a case repor‚”

ŠÔ•” ŒŤŠ°iś’ˇ‰ď•{’†•a‰@jA“y×H —˜•vA‘ĺ–k ~–çA’ˇč ÷ŽœAŒ´“c ŽŒ›AÂŽR ‘׍FA‹v‘ş Šx‰›A‘ž“c ’‰MAŒĂě ‰Ŕ‰›A ”ž’J ˆŔ’ĂŽq

ŠÖźœ‘ŽîƒtƒH[ƒ‰ƒ€‚É“o˜^‚ł‚ę‚˝577—á‚ĚÇŒóŤœ‘ŽîÇ—á‚Ě—Ő°“I‰đÍ

ŽÄŽR _•FA‹ŕŽq mbAŹ™ ’qA‘ž“c Œ’‰îA“c’† G˜aA•Ł“c ^ˆęA•“c ƒ–çA”Ş–Ř G’jA’†’J ‰pmA‹ŕ‘q ÷

FN ‘ć4ŽŸŒ¤‹† Low Risk ; CFPM vs LVFX

‹g“c Œ÷A”öŁ Œ÷A‚‹´ •×A“ú–ě ‰ë”VA”¨’† ˆęśA’†”ö ‹gFAŹŒŠ OA‘剎•~ ˆę”nAˆÉ“Ą ‘ôśA“c‘ş ˜a•v

Carbapenems are as useful as cefepime for the treatment of febrile neutropenia associated with hematological disorders
’†ě –őÍA—é–Ř Œ›ŽjA‘ž“c Œ’‰îA“ú–ě ‰ë”VA‘剎•~ ˆę”nA‹ŕŠŰ ş‹vA“c‘ş ˜a•vA‰Y•” ť•vAł‰Ş “O

 

‘ć101‰ń‹ß‹EŒŒ‰tŠw’n•ű‰ď
ƒeƒCƒWƒ“ƒz[ƒ‹A‘ĺăA6ŒŽ28“ú

ƒgƒŠƒ\ƒ~[‚W‚𔺂¤MDS(RCMD)‚ɍ‡•š‚ľ‚˝DŽ_‹…ŤŽ‹_Œo‰Š
’ˇč÷ŽœAź–{ŒőFA’†ŞF•FAN@G’jA–‹“ŕ—z‰îAN@Žj˜NA’†‘O”Ž‹vA“ú–ě‰ë”V

 

40th Annual Meeting of the European Society for Blood and Marrow Transplantation

Milan, Italy@3ŒŽ20“úE4ŒŽ2“ú

PH-P373
Promising outcomes from intra-arterial steroid infusions in patients with treatment-resistant acute gastrointestinal graft-versus-host disease.

Nishimoto M, Koh H, Nakamae H, Hirose A, Nakamae M, Nakane T, Hayashi Y, Okamura H, Yoshimura T, Koh S, Nanno S, Hamamoto S, Yamamoto A, Sakai Y, Nishida N, Matsuoka T, Miki Y, Hino M

PH-AB083
Diagnostic value of serum ferritin and risk factors for hemophagocytic sydrome following allogeneic hematopoietic cell transplantation .

Nanno M, Koh H, Nakashima Y, Katayama T, Kuno M, Makuuchi Y, Nagasaki J, Takakuwa T, Okamura H, Koh S, Yoshimura T, Nishimoto M, Nakamae M, Hirose A, Nakane T, Nakao Y, Nakamae H, Hino M

 

2014 BMT tandem meeting

Dallas, Texas@2ŒŽ26“úE3ŒŽ2“ú

3593
Voriconazole vs. itraconazole for antifungal prophylaxis in patients with GVHD:A prospective randomized trial

Hayashi Y, Kanda Y, Nakamae H, Kanamori H, Ohashi K, Hidaka M, Yano S, Hatanaka K, Kono A, Moriuchi Y, Ago H, Yamashita T, Takata T, Yoshida M, Hino M, Yamaguchi T, Fukuda T

 

‘ć36‰ń“ú–{‘˘ŒŒ×–EˆÚAŠw‰ď‘‰ď
‰Ť“ę@3ŒŽ7“úE9“ú
O13-5
—\Œă•s—ǁAŽĄ—Ă’ďRŤ‹}Ť
”’ŒŒ•aAMDS‚ɑ΂ˇ‚éˆÚAŒăCY‘ĺ—Ę—Ă–@‚É‚ć‚éHLA”ź‡’v––˝ŒŒŠ˛×–EˆÚA‚Ě’PŽ{Ý‘OŒü‚ŤpilotŒ¤‹†
’†‘O”Ž‹vAN@G’jAź–{ŒőFA’†“ˆN”ŽA“ě–ě@’qA‹g‘ş‘ě˜NAN@Žj˜NA‰Ş‘ş_ŽjA–‹“ŕ—z‰îA‹v–ě‰ë’qA’†ŞF•FA’†‘O”ü‰ŔAœAŁ’ŠśA“ú–ě‰ë”V
O12-1
ŠłŽŇ
‚Ćƒhƒi[‚ĚKIRˆâ“`ŽqŒ^‚ވڐAŒăCY‘ĺ—Ę—Ă–@‚đ—p‚˘‚˝ƒnƒvƒˆÚAŒă‚ĚÄ”­‚É‹y‚Ú‚ˇ‰e‹ż
N@G’jA’†‘O”Ž‹vA–‹“ŕ—z‰îA‹v–ě‰ë’qA’ˇč÷ŽœAN@Žj˜NA‰Ş‘ş_ŽjA‹g‘ş‘ě˜NA“ě–ě@’qAź–{ŒőFAˆäă—LŠóŽqAœAŁ’ŠśA’†‘O”ü‰ŔA’†“ˆN”ŽA”‹Œ´Œ‰’ʁAŽ›“c–FŽ÷A’†ŞF•FA“ú–ě‰ë”V
O12-2
ˆÚAŒă
CY‘ĺ—Ę—Ă–@‚đ—p‚˘‚˝ŒŒ‰ŽŇŠÔHLA”ź‡’v––˝ŒŒŠ˛×–EˆÚA‚É‚¨‚˘‚āAƒhƒi[HLA“ÁˆŮ“IR‘Ě‚Ş‰AŤ‰ť‚ľś’…‚ɐŹŒ÷‚ľ‚˝‚Q—á
’†“ˆN”ŽA’ˇč÷ŽœAź–{ŒőFAN@G’jAœAŁ’ŠśA’†‘O”ü‰ŔA’†‘O”Ž‹vA“ú–ě‰ë”V
O24-4
ŹlÄś•s—ǐŤ•nŒŒ‚̐ś’…•s‘S‚ɑ΂ˇ‚é‚Q‰ń–Ú“ŻŽí‘˘ŒŒŠ˛×–EˆÚA‚ĚŒŸ“˘[“ú–{‘˘ŒŒŠ˛×–EˆÚAŠw‰ď@ŹlÄś•s—ǐŤ•nŒŒWorking group.
‘吟@NA‰ęŒĂ^ˆęAN@G’jAX@‹B•FA’†”öáÁ“ńA“ŕ“c’ź”VA‘ĺ‹´ˆę‹PAâŠŞ@šćAX“‡‘×—YA‰Á“Ą„“ńA—é–Ř—Ľ˜NAŽRčGl
O29-1
HLAˆę’vŒŒ‰‚Ü‚˝‚Í7-8/8HLAˆę’v”ńŒŒ‰ƒhƒi[‚Š‚ç‚Ě“ŻŽí‘˘ŒŒŠ˛×–EˆÚA‚É‚¨‚Ż‚éMMF‚¨‚ć‚ŃƒJƒ‹ƒVƒjƒ…[ƒŠƒ“‘jŠQÜ‚đ—p‚˘‚˝GVHD—\–h‚Ě—L—pŤF‘˝Ž{Ý‹¤“Ż‘ć2‘Š—Տ°ŽŽŒą
’†ŞF•FA’†‘O”Ž‹vA•ŕVĘŽqA‰Ş‘ş“Ä•vA“ú‚“šOAŽR‰ş‘ě–çA‰Í–쏲•vAÄ“Ą@Œ’AÂŽR‘׍FA”¨’†ˆęśA•ĐŽR‹`—YA–ňŽt_Œö˜aAźˆä—˜[A‚ŒŠş—ǁAŽRŒű‘ń—mA“ú–ě‰ë”VA•Ÿ“c—˛_
P-B1-7
Šˆ“ŽŤăŠ{“´‰Š‚đ‡•š‚ľ‚˝‰ťŠw—Ă–@—đ‚Ě‚Č‚˘’áŒ`ŹŤMDS‚ɑ΂ľASeattleŒ^ƒ~ƒjˆÚA‚đŽ{s‚ľ‚˝‚P—á.
’†“ˆN”ŽAdâ@ŽŔA’†ŞF•FAź–{ŒőFAN@G’jA’†‘O”Ž‹vA“ú–ě‰ë”V
P-C1-5
ä`‘ŃŒŒˆÚAŒăˆęŽŸś’…•s‘S‚ɑ΂ľ‚ĈڐAŒăCY‘ĺ—Ę—Ă–@‚É‚ć‚錌‰ŽŇŠÔHLA”ź‡’vˆÚA‚Őś’…‚đ“ž‚˝Bechet•a‚ĆMDS‚Ě•š”­—á
‹g‘ş‘ě˜NA’ˇč÷ŽœAˆî—tWŽqA‹v–ě‰ë’qAź–{ŒőFAN@G’jAœAŁ’ŠśA’†‘O”ü‰ŔA”‹Œ´Œ‰’ʁA’†“ˆN”ŽAŽ›“c–FŽ÷A’†ŞF•FA’†‘O”Ž‹vA“ú–ě‰ë”V
P-T1-1
ˆÚAŒăCY‘ĺ—Ę—Ă–@‚É‚ć‚éHLA”ź‡’vˆÚAŒă‚Ě”’ŒŒ•a•ŞŽqÄ”­‚ɑ΂ľ‚ÄDLI‚Ş—LŒř‚Ĺ‚ ‚Á‚˝ˆę—á
N@Žj˜NA’†‘O”Ž‹vA–‹“ŕ—z‰îA‹v–ě‰ë’qAâ•”^“Ţ”üA’ˇč÷ŽœA‰Ş‘ş_ŽjA“ě–ě@’qA‹g‘ş‘ě˜NAź–{ŒőFA’†“ˆN”ŽA”‹Œ´Œ‰’ʁAœAŁ’ŠśA’†‘O”ü‰ŔAŽ›“c–FŽ÷AN@G’jA’†ŞF•FA’†”ö‹gFA“ú–ě‰ë”V
P-Z1-3
‘˘ŒŒŠ˛×–EˆÚAŠłŽŇ‚ĚƒŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“‰î“üŒř‰Ę‚Ć“]“|‚ɂ‚˘‚Ä
ŽR‰ş[ái•{’†•a‰@jAŽľ–ě‚ł‚â‚ŠA•ŸˆäË“ńAŽč’ˍN‹MA”ž’JˆŔ’ĂŽqAÂŽR‘׍F
P-G2-5
APL‚ɑ΂ľ‚ÄŽŠ‰Ć‘˘ŒŒŠ˛×–EˆÚAŒă‚É‚P‚R”N‚Ě’ˇŠú‚ĚŒo‰ß‚đŒo‚ÄŽĄ—ĂŠÖ˜A”’ŒŒ•a‚đ”­Ç‚ľA“ŻŽí‘˘ŒŒŠ˛×–EˆÚA‚đŽ{s‚ľ‚˝ˆę—á
Œ´“cŽ“żi•{’†•a‰@jA‘ĺ–k~–çA‚ŒK‹PlAŠÔ•”ŒŤŠ°AÂŽR‘׍FA‹v‘şŠx‰›A”ž’JˆŔ’ĂŽq
P-J‚Q-‚P
HLA•s“K‡ŒŒ‰ŽŇŠÔ‘˘ŒŒŠ˛×–EˆÚA‚đŽ{s‚ľ‚˝Œ`Žż×–E”’ŒŒ•a‚Ě‚P—á
‚ŒK‹Pli•{’†•a‰@jA‘ĺ–k~–çAŒ´“cŽ“żAŠÔ•”ŒŤŠ°AÂŽR‘׍FA‹v‘şŠx‰›A”ž’JˆŔ’ĂŽq
O7-4
‹}Ť”’ŒŒ•aŽĄ—ĂŒă‚̐śŠˆ‚ĚŽżiQOLj‚ÉŠÖ‚ˇ‚鉥’f“IŒ¤‹†FˆÚA‚ƉťŠw—Ă–@‚Ě”äŠr
•ŕVĘŽqAŽRŒű‘ń—mAX@‹B•FA‹ŕX•˝˜aA“ĄŕV@MA‘吟@NAŒb”üé•FA‰Í–쏲•vA“ú–ě‰ë”VA’†˘ŒĂ’mşA–ź˜a—Rˆę˜YAÄ“Ą•śŒěA‹ß“Ą’‰ˆęA‹´–{–žŽqA•Ÿ“cűé_
O24-3
Äś•s—ǐŤ•nŒŒ‚É‚¨‚Ż‚鎞ŠłŠ´ŽóŤHLAƒAƒŠƒ‹‚Ɛś’…•s‘S‚Ć‚ĚŠÖŒW
ŽRčGlAX@‹B•FAN@G’jA‘吟@NA‰ęŒĂ^ˆęA‹{‘şkˆęAŹŕVK‘ׁA“ŕ“c’ź ”VA‘ĺ‹´ˆę‹PA˛”ö@_AâŠŞ@šćAX“‡‘×—YA‰Á“Ą„“ńA—é–Ř—Ľ˜NA’†”öáÁ“ń
ŠĹO2-‚S
‘˘ŒŒŠ˛×–EˆÚAƒTƒ|[ƒgƒ`[ƒ€‚Ş•ř‚Ś‚Ä‚˘‚é—Ď—“I–â‘č‚Ć‘Îˆ
’ß“c—ŒbAŽRčm”üAˆ˘•””ü˛ŽqA‹{–{’qŽqA‰L’rƒŽq
P-ŠĹB1-3
‘˘ŒŒ×–EˆÚA•a“‚É‚¨‚Ż‚éƒJƒ“ƒtƒ@ƒŒƒ“ƒX‚ĚŒťó‚Ɖۑč.
ŽRčm”üA“cŒ´łŒbA’ß“c—ŒbA‹{–{’qŽqA‰L’rƒŽqA“ú–ě‰ë”V
P-ŠĹF1-3
‰ťŠw—Ă–@‚¨‚ć‚Ń‘˘ŒŒŠ˛×–EˆÚAŒă‚̐HŽ–ƒpƒ“ƒtƒŒƒbƒg‚Ě“dŽq‰ť
ŁŒË—F”üA“Ą“c“Ţ•äA‹{č—œšAŽRč—zŽqA‹{–{’qŽqA‰L’rƒŽqA‰ÔŽR‰ŔŽqAź–{ŒőFA“ú–ě‰ë”V
P-ŠĹF2-3
ŒŒ‰t“ŕ‰ČŠO—ˆŠłŽŇ‚̐HŽ–ŰŽćó‹ľ”cˆŹ‚Ɖh—{ŠÇ—‰î“ü‚ĚˆÓ‹`‚ÉŠÖ‚ˇ‚é’˛¸
‰ÔŽR‰ŔŽqA“Ą–{_’Aź‰Y”üKA’†ŞF•FA“ú–ě‰ë”V

 

‘ć203‰ń“ú–{“ú–{“ŕ‰ČŠw‰ď‹ß‹E’n•ű‰ď

‘ĺăA3ŒŽ1“ú
‘ĺ‹…Ť•nŒŒ‚ɉÁ‚Ś‚ÄLDă¸CŒŒŹ”ÂŒ¸­CƒnƒvƒgƒOƒƒrƒ“’ቺ‚đ’ć‚ľ‚˝ƒrƒ^ƒ~ƒ“B12Œ‡–RÇ
ŠÔ•”ŒŤŠ°iś’ˇ‰ď•{’†•a‰@j,‘ĺ–k~–çC’ˇč÷ŽœCŒ´“cŽŒ›CÂŽR‘׍FC‹v‘şŠx‰›C‘ž“c’‰MCŒĂě‰Ŕ‰›Cęm’JˆŔ’ĂŽq
Rituximab‚Ş‘tŒř‚ľ‚˝“ŤŒŒđŤŒŒŹ”ÂŒ¸­ŤŽ‡”Á•a‚Ě‚P—á
•“c^ˆßŽq, ’†“ˆN”Ž, ’†ŞF•F, ź–{ŒőF, N@G’j, ’†‘O”Ž‹v, “ú–ě‰ë”V

 

2013”N

‘ć202‰ń“ú–{“ŕ‰ČŠw‰ď‹ß‹E’n•ű‰ď
‘ĺă‘ŰŒđ—ŹƒZƒ“ƒ^[A‘ĺăA12ŒŽ14“ú

”ńƒzƒWƒLƒ“ƒŠƒ“ƒpŽî‚ɑ΂ˇ‚鉝Šw—Ă–@Œă‚É”­Ç‚ľ‚˝AőF‘ĚˆŮít811;16)(q23;p13)‚𔺂¤ŽĄ—ĂŠÖ˜A‹}Ťœ‘Ť”’ŒŒ•a
ŠÔ•”ŒŤŠ°iś’ˇ‰ď•{’†•a‰@jA‘ĺ–k~–çA’ˇčőŽœAŒ´“cŽŒ›AÂŽR‘׍FA‹v‘şŠx‰›A‘ž“c’‰MAŒĂě‰Ŕ‰›A”ž’JˆŔ’ĂŽq

 

55th American Society of Hematology
New OrleansADec 7-10
3404
HLA Haplo-Identical Peripheral Blood Stem Cell Transplantation Using High-Dose Cyclophosphamide Post-Transplantation For Poor Prognosis Or Refractory Acute Leukemia and Myelodysplastic Syndrome: A Prospective Pilot Study At a Single Center

Nakamae H, Koh H, Nishimoto M, Nakashima Y, Nanno S, Yoshimura T, Koh S, Okamura H, Nagasaki J, Nakane T, Nakamae M, Hirose A, Hino M

1536
A New Strategy Of MDS Treatment With Azacitidine (AZA): Induction With AZA Combined With Low Dose AraC Followed By Maintenance Therapy With AZA

Hirai MiŽl“V‰¤Ž›•a‰@j, Nakane T, Inoue A, Hashimura M, Aimoto M, Sakamoto E, Nakamae H, Hino M

4586[‹¤“ŻŒ¤‹†]
Gvhd Prophylaxis With Mycophenolate Mofetil and Calcineurin Inhibitor In Allogeneic Hematopoietic Cell Transplantation From HLA-Matched Siblings Or 7–8/8 HLA-Matched Unrelated Volunteer Donors: A Japanese, Multicenter, Phase II Trial

Nakane T, Nakamae H, Kurosawa S, Okamura A, Hidaka M, Yamashita T, Kohno A, Saito T, Aoyama Y, Hatanaka K, Katayama Y, Yakushijin K, Matsui T, Takami A, Yamaguchi T, Hino M, FukudaT

2729[‹¤“ŻŒ¤‹†]
Nilotinib Following Molecular Suboptimal Response (SoR) To Imatinib In Japanese Patients (pts) With Chronic Myeloid Leukemia In Chronic Phase (CML-CP): 12 Month Follow-Up From The SENSOR Study

Miyamura K, Miyamoto T, Kurokawa M, Tanimoto M, Yamamoto K, Taniwaki M, Kimura S, Ohyashiki K, Kawaguchi T, Matsumura I, 0Hata T, Tsurumi H, Saito S, Hino M, Tadokoro S, Meguro K, Hyodo H, Yamamoto M, Kubo K, Tsukada J, Kondo m, Amagasaki T, Kawahara E, Yanada M

3385[‹¤“ŻŒ¤‹†]
Retrospective Analysis Of The Recent Treatment Strategies For The Patients With Myeloma-Related Diseases Registered In Kansai Myeloma Forum

Tanaka H, Kosugi S, Kida T, Ohta K, Yamamura R, Shibayama H, Kohara T, Kaneko H, Fuchida S, Kobayashi M, Miyamoto K, Shindo M, Kuroda J, Uoshima N, Matsumura Y, Yoshii Y, Kamitsuji Y, Boku S, Ishii K, Matsuda M, Takahashi T, Hamada T, Adachi Y, Nakatani E, Nomura S, Taniwaki M, Takaori A, Shimazaki C, Tsudo M, Hino M, Matsumura I, Kanakura Y

4270[‹¤“ŻŒ¤‹†]
Hepatitis B and C Virus Infections Are Not Associated With Worse Clinical Outcomes After Autologous Stem Cell Transplantation: On Behalf Of The Adult Lymphoma Working Group Of The Japan Society For Hematopoietic Cell Transplantation (JSHCT)

Kato H, Chihara D, Kato K, Kim S-W, Mori T, Sawa M, Ohno Y, Hashimoto H, Hino M, Iwato K, Chou T, Sakamaki H, Suzuki R, Suzumiya J

3998[‹¤“ŻŒ¤‹†]
Discontinuation Of Dasatinib In Patients With CML Who Have Maintained Complete Molecular Response For At Least One Year: Results From a Prospective Discontinuation (DADI) Trial

Tanaka H, Imagawa J, Okada M, Nakamae H, Hino M, Murai K, Ishida Y, Kumagai T, Sato S, Ohashi K, Sakamaki H, Wakita H, Uoshima N, Nakagawa Y, Minami Y, Ogasawara M, Takeoka T, Akasaka H, Morita S, Sakamoto J, Kimura S

Online-Only-201
Diagnostic Value Of Serum Level Of Soluble CD14-Subtype In Febrile Neutropenia In Patients With Hematologic Disorders

Koh H, Nakamae H, Aimoto M, Katayama T, Hirose A, Nakamae M, Hino M

 

‘ć100‰ń‹ß‹EŒŒ‰tŠw’n•ű‰ď
ƒRƒ“ƒOƒŒƒRƒ“ƒxƒ“ƒVƒ‡ƒ“ƒZƒ“ƒ^[A11ŒŽ30“ú
ˆŤŤƒŠƒ“ƒpŽî`clinical question‚ĆOLSG‚Ě–đŠ„
“ú–ě‰ë”V
ä`‘ŃŒŒˆÚAŒăCoprinopsis Cinerea (Hormgraphiella Aspergillataj‚É‚ć‚é”dŽíŤŠ´őÇ‚đ”­Ç‚ľ‚˝‚P—á
“ě–ě@’qA’†ŞF•FA‰Ş‘ş_ŽjAź–{ŒőFA
N@G’jA’†‘O”Ž‹vA“ú–ě‰ë”VA‘ĺŕV­•FA‘ş’ˇ•ŰŒ›A‹TˆäŽ•F
BRAF•ĎˆŮ‰AŤACD5ECD33‰AŤACD103‰AŤ‚Ě•\–ĘŒ`Žż‚đ’ć‚ľ‚˝Hairy cell leukemia
ŠÔ•”ŒŤŠ°iś’ˇ‰ď•{’†•a‰@jA‘ĺ–k~–çA‚ŒK‹PlAŒ´“cŽŒ›AÂŽR‘׍FA‹v‘şŠx‰›A‘ž“c’‰MAŒĂě‰Ŕ‰›A”ž’JˆŔ’ĂŽq

 

‘ć60‰ń“ú–{—Տ°ŒŸ¸ˆăŠw‰ď
_ŒË‘Ű‰ď‹cęA_ŒËA10ŒŽ31“ú-11ŒŽ1“ú
‘Ű•W€’l‚Ö‚Ě•ĎŠˇ‰Â”\‚ČBCR-ABL1 mRNA‘Ş’čƒLƒbƒg‚Ě‘˝Ž{Ý—Տ°Ť”\ŽŽŒą
’†’J@’†A‹{‘şkˆęA‰Ş–{^ˆę˜YA”–ˆä‹IŽqAÔŽi_ˆęA“ú–ě ‰ë”VA’†˘ŒĂ’mşA‚‹´’źlA’rK@˝A“o@•×A’ź]˜aŽ÷
œ‘•W–{‚É‚ć‚éITP”ť’čŠî€‚ɂ‚˘‚Ä‚ĚŒŸ“˘
“ĄŒ´–qŽqA’r–{@ĘA“Ąˆäˆę‹MAĄˆäd—ǁA‹v•Ű“c@_A•E–ě‘×”ŽA’†‘O”Ž‹vA“ú–ě‰ë”V

 

‘ć51‰ń “ú–{ŠŕŽĄ—ĂŠw‰ďŠwpW‰ď
‹ž“sA10ŒŽ24“ú-25“ú
ŽŠ‰Ć––˝ŒŒŠ˛×–EˆÚAŒă‚Éneutropenic enterocolitis‚đ‡•š‚ľ‚˝ ”ńHodgkinƒŠƒ“ƒpŽî
ź‰Ş‘ĺ•ăiś’ˇ‰ď•{’†•a‰@j, ŠÔ•”ŒŤŠ°, ‘ĺ–k~–ç, űüŒK‹Pl, Œ´“cŽŒ›, ÂŽR‘׍F, ‹v‘şŠx‰›, ‘ž“c’‰M, ŒĂě‰Ŕ‰›, ęm’JˆŔ’ĂŽq
Azacitidine“Š—^‚Ş‘tŒř‚ľ‚˝, őF‘ĚˆŮídel(20q)‚đ—L‚ˇ‚é –Ťœ‘’P‹…Ť”’ŒŒ•a
ŠÔ•”ŒŤŠ°iś’ˇ‰ď•{’†•a‰@j, ‘ĺ–k~–ç, ‚ŒK‹Pl, Œ´“cŽŒ›, ÂŽR‘׍F, ‹v‘şŠx‰›, ‘ž“c’‰M, ŒĂě‰Ŕ‰›, ęm’JˆŔ’ĂŽq

 

‘ć75‰ń“ú–{ŒŒ‰tŠw‰ď‘‰ď
ƒƒCƒgƒ“ŽD–yAŽD–yA10ŒŽ11“úE13“ú

OS-1-24
Risk factor hor hemophagositic syndrome following allogeneic hematopoietic cell transplamtaion
Nanno S, Koh H, Sakabe M, Nagasaki J, Okamura H, Koh S, Yoshimura T, Inaba A, Aimoto M, Nishimoto M, Hirose A, Nakamae M, Nakashima Y, Hagihara K, Nakao Y, Nakane T, Terada Y, Nakamae H, Hino M

OS-1-134
dasatinb“ŕ•ž‚É‚ć‚čCMLƒNƒ[ƒ“‚É‚ć‚é‚ƍl‚Ś‚ç‚ę‚éd“x‚̍œ‘—}§‚đ’E‚ľ‚˝Ç—á
’†“ˆN”ŽA’†‘O”Ž‹vAâ•”^“Ţ”üAź–{ŒőFAN@G’jA“ú–ě‰ë”V
OS-2-33i‹¤“ŻŒ¤‹†j
MP therapy for Multiple myeloma in the era of new agents in Kansai Myeloma Forum
Shimura Y, Kuroda J, Ohta K, Tanaka H, Shibayama H, Kohara T, Kosugi S, Kida T, Fuchida S, Miyamoto K, Shindo M, Kobayashi M, Kaneko H, Uoshima N, Matsumura Y, Yoshii Y, Kamitsuji Y, Ishii K, Matsuda M, Takahashi T, Hamada T, Tsudo M, Shimazaki C, Takaori A, Nomura S, Hino M, Matsumura I, Taniwaki M, Kanakura Y
OS-2-140i‹¤“ŻŒ¤‹†j
Prognostic analysis of angioimmunoblastic T cell lymphoma (AITL) cases from OLSG registry
Mitsui H, Kamae T, Kuyama J, Nakatani E, Fujii N, Sugahara H, Shibano M, Azenishi Y, Shimizu Y, Uoshima N, Shibayama H, Hattori H, Maeda Y, Nakagawa M, Kim EH, Harada H, Wada Y, Miyoshi T, Tominaga N, Fushimi H, Take H, Arima N, Hashimoto K, Okada M, Kourogi T, Terada Y, Yamauchi A, Ueda S, Morii E, Hino M
OS-2-165i‹¤“ŻŒ¤‹†j
SIL2R at the diagnosis is an independent prognostic factor for FL (OLSG cohort analysis)
Kohara T, Shibayama H, nakatani E, Take H, Tsukaguchi M, Tokumine Y, Uoshima N, Soma T, Hattori H, Azenishi Y, Sugahara H, Maeda M, Tamaki T, Ueda S, Fujii S, Kubota T, Arima N, Mitsui H, Yoshida H, Tabata R, Okamoto T, Urase F, Morii E, Kanakura Y, Hino M
OS-3-4i‹¤“ŻŒ¤‹†j
uRIST with low-dose ATG-F multicenter phase II trial
Fuji S, Kim SW, Yano S, Hagiwara S, Nakamae H, Hidaka M, Ito T, Ohashi K, Hatanaka K, Takami A, Kurosawa S, Yamashita T, Yamaguchi T, Fukuda T
OS-3-32i‹¤“ŻŒ¤‹†j
Retrospective analysis of clinical course of 123 MGUS and 54 SMM patients registered in KMF
Ohta K, Yamamura R, Takeoka Y, Tanaka H, Shibayama H, Kohara T, Kosugi S, Kida T, Fuchida S, Miyamoto K, Shindo M, Kobayashi M, Kuroda J, Kaneko H, Uoshima N, Mathumura Y, Yoshii Y, Ishii K, Matsuda M, Takahashi T, Hamada T, Nakatani E, Tsudo M, Shimazaki C, Takaori A, Taniwaki M, Nomura S, Hino M, Matsumura I, Kanakura Y
OS-3-43i‹¤“ŻŒ¤‹†j
Nirotinib vs imatinib for newly-diagnosed CML-CP: ENESTnd 48 month update in Japanese patients
Fukuda T, Nakamae H, Shibayama H, Kurokawa M, Nakaseko C, Kanda Y, Nagai T, Ohnishi K, Matsumura I, Matsuda A, Amagasaki T, Ito K
OS-3-44i‹¤“ŻŒ¤‹†j
Nirotinib in CML-CP patients with suboptimal response (SoR) to imatinib (IM): SENSOR 12-month data
Miyamura K, Miyamoto T, Kurokawa M, Tanimoto M, Yamamoto K, Taniwaki M, Kimura S, Ohyashiki K, Kawaguchi T, Matsumura I, Hata T, Tsurumi H, Naoe T, Hino M, Tadokoro S, Meguro K, Hyodo H, Yamamoto M, Kubo K, Tsukada J, Amagasaki T, Kondo M, Kawabata E, Yanada M
OS-3-49i‹¤“ŻŒ¤‹†j
Phase I/II trial of imatinib dose reduction study for CML-CP patients: The JALSG CML-DR1 study
Ishikawa M, Ohnishi K, Miyamura K, Aoyama Y, Uoshima N, Naoe T
OS-3-50i‹¤“ŻŒ¤‹†j
Clinical performance study of a BCR-ABL1 kit which reports BCR-ABL1 mRNAon an international scale
Hino M, Miyamura K, Okamoto S, Usui N, Akashi K, Nakaseko C, Takahashi N, Nakatani N, Nobori T, Naoe T
OS-3-73i‹¤“ŻŒ¤‹†j
Lenalidomide and dexamethasone for relapsed/refractory multiple myeloma in Kansai Myeloma Forum
Kobayashi T, Kuroda J, Ohta K, Tanaka H, Shibayama H, Kohara T, Kosugi S, Kida T, Fuchida S, Miyamoto K, Shindo M, Kobayashi M, Kaneko H, Uoshima N, Matsumura Y, Yoshii Y, Kamitsuji Y, Ishii K, Matsuda M, Takahashi T, Hamada T, Tsudo M, Shimazaki C, Takaori A, Nomura S, Hino M, Matsumura I, Taniwaki M, Kanakura Y
OS-3-92i‹¤“ŻŒ¤‹†j
Voriconazole vs itraconazole for antifungal prophylaxis in patients with GVHD: A randomized trial
Hayashi Y, Kanda Y, Nakamae H, Kanamori H, Ohashi K, Hidaka M, Yano S, Hatanaka K, Kohno A, Moriuchi Y, Ago H, Yamashita T, Hino M, Yamaguchi T, Fukuda T
OS-3-156i‹¤“ŻŒ¤‹†j
HDT with auto-PBSCT for myeloma in the new-agent era: A retrospective analysis of KMF registry
Kosugi S, Ohta K, Tanaka H, Shibayama H, Kohara T, Kida T, Fuchida S, Miyamoto K, Shindo M, Kobayashi M, Kuroda J, Kaneko H, Uoshima N, Matsumura Y, Yoshii Y, Kamitsuji Y, Ishii K, Matsuda M, Takahashi T, Hamada T, Nakatani E, Tsudo M, Shimazaki C, Takaori A, Taniwaki M, Nomura S, Hino M, Matsumura I, Kanakura Y
OS-3-163i‹¤“ŻŒ¤‹†j
Retrospective analysis of 434 symptomatic myeloma cases registered in Kansai Myeloma Forum
Shibayama H, Ohta K, Tanaka H, Kohara T, Kosugi S, Kida T, Fuchida S, Miyamoto K, Shindo M, Kobayashi M, Kuroda J, Kaneko H, Uoshima N, Matsumura Y, Boku S, Kamitsuji Y, Ishii K, Matsuda M, Takahashi T, Hamada T, Nakatani E, Tsudo M, Shimazaki C, Takaori A, Taniwaki M, Nomura S, Hino M, Matsumura I, Kanakura Y
PS-1-85
ƒAƒUƒVƒ`ƒWƒ“ŽĄ—Ă’†‚É‹}Ť”’ŒŒ•a‰ť‚ľ‚˝‚Q—á
•˝ˆä@ŠwiŽl“V‰¤Ž›•a‰@jAâ–{Œb—˜“ށA‹´‘şŒő°Aˆäă“ÖŽiA‘Š–{Ž÷AŽsŒ´O‘PA’†‘O”Ž‹vA“ú–ě‰ë”V
PS-1-100
"myeloid neoplasm with PDGFA rearrangement" with rare chromosomal abnormarity t(14;12)(q12;p13)
Yoshida Mi‘ĺăŽs—§‘‡ˆă—ĂƒZƒ“ƒ^[j, Kanashima H, Nakao T, Ueda H, Manabe M, Murakami A, Tamagawa N, Yorifuji T, Yamane T
PS-1-149
Bendamustine‚É‚ć‚č•nŒŒ‚̉ü‘P‚Ş‚Ý‚ç‚ę‚˝ŠŚ—â‹ĂW‘fÇ‡•šŹƒŠƒ“ƒp‹…ŤƒŠƒ“ƒpŽî‚Ě‚P—á
‹v–ě‰ë’qi‘ĺăŽs—§‘‡ˆă—ĂƒZƒ“ƒ^[jA’†”ö—˛•śA‹T“c—˜–žA‹g“c‘SGA‹ŕ“‡@LAŽRŞF‹v

PS-1-217
“–‰@‚É‚¨‚Ż‚éÄ”­–”‚͓Ť‚̍‚—îŽŇˆŤŤƒŠƒ“ƒpŽî‚ɑ΂ˇ‚égemcitabine‚ĚŽg—pŒoŒą
ˆäă“ÖŽiiŽl“V‰¤Ž›•a‰@jAâ–{Œb—˜“ށAŽsŒ´O‘PA‘Š–{Ž÷A‹´‘şŒő°A“ú–ě‰ë”VA•˝ˆä@Šw

PS-1-225
Angioimmunoblastic T cell lymphoma complicated by endocapillary glomerulonephritis
Nanno S, Nakamae H, Kuwamura Y, Ishimura E, Sakabe M, Inaba A, Koh S, Yoshimura T, Nishimoto M, Hayashi Y, Terada Y, Nakane T, Ohsawa M, Hino M

PS-2-161
Multiple thrombosis with chromosomal abnormalities of t(8;22) in a patient with Burkitt leukemia
Takakuwa Tiś’ˇ‰ď•{’†•a‰@j, Ohkita J, Harada N, Manabe M, Aoyama Y, Kumura T, Mugitani A
PS-2-172
New encouraging treatment strategy: Short cycles BR followed by RT for limited stage transformed FL
Terada Y, Inaba A, Yoshida A, Kuwae Y, Koh H, Nakane T, Nakamae H, Hosono M, Ohsawa M, Shiomi S, Hino M
PS-2-182
T cell rich B cell lymphoma: An unusual case with both T- and B-cell genotypes
Ohta Tiś’ˇ‰ď•{’†•a‰@j, Sugaya Y, Furukawa Y, Mugitani A, Hino M
PS-2-221
Successful treatment for peripheral ATL cells with Mogamulizumab and for lymphnodes with radiation
Harada Niś’ˇ‰ď•{’†•a‰@j, Ohkita J, Takakuwa T, Manabe M, Aoyama Y, Kumura T, Mugitani A
PS-2-233
A case of anaplastic large cell lymphoma relapsed after breast reconstitution with silicone implants
Nakao Ti‘ĺăŽs—§‘‡ˆă—ĂƒZƒ“ƒ^[j, Yoshida M, Kanashima H, Fukushima H, Sugiyama H, Inoue T, Yamane T
PS-2-344
Guillain Barre like syndrome following allogeneic cord blood transplantation in a patient with BPDCN
Nakano Hiś’ˇ‰ď•{’†•a‰@j, Takakuwa T, Harada N, Manabe M, Aoyama Y, Kumura T, Mugitani A

PS-1-61i‹¤“ŻŒ¤‹†j
Preliminary report of a phase 1/2 study of ponatinib in Japanese patients with Ph+ leukemia
Tauchi T, Tojo A, Nakamae H, Kobayashi Y, Okamoto S, Miyamura K, Kyo T, Iwasaki H, Hatake K, Usui N, Narasimhan NI, Hu S, Yanase K, Zhang J, Naoe T, Ohyashiki K

 

‘ć199‰ń“ŕ‰ČŠw‰ď‹ß‹E’n•ű‰ď

‹ž“sA9ŒŽ7“ú
‰EăŽˆ‹Ř—͒ቺ‚Ĺ”­Ç‚ľ‚˝_ŒoƒŠƒ“ƒpŽî‚Ě‚P—á
‹T“c˜a–ži‘ĺăŽs—§‘‡ˆă—ĂƒZƒ“ƒ^[jA’†”ö—˛•ś, A“c‰p–ç, ‹g“c‘SGA‹ŕ“‡@LAŽRŞF‹v
ˆŤŤƒŠƒ“ƒpŽî‚Ş‹^‚í‚ę‚˝ˆÝŠŕ”dŽíŤœ‘ŠŕŽîÇ‚Ě‚P—á
‘ĺ–k~–çiś’ˇ‰ď•{’†•a‰@jA‚ŒK‹PlAŒ´“cŽŒ›AŠÔ•”ŒŤŠ°AÂŽR‘׍FA‹v‘şŠx‰›A”ž’JˆŔ’ĂŽqA‘ž“c’‰M
von Willebrand•a‚ɍ‡•š‚ľ‚˝—‘‘ƒoŒŒ‚Ě‚P—á
‹v‘şŠx‰›iś’ˇ‰ď•{’†•a‰@jAÂŽR‘׍FAŠÔ•”ŒŤŠ°A‚ŒK‹PlAŒ´“cŽŒ›A‘ĺ–k~–çA”ž’JˆŔ’ĂŽq

 

IDWeek 2013

San FranciscoA10ŒŽ2“ú-6“ú
Diagnostic usefulness of a new in situ hybridization method for detection of global bacterial DNA in febrile neutropenia
Aimoto M, Koh, H, Matsuhisa A, Inoue S, Katayama T, Nagasaki J, Sakabe M, Okamura H, Yoshimura T, Inaba A, Koh S, Nanno S, Nishimoto M, Nakashima Y, Hirose A, Nakamae M, Hagihara K, Terada Y, Nakane T, Nakamae H, Hino M

 

‘ć14‰ń “ú–{ŒŸ¸ŒŒ‰tŠw‰ďŠwpW‰ď

“Œ‹žA7ŒŽ27“ú
‘S˜r“]Ŕ der(5;17)(p10;q10)‚𔺂Á‚˝‘˘ŒŒŠíŽîᇠ3—á‚̉đÍ
ŠÔ•”ŒŤŠ°iś’ˇ‰ď•{’†•a‰@j, ‘ĺ–k~–ç, ‚ŒK‹Pl, Œ´“cŽŒ›, ÂŽR‘׍F, ‹v‘şŠx‰›, ‘ž“c’‰M, ŒĂě‰Ŕ‰›, ęm’JˆŔ’ĂŽq

 

‘ć45‰ń“ú–{ˆăŠw‹łˆçŠw‰ď

ç—tA7ŒŽ26“ú-27“ú
ˆăŠw‰Č‚T”Nś‚Ö‚Ě’†SĂ–ŹúŽh‘}“üƒVƒ~ƒ…ƒŒ[ƒVƒ‡ƒ“ŽŔK‚ĚŽŽ‚Ý
’†ŞF•FA‰œ@KŽqA‰Ş“c–žŽqAŽń“Ą‘žˆęA“ú–ě‰ë”VAœA‹´ˆę—T

 

‘ć11‰ń“ú–{—Տ°Žîᇊw‰ď
ĺ‘䍑ŰƒZƒ“ƒ^[Aĺ‘äA‚WŒŽ29“ú-31“ú
G•˝ă”çŠŕ‚đœ‚­isAÄ”­”ńŹ×–E”xŠŕ‚ɑ΂ˇ‚éBevacizumab•š—p‰ťŠw—Ă–@ ‚ĚŒă•űŽ‹“IŒŸ“˘
^ çéŽői‘ĺă•{Ďś‰ď–ě]•a‰@jA“Ą’J —m‘ž˜NAŽR‰Ş V”ށA“ú–ě ‰ë”V
ˆęŽ{Ý‚É‚¨‚Ż‚鏬×–E”xŠŕ‚ɑ΂ˇ‚鉝Šw—Ă–@‚ÉŠÖ‚ˇ‚éŒă•űŽ‹“IŒŸ“˘ .
“Ą’J —m‘ž˜Ni‘ĺă•{Ďś‰ď’†’Ă•a‰@jA^ çéŽő
Reciprocal t(7;11)(p15;p15): A rare but recurrent translocation in acute myeloid leukemia. Report of 3 cases.
ŠÔ•”ŒŤŠ°iś’ˇ‰ď•{’†•a‰@j,‘ĺ–k~–ç, Œ´“cŽŒ›, ‚ŒK‹Pl, ÂŽR‘׍F, ‹v‘şŠx‰›, ‘ž“c’‰M, ŒĂě‰Ŕ‰›, ęm’JˆŔ’ĂŽq

 

‘ć99‰ń‹ß‹EŒŒ‰tŠw’n•ű‰ď
ƒeƒCƒWƒ“ƒz[ƒ‹A6ŒŽ22“ú

––˝ŒŒ‚ĹCD25‰AŤAƒŠƒ“ƒpß‚ĹCD25—zŤ‚đŽŚ‚ľ‚˝ŹlT×–E”’ŒŒ•a^ƒŠƒ“ƒpŽî
‹g“c‘SGi‘ĺăŽs—§‘‡ˆă—ĂƒZƒ“ƒ^[jA‹T“c˜a–žA‹ŕ“‡@LA’†”ö—˛•śAŽRŞF‹vA‚@‹N—Ç
A“c粏‡ŽqAź‰Ş‰ë—Y

EvansÇŒóŒQ”­ÇŒă20”N‚ĚŒo‰ß‚đŒo‚ăN[ƒ€ƒX‰AŤ—nŒŒŤ•nŒŒ‚𔺂¤DLBCL‚đ‡•š‚ľ‚˝‚P—á
‹g‘ş‘ě˜NA’†ŞF•FAˆî—tWŽq
AN@G’jA’†”ö‹gFA’†‘O”Ž‹vA“ú–ě‰ë”VA“Ą–ěŒbŽOAŒüˆä@ŒĺA‹Tč–LŽŔ

“–‰@‚É‚¨‚Ż‚éƒ{ƒ‹ƒeƒ]ƒ~ƒu”牺“Š—^‚ĚŽg—pŒoŒą.
‚ŒK‹Pliś’ˇ‰ď•{’†•a‰@jA‘ĺ–k~–çAŒ´“cŽŒ›
AŠÔ•”ŒŤŠ°AÂŽR‘׍FA‹v‘şŠx‰›A”ž’JˆŔ’ĂŽq

 

‘ć18‰ń “ú–{ŠÉ˜aˆă—ĂŠw‰ďŠwp‘ĺ‰ď

_ŒËA6ŒŽ8“ú
‘˘ŒŒŠíŽîᇂɑ΂ˇ‚éI––Šúf—Ă‚ĚŽŔ‘Ô’˛¸ (’PŽ{ÝŒă•űŽ‹“IŒ¤‹†)
ŠÔ•”ŒŤŠ°iś’ˇ‰ď•{’†•a‰@j, ‘ĺ–k~–ç,‚ŒK‹Pl,Œ´“cŽŒ›,ÂŽR‘׍F,‹v‘şŠx‰›, ‘ž“c’‰M,ŒĂě‰Ŕ‰›,ź‰i^ŽŔ,ęm’JˆŔ’ĂŽq

 

‘ć200‰ń“ú–{“ú–{“ŕ‰ČŠw‰ď‹ß‹E’n•ű‰ď

_ŒËA6ŒŽ8“ú
Azacitidine“Š—^‚É‚ć‚č, ‡•š‚ľ‚˝äXŠŕ‚ĚŽîᇃ}[ƒJ[‚ŞˆęŽž“I ‚ɒቺ‚ľ‚˝ŽĄ—ĂŠÖ˜Aœ‘ˆŮŒ`ŹÇŒóŒQ
ŠÔ•”ŒŤŠ°iś’ˇ‰ď•{’†•a‰@j, ‘ĺ–k~–ç, ‚ŒK‹Pl, Œ´“cŽŒ›, ÂŽR‘׍F, ‹v‘şŠx‰›, ‘ž“c’‰M, ŒĂě‰Ŕ‰›, ęm’JˆŔ’ĂŽq

 

1st International Symposium of Training Plan for Oncology Professionals

‘ĺăA3ŒŽ16“ú
Prognostic value for survival of serum ferritin levels before and after allogeneic hematopoietic cell trasnplantation (HCT)
Koh S

 

‘ć35‰ń“ú–{‘˘ŒŒ×–EˆÚAŠw‰ď‘‰ď
ÎěŒ§—§‰šŠy“°A‹ŕ‘ňA3ŒŽ7“úE9“ú
SY2-5u‘ă‘ֈڐAƒ\[ƒX‚Ě‘I‘đFHLA“K‡ŒŒ‰ƒhƒi[‚Ş‚˘‚Č‚˘‚Ć‚Ť‰˝‚đ‘I‚ԁHv
ˆÚAŒă‚Ě‘ĺ—ĘƒVƒNƒƒzƒXƒtƒ@ƒ~ƒhiCY)‚đ•š—p‚ľ‚˝ŒŒ‰ŽŇŠÔHLAƒnƒvƒˆę’vˆÚA
’†‘O”Ž‹v
WS4-2
“ŻŽí‘˘ŒŒ×–EˆÚAŒăŒŒ‹…ćÐHÇŒóŒQ‚̐f’f
.
N@G’j
P1-130
“Œ‘ĺˆă‰ČŒ¤•űŽŽ“ą“üŒă‚ĚAraC/CY/TBI‚đ‘Oˆ’u‚É—p‚˘‚˝”ńŒŒ‰ä`‘ŃŒŒˆÚAŹŃ‚̕ωť.
ź–{ŒőFA’†‘O”Ž‹vAœAŁ’ŠśA
”~–{—R—˘A’†‘O”ü‰ŔAN@G’jA’†ŞF•FA“ú–ě‰ë”V
P2-208
“–‰@‚É‚¨‚Ż‚éƒXƒeƒƒCƒh’ďRŤEˆË‘śŤ‹}ŤGVHD‚ɑ΂ˇ‚鏭—ĘƒTƒCƒ‚ƒOƒƒuƒŠƒ“iATGjŽĄ—ÐŹŃ
ź–{ŒőFA’†‘O”Ž‹vAœAŁ’ŠśA
”~–{—R—˘A’†‘O”ü‰ŔAN@G’jA’†ŞF•FA“ú–ě‰ë”V

P2-311
“ŻŽí‘˘ŒŒŠ˛×–EˆÚAŒă‚ĚŒŒ´ƒtƒFƒŠƒ`ƒ“’l‚̐„ˆÚ‚Ć—\Œă—\‘Ş‚É‚¨‚Ż‚éd—vŤ.
’†‘O”ü‰ŔA’†‘O”Ž‹vAN@G’jA
’†ŞF•FA’†“ˆN”ŽAœAŁ’ŠśAŽ›“c–FŽ÷A”‹Œ´Œ‰’ʁAź–{ŒőF

P1-060
“–‰@‚É‚¨‚Ż‚é‚Ń‚Ü‚ńŤ‘ĺ×–EŒ^B×–EƒŠƒ“ƒpŽî‚ɑ΂ˇ‚鎊‰Ć––˝ŒŒŠ˛×–EˆÚA•š—p‘ĺ—ʉťŠw—Ă–@
‹ŕ“‡@Li‘ĺăŽs—§‘‡ˆă—ĂƒZƒ“ƒ^[jA‹g“c‘SGAŹě‹g•FA’†”ö—˛•śAˆäă@Œ’AŽRŞF‹v
P1-027
“ŻŽíˆÚAŒăÄ”­‚ɑ΂ˇ‚éÄˆÚA‚ĚŒoŒą.
ŠÔ•”ŒŤŠ°iś’ˇ‰ď•{’†•a‰@jAÂŽR‘׍FA”¨’†ˆęśA‹›“ˆM•FAă’Ň—R—˘A‹gˆä—R”üA‹Ę’urŽĄ

OS-2
HLA6RŒ´“K‡ŒŒ‰AHLA1RŒ´•s“K‡ŒŒ‰AHLA8/8ƒAƒŠƒ‹“K‡”ńŒŒ‰ŽŇŠÔˆÚA‚Ě’PŽ{Ý‚É‚¨‚Ż‚éˆÚAŹŃ‚Ě”äŠrŒŸ“˘
—с@—ÇŽ÷i‘—§‚Ş‚ńŒ¤‹†ƒZƒ“ƒ^[’†‰›•a‰@jA“Ą@d•vA“c“‡ŒŚŽqAˆÉ“Ą@•ŕAˆäă–žˆĐA‚–ě‹vmŽqA‹´–{Ž‰ŔAă“c—ş‰îA—ł–ě^—YA^‰Ćhˆę˜YA‰Ť’†Œh“ńA•ŕVĘŽqA‹ŕ@ŹŒłA“c–ěč—˛“ńA•˝‰Ć—E“ńAŽR‰ş‘ě–çA•Ÿ“c—˛_

ŠĹP1-42
ƒŠƒnƒrƒŠƒpƒ“ƒtƒŒƒbƒgěŹ‚É‚ć‚éŠĹŒěŽt‚ĚˆÓŽŻ‚̕ωť.
‘şă˜a‘ăAXě”ސç‘ăAV‘î”ü‰ŔA‹{–{’qŽqAˆîč…“ŢŽq

2012”N

54th American Society of Hematology
AtlantaADec 8-11
1187
Tolerated, Low-Dose Deferasirox : Successful Three Cases of Aplastic Anemia and 34 Cases of MDS

Hirai MiŽl“V‰¤Ž›•a‰@j, Yamamura R, Nakamae H, Terada Y, Inoue A, Hashimura M, Ichihara H, Sakamoto E, Hino M

1628[‹¤“ŻŒ¤‹†]
Short Cycle of Immunochemotherapy Followed by Radiation Therapy Compared with Prolonged Cycles of Immunochemotherapy for Localized DLBCL : The Osaka Lymphoma Study Group (OLSG) Retrospective Analysis

Terada Y, Take H, Shibayama H, Hashimoto K, Kuwayama M, Fujii N, Azenishi Y, Maeda Y, Yamagami T, Uoshima N, Tsukaguchi M, Semba O, Misui H, Ueda S, Soma T, Nakagawa M, Matuda M, Urase F, Kiyoi T, Yoshida H, Sugahara H, Yamashita K, Tominaga N, Kubota T, Arima N, Mori S, Tamaki T, Okamoto T, Anzai N, Akasaka H, Tabata R, Ikeda J, Wada N, Aozasa K, Hino M

1037[‹¤“ŻŒ¤‹†]
Cefozoplan, Meropenem, or Imipenem-Cilastatin Versus Cefepime As an Empirical Therapy in High Risk Febrile Neutropenic Adult Patients: A Multicenter Prospective Randomized Trial

Nakane T, Tamaki T, Tamura K, Yoshida I, Fukushima T, Tatsumi Y, Nakagawa Y, Hatanaka K, Takahashi T, Akiyama N, Tanimoto M, Ohyashiki K, Urabe A, Masaoka T, Kanamaru A

3095[‹¤“ŻŒ¤‹†]
Older Age Increases Non-Relapse Mortality in Patients with Grade II–IV Acute Gvhd After Allogeneic Hematopoietic Cell Transplantation: A Retrospective Analysis of the Japanese Trump Database

Nakane T, Fukuda T, Kanda J, Taniguchi S, Eto T, Ohashi K, Morishima Y, Nagamura T, Sakamaki H, Atsuta Y, Murata M

3046[‹¤“ŻŒ¤‹†]
Clinical Factors Predicting the Response of Acute Graft-Versus-Host Disease to Corticosteroid Therapy

Murata M, Nakasone H, Kanda J, Nakane T, Furukawa T, Fukuda T, Taniguchi S, Mori T, Eto T, Morishima Y, Nagamura-Inoue T, Yabe H, Atsuta Y, Sakamaki H, Suzuki R

3027[‹¤“ŻŒ¤‹†]
Reduced-Intensity Versus Myeloablative Conditioning Allogeneic Hematopoietic Stem Cell Transplantation for Patients Aged Over 45 Years with Acute Lymphoblastic Leukemia (ALL) in Remission: A Study From the ALL Working Group of the Japan Society for Hematopoietic Cell Transplantation (JSHCT)

Tanaka J, Kanamori H, Nishiwaki S, Ohashi K, Taniguchi S, Nakamae H, Katayama Y, Morishima Y, Suzuki R, Kato K, Sakamaki H, Nishimoto N, Masauzi N

 

‘ć199‰ń“ŕ‰ČŠw‰ď‹ß‹E’n•ű‰ď

‘ĺăA12ŒŽ8“ú
ƒ‚ƒKƒ€ƒŠƒYƒ}ƒuťÜiƒ|ƒeƒŠƒWƒIj‚Ě“–‰@‚Ĺ‚ĚŽg—pó‹ľ
Œ´“cŽŒ›i•{’†•a‰@jA’†–ě—TŽj, ‚ŒK‹Pl, ‰Ş–{Gˆę˜Y, ŠÔ•”ŒŤŠ°AÂŽR‘׍F, ‹v‘şŠx‰›, ęm’JˆŔ’ĂŽq

 

‘ć98‰ń‹ß‹EŒŒ‰tŠw’n•ű‰ď
‹ž“sƒeƒ‹ƒTA12ŒŽ1“ú

Œ¸—ĘR-Bendamustine‚É‚ÄŠ°‰đ‚Ş“ž‚ç‚ę‚˝‰‰ÄŽĄ—Ă’ďRŤ‚¨‚ć‚ŃÄ”­mantle cell lymphoma.
•SŁ@‘ĺiJR‘ĺă“S“š•a‰@jA›–ěˆŔŠěA‚@‹N—Ç
A˜a“cŸ–ç

ƒ{ƒ‹ƒeƒ]ƒ~ƒu‚đ”牺“Š—^‚ľ‚˝IgDŒ^‘˝”­Ťœ‘Žî‚Ě‚PÇ—á.
‚ŒK‹PlAŒ´“cŽŒ›A’†–ě—TŽjA‰Ş–{Gˆę˜YAŠÔ•”ŒŤŠ°A‹v‘şŠx‰›A”ž’JˆŔ’ĂŽq
’†••a•Ď‚É”ş‚¤”A•öÇ‚đ‡•š‚ľ‚˝3q21q26‚¨‚ć‚Ń7őF‘ĚˆŮí‚đ—L‚ˇ‚éAML‚Ěˆę—á
“ě–ě@’qA”‹Œ´Œ‰’ʁAâ•”^“Ţ”üAˆî—tWŽqAź–{ŒőFAN@G’jA’†‘O”Ž‹vA“ú–ě‰ë”VA‰i“c—F‹MA‰ş–ě‘ž˜Y

‹H‚ȐőF‘ĚˆŮít(4;12)(q12;p13)‚đ—L‚ˇ‚鍜‘ˆŮŒ`ŹÇŒóŒQ‚Ě‚P—á
‹g“c‘SGAŹě‹g•FA‹ŕ“‡@LA’†”ö—˛•śAŽRŞF‹vAŠÔ•”ŒŤŠ°

 

‘ć59‰ń“ú–{—Տ°ŒŸ¸ˆăŠw‰ď
‹ž“s‘—§‘Ű‰ďŠŮA11ŒŽ29“ú-12ŒŽ2“ú

O-001
ŒŒ’†ƒCƒ“ƒXƒŠƒ“‘Ş’č‚É‚¨‚Ż‚é25“ƒ|ƒŠƒGƒ`ƒŒƒ“ƒOƒŠƒR[ƒ‹’ž“a–@‚ĚŒŸ“˘.
ěŒ´GŒbA•E–ě‘×”ŽA‹v•Ű“c@_A’†‘O”ü‰ŔA“ú–ě‰ë”V

O-180
“ŻŽí‘˘ŒŒŠ˛×–EˆÚA‘O‚¨‚ć‚сAˆÚAŒă‚ĚŒŒ´ƒtƒFƒŠƒ`ƒ“’l‚Ş—\Œă‚É—^‚Ś‚é‰e‹ż‚̕“IŒŸ“˘.
’†‘O”ü‰ŔA’†‘O”Ž‹vAN@G’jA’†ŞF•FAœAŁ’ŠśA’†“ˆN”ŽA“ú–ě‰ë”V
O-200
ƒGƒ‰ƒXƒgƒOƒ‰ƒtƒB[(Fibroscan502)‚đ—p‚˘‚˝–ŤŠĚŽžŠł‚̐i“W“x•]‰ż‚ĚŒŸ“˘
ŽR‰ş^—ŽqA‹´–{‚ ‚ä‚݁A•“cßŽqA•“c@łA“Ąˆä‰pŽ÷AXě_ˆŔA’†‘O”ü‰ŔA•E–ě‘×”ŽA“ú–ě‰ë”V

O-361
ĚŒŒŽx‰‡ƒVƒXƒeƒ€ForYou‚đ—p‚˘‚˝ĚŒŒŽžƒgƒ‰ƒuƒ‹‰ń”đ‚Ö‚ĚŽć‚č‘g‚݂ɂ‚˘‚Ä
“ĄŒ´–qŽqA…Œ´—SŽŸAĄˆäd—ǁA•E–ě‘×”ŽA’†‘O”ü‰ŔA“ú–ě‰ë”V

 

‘ć50‰ń“ú–{ŠŕŽĄ—ĂŠw‰ďŠwpW‰ď
‰Ą•lA10ŒŽ25“ú
H“šŠŕ‚ɑ΂ˇ‚épŒă‰ťŠw—Ă–@Œă‚É”­Ç‚ľ‚˝ŽĄ—ĂŠÖ˜A‹}Ťœ‘Ť”’ŒŒ•a.
ŠÔ•”ŒŤŠ°i•{’†•a‰@jAŹâ‹ŃŽi, Œ´“cŽŒ›, ’†–ě—TŽj, ‚ŒK‹Pl, ‰Ş–{Gˆę˜Y, ÂŽR‘׍F, ‹v‘şŠx‰›, ęm’JˆŔ’ĂŽq

 

‘ć74‰ń“ú–{ŒŒ‰tŠw‰ď‘‰ď
‹ž“s‘Ű‰ďŠŮA‹ž“sA10ŒŽ19“úE21“ú

OS-1-50i‹¤“ŻŒ¤‹†j
Ä”­ƒnƒCƒŠƒXƒN“ŻŽí‘˘ŒŒŠ˛×–EˆÚAŒăŠłŽŇ‚ɑ΂ˇ‚éWT1ƒyƒvƒ`ƒhƒƒNƒ`ƒ“‘ć‚P‘Š—Տ°ŽŽŒą
•Űĺ’ź‹Bi‘ĺă‘ĺŠwjA‘O“c“NśA•Ÿ“‡Œ’‘ž˜YAX–{‘n˘ŽqA’†“c@A’†]‹gŠóAź“cƒKA’Řˆäş”ŽA‹ß“Ą’‰ˆęA–ĺ˜e‘ĽŒőA“ú–ě‰ë”VA”ö˜H—S‰îA‰Ş@–FOAŒFƒm‹˝@~A‹ŕ‘q@÷A™ŽRŽĄ•v

OS-1-74
‘˝”­Ťœ‘Žî‚Ě•aŠúf’f‚É‚¨‚Ż‚éFDG-PET/CT‚Ě—L—pŤ.
ŽR‘ş—ş‰îiĎś‰ď’†’Ă•a‰@jAŁ‰YGâMAr–؁@‘ńA“Ą’J—m‘ž˜NA•‰ŞNMA
^@çéŽőAŹâ‚ł‚¨‚čA‰Ş‘şŒő‰pA‘ž“cŒ’‰î

OS-1-135i‹¤“ŻŒ¤‹†j
Cord blood transplantation for adult T-cell leukemia/lymphoma: The JSHCT WG study.
Kato Ki‹ăB‘ĺŠwj, Cho I, Wake A, Uike N, Taniguchi S, Moriuchi Y, Miyazaki Y, Hino M, Akashi K, Sakamaki H, Kato K, Suzuki R, Yamanaka T, Utsunomiya A

OS-1-146i‹¤“ŻŒ¤‹†j
DLI for 1st hematologic relapse of AML: A retrospective nationwide analysis by JSHCT Adult AML WG.
Takami Ai‹ŕ‘ň‘ĺŠwj, Fukuda T, Miyazaki Y, Hino M, 1kanamori H, Morishima Y, Tanaka J, Atsuta Y, Kanda Y, Yamaguchi T, Nakao S, Kuwatsuka Y, Yano S, Yokoyama H
OS-1-169(‹¤“ŻŒ¤‹†)
Randomized controlled study of the efficacy of 3 antibiotics for the empiric therapy of FN patients.
Hatanaka Ki˜a‰ĚŽRˆă‰Č‘ĺŠwj, Nakane T, Hino M, Tamaki T, Takada T, Yoshida I, Fukushima T, Tatsumi Y, Tanimoto M, Urabe A, Masaoka T, Kanamaru A, Tamura K
PS-1-67
AML (M7) from 5q-syndrome with JAK2 mutation achieved complete remission by standard chemotherapy.
Okamoto Si•{’†•a‰@j, Harada N, Nakano H, Takakuwa T, Manabe M, Aoyama Y, Kumura T, Ohta T, Furukawa Y, Mugitani A
PS-1-77
­—ĘƒVƒ^ƒ‰ƒrƒ“+ƒAƒNƒ‰ƒ‹ƒrƒVƒ“+ƒAƒUƒVƒ`ƒWƒ“—Ă–@‚Ĺ—ÇD‚ČŒo‰ß‚ÉŽŠ‚Á‚˝–Ťœ‘’P‹…Ť”’ŒŒ•a‚Ě2—á.
‹´‘şŒő°iŽl“V‰¤Ž›•a‰@jAˆäă“ÖŽiAŽsŒ´O‘PAâ–{Œb—˜“ށA•˝ˆä@ŠwA“ú–ě‰ë”V

PS-1-81
FISH of blood and buccal mucosa is useful to identify constitutional trisomy 8 mosaicism in +8 MDS.
Takeoka YiĎś‰ď’†’Ă•a‰@j, Yamamura R, Kosaka S, Fujitani Y, Araki T, Koh G, Ohta K

PS-1-84
Acute fibrinous and organizing pneumonia (AFOP) associated with MDS complicated by hemophagocytosis.
Nanno S, Koh H, Manabe M, Yoshida M, Okamura H, Bingo M, Koh S, Yoshimura T, Inaba A, Aimoto M, Nishimoto M, Hayashi Y, Hirose A, Nakamae M, Hagihara K, Nakao Y, Nakane T, Tarada Y, Nakamae H, Ohsawa M, Hino M

PS-1-194
R-CHOP compared with R-CHOP plus RT for localized DLBCL: A retrospective OLSG study.
Terada Y, Take H, Shibayama H, Hashimoto K, Kuwayama M, FujiiN, Azenishi Y, Maeda Y, Yamagami T, Uoshima N, Tsukaguchi M, Semba O, Mitsui H, Ueda S, Soma T,
Matsuda M, Urase F, Kiyoi T, Yoshida H, Sugahara H, Yamashita K, Tominaga N, Kubota T, Arima N, Mori S, Tamaki T, Okamoto T, Wada N, Aozasa K, Hino M

PS-1-300
Chronic GVHD-related polymyositis and hepatitis that occurred subsequent to a bruise of the thigh.
Koh S
Akoh H, Sakabe M, Yoshida M, Okamura H, Inaba A, Bingo M, Yoshimura T, Nanno S, Nishimoto M, Hayashi Y, Hirose A, Nakamae M, Hagihara K, Nakane T, Terada Y, Nakamae H, Ohsawa M, Hino M

PS-1-326i‹¤“ŻŒ¤‹†j
A survey of vaccination after allogeneic hematopoietic stem cell transplantation in Hanwa Area.
Yakushijin Ki_ŒË‘ĺŠwj, Fuji S, Aoyama Y,
Uoshima N, Kamitsuji Y, Tamaki H, Nakane T, Hatanaka K, Mathui K, Yonetani N, Matsuoka H
PS-1-339
Trends in the antibiotic-susceptibility of pathogens of bacteria in the hematology department.
Fujitani YiĎś‰ď’†’Ă•a‰@j, Takahashi M, Araki T, Takeoka Y, Koh G, Kosaka S, Yamamura R, Ohta K
OS-2-134i‹¤“ŻŒ¤‹†j
Nilotinib in CML patients with suboptimal response to imatinib: Early results from the SENSOR study.
Miyamoto Mi‹ăB‘ĺŠwj, Miyamura K, Kurokawa M, Tanimoto M, Yamamoto K, Taniwaki M, Kimura S, Ohyashiki K, Kawaguchi T, Matsumura I, Hata T, Tsurumi H, Naoe T, Hino M, Tadokoro S, Meguro K, Hyodo H, Yamamoto M, Kubo K, Tsukada J, Kondo M, Amagasaki T, Kawahara E, Yanada M

OS-2-137i‹¤“ŻŒ¤‹†j
Nilotinib vs imatinib for newly-diagnosed CML-CP:36-month update with PK analysis in Japanese pts.
Kanda Yié‹Ęˆă‰Č‘ĺŠwj, Nakamae H, Shibayama H, Kurokawa M, Nakaseko C, Fukuda T, Nagai T, Ohnishi K, Mathumura I, Mathuda A, Amagasaki T, Kojo N, Kawahara E

PS-2-64
ƒAƒUƒVƒ`ƒWƒ“ŽĄ—Ă‚đs‚Á‚˝24Ç—á.
•˝ˆä@ŠwiŽl“V‰¤Ž›•a‰@jA•SŁ@‘ĺA‹´‘şŒő°Aˆäă“ÖŽiAŽsŒ´O‘PAâ–{Œb—˜“ށA–p@‹ÎAA‚@‹N—ǁA’†”ö‹gFA”‹Œ´Œ‰’ʁA’†ŞF•FAŽRŞF‹vA’†‘O”Ž‹vA“ú–ě‰ë”V
PS-2-104
A rare der(Y)t(Y;1)(q12;q12) in a patient with post-polycythemic myelofibrosis: A case presentation.
Mabane Mi•{’†•a‰@j, Harada N, Nakano H, Takakuwa T, Okamoto S, Aoyama Y, Kumura T, Ohta K, Furukawa Y, Mugitani A
PS-2-142
EBV-associated T/NK cell lymphoma after radioimmunotherapy and Rituximab for follicularlymphoma.
Mugitani Ai•{’†•a‰@j, Harada N, Nakano H, Takakuwa T, Okamoto S, Manabe M, Aoyama Y, Kumura T, Ohta K, Furukawa Y, Hanai J, Inoue T
PS-2-279
A case of chronic pulumonary hypertension caused by pulmonary microembolism in patient of ET.
Koh GiĎś‰ď’†’Ă•a‰@j, Fujitani Y, Takeoka Y, Kosaka S, Yamanura R, Ohta K
OS-3-34
Older age is an influencing factor in increased NRM after aGVHD: A retrospective analysis from TRUMP
Nakane T, Fukuda T, Kanda J, Taniguchi S, Eto T, Ohashi K, Morishima Y, Nagamura T, Sakamaki H, Atsuta Y, Murata M

SH-45
Azacitidine‚Ć‘ź‚̍RŠŕÜ‚Ć‚Ě•š—p‚Ş‘tŒ÷‚ľ‚˝MDS overt AML‚Ě1Ç—á
ˆäă“ÖŽiiŽl“V‰¤Ž›•a‰@jAâ–{Œb—˜“ށAŽsŒ´O‘PA‹´‘şŒő°A•˝ˆä@ŠwA“ú–ě‰ë”V

 

‘ć17‰ń“ú–{ŠÉ˜aˆă—ĂŠw‰ďŠwp‘ĺ‰ď
_ŒËA6ŒŽ23“ú
Šç–Ę‚ĚŽîᎌ`ŹŤ•a•Ď‚ɑ΂ľ‚ÄMohs“îp‚đŽg—p‚ˇ‚é‚ą‚Ć‚É‚ć‚č, ‰ťŠw—Ă–@ŠúŠÔ’†‚̏ǏóŠÉ˜a‚މ”\‚Ĺ‚ ‚Á‚˝ˆŤŤƒŠƒ“ƒpŽîÇ—á.
ŠÔ•”ŒŤŠ°i•{’†•a‰@jA,ăŒ´TŽi, •˝“‡ĘŽq, ‹g‰ŞŒ[Žq, ‰Ş–{Gˆę˜Y, ÂŽR‘׍F, ‹v‘şŠx‰›, ‘ž“c’‰M, ź‰i^ŽŔ, ęm’JˆŔ’ĂŽq

 

52nd Interscience Conference on Antimicrobial Agents and Chemotherapy


San FranciscoASep 9-12

D-1402
Usefulness of Procalcitonin and C-Reactive Protein as Diagnostic Markers of Bacterial Infection in Febrile Neutropenia

Aimoto M, Koh H, Bingo M, Yoshida M, Okamura H, Yoshimura T, Inaba A, Koh S, Nanno S, Nishimoto M, Hayashi Y, Hirose A, Nakamae M, Hagihara K, Terada Y, Nakane T, Nakamae H, Hino M

 

‘ć198‰ń“ú–{“ŕ‰ČŠw‰ď‹ß‹E’n•ű‰ď
‹ž“sƒeƒ‹‚łA‹ž“sA9ŒŽ8“ú
‹š‘BMALTƒŠƒ“ƒpŽî‚Ě1—á.
’†”ö—˛•śi‘ĺăŽs—§‘‡ˆă—ĂƒZƒ“ƒ^[jA‹g“c‘SGAŹě‹g•FA‹ŕ“‡@LAŽRŞF‹vA•Ÿ“‡—TŽqAˆäă@Œ’

 

16th International Congress of Dietetics


SydneyASep 5-8

Practical Approach Conducted by NST to Standardize Diet Guidelines for Immunosuppressed Patients

Hanayama Y, Fujimoto H, Tamehira A, Takaki S, Nishimoto M

 

‘ć13‰ń“ú–{ŒŸ¸ŒŒ‰tŠw‰ď
‚’ÎŒť‘ăŒ€ęA‘ĺăA7ŒŽ28“úE29“ú
őF‘ĚˆŮíder(5;19)(p10;q10)‚𔺂Á‚˝AML2—á‚ĚŒŸ“˘
ŠÔ•”ŒŤŠ°i•{’†•a‰@jA‚ŒK‹PlA’†–ě—TŽjAŒ´“cŽŒ›A‰Ş–{Gˆę˜YAÂŽR‘׍FA‹v‘şŠx‰›A‘ž“c’‰MAŒĂě‰Ŕ‰›A”ž’JˆŔ’ĂŽq

 

‘ć10‰ń“ú–{—Տ°Žîᇊw‰ď
‘ĺă‘Ű‰ď‹cęA‘ĺăA7ŒŽ26“úE28“ú

ŠÖßƒŠƒEƒ}ƒ`‚ĚŽĄ—Ă’†‚ÉŒz•”ƒŠƒ“ƒpßŽî’Ł‚Ĺ”­Ç‚ľŽĄ—Ă‚Ě’†Ž~‚É‚ć‚Á‚ÄˆęŽž“I‚ÉŽîᇂ̎Š‘R‘ޏk‚ŞŠĎŽ@‚ł‚ę‚˝Œ´”­•s–ž‘BŠŕ.
“Ą’J—m‘ž˜NiĎś‰ď’†’Ă•a‰@jA^@çéŽőAŽR‘ş—ş‰îA•‰ŞNMAŹâ‚ł‚¨‚č
Ar–؁@‘ńA‘ž“cŒ’‰îA“ú–ě‰ë”V

Žq‹{čňŠŕŽĄ—Ă10”NŒă‚É”­ś‚ľ‰ťŠw—Ă–@‚Ş—LŒř‚Ĺ‚ ‚Á‚˝‰“Šu“]ˆÚ‚𔺂¤ăč–ĺŠŕ‚ĚÇ—á.
^@çéŽőiĎś‰ď’†’Ă•a‰@jA“Ą’J —m‘ž˜NAŽR‘ş —ş‰îA•‰Ş NMAŹă ‚ł‚¨‚čAr–Ř ‘ńA‘ĺ“c Œ’ ‰îA“ú–ě ‰ë”V

’ź’°Šŕ‚ɑ΂ˇ‚éS-‚P—Ă–@Œă‚É”­Ç‚ľ‚˝–Ťœ‘Ť”’ŒŒ•a.
ŠÔ•”ŒŤŠ°i•{’†•a‰@jAź‹F•śAŒ´“cŽŒ›A’†–ě—TŽjA‚ŒK‹PlA‰Ş–{Gˆę˜YAÂŽR‘׍FA‹v‘şŠx‰›A”ž’JˆŔ’ĂŽq

 

‘ć97‰ń‹ß‹EŒŒ‰tŠw’n•ű‰ď
ƒeƒCƒWƒ“ƒz[ƒ‹A6ŒŽ23“ú

20
Žîᇕö‰óÇŒóŒQDIC‚ɑ΂ľ‚ÄŠŁ‘‡lƒtƒBƒuƒŠƒmƒQƒ“ťÜ‚ŞPhALL.
ÂŽR‘׍Fi•{’†•a‰@jA‰Ş–{Gˆę˜YAŠÔ•”ŒŤŠ°A‹v‘şŠx‰›A”ž’JˆŔ’ĂŽq

31
SMILE—Ă–@‚ĹCR‚đ“ž‚é‚ŕ‚ť‚ĚŒăƒAƒOƒŒƒbƒVƒuNK×–E”’ŒŒ•a—l‚Ě•a‘Ô‚đ’ć‚ľ‚˝ăŠ{Ž•“÷Œ´”­NK/T×–EƒŠƒ“ƒpŽî‚Ě‚P—á.
•SŁ@‘ĺi‘ĺă“S“š•a‰@jA›–ěˆŔŠěA‚@‹N—ǁA˜a“cŸ–çAÎ“c‰p˜a
38
ˆÚAŒă”ÄŒŒ‹…Œ¸­‚đ—ˆ‚ľ‚˝œ‘ƒpƒ‹ƒ{ƒEƒCƒ‹ƒXŠ´őÇ‚Ě‚P—á
‹g‘ş‘ě˜NA’†ŞF•FA‰Ş‘ş_ŽjAˆî—tWŽqAN@Žj˜NA“ě–ě@’qAź–{ŒőFAN@G’jA’†‘O”Ž‹vA“ú–ě‰ë”V

‹łˆçu‰‰
CMLf—Ă‚É‚¨‚Ż‚éĹV‚Ě˜b‘č
’†‘O”Ž‹v

 

‘ć197‰ń“ú–{“ŕ‰ČŠw‰ď‹ß‹E’n•ű‰ď
_ŒË‘Ű‰ď‹cęA_ŒËA6ŒŽ9“ú
34
Morganella MorganiiŒŒ—ŹŠ´ő‚ć‚čSŠO–Œ‰Š‚đ”­Ç‚ľSƒ^ƒ“ƒ|ƒi[ƒf‚đ’ć‚ľ‚˝‘˝”­Ťœ‘Žî‚Ě‚P—á.
Źě‹g•Fi‘ĺăŽs—§‘‡ˆă—ĂƒZƒ“ƒ^[jA‹ŕ“‡@LA’†”ö—˛•śAŽRŞF‹v
138
“ŻŽí‘˘ŒŒŠ˛×–EˆÚAiallo-HSCTjŒă‚̏ŠˆŕCIPS(calcineurin-inhibitor induced pain syndrome)‚Ě2—á.
’†”ö‹gFA‰Ş‘ş_ŽjAź–{ŒőFA—с@—ÇŽ÷AN@G’jA’†ŞF•FA’†‘O”Ž‹vA“ú–ě‰ë”V

146
“ű–[‚É•a•Ď‚Ş‚Ý‚ç‚ę‚˝ALK‰AŤ–˘•Ş‰ť‘ĺ×–EŒ^ƒŠƒ“ƒpŽî
ŠÔ•”ŒŤŠ°i•{’†•a‰@jA‚ŒK‹PlA’†–ě—TŽjAŒ´“cŽŒ›A‰Ş–{Gˆę˜YAÂŽR‘׍FA‹v‘şŠx‰›A‘ž“c’‰MAŒĂě‰Ŕ‰›A”ž’JˆŔ’ĂŽq

 

‘ć59‰ń“ú–{—AŒŒE×–E—Ă–@Šw‰ď
‹ž‰¤ƒvƒ‰ƒUA“Œ‹žA4ŒŽ14“úE16“ú
—⎎ŽŠŒČR‘Ě‚Ć“ŻŽíR‘Ě‚đ•š‚šŽ‚‚˝‚ß“K‡ŒŒ‚Ě‘I‘đ‚É‹ę—ś‚ľ‚˝1Ç—á.
•“c^ˆęi—AŒŒ•”jAź–{—L‹IA”ö“ˆŹŽqA“Ą–ěŒhŽOA“cŽçş”ŽA‰Í“c‘Ľ•śA‰Ş‘ş_ŽjA“ú–ě‰ë”V

 

‘ć109‰ń“ú–{“ŕ‰ČŠw‰ďu‰‰‰ď
‚Ý‚â‚ą‚ß‚Á‚šA‹ž“sA4ŒŽ13“úE15“ú
643
”­ěŤ–éŠÔŒŒF‘f”AÇŠłŽŇ‚ɑ΂ˇ‚é“–‰@‚¨‚ć‚ŃŠÖ˜AŽ{Ý‚Ĺ‚ĚƒGƒNƒŠƒYƒ}ƒu“Š—^ŒoŒą.
N@Žj˜NA’†ŞF•FAÂŽR‘׍FAŽR‘ş—ş‰îA‘ž“cŒ’‰îA‹ŕ“‡@LAˆäă“ÖŽiA“ú–ě‰ë”V

 

‘ć27‰ń“ú–{Ă–ŹŒo’°‰h—{Šw‰ď
_ŒË‘Ű‰ď‹cęA_ŒËA2ŒŽ23“úE24“ú
643
ä`‘ŃŒŒˆÚAŠłŽŇ‚ɑ΂ľ‚ăOƒ‹ƒ^ƒ~ƒ“ťÜ‚Ě•ž—p‚Ş—LŒř‚Ĺ‚ ‚Á‚˝1—á.
ˆäăŽŽqAˆ×•˝ˆşŽqAĄˆä—ÁAŠâŒŠ–žŽqAˆîč…“ŢŽqA‰ÔŽR‰ŔŽqA“Ą–{_’Aź–{ŒőFA’†ŞF•FA“ú–ě‰ë”V

 

‘ć34‰ń“ú–{‘˘ŒŒ×–EˆÚAŠw‰ď‘‰ď
‘ĺă‘Ű‰ď‹cęA‘ĺăA2ŒŽ24“úE25“ú
YS1-6iĹ—DGŒű‰‰Üj
ƒCƒ“ƒtƒ‹ƒGƒ“ƒUBŒ^RŒ´—zŤ‚ŞŽ‘ą‚ľ‚˝ó‘Ô‚Ĺ”ńŒŒ‰“ŻŽíœ‘ˆÚA‚đŽ{s‚ľ‚˝AML with MRC‚Ě‚P—á.
â•”^“Ţ”üA‰Ş‘ş_ŽjA‹g“c‘SGAN@G’jA”őŒă^“oAˆî—tWŽqA“ě–ě@’qA‘Š–{Ž÷Aź–{ŒőFA—с@—ÇŽ÷AŠÔ•”ŒŤŠ°A’†ŞF•FAœAŁ’ŠśA’†‘O”ü‰ŔAŽ›“c–FŽ÷A”‹Œ´Œ‰’ʁA’†”ö‹gFA’†‘O”Ž‹vA“ú–ě‰ë”V
OS1-077
“ŻŽí‘˘ŒŒŠ˛×–EˆÚAŒă–ŤŠú‚É‚¨‚Ż‚éS‹@”\áŠQƒŠƒXƒNˆöŽq‚Ě•]‰ż.
ź–{ŒőFA’†‘O”Ž‹vA’†ŞF•FA
N@G’jA—с@—ÇŽ÷A’†‘O”ü‰ŔA‹g“c‘SGA”őŒă^“oA‰Ş‘ş_ŽjA‘Š–{Ž÷AŠÔ•”ŒŤŠ°A‹g‘ş‘ě˜NAˆî—tWŽqA“ě–ě@’qAœAŁ’ŠśA”‹Œ´Œ‰’ʁA’†”ö‹gFAŽ›“c–FŽ÷A“ú–ě‰ë”V
OS1-083
“ŻŽí‘˘ŒŒŠ˛×–EˆÚAŒăDŽ_‹…‘‘˝‚¨‚ć‚Ń‚ť‚Ě’ö“x‚ވڐA—\Œă‚Ö—^‚Ś‚é‰e‹ż‚ɂ‚˘‚Ä‚ĚŒŸ“˘.
’†ŞF•FA’†‘O”Ž‹vAœAŁ’ŠśA
N@G’jA’†‘O”ü‰ŔA—с@—ÇŽ÷Aź–{ŒőFA‹g“c‘SGA”őŒă^“oA‰Ş‘ş_ŽjA”~–{—R—˘Aˆî—tWŽqA‹g‘ş‘ě˜NAŽsŒ´O‘PA“ě–ě@’qA”‹Œ´Œ‰’ʁAŽ›“c–FŽ÷A“ú–ě‰ë”V

OS2-050
”ńŒŒ‰ŽŇ––˝ŒŒŠ˛×–EĚŽć‚É‚¨‚Ż‚éŽ{Ý“ŕCTC‚Ćƒoƒ“ƒNƒR[ƒfƒBƒl[ƒ^[‚Ě‹Ś“­‚ĚŽŽ‚Ý.
”~–{—R—˘A’†‘O”ü‰ŔAœAŁ’Šś
A”óŒű’qŽqA•ĐŽR‹MŽqA’Ă“c@ňA’†ŞF•FA“ú–ě‰ë”V

PS-A-048
‘˘ŒŒ×–EˆÚAŒă‚Ě–ŤGVHD‚É‚ć‚éŠp–ŒúEE’×ᇂɑ΂ľ‚Ä•\‘wŠp–ŒˆÚA‚ĆŽŠŒČŒŒ´“_Šá‚Ş—LŒř‚Ĺ‚ ‚Á‚˝ˆę—á.
‹g“c‘SGAN@G’jA‰Ş‘ş_ŽjA”őŒă^“oAˆî—tWŽqA“ě–ě@’qA‘Š–{Ž÷Aź–{ŒőFA—с@—ÇŽ÷AŠÔ•”ŒŤŠ°A’†ŞF•FAœAŁ’ŠśA’†‘O”ü‰ŔAŽ›“c–FŽ÷A”‹Œ´Œ‰’ʁA’†”ö‹gFA’†‘O”Ž‹vA•Ä“c@ĺA”’–Ř–M•FA“ú–ě‰ë”V
PS-B-071
POEMSÇŒóŒQ‚ÉŽŠ‰Ć––˝ŒŒŠ˛×–EˆÚA‚đŽ{s‚ľ‚˝ˆę—á.
‹ŕ“‡@Li‘ĺăŽs—§‘‡ˆă—ĂƒZƒ“ƒ^[jAŹě‹g•FAŒüˆä@ŒĺA’†”ö—˛•śA’†–ě@’qAˆäă@Œ’AŽRŞF‹v

ŠĹPS-A-060
‘˘ŒŒ×–EˆÚAŠłŽŇ‚ɑ΂ˇ‚鎕‰Č˜AŒgƒVƒXƒeƒ€‚̍\’z.
™ŽRK—é
Aź–{“TŽqAź‰Y—TŽqAŠâŒŠ–žŽqAŽR–ě–őŽqA‹{–{’qŽqAˆîč…“ŢŽqA“ú–ě‰ë”V

 

2011”N

‘ć196‰ń“ú–{“ŕ‰ČŠw‰ď‹ß‹E’n•ű‰ď
‹ž“sƒeƒ‹ƒTA‹ž“sA12ŒŽ17“ú
‘Ζƒáƒ‚É‚Ä”­Ç‚ľƒ‰ƒ“ƒ_ƒ€”畆śŒŸ‚ɂĐf’f‚ľ“ž‚˝ŒŒŠÇ“ŕ‘ĺ×–EŒ^BƒŠƒ“ƒpŽî‚Ě‚P—á.
•SŁ@‘ĺiJR‘ĺă“S“š•a‰@jA›–ěˆŔŠěA‚@‹N—ǁA˜a“cŸ–çA–Ř‘şĘA´–ě@ˆ¤AŽR–{F“żAŠâ–{ˆęG
H. influenzae‚É‚ć‚é”x‰Š‚Š‚çSƒ^ƒ“ƒ|ƒi[ƒf‚đ—ˆ‚ľ‚˝ˆŤŤƒŠƒ“ƒpŽî‚Ě‚P—á.
Œüˆä@Œĺi‘ĺăŽs—§‘‡ˆă—ĂƒZƒ“ƒ^[jA‹ŕ“‡@LA’†”ö—˛•śAŽRŞF‹vA‹gˆä—R”üAŠÔ•”ŒŤŠ°Aâ–{Œb—˜“ށAŽč“‡”Ž•ś

 

53th American Society of Hematology
San-DiegoADec 10-13
2000
Risk Factors Affecting Cardiac Left Ventricular Systolic and Diastolic Function and Hypertrophy in the Chronic Phase Post-Allogeneic Hematopietic Cell Transplantation

Nishimoto M, Nakamae H, Nakane T, Koh H, Hayashi Y, Nakamae M, Yoshida M, Bingo M, Okamura H, Aimoto M, Manabe M, Yoshimura T, Inaba A, Nanno S, Hirose A, Hagihara K, Nakao Y, Terada Y, Hino M

3764
Immunoprofile of Patients with Chronic Myeloid Leukemia Treated with Imatinib, Nilotinib or Dasatinib

Hayashi Y, Nakamae H, Katayama T, Nakane T, Koh H, Nishimoto M, Nakamae M, Yoshida M, Bingo M, Okamura H, Aimoto M, Manabe M, Yoshimura T, Inaba A, Nanno S, Hagihara K, Nakao Y, Terada Y, Hino M

3071[‹¤“ŻŒ¤‹†]
Double-Unit Cord Blood Transplantation for Hematological Malignancies in Japan: Multicenter Phase II Study (C-SHOT 0507)

Wake A, Kai SR, Okada M, Kurata M, Atsuta Y, Ishikawa J, Hino M, Aotsuka N , Kasai M, Misawa M, Taniguchi S, Kato S

452[‹¤“ŻŒ¤‹†](oral)
Nilotinib Versus Imatinib in Patients (pts) with Newly Diagnosed Philadelphia Chromosome-Positive (Ph+) Chronic Myeloid Leukemia in Chronic Phase (CML-CP): ENESTnd 36-Month (mo) Follow-up

Saglio G, LeCoutre PD, Pasquini R, Jootar S, Nakamae H, Flinn IW, Hochhaus A, Hughes TP, Larson RA, Hoenekopp A, Gallagher NJ, Yu R, Blakesley RE, Kim DW, Kantarjian HM

1935[‹¤“ŻŒ¤‹†]
Fludarabine-Based Reduced Intensity Hematopoietic Stem Cell Transplantation (RIST) for Patients Aged 50-70 Years with Acute Lymphoblastic Leukemia (ALL) in Remission: A Study From the ALL Working Group of the Japan Society for Hematopoietic Cell Transplantation (JSHCT)

Kanamori H, Kako S, Kato H, Nishiwaki S, Furukawa T, Saito M, Taniguchi S, Nakamae H, Yujiri T, Naganuma-Inoue T, Morishima Y, Suzuki R, Sakamaki H, Tanaka  J

 

‘ć96‰ń‹ß‹EŒŒ‰tŠw’n•ű‰ď
ƒeƒCƒWƒ“ƒz[ƒ‹A‘ĺăA11ŒŽ12“ú
ä`‘ŃŒŒˆÚAŒă‚ɐSƒ^ƒ“ƒ|ƒi[ƒf‚đ”­Ç‚ľS”X‰t‚Š‚çHHV6 DNA‚ŞŒŸo‚ł‚ę‚˝ˆę—á.
‹g“c‘SGAN@G’jA‰Ş‘ş_ŽjA”őŒă^“oAź–{ŒőFA—с@—ÇŽ÷AŠÔ•”ŒŤŠ°A ’†ŞF•FA’†‘O”Ž‹vA“ú–ě‰ë”V
ƒEƒTƒMATG“Š—^‚É‚Ä‹}Œƒ‚ȩ̍y‘f‚̏㏸‚đ”F‚ß‚˝Äś•s—ǐŤ•nŒŒ.
•SŁ@‘ĺiJR‘ĺă“S“š•a‰@jA›–ěˆŔŠěA‚@‹N—ǁA˜a“cŸ–ç
‘˝”­Ťœ‘Žî‚ɑ΂ˇ‚éƒ{ƒ‹ƒeƒ]ƒ~ƒu‚Ědose intensity‚Ć—\Œă‚ɂ‚˘‚Ä‚ĚŒŸ“˘.
‰Ş–{Gˆę˜Yiś’ˇ‰ď•{’†•a‰@jAN@Žj˜NAÂŽR‘׍FA‹v‘şŠx‰›A”ž’JˆŔ’ĂŽqA‘ž“c’‰MAŒĂě‰Ŕ‰›

 

‘ć49‰ń“ú–{ŠŕŽĄ—ĂŠw‰ďŠwpW‰ď
–źŒĂ‰Ž‘Ű‰ď‹cęA–źŒĂ‰ŽA10ŒŽ27“úE29“ú
5”ԐőF‘Ě’ˇ˜rŒ‡Ž¸‚𔺂¤œ‘ˆŮŒ`ŹÇŒóŒQ‚ɑ΂ˇ‚郌ƒiƒŠƒhƒ~ƒh‚ĚŽg—pŒoŒą.
ęm’JˆŔ’ĂŽqAN@Žj˜NA‰Ş–{Gˆę˜YAÂŽR‘׍FA‹v‘şŠx‰›A‘ž“c’‰MAŒĂě‰Ŕ‰›A•SŁ@‘ĺA•˝ˆä@ŠwA“Ą’J—m‘ž˜YA‘ž“cŒ’‰îA“ú–ě‰ë”V
R-CHOP—Ă–@‚ĹŠŽ‘SŠ°‰đ‚đ“ž‚˝‘O—§‘BŒ´”­‚Ń‚Ü‚ńŤ‘ĺ×–EŒ^B×–EƒŠƒ“ƒpŽîÇ—á.
ŠÔ•”ŒŤŠ°, —Ń—ÇŽ÷, ‹gˆä—R”ü, ŒüˆäŒĺ, â–{Œb—˜“Ţ, ‹ŕ“‡L, —tŽR‘ô–, ‹v•Ű—E‹L, •Ÿ“‡—TŽq, ˆäăŒ’, Žč“‡”Ž•ś

 

‘ć73‰ń“ú–{ŒŒ‰tŠw‰ď‘‰ď
–źŒĂ‰Ž‘Ű‰ď‹cęA–źŒĂ‰ŽA10ŒŽ14“úE16“ú

OS-1-52
Experience of lenalidomide therapy for multiple myeloma in a community setting in Osaka.
Takaoka Yi‘ĺă•{Ďś‰ď’†’Ă•a‰@jAOhta KAYamamura RAKosaka SAFujitani YAInaba AAMugitani AAKumura TAAoyama YAIchihara HAKoh SAYamane TAKanashima HASakamoto EAHashimura MAYoshii YAHirai MAMomose DAWada KAKoh KRASugano YAOkamoto SATeshima HANakao TAHino M

OS-1-111
Serum cytokine profiles in hemophagocytic syndrome after allogeneic hematopoietic cell transplant.
Koh HAKoh KRANakane TASakamoto EAKatayama TANakamae MATerada YANakamae HAYamane TAHino M

PS-1-104
A rare case of CD7+, CD56+ and Ph-positive early precursor B-ALL.
Yoshida MANakane TAOkamura HABingo MAAimoto MANishimoto MAHayashi YAManabe MAKoh HAHagihara KANakamae MATerada YANakamae HAHino M
OS-2-4(‹¤“ŻŒ¤‹†)
The TARGET system provides more practical and general features compared with the IRIS study.
Tauchi TAKizaki MAOkamoto SAHanaka HATanimoto MAInokuchi KASaburi YAHino MAIsobe YAOshimi KADan KAOhyashiki KAIkeda Y
OS-2-6(‹¤“ŻŒ¤‹†)
Dasatinib versus Imatinib in patients with newly diagnosed chronic-phase CML: Japanese subanalysis.
Ogura MANakamae HAFujisawa SAIshizawa KATaniwaki MAUtsunomiya AAMatsue KATamura KAUsuki KATanimoto MAIshida YAAkiyama HASakai RAKasai MAHino MATakeyama KASeriu TABradley-Garelik MBAZhu C
OS-2-10(‹¤“ŻŒ¤‹†)
Multi-center clinical study evaluating the CMR/MMR ratio of CML-CP by high-sensitive IS-Q-PCR test.
Nishiwaki KATakahashi NAWakita HAShinohara YATakahara SASano KAMasuoka HAAotsuka NAMatsuura YAHirasawa AANakamura HAKashimura MAFukazawa MATanaka HANakagawa YAMatsue KAItoh KAHatano YAKuroki JANakayama YAIchikawa YAChubachi AANimura TAMotegi MAMugitani AANakane TANakamae HAHino MASawada KAMiyazaki Y
PS-2-147
Cold-AIHA in a case of MDS relapsed after allogeneic bone marrow transplantation.
Okamura HANakane TAYoshida MABingo MAAimoto MANishimoto MAHayashi YAManabe MAKoh HANakamae MATerada YANakamae HAHino M

PS-2-172
Primary gastric T-cell lymphoma without Human T cell Leukemia Virus Type 1: a case report.
Manabe MAYamane TAInaba AANanno SAInoue AAAimoto MAOkamura HAYoshida MABingo MANishimoto MAHayashi YAKoh HANakane TANakamae MAHagihara KATerada YANakamae HANakamura MAMuguruma KAOhsawa MA
Hino M

PS-2-208
Reversible posterior leukoencephalopathy following acute pancreatitis in a patient with leukemia.
Nishimoto MAKoh HAHayashi YAManabe MABingo MAYoshoda MAOkamura HAHirose AANakamae MAHagihara KANakane TATerada YANakamae HAHino M
OS-3-100
The immunoprofile of patients with CML treated with imatinib, nilotinib or dasatinib.
Hayashi YANakamae HAKatayama TANakane TAKoh HANishimoto MANakamae MAYoshida MABingo MAOkamura HAAimoto MAManabe MAHagihara KANakao YATerada YAHino M
OS-3-157
Empirical voriconazole therapy for febrile neutropenic patients with hematological disorders.
Koh HAHino MAOhta KAIino MAUrase FAYamaguchi MAYamanouchi JAUsui NAYoshida MATanimoto MAOhyashiki KAUrabe AATamura KAKanamaru AAMasaoka T

 

‘ć195‰ń“ú–{“ŕ‰ČŠw‰ď‹ß‹E’n•ű‰ď
‘ĺă‘ŰŒđ—ŹƒZƒ“ƒ^[A‘ĺăA9ŒŽ10“ú
ä`‘ŃŒŒˆÚAŒă‚ɃgƒLƒ\ƒvƒ‰ƒYƒ}”]Ç‚đ”­Ç‚ľ‚˝œ‘ˆŮŒ`ŹÇŒóŒQ‚Ě‚P—á.
ˆî—tWŽqAź–{ŒőFAN@G’jA—с@—ÇŽ÷A‰Ş‘ş_ŽjA ’†ŞF•FA’†‘O”Ž‹vA“ú–ě‰ë”VA‰ş–ě‘ž˜Y

 

‘ć9‰ń“ú–{—Տ°Žîᇊw‰ďŠwpW‰ď
ƒpƒVƒtƒBƒR‰Ą•lA‰Ą•lA7ŒŽ21“úE23“ú
pŒă8”N‚đŒo‰ß‚ľ, œ‘ŠŕŽîÇ‚đ’ć‚ľ‚čĔ­‚ľ‚˝ˆÝŠŕÇ—á.
ŠÔ•”ŒŤŠ°, ‹gˆä—R”ü, ŒüˆäŒĺ, â–{Œb—˜“Ţ, ‹ŕ“‡L, ‘O“cˆęÎ, ‹v•Ű—E‹L, •Ÿ“‡—TŽq, ˆäăŒ’, Žč“‡”Ž•ś

 

‘ć15‰ń“ú–{‚Ş‚ń–ƉuŠw‰ď‘‰ď
ç—˘ƒ‰ƒCƒtƒTƒCƒGƒ“ƒXƒZƒ“ƒ^[A‘ĺăA6ŒŽ30“úE7ŒŽ1“ú
‘˘ŒŒŠ˛×–EˆÚAŒăŠłŽŇ‚ɑ΂ˇ‚éWT1ƒƒNƒ`ƒ“–Ɖu—Ă–@.
•Űĺ’ź‹BA‘O“c“NśAŽRŞF‹vA“ú–ě‰ë”VAX–{‘n˘ŽqAŒ´@ˆę^A’†“cAź“cƒKA’Řˆäş”ŽA”ö˜H—S‰îA‰Ş@–F

 

‘ć95‰ń‹ß‹EŒŒ‰tŠw’n•ű‰ď
“sƒzƒeƒ‹ƒjƒ…[ƒAƒ‹ƒJƒCƒbƒNA“ňčA6ŒŽ18“ú
”ńŒŒ‰ŽŇŠÔ“ŻŽí‘˘ŒŒŠ˛×–EˆÚAŒăAŽŠ—Ľ_ŒoáŠQ‚đ’ć‚ľ‚˝HHV6”]‰ŠEŇ‘‰Š‚Ěˆę—á.
ź–{ŒőFA’†‘O”Ž‹vA—с@—ÇŽ÷AŠÔ•”ŒŤŠ°AN@G’jA’†ŞF•FAœAŁ’ŠśA’†‘O”ü‰ŔAŽ›“c–FŽ÷A“ú–ě‰ë”V
HBVŠÖ˜AŒŒ‹…ćÐHÇŒóŒQ‚ĚŽŠ‘RŠ°‰đ‚É‘ą‚ŤƒzƒWƒLƒ“ƒŠƒ“ƒpŽî‚ĚÄ”­‚đ”F‚ß‚˝‚—îŽŇ—á.
˜a“cŸ–çiJR‘ĺă“S“š•a‰@jA‹g‘ş‘ě˜NA›–ěˆŔŠěA‚@‹N—ǁAÎ“c‰p˜a
“–‰@‚É‚¨‚Ż‚é”­ěŤ–éŠÔŒŒF‘f”AÇŠłŽŇ‚ɑ΂ˇ‚éƒGƒNƒŠƒYƒ}ƒu‚ĚŽg—pŒoŒą.
N@Žj˜Niś’ˇ‰ď•{’†•a‰@jA‰Ş–{Gˆę˜YAÂŽR‘׍FA‹v‘şŠx‰›A”ž’JˆŔ’ĂŽqA‘ž“c’‰MAŒĂě‰Ŕ‰›
‹łˆçu‰‰
Aggressive lymphoma‚ĚŽĄ—Á`Šî‘b‚Š‚çĹV’mŒŠ‚܂Ł`
.

Ž›“c–FŽ÷

 

‘ć194‰ń“ú–{“ŕ‰ČŠw‰ď‹ß‹E’n•ű‰ď
“Ţ—ÇŒ§—§•ś‰ť‰ďŠŮA“ޗǁA6ŒŽ11“ú
ŠŕŤ‘–Œ‰Š‚ɑ΂ľ‚Äerlotinib‚Ş—LŒř‚Ĺ‚ ‚Á‚˝”x‘BŠŕpŒăÄ”­Ç—á.
ŠÔ•”ŒŤŠ°, Œő‰Ş–ÎŽ÷, ”~ě‰Á“ŢŽq, “c’†G“T, ‹g‘şŹ‰›, –Ř‘ş’B˜Y, •“cŒi•q, H“ĄVŽO, •˝“cˆęl

 

‘ć65‰ń“ú–{Œđ’ĘˆăŠw‰ď‘‰ď
ƒƒ‹ƒpƒ‹ƒN‹ž“sA‹ž“sA6ŒŽ4“úE5“ú
EBVÄŠˆŤ‚𔺂¤ŒŒ‹…ćÐHÇŒóŒQ‚É‘ą‚˘‚čĔ­‚đ”F‚ß‚˝‚—îƒzƒWƒLƒ“ƒŠƒ“ƒpŽî.
˜a“cŸ–çiJR‘ĺă“S“š•a‰@j
“Á•Ęu‰‰I
“ŻŽí‘˘ŒŒŠ˛×–EˆÚA‚ĚŒťó.
“ú–ě‰ë”V

 

‘ć97‰ń“ú–{Á‰ťŠí•aŠw‰ď‘‰ď
‹ž‰¤ƒvƒ‰ƒUƒzƒeƒ‹A“Œ‹žA5ŒŽ13“úE15“ú
ˆÝŒ´”­ˆŤŤƒŠƒ“ƒpŽî(DLBCL)‚ÉR-CHOP—Ă–@‚đŽ{s‚ľŠ°‰đ‚Ş“ž‚ç‚ę‚˝’źŒăA“Ż•”ˆĘ‚É‘ŠúˆÝŠŕ‚đ”F‚ß‚˝Ç—á.
^@çéŽőA‘ĺ“cGˆęA…ă—zA”nęŠóˆę˜YAÂˆäˆęŒ›A•˝’Ë‘ń–çA”‹Œ´Œ‰’ʁAă™—TŽqA™ŽR—S”VA“ú–ě‰ë”V

 

‚đƒNƒŠƒbƒN‚ľ‚Ä‚˘‚˝‚ž‚­‚Ć˜a•ś´˜^‚Ş‚˛——‚˘‚˝‚ž‚Ż‚Ü‚ˇi‹¤“ŻŒ¤‹†ˆČŠOjB

‘ć33‰ń“ú–{‘˘ŒŒ×–EˆÚAŠw‰ď‘‰ď
ˆ¤•QŒ§Œ§–Ż•ś‰ť‰ďŠŮAźŽRA3ŒŽ9“úE10“ú
PS-1-100
ä`‘ŃŒŒˆÚAŒă‚ɍ‡•š‚ľ‚˝ŽŠŒČ–ƉuŤbó‘BŽžŠł‚Ě1Ç—á.
ˆäă“ÖŽii‘ĺăŽs—§‘ĺŠw‘ĺŠw‰@ˆăŠwŒ¤‹†‰ČŒŒ‰tŽîᇐ§ŒäŠwjA’†ŞF•FA’†‘O”Ž‹vAN@G’jA’†‘O”ü‰ŔA—с@—ÇŽ÷Aź–{ŒőFA‘Š–{Ž÷A”őŒă^“oA‹g‘ş‘ě˜NA‰Ş‘ş_ŽjA‹g“c‘SGAŠÔ•”ŒŤŠ°AœAŁ’ŠśA’†”ö‹gFAŽ›“c–FŽ÷A‚@‹N—ǁAŽRŞF‹vA“ú–ě‰ë”V
PS-1-015
”ńŠ°‰đŠú‚É“ŻŽí‘˘ŒŒŠ˛×–EˆÚAiHCTj‚đŽ{s‚ł‚ę‚˝”’ŒŒ•aŠłŽŇ‚Ě’ˇŠúś‘ś‚ÉŠń—^‚ˇ‚éˆöŽq‚ĚŒŸ“˘.
N@G’ji‘ĺăŽs—§‘ĺŠw‘ĺŠw‰@ˆăŠwŒ¤‹†‰ČŒŒ‰tŽîᇐ§ŒäŠwjA’†‘O”Ž‹vA’†ŞF•FA—с@—ÇŽ÷Aź–{ŒőFA‘Š–{Ž÷Aˆäă“ÖŽiAŠÔ•”ŒŤŠ°A”őŒă^“oA‹g“c‘SGA‰Ş‘ş_ŽjA”~–{—R—˘AˆäăŒb—˘A‘Š–{@—–AœAŁ’ŠśA’†‘O”ü‰ŔAŽ›“c–FŽ÷A‚@‹N—ǁAŽRŞF‹vA“ú–ě‰ë”V
PS-2-079
“ŻŽíœ‘ˆÚAŒă‚ɉĄ’fŤŇ‘‰Š‚đ‡•š‚ľ‚˝‹}ŤƒŠƒ“ƒpŤ”’ŒŒ•a.
ŠÔ•”ŒŤŠ°i‘ĺăŽs—§‘ĺŠwŒŒ‰t“ŕ‰ČE‘˘ŒŒ×–EˆÚA‰ČjA’†ŞF•FAˆÉ“Ą˜a”ŽA‰Ş‘ş_ŽjA”őŒă^“oA‹g“c‘SGAˆäă“ÖŽiA‘Š–{Ž÷Aź–{ŒőFA—с@—ÇŽ÷AN@G’jA’†‘O”ü‰ŔAŽ›“c–FŽ÷A’†‘O”Ž‹vA’†”ö—˛•śA’†”ö‹gFA‚@‹N—ǁAŽRŞF‹vA“ú–ě‰ë”V
PS-1-017
“–‰Č‚É‚¨‚Ż‚éPh—zŤALL‚Ě“ŻŽí‘˘ŒŒŠ˛×–EˆÚAŹŃ‹y‚Ń—\ŒăˆöŽq‚ĚŒŸ“˘.
‹g‘ş‘ě˜Ni‘ĺăŽs—§‘ĺŠw‘ĺŠw‰@ˆăŠwŒ¤‹†‰ČŒŒ‰tŽîᇐ§ŒäŠwjA’†ŞF•FAœAŁ’ŠśAN@G’jA’†‘O”ü‰ŔA‘Š–{@—–AˆäăŒb—˘A‘Š–{Ž÷Aˆäă“ÖŽiAź–{ŒőFA—с@—ÇŽ÷AŽ›“c–FŽ÷A’†”ö‹gFA’†‘O”Ž‹vA‚@‹N—ǁAŽRŞF‹vA“ú–ě‰ë”V
ŠĹŒěPS-1-07
ƒŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“‚ÉWII Fit‚đŽć‚č“ü‚ę‚˝Œř‰Ę‚ƍĄŒă‚̉ۑč.
Xě”ސç‘ăi‘ĺăŽs—§‘ĺŠwˆăŠw•”•‘Ž•a‰@ŒŒ‰t“ŕ‰Č•a“jAěŒł—˘A™ŽRK—éA‘şŒű—SŽqA”g•˝m”üA‹{–{’qŽqAˆîč…“ŢŽqA‰şÎ•xKA“ě•”˝ŽĄ
ŠĹŒěPS-1-09
‘˘ŒŒŠ˛×–EˆÚAŒăÄ”­‚ľ‚˝ˆŤŤƒŠƒ“ƒpŽîŠłŽŇ‰Ć‘°‚ŞÝ‘î—Ă—{‘I‘đŒă‚É‘ĚŒą‚ľ‚˝‚ą‚Ć.
’ß“c—Œbi‘ĺăŽs—§‘ĺŠwˆăŠw•”•‘Ž•a‰@ŒŒ‰t“ŕ‰Č•a“jAŽRčm”üA”g•˝m”üAˆîč…“ŢŽqA‹{č‹žŽq
ŠĹŒěPS-2-03
ˆÚA•a“‚É‚¨‚Ż‚銳ŽŇˆă—ĂŽŇŒđ—Ź‰ď‚ĚŽŔ‘H•ń.
ŽRčm”üi‘ĺăŽs—§‘ĺŠwˆăŠw•”•‘Ž•a‰@@ŒŒ‰t“ŕ‰Č•a“jAŽoě”ü—R‹IA‘˝ŽĄ”䐴ŽqA”g•˝m”üA‹{–{’qŽqA’ß“c—ŒbAˆîč…“ŢŽq
‹¤“ŻWS2-18-2
Œ’íƒhƒi[‚Š‚ç‚Ě––˝ŒŒŠ˛×–EĚŽćŽž‚ĚŒŒŠÇƒAƒNƒZƒX‚Ě‚˝‚ß‚ĚƒfƒoƒCƒX‚ÉŠÖ‚ˇ‚é‘S‘’˛¸.
”¨’†ˆęśi˜a‰ĚŽRŒ§—§ˆă‰Č‘ĺŠw—AŒŒEŒŒ‰tŽžŠłŽĄ—Ă•”jA—é–Ř—Ľ˜NA”M“c—RŽqA“ú–ě‰ë”VA–L“ˆ’“żAŹŽ›—ǏŽAĄ‘ş‰ëŠ°
‹¤“ŻWS2-20-1
–˘•Ş‰ť‘˘ŒŒŠ˛×–E‚ĚŽxŽ”\‚đŽ‚Âƒqƒgœ‘—R—ˆŠÔ—tŒnŠ˛×–E‚Ě—\Šú“I•Ş—Ł‚Ć‚ť‚Ě‹@”\‰đÍ.
ź‰Ş—R˜aiŠÖźˆă‰Č‘ĺŠw‘ĺŠw‰@ˆăŠwŒ¤‹†‰ČŠ˛×–Eś•¨ŠwjA˛X–؁@–LA‚‹´š–çA’†’Ë—˛‰îAˆäă‰ë”üAŹěŒ[‹ąA‚‹´—˛KAÎě@~A“ú–ě‰ë”VA‰’“c¸ş

2010”N
–{”N‚ć‚艉‘č–źA”­•\ŽŇ‚̏‡‚Ĺ‹LÚ‚ľ‚Ä‚¨‚č‚Ü‚ˇ
ŠeŠw‰ď‚É‚¨‚Ż‚鉉‘č‡˜‚Í•M“ŞŽŇ‚đŒÜ\‰š‡‚Ĺ•Ŕ‚ׂè‚č‚Ü‚ˇ
‚đƒNƒŠƒbƒN‚ľ‚Ä‚˘‚˝‚ž‚­‚Ć˜a•ś´˜^‚Ş‚˛——‚˘‚˝‚ž‚Ż‚Ü‚ˇi‹¤“ŻŒ¤‹†ˆČŠOjB
52th American Society of Hematology
OrlandADec 4-7
3551
Factors That Contribute to Long-Term Survival In Patients with Leukemia Not In Remission at Allogeneic Hematopoietic Cell Transplantation

Koh H, Nakamae H, Nakane T, Manabe M, Hayashi Y, Nishimoto M, Umemoto K, Nakamae M, Hirose A, Inoue E, Inoue A, Yoshida M, Bingo M, Okamura H, Aimoto R, Aimoto M, Terada Y, Koh KR, Yamane T, Hino M

1180[‹¤“ŻŒ¤‹†]
Safety and Risk of Allogeneic Peripheral Blood Stem Cell Donation: The Comprehensive Report of Nation-Wide Consecutively Pre-Registered 3,264 Family Donor Survey In 10years Project by Japan Society for Hematopoietic Cell Transplantation

Kodera Y, Yamamoto K, Kato S, Harada M, Kanda Y, Hamajima N, Asano S, Ikeda Y, Imamura M, Kawa K, Morishima Y, Nakahata T, Tanimoto M, Dohy H, Tanosaki R, Shiobara S, Kim SW, Nagafuji K, Hino M, Miyamura K, Suzuki R

3852[‹¤“ŻŒ¤‹†]
Prospective Isolation and Functional Characterization of Human Bone Marrow-Derived Hematopoietic Stem Cell-Supportive Mesenchymal Stromal Cells

Matsuoka Y, Sasaki Y, Takahashi M, Nakatsuka R, Uemura Y, Inoue M, Ogawa H, Takahashi T, Ishikawa J, Hino M, Sonoda Y

2287[‹¤“ŻŒ¤‹†]
Seven-Year Follow-up of Patients Receiving Imatinib for the Treatment of Chronic Myelogenous Leukemia by the TARGET System.

Tauchi T, Kizaki M, Okamoto S, Tanaka H, Tanimoto M, Inokuchi K, Murayama T, Saburi Y, Hino M, Tsudo M, Shimomura T, Isobe Y, Oshimi K, Dan K, Ohyashiki K, Ikeda Y


‘ć94‰ń‹ß‹EŒŒ‰tŠw’n•ű‰ď
ƒsƒAƒU’WŠCAŽ ‰ęA11ŒŽ6“ú
‰‰‘č”ԍ†10
‚Ń‚Ü‚ńŤ‘ĺ×–EŒ^B×–EƒŠƒ“ƒpŽî‚đ”­Ç‚ľ‚˝“ŻŽí‘˘ŒŒŠ˛×–EˆÚAƒhƒi[‚Ě1—á.
N@Žj˜Ni•{’†•a‰@ŒŒ‰tŽžŠłƒZƒ“ƒ^[jAŽsŒ´O‘PAÂŽR‘׍FA‹v‘şŠx‰›A‘ž“c’‰MAŒĂě‰Ŕ‰›Aęm’JˆŔ’ĂŽq
‰‰‘č”ԍ†32
ƒvƒŠƒ“—U“ą‘Ě“Š—^Œă‚ɃAƒfƒmƒEƒCƒ‹ƒXiAdVj-oŒŒŤäNă÷‰ŠiHCj‚đ—ˆ‚ľ‚˝ˆŤŤƒŠ
ƒ“ƒpŽî‚Ě2—á.
™ŽR—T”ViĎś‰ď–ě]•a‰@jAă™—TŽq

‘ć72‰ń“ú–{ŒŒ‰tŠw‰ďŠwpW‰ď
ƒpƒVƒtƒBƒR‰Ą•lA‰Ą•lA9ŒŽ24-26“ú
PS-2-152
Autoimmune hemolytic anemia with trisomy X chromosome abnormality.
ŽOőF‘ĚˆŮí‚đ”F‚ß‚˝ŽŠŒČ–ƉuŤ—nŒŒŤ•nŒŒ.
‘ž“c’‰Mi•{’†•a‰@ŒŒ‰tŽžŠłƒZƒ“ƒ^[jA‰v‰Ş@—DAŒĂě‰Ŕ‰›AŽsŒ´O‘PAÂŽR‘׍FA‹v‘şŠx‰›Aęm’JˆŔ’ĂŽqA“ú–ě‰ë”V
PS-1-27
ƒNƒ[ƒ“•a‚ĆSWEET•a‚ĚŽĄ—ĂŒo‰ß’†‚É‘˝”­Ťœ‘Žî‚đ”­Ç‚ľ‚˝ˆę—á.
‹ŕ“‡@Li‘ĺăŽs—§‘‡ˆă—ĂƒZƒ“ƒ^[ŒŒ‰t“ŕ‰ČjA‹´‘şŒő°A‹gˆä—R”üAŒüˆä@ŒĺAâ–{Œb—˜“ށAˆäă@Œ’AŽč“‡”Ž•ś
PS-2-37
Early start of Bortezomib may contribute to better survival of Japanese multiple myeloma patients.
‘Šúƒ{ƒ‹ƒeƒ]ƒ~ƒu“Š—^‚Í–{–M‘˝”­Ťœ‘Žîś‘ś‚ɂ悢‰e‹ż‚đ‹y‚Ú‚ˇ.
Źâ‚ł‚¨‚či‘ĺă•{Ďś‰ď’†’Ă•a‰@ŒŒ‰t“ŕ‰ČjAŽR‘ş—ş‰îAN@G’jAˆî—tWŽqA•‰ŞNMAŽRŞF‹vA“ú–ě‰ë”VA‘ž“cŒ’‰î
OS-2-32
—AŒŒŒă“S‰ßčÇ‚ɑ΂ˇ‚éŒoŒű“SƒLƒŒ[ƒgÜDeferasirox‚ĚŽg—pŒoŒą.
Ž›“c–FŽ÷i‘ĺăŽs—§‘ĺŠw‘ĺŠw‰@ŒŒ‰tŽîᇐ§ŒäŠwjAŽR‘ş—ş‰îAâ–{Œb—˜“ށAă–{e•FAŽRŞF‹vAÂŽR‘׍FA•˝ˆä@ŠwAŽč“‡”Ž•śAęm’JˆŔ’ĂŽqA‘ž“cŒ’‰îA“ú–ě‰ë”V
PS-1-157
ƒNƒ[ƒ“•aŽĄ—Ă’†‚É”­Ç‚ľ‚˝ACD13A33‰AŤ‚Ě‹}Ťœ‘’P‹…Ť”’ŒŒ•a‚Ě1—á.
ź–{ŒőFi‘ĺăŽs—§‘ĺŠwŒŒ‰t“ŕ‰Č‘˘ŒŒ×–EˆÚA‰ČjA’†‘O”Ž‹vAˆäă“ÖŽiA‘Š–{@—–A‘Š–{Ž÷A—с@—ÇŽ÷AN@G’jA’†ŞF•FAœAŁ’ŠśA’†‘O”ü‰ŔAŽ›“c–FŽ÷A‚@‹N—ǁAŽRŞF‹vA“n•ÓŒ›ŽĄA“ú–ě‰ë”V
PS-1-81
HLAˆę’v“Ż–E‚Š‚ç‚̍œ‘ˆÚAŒăÄ”R‚̏dÇÄś•s—ǐŤ•nŒŒ‚ɑ΂ľA“Żˆęƒhƒi[‚Š‚ç‚ĚRIC-PBSCT‚đŽ{s‚ľ‚˝ˆę—á.
—с@—ÇŽ÷i‘ĺăŽs—§‘ĺŠw‘ĺŠw‰@ŒŒ‰tŽîᇐ§ŒäŠwjA’†ŞF•FA’†‘O”Ž‹vAN@G’jA’†‘O”ü‰ŔAź–{ŒőFAˆäăŒb—˘Aˆäă“ÖŽiA‘Š–{Ž÷A‘Š–{Ž÷A‹g“c‘SGAŽ›“c–FŽ÷A‚@‹N—ǁAŽRŞF‹vA“ú–ě‰ë”V
SH-33
A-68-year-old-man with unconsciousness after influenza virus infection.
ƒCƒ“ƒtƒ‹ƒGƒ“ƒUœëŠłŒă‚ɈӎŻÁŽ¸‚ɊׂÁ‚˝68Î’jŤ—á.
ŒĂě‰Ŕ‰›i•{’†•a‰@ŒŒ‰tŽžŠłƒZƒ“ƒ^[jAęm’JˆŔ’ĂŽqA‹v‘şŠx‰›AÂŽR‘׍FAŽsŒ´O‘PAN@Žj˜NA‘ĺ˜H@„
PS-2-35
Salvage therapy with THALED for refractory or relapsed multiple myeloma.
ŽĄ—Ă’ďRŤ‚ ‚邢‚͍Ĕ­‘˝”­Ťœ‘Žî‚ɑ΂ˇ‚éƒTƒŒƒh‚đ—p‚˘‚˝ƒTƒ‹ƒx[ƒW—Ă–@.
ęm’JˆŔ’ĂŽqi•{’†•a‰@ŒŒ‰tŽžŠłƒZƒ“ƒ^[jAN@Žj˜NAŽsŒ´O‘PAÂŽR‘׍FA‹v‘şŠx‰›A‘ž“c’‰MAŒĂě‰Ŕ‰›
[‹¤“ŻŒ¤‹†]
OS-1-21
Prospective isolation and functional characterization of human marrow-derived MSCs.
Matsuoka Y (Dept. Stem Cell Biol., Kansai Med Univ.), Sasaki Y, Takahashi M, Nakatsuka R, Inoue M, Ogawa H, Takahashi T, Ishikawa J, Hino M, Uemura Y, Sonoda Y
[‹¤“ŻŒ¤‹†]
OS-1-42
Efficacy of a new protocol, CAG-G-GO (GO following CAG and G-CSF), for refractory or relapsed AML.
Matsuoka H (Oncology/Hematology, Kobe Univ.), Kurimoto M, Uneda S, Shimanuki M, Hosoi H, Murata S, Nohgawa M, Sakaguchi R, Hino M, Yamane T, Sakamoto C, Ohta K, Mugitani A, Aoyama Y, Sonoki T, Hatanaka K, Nakakuma H
[‹¤“ŻŒ¤‹†]
OS-1-161
Chemokines/soluble adhesion molecules in febrile neutropenic with hematologic malignancies.
Ichihara HiDep. of Hematology, Seichokai Fushu Hospitalj, Kumura T, Matsuda M, Itagaki N, Aoyama Y, Kou S, Ishii K, Mugitani A, Tsukaguchi M, Kubota T, Urase F, Maeda Y
[‹¤“ŻŒ¤‹†]
OS-2-165
Clonogenic myeloma progenitor cells reside in the CD19-CD38++ plasma cell population.
Hosen N (Dept. of Functional Diagnostic, Osaka Univ.), Kishida S, Matsuoka Y, Ichihara H, Mugitani S, Aoyama Y, Kawakami M, Yamaguchi T, Murakami M, Fuji S, Tamaki H, Nakao T, Oka Y, Hino M, Sugiyama H
[‹¤“ŻŒ¤‹†]
Dasatinib compared with imatinib in newly diagnosed chronic myelogenous leukemia in chronic phase.
Nakamae H (Hematology, Graduate School of Medicine, Osaka City Univ.), Shah N, Hochhaus A, Cortes J, Shah S, Ayala M, Moiraghi B, Bradley-Garelik MB, Zhu C, Baccarani M, Kantarjian H.
[‹¤“ŻŒ¤‹†]
OS-3-75
MMSC-1 as a novel target molecule for monoclonal antibody therapy against multiple myeloma.
Hosen N (Dept. of Functional Diagnostic, Osaka Univ.), Kishida S, Matsuoka Y, Ishihara H, Aoyama Y, Mugitani A, Kawakami M, Yamagami T, Murakami M, Tamaki H, Nakao T, Fuji S, Nakajima H, Hino M, Oka Y, Sugiyama H
[‹¤“Ż•ń]
PS-1-75
RIST‚É‚ć‚č—ǍD‚ČŒo‰ß‚đ“ž‚Ä‚˘‚éA”­Ç1”N‚ĹŠĽ“Ž–ŹE”]“Ž–Ź•ÂÇ‚đ‚Ť‚˝‚ľ‚˝CAEBV‚Ě26Î‚̏—Ť.
ŽR“c‰Ŕ˘i‘ĺă•{—§•ęŽqˆă—ĂƒZƒ“ƒ^[ŒŒ‰tEŽîᇉȁjAˆŔˆäš”ŽA˛“Ą^•äA‹ß“Ą@“AŕV“c–ž‹vAŽž­’č—YAˆäă‰ë”üA‰Í’Ă—R‹IŽqAźěł‘ĽA‰Ô’J˛‹vAŽO‹´@–LA“ú–ě‰ë”VA‰Í@Œh˘

‘ć192‰ń“ú–{“ŕ‰ČŠw‰ď‹ß‹E’n•ű‰ď—á‰ď
‘ĺă‘ŰŒđ—ŹƒZƒ“ƒ^[A‹ž“sA9ŒŽ11“ú
‰‰‘č156
ˆâ“`Žq‘g‚ÝŠˇ‚Śƒgƒƒ“ƒ{ƒ‚ƒWƒ…ƒŠƒ“(rTM)‚Ş—LŒř‚Ĺ‚ ‚Á‚˝ŽY‰ČDIC‚Ě3Ç—á.
‹v‘şŠx‰›iś’ˇ‰ď•{’†•a‰@ŒŒ‰tŽžŠłƒZƒ“ƒ^[jAÂŽR‘׍FAŽsŒ´O‘PAN@Žj˜NAęm
’JˆŔ’ĂŽqA‘ě‚ЂƂ݁i“Ż@ŽY•wl‰ČjA s‰ŞŒc‰îA–؉ş@’eA’†ěšŽqA ŽRč‘Ľs
‰‰‘č157
œ‘ˆŮŒ`ŹÇŒóŒQ‚ĚŒo‰ß’†‚É”­Ç‚ľ‚˝Œă“VŤŒŒ—F•aA‚Ě1—á.
‹´‘şŒő°i‘ĺăŽs—§‘‡ˆă—ĂƒZƒ“ƒ^[ŒŒ‰t“ŕ‰ČjA‹gˆä—R”üAŒüˆä@ŒĺAâ–{Œb—˜“ށA‹ŕ“‡@LAŽč“‡”Ž•ś
‰‰‘č168
POEMSÇŒóŒQ‚É—ŢŽ—‚Ě•a‘Ô‚đ’ć‚ľ‚˝ƒNƒŠƒIƒOƒƒuƒŠƒ“ŒŒÇ‡•šMALTƒŠƒ“ƒpŽî‚Ě1—á.
”őŒă^“oi‘ĺăŽs—§‘ĺŠwˆăŠw•”•t‘Ž•a‰@ŒŒ‰t“ŕ‰ČE‘˘ŒŒ×–EˆÚA‰ČjA—с@—ÇŽ÷A‚@‹N—ǁAN@G’jA’†ŞF•FA’†‘O”ü‰ŔAŽ›“c–FŽ÷A’†‘O”Ž‹vAŽRŞF‹vA“ú–ě‰ë”V

‘ć11‰ń“ú–{ŒŸ¸ŒŒ‰tŠw‰ď
“Œ‹žƒrƒbƒOƒTƒCƒgA“Œ‹žA7ŒŽ25“ú
‰‰‘č56
őF‘ĚˆŮít(4;12)(q12;p13)‚đ—L‚ˇ‚éŽá”N”­ÇAML with myelodysplasia-related
changes‚Ě1—á.
ŠÔ•”ŒŤŠ°i‘ĺăŽs—§‘ĺŠwˆăŠw•”ŒŒ‰t“ŕ‰ČE‘˘ŒŒ×–EˆÚA‰ČjA’†‘şPmA’†‘şƒŽqA
•ŸŽR’qŽqA[“cŒb—˜“ށAˆäă“ÖŽiA“ú–ě‰ë”V

‘ć93‰ń‹ß‹EŒŒ‰tŠw’n•ű‰ď
ƒeƒCƒWƒ“ƒz[ƒ‹A‘ĺăA6ŒŽ19“ú
‰‰‘č40
EDTA‚É‚ć‚錌Ź”‰qŻŒ¸­‚đ”F‚ß‚˝Œ’íl‚Ě1—á.
N@Žj˜Ni•{’†•a‰@ŒŒ‰tŽžŠłƒZƒ“ƒ^[jAŽsŒ´O‘PAÂŽR‘׍FA‹v‘şŠx‰›Aęm’JˆŔ’ĂŽqA‘ž“c’‰MAŒĂě‰Ŕ‰›
‰‰‘č21
‘˝”­Ťœ‘Žî‚ĚŒo‰ß’†‚Éplasmablastic transformation‚đ—ˆ‚ľ‚˝1—á.
Œüˆä@Œĺi‘ĺăŽs—§‘‡ˆă—ĂƒZƒ“ƒ^[ŒŒ‰t“ŕ‰ČjA‹gˆä—R”üAŠÔ•”ŒŤŠ°A‹ŕ“‡@LAâ–{Œb—“ށAŽč“‡”Ž•śAŒŽ‰Ş‘ě”nA•Ÿ“‡—TŽqAˆäă@Œ’
‰‰‘č31
“î•”‘gD‚Ö‚Ě‚Ń‚Ü‚ńŤZ‚ɂčĔ­‚ľ‚˝HHV-8(-)HIV(-)Eprimary effusion lymphoma—lƒŠƒ“ƒpŽî‚Ě2—á.
‹g‘ş‘ě˜Ni‘ĺă“S“š•a‰@ŒŒ‰t“ŕ‰ČjA‰Ş–{Gˆę˜YA›–ěˆŔŠěA˜a“cŸ–ç

‘ć191‰ń“ú–{“ŕ‰ČŠw‰ď‹ß‹E’n•ű‰ď—á‰ď
ŽĹ—–‰ďŠŮA‹ž“sA6ŒŽ12“ú
‰‰‘č77
‹}Ť‘Oœ‘Ť”’ŒŒ•a(APL)‚ɍ‡•š‚ľ‚˝”dŽíŤŒŒŠÇ“ŕ‹ĂŒĹÇŒóŒQ(DIC)‚ɑ΂ľƒŠƒRƒ“ƒrƒiƒ“ƒgƒgƒƒ“ƒ{ƒ‚ƒWƒ…ƒŠƒ“‚đ—p‚˘‚˝2Ç—á‚ĚŒŸ“˘.
ŽsŒ´O‘Piś’ˇ‰ď•{’†•a‰@ŒŒ‰tŽžŠłƒZƒ“ƒ^[jAN@Žj˜NAÂŽR‘׍FA‹v‘şŠx‰›Aęm’JˆŔ’ĂŽqA‘ž“c’‰M, ŒĂě‰Ŕ‰›
‰‰‘č83
cŠuŒ´”­NHL(DLBCL)‚̉ťŠw—Ă–@ŒăA‘ĺ“Ž–Ź‰đ—Ł‚đ”­Ç‚ľ‚˝1—á.
›–ěˆŔŠěi‘ĺă“S“š•a‰@ŒŒ‰t“ŕ‰ČjA˜a“cŸ–çA‰Ş–{Gˆę˜YA‹g‘ş‘ě˜NAŹŽR@mA–p@‹ÎAA“ú–ě‰ë”V
‰‰‘č84
Hyper-CVAD‚ĹŠ°‰đ“ą“üŒăAmolecular remission‚É“ž’B‚ľ‚˝ŹlE2A-PBX1—zŤALL‚Ě2—á
›–ěˆŔŠěi‘ĺă“S“š•a‰@ŒŒ‰t“ŕ‰ČjA˜a“cŸ–çA‰Ş–{Gˆę˜YA‹g‘ş‘ě˜NA“ú–ě‰ë”V

‘ć32‰ń“ú–{‘˘ŒŒ×–EˆÚAŠw‰ď‘‰ď
ƒAƒNƒgƒVƒeƒB•lźEƒI[ƒNƒ‰ƒAƒNƒgƒVƒeƒBƒzƒeƒ‹•lźA•lźA2ŒŽ19“úA20“ú
PS-1-49
ƒŔŽŐ’f–ňiCarvediolj‚É‚ć‚čRƒKƒ“Ü‚É‚ć‚é–ňÜŤS‹ŘÇ‚މü‘P‚ľA“ŻŽí‘˘ŒŒŠ˛×–EˆÚA‚đŽ{s‚ľ“ž‚˝‹}Ťœ‘Ť”’ŒŒ•a‚Ě1—á.
@ÂŽR‘׍FiŽĐ‰ďˆă—Ă–@lś’ˇ‰ď•{’†•a‰@ŒŒ‰tŽžŠłƒZƒ“ƒ^[jAŽsŒ´O‘PAN@Žj˜NA‹v‘şŠx‰›Aęm’JˆŔ’ĂŽq
ŠĹPS-1-35
‘˘ŒŒ×–EˆÚAŠłŽŇ‚ĚŒűo”S–ŒáŠQ‚ɑ΂ˇ‚éƒOƒŠƒZƒŠƒ“ŠÜšu‚Ě—LŒřŤ.
@Žoě”ü—R‹Ii‘ĺăŽs—§‘ĺŠwˆăŠw•”•‘Ž•a‰@ŒŒ‰t“ŕ‰ČE‘˘ŒŒ×–EˆÚA‰Č•a“jA’†ŞF•FA‹{č‹žŽqA“ú–ě‰ë”V
PS-1-95
“ŻŽí‘˘ŒŒŠ˛×–EˆÚAŒă‚ɍ‡•š‚ľ‚˝’°ŠÇ”X–EŤ‹CŽîÇ‚Ě1Ç—á.
@ˆäă“ÖŽii‘ĺăŽs—§‘ĺŠwˆăŠw•”ŒŒ‰t“ŕ‰ČE‘˘ŒŒ×–EˆÚA‰ČjA’†‘O”Ž‹vA’†ŞF•FAN@G’jA’†‘O”ü‰ŔA—с@—ÇŽ÷Aź–{ŒőFA‹g‘ş‘ě˜NAˆäăŒb—˘A‘Š–{@—–A‘Š–{Ž÷AŽ›“c–FŽ÷A‚@‹N—ǁAŽRŞF‹vA“ú–ě‰ë”V
PS-2-101
46,XY,t(9;12)(q34;q22)‚đ—L‚ˇ‚閝Ťœ‘‘BŤŽžŠł‚É“ń“x‚Ěä`‘ŃŒŒˆÚA‚đŽ{s‚ľ‚˝ˆę—á.
@‹ŕ“‡@Li‘ĺăŽs—§‘‡ˆă—ĂƒZƒ“ƒ^[ŒŒ‰t“ŕ‰ČjAŠÔ•”ŒŤŠ°A‹gˆä—R”üAŒüˆä@ŒĺAâ–{Œb—˜“ށAˆäă@Œ’AŽč“‡”Ž•ś
ŠĹPS-2-9
‘˘ŒŒ×–EˆÚAŠłŽŇ‚̐HŽ–Žw“ąƒ}ƒjƒ…ƒAƒ‹‚̍쐬‚đŽŽ‚Ý‚Ä.
@ŒK–ź“ÖŽqi‘ĺăŽs—§‘ĺŠwˆăŠw•”•‘Ž•a‰@ŒŒ‰t“ŕ‰ČE‘˘ŒŒ×–EˆÚA‰Č•a“jA“ˆ˜Hť’qAĄˆä—ÁA‚‹´’źŽqA™ŽRK—éAŠâŒŠ–žŽqA”g•˝m”üA’ß“c—ŒbA‹{č‹žŽqA‰ÔŽR‰ŔŽqA“Ą–{_‹BA’†‰Ć´—˛A’†ŞF•FA“ú–ě‰ë”V
ŠĹPS-1-8
‘˘ŒŒ×–EˆÚA‚đ‘I‘đ‚ˇ‚éŠłŽŇ‚Ö‚ĚˆÓŽuŒˆ’čŽx‰‡‚ĚŒťó‚Ɖۑč.
@{ě”üKi‘ĺăŽs—§‘ĺŠwˆăŠw•”•‘Ž•a‰@ŒŒ‰t“ŕ‰ČE‘˘ŒŒ×–EˆÚA‰Č•a“jAŽRčm”üA’ß“c—ŒbA‹{č‹žŽq
PS-2-24
ƒVƒNƒƒXƒ|ƒŠƒ“iCsAj{’ZŠúƒƒ\ƒgƒŒƒLƒZ[ƒgisMTXj‚đGVHD—\–h‚Ć‚ľ‚˝”ńT×–Eœ‹ŽE”ńTBI‰ş‚Ĺ‚Ěœ‘”ń”j‰ó“I”ńŒŒ‰ŽŇŠÔ“ŻŽíœ‘ˆÚAiu-RISTj‚ĚŒŸ“˘.
@’†ŞF•Fi‘ĺăŽs—§‘ĺŠwˆăŠw•”ŒŒ‰t“ŕ‰ČE‘˘ŒŒ×–EˆÚA‰ČjA’†‘O”Ž‹vAN@G’jA’†‘O”ü‰ŔA—с@—ÇŽ÷Aź–{ŒőFA‹g‘ş‘ě˜NAˆäăŒb—˘Aˆäă“ÖŽiA‘Š–{@—–A‘Š–{Ž÷AŽ›“c–FŽ÷A‚@‹N—ǁAŽRŞF‹vA“ú–ě‰ë”V
ŠĹPS-2-30
‘˘ŒŒ×–EˆÚAŠłŽŇ‚̑މ@Œă‚Ě–â‘č“_`ŠO—ˆ‚Ć‚Ě˜AŒg‚đŽŽ‚Ý‚Ä`
@”g•˝m”üi‘ĺăŽs—§‘ĺŠwˆăŠw•”•‘Ž•a‰@ŒŒ‰t“ŕ‰ČE‘˘ŒŒ×–EˆÚA‰Č•a“jA’ß“c—ŒbA‹{č‹žŽq
PS-2-127
”’ŒŒ‹…’ቺŠłŽŇ‚É‚¨‚Ż‚éHŽ–“ŕ—e‚ĚŒŸ“˘.
@‰ÔŽR‰ŔŽqi‘ĺăŽs—§‘ĺŠwˆăŠw•”•‘Ž•a‰@‰h—{•”jA–Ń—˜ŒbŽqA“Ą–{_‹BA“ĺˆä@éAâ‰ş—TŽqAÎě‰Ŕ‘ăŽqA–ěˆä—œA”d–”ü‰ŔA•ž•”rˆęA’Ë“c’čMAŒK–ź“ÖŽqA“ˆ˜Hť’qAŠâŒŠ–žŽqA”g•˝m”üA‹{č‹žŽqA’†ŞF•FA“ú–ě‰ë”V
PS-1-12
Ara-C+CY+TBI‚đ‘Oˆ’u‚Ć‚ľ‚˝”ńŒŒ‰ä`‘ŃŒŒˆÚA‚Ě—\ŒăˆöŽq‚Ě“–‰Č‚Ĺ‚ĚŒŸ“˘.
@—с@—ÇŽ÷i‘ĺăŽs—§‘ĺŠwˆăŠw•”ŒŒ‰tE‘˘ŒŒ×–EˆÚA‰ČjA’†ŞF•FA’†‘O”Ž‹vAN@G’jA’†‘O”ü‰ŔAź–{ŒőFA‹g‘ş‘ě˜NAˆäăŒb—˘Aˆäă“ÖŽiA‘Š–{@—–A‘Š–{Ž÷AŽ›“c–FŽ÷A‚@‹N—ǁAŽRŞF‹vA“ú–ě‰ë”V
PS-2-99
őF‘ĚˆŮít(16;21)(p11;q22)‚đ—L‚ľAä`‘ŃŒŒˆÚAŒă2”N‚ĚŒo‰ß‚ĹÄ”­‚đ—ˆ‚ľ‚˝‹}Ťœ‘Ť”’ŒŒ•a.
@ŠÔ•”ŒŤŠ°i‘ĺăŽs—§‘‡ˆă—ĂƒZƒ“ƒ^[ŒŒ‰t“ŕ‰ČjA‹ŕ“‡@LA‹gˆä—R”üAŒüˆä@ŒĺAâ–{Œb—˜“ށA•XŽşŒöGA‘ž“cŒ’‰îAˆäă@Œ’AŽč“‡”Ž•ś
PS-1-56
“–‰@‚É‚ÄŽŠ‰ĆˆÚA‚đŽ{s‚ľ‚˝ƒAƒ~ƒƒCƒh[ƒVƒX‚ɑ΂ˇ‚錟“˘.
@Œüˆä@Œĺi‘ĺăŽs—§‘‡ˆă—ĂƒZƒ“ƒ^[ŒŒ‰t“ŕ‰ČjAŠÔ•”ŒŤŠ°Aâ–{Œb—˜“ށA‹ŕ“‡@LAŽč“‡”Ž•ś
PS-2-35
“–‰Č‚É‚¨‚Ż‚éˆŤŤƒŠƒ“ƒpŽî‚̑΂ˇ‚鎊ŒČ––˝ŒŒŠ˛×–EˆÚA‚ĚŒă•űŽ‹“I‰đÍ.
@‹gˆä—R”üi‘ĺăŽs—§‘‡ˆă—ĂƒZƒ“ƒ^[ŒŒ‰t“ŕ‰ČjA‹ŕ“‡@LAŒüˆä@ŒĺAŠÔ•”ŒŤŠ°Aâ–{Œb—˜“ށAˆäă@Œ’
[‹¤“ŻŒ¤‹†]
WS-2-11-1
@‘˘ŒŒŠ˛×–EˆÚA‚đŽ{s‚ľ‚˝––˝T ×–EƒŠƒ“ƒpŽî330–ź‚̉đÍ:JSCTŒ¤‹†‰ď“úŠŘ‹¤“Ż’˛¸Œ¤‹†.
@‹ŕ@ŹŒłA—é–Ř—Ľ˜NAŒá‹˝_ŒúAĄ‘ş‰ëŠ°A˜aŸ†@“ցA‹g“c@‹ŞAÎě—˛”VA”¨’†ˆęśAŽO‰YŸ_A“ú–ě‰ë”VA‘ëŕV@~AŽR–{@‹A‘O“c‰ĂMAˆÉ“¤’ÍG“ńA—é–؏~ŽiAź–ě‹gGA’ˇ“ĄG“ńA‚ă—mˆęAChul Soo KimAŒ´“cŽŔŞ

2009”N
‚đƒNƒŠƒbƒN‚ľ‚Ä‚˘‚˝‚ž‚­‚Ć˜a•ś´˜^‚Ş‚˛——‚˘‚˝‚ž‚Ż‚Ü‚ˇB
ŠeŠw‰ď‚É‚¨‚Ż‚鉉‘č‡˜‚Í•M“ŞŽŇ‚đŒÜ\‰š‡‚Ĺ•Ŕ‚ׂè‚č‚Ü‚ˇ

‘ć92‰ń‹ß‹EŒŒ‰tŠw’n•ű‰ď
ƒƒ‹ƒpƒ‹ƒN‹ž“sA‹ž“sA12ŒŽ12“ú
N@Žj˜Niś’ˇ‰ď•{’†•a‰@ŒŒ‰tŽžŠłƒZƒ“ƒ^[jAŽsŒ´O‘PAÂŽR‘׍FA‹v‘şŠx‰›A
ęm’JˆŔ’ĂŽqA‘ž“c’‰MAŒĂě‰Ŕ‰›
”xƒ€ƒR[ƒ‹Ç‚đ‡•š‚ľ‚˝œ‘ˆŮŒ`ŹÇŒóŒQ‚ĚˆęÇ—á.
‰‰‘č23
ŠÔ•”ŒŤŠ°i‘ĺăŽs—§‘‡ˆă—ĂƒZƒ“ƒ^[ŒŒ‰t“ŕ‰ČjA‹ŕ“‡@LA‹gˆä—R”üAŒüˆä@
ŒĺAâ–{Œb—˜“ށAŽč“‡”Ž•śAŠâˆäŒŞˆçA‹v•Ű—E‹LA•Ÿ“‡—TŽqAˆäă@Œ’
‘–ŒŽî—l‚Ě‰ć‘œ‚đ’ć‚ľ‚Ä”­Ç‚ľAŒo‰ß’†‚É‘˝”­Ťœ‘Žî‚ւ̐is‚Ş‚Ý‚ç‚ę‚˝‘ŠOŒ`
Žż×–EŽî.
‰‰‘č8
‹g‘ş‘ě˜Ni‘ĺăŽs—§‘ĺŠwˆăŠw•”•‘Ž•a‰@ŒŒ‰t“ŕ‰ČE‘˘ŒŒ×–EˆÚA‰ČjA’†ŞF•FAˆäă“ÖŽiAˆäăŒb—˘Aź–{ŒőFA—с@—ÇŽ÷A”~–{—R—˘A’†‘O”ü‰ŔAŽ›“c–FŽ÷A’†‘O”Ž‹vA‚@‹N—ǁAŽRŞF‹vA“ú–ě‰ë”V
”牺–Iâ|D‰Š—lT×–EƒŠƒ“ƒpŽîiSPTCLj‚Ě3—á.
‰‰‘č19
˜a“cŸ–çiJR‘ĺă“S“š•a‰@ŒŒ‰t“ŕ‰ČjA‰Ş–{Gˆę˜YA›–ěˆŔŠě
AraC­—Ę—Ă–@Œă‚ĚŽc‘ś‰č‹…‚ɑ΂ľƒfƒLƒTƒƒTƒ]ƒ““Š—^‚Ş’˜Œř‚ľAŠŽ‘SŠ°‰đ‚ÉŽŠ‚Á‚˝‚—îŽŇ‹}Ť”’ŒŒ•a.
‰‰‘č28
ƒVƒ“ƒ|ƒWƒEƒ€
’†‘O”Ž‹vi‘ĺăŽs—§‘ĺŠwˆăŠw•”•‘Ž•a‰@ŒŒ‰t“ŕ‰ČE‘˘ŒŒ×–EˆÚA‰Čj
‚ ‚Č‚˝‚Č‚ç‚Ç‚¤‚ˇ‚鑢ŒŒŠ˛×–EˆÚA`HLA“K‡ŒŒ‰ŽŇ‚Ş“ž‚ç‚ę‚Č‚˘Žž`
2)”ńŒŒ‰ŽŇŠÔœ‘”ń”j‰ó“I“ŻŽíœ‘E––˝ŒŒ‘˘ŒŒŠ˛×–EˆÚA‚ĚŒťó.

‘ć71‰ń“ú–{ŒŒ‰tŠw‰ďŠwpW‰ď
‘—§‹ž“s‘Ű‰ďŠŮA‹ž“sA10ŒŽ23“úA24“úA25“ú
‹ŕ“‡@Li‘ĺăŽs—§‘‡ˆă—ĂƒZƒ“ƒ^[ŒŒ‰t“ŕ‰ČjAŠÔ•”ŒŤŠ°A‹gˆä—R”üAŒüˆä@ŒĺAâ–{Œb—˜“ށAˆäă@Œ’AŽč“‡”Ž•ś
–ŤŠˆ“ŽŤEBƒEƒCƒ‹ƒXŠ´őÇ‚É“ŻŽí––˝ŒŒŠ˛×–EˆÚA‚đŽ{sŒă“ńŽŸŤ”’ŒŒ•a‚đ”­Ç‚ľ‚˝ˆę—á.
‰‰‘č PS-2-55
‹v‘şŠx‰›iŽĐ‰ďˆă—Ă–@l•{’†•a‰@ŒŒ‰t“ŕ‰ČjAÂŽR‘׍FAŽsŒ´O‘PAN@Žj˜NAęm’JˆŔ’ĂŽq
“–‰@‚É‚¨‚Ż‚鎥—Ă’ďRŤ‘˝”­Ťœ‘Žî‚ɑ΂ˇ‚éBortezomib‚ĚŽĄ—ĂŒoŒą.
‰‰‘č PS-2-201
Źâ‚ł‚¨‚či‘ĺă•{Ďś‰ď’†’Ă•a‰@ŒŒ‰t“ŕ‰ČjA‘ž“cŒ’‰îA’†”ö‹gFA‹v‘şŠx‰›A”‹Œ´Œ‰’ʁAâ–{Œb—˜“ށA‰Ş–{Gˆę˜YA—с@—ÇŽ÷A‘Š–{@—–A”~–{—R—˘AŽ›“c–FŽ÷A•‰ŞNMA’†ŞF•FAN@G’jA“ú–ě‰ë”V
ƒCƒgƒ‰ƒRƒiƒ][ƒ‹’ŽË–ň‚É‚ć‚éŒoŒą“IŽĄ—Ă‚ĚEORTC/MSGf’fŠî€‚ÉŠî‚Ă‚˘‚˝—LŒřŤ‰đÍ.
‰‰‘č PS-2-220
Ž›“c–FŽ÷i‘ĺăŽs—§‘ĺŠwŒŒ‰tŽîᇐ§ŒäŠwjA’†‘O”Ž‹vA‘Š–{@—–A‹ŕ“‡@LAâ–{Œb—˜“ށAˆäă“ÖŽiA‹g‘ş‘ě˜NAˆäăŒb—˘Aź–{ŒőFA—с@—ÇŽ÷AN@G’jA’†ŞF•FA’†‘O”ü‰ŔA‚@‹N—ǁAŽRŞF‹vA’†”ö‹gFA‘ž“cŒ’‰îAęm’JˆŔ’ĂŽqAŽč“‡”Ž•śA“ú–ě‰ë”V
Ä”­E“ŤBcl-2/IgH—zŤ‚ë‚Ů‚¤ŤƒŠƒ“ƒpŽî‚ɑ΂ˇ‚éCladribine—Ă–@.
‰‰‘č OS-3-65
“Ą’J—m‘ž˜Ni‘ĺă•{Ďś‰ď’†’Ă•a‰@ŒŒ‰t“ŕ‰ČjA‚‹´”ü—R‹IAˆî—tWŽqAŠÔ•”ŒŤŠ°AŹâ‚ł‚¨‚čAŽR‘ş—ş‰îA‘ž“cŒ’‰î
‘˘ŒŒŠíŽžŠł‚É”ş‚¤”­”MŤD’†‹…Œ¸­Ç‚ɑ΂ˇ‚éƒZƒtƒFƒsƒ€‚Ě—LŒřŤ‚ÉŠÖ‚ˇ‚éŒă•űŽ‹“IŒŸ“˘.
‰‰‘čPS-2-41
ŠÔ•”ŒŤŠ°i‘ĺăŽs—§‘‡ˆă—ĂƒZƒ“ƒ^[ŒŒ‰t“ŕ‰ČjA•“cWŽiA‹gˆä—R”üAŒüˆä@ŒĺAâ–{Œb—˜“ށA‹ŕ“‡@LA‹v•Ű—E‹LA•Ÿ“‡—TŽqAˆäă@Œ’AŽč“‡”Ž•ś
”dŽíŤŒŒŠÇ“ŕ‹ĂŒĹ‚𔺂Á‚˝œ‘ŠŕŽîÇ‚Ě4—á.
‰‰‘č PS-2-256
Œüˆä@Œĺi‘ĺăŽs—§‘‡ˆă—ĂƒZƒ“ƒ^[ŒŒ‰t“ŕ‰ČjAŠÔ•”ŒŤŠ°Aâ–{Œb—˜“ށA‹ŕ“‡@LA’†‘ş‹§GA•SŁ@‘ĺA“ú–ě‰ë”VAŒK]—DŽqAŽá‹ˇŒ¤ˆęAŽč“‡”Ž•ś
Œă“VŤ–Ɖu•s‘SÇŒóŒQ‚ɍ‡•š‚ľ‚˝—œóâ|Œ´”­”ńƒzƒWƒLƒ“ƒŠƒ“ƒpŽî‚Ěˆę—á.
‰‰‘čPS-2-105
ęm’JˆŔ’ĂŽqAN@Žj˜NAŽsŒ´O‘PAÂŽR‘׍FA‹v‘şŠx‰›A‘ž“c’‰MAŒĂě‰Ŕ‰›
‘˝”­Ťœ‘Žî‚ɑ΂ˇ‚éƒTƒŒƒhƒJƒvƒZƒ‹100‚ĚŽg—pŒoŒą.
‰‰‘čPS-2-192
ŽR‘ş—ş‰îi‘ĺă•{Ďś‰ď’†’Ă•a‰@ŒŒ‰t“ŕ‰ČjAâ–{Œb—˜“ށAŽ›“c–FŽ÷Aă–{e•FAŹâ‚ł‚¨‚čAÂŽR‘׍FAŽ†’J•x•vAŽč“‡”Ž•śAęm’JˆŔ’ĂŽqA‘ž“cŒ’‰îA“ú–ě‰ë”V
—AŒŒŒă“S‰ßčÇ‚ɑ΂ˇ‚éŒoŒűƒLƒŒ[ƒgÜideferasiroxj‚ĚŽg—pŒoŒą.
‰‰‘č0S-2-142
‹gˆä—R”üi‘ĺăŽs—§‘‡ˆă—ĂƒZƒ“ƒ^[ŒŒ‰t“ŕ‰ČjAŠÔ•”ŒŤŠ°AŒüˆä@ŒĺAâ–{Œb—˜“ށA‹ŕ“‡@LAˆäă@Œ’AŽč“‡”Ž•ś
t(9;22;16)(q34;q11;q24)‚𔺂Á‚˝–Ťœ‘Ť”’ŒŒ•a.
‰‰‘č PS-3-42
Tadanobu OhtaiŽĐ‰ďˆă—Ă–@l•{’†•a‰@ŒŒ‰tŽžŠłƒZƒ“ƒ^[j, Kazusuke Oguma, Yoshio Furukawa, Shiro Koh, Hiroyoshi Ichihara, Yasutaka Aoyama, Takeo Kumura, Atsuko Mugitani, Masayuki Hino
Two cases of spur cell anemia with difficulty diagnosis from MDS.
‰‰‘č PS-3-149
‘˝Ž{Ý‹¤“ŻŒ¤‹†
ź‰Ş@Li˜a‰ĚŽRŒ§—§ˆă‰Č‘ĺŠwŒŒ‰t“ŕ‰ČjAŒI–{”ü˜aA‰Ô‰ŞL‰ŔA”ΓcŽu–ƒA“‡ŠŃ‰h–íA×ˆä—TŽ÷A‘ş“cËŒáA’źě‹§°AăŒű@—ՁA“ú–ě‰ë”VAŽRŞF‹vAă–{e•FA‘ž“cŒ’‰îAęm’JˆŔ’ĂŽqAÂŽR‘׍FA‰€–؍FŽuA’†ŒFGŠě
Ä”­E“ŤAML‚ɑ΂ˇ‚éCAG—Ă–@‚¨‚ć‚ŃG-CSFćsƒQƒ€ƒcƒYƒ}ƒuƒIƒ]ƒKƒ}ƒCƒVƒ“iGOj—Ă–@.
‰‰‘čOS-2-2
‘˝Ž{Ý‹¤“ŻŒ¤‹†
”Ń“c”ü“ŢŽqiˆ¤’mˆă‰Č‘ĺŠw‘˘ŒŒ×–EˆÚAU‹ťŠń•tuŔjA•Ÿ“cűé_A’r‹T˜a”ŽA‹gŒ´@“NAŹěŒ[‹ąA’JŒűCˆęA‚ŒŠş—ǁAˆŔ•”NMA“ú–ě‰ë”VA‰q“Ą“O–çA”M“c—RŽqA“c’†~ŽiA—é–Ř—Ľ˜N
‰ä‚ލ‘‚É‚¨‚Ż‚錌‰“ŻŽí‘˘ŒŒŠ˛×–EˆÚA‚Ĺ‚ĚMycophenolate MofetiliMMFjŽg—p‘S‘ŽŔ‘Ô’˛¸Œ‹‰Ę•ń.
‰‰‘č OS-3-106

‘ć189‰ń“ú–{“ŕ‰ČŠw‰ď‹ß‹E’n•ű‰ď
‘ĺă‘ŰŒđ—ŹƒZƒ“ƒ^[A‘ĺăA9 ŒŽ26“ú
óˆäƒŽuiJR‘ĺă“S“š•a‰@ŒŒ‰t“ŕ‰ČjA‰Ş–{Gˆę˜YA›–ěˆŔŠěA˜a“cŸ–ç
Šˆ“ŽŤEBVŠ´ő‚Ć‚ĚŠÖ˜A‚Ş‹^‚í‚ę‚˝Coombs‰AŤŽŠŒČ–ƉuŤ—nŒŒŤ•nŒŒ
ŒŒ‰t3 ‰‰‘č115

ŽsŒ´O‘Pi•{’†•a‰@EŒŒ‰tŽžŠłƒZƒ“ƒ^[jAÂŽR‘׍FA‹v‘şŠx‰›AN@Žj˜NA‘ž“c’‰MAŒĂě‰Ŕ‰›Aęm’JˆŔ’ĂŽq
ƒ{ƒŠƒRƒiƒ][ƒ‹‚ĹQT‰„’ˇAtorsardes de pointes‚𐜂ś‚˝”’ŒŒ•aÇ—á.
‘ć91‰ń‹ß‹EŒŒ‰tŠw’n•ű‰ďA“ޗǁA6ŒŽ20“ú
‰Ş–{Gˆę˜Yi‘ĺă“S“š•a‰@EŒŒ‰t“ŕ‰ČjA›–ěˆŔŠěA˜a“cŸ–ç
ATRA—Ă–@‚É‚ć‚銰‰đŒă8”N–ڂɍĔ­AATRAEˆŸáĺŽ_‚ĚŒđ‘Ö“Š—^‚ɂčēx•ŞŽqŠ°‰đ‚đ“ž‚˝‚—î‹}Ť‘Oœ‘‹…Ť”’ŒŒ•a.
‘ć91‰ń‹ß‹EŒŒ‰tŠw’n•ű‰ďA“ޗǁA6ŒŽ20“ú
ź–{ŒőFi‘ĺăŽs—§‘ĺŠw‘ĺŠw‰@EŒŒ‰tŽîᇐ§ŒäŠwjA‚@‹N—ǁAN@G’jA’†ŞF•FAŽ›“c–FŽ÷A’†‘O”ü‰ŔA’†‘O”Ž‹vAŽRŞF‹vA“ú–ě‰ë”V
CCyR‚ĹŒo‰ß’†Amp-CML‚Ş‘‰Á‚ľ’†•_ŒoZ‚Ĺ‹}Ť“]‰ť‚ľ‚˝CML‚Ě1—á.
‘ć91‰ń‹ß‹EŒŒ‰tŠw’n•ű‰ďA“ޗǁA6ŒŽ20“ú
‹gˆä—R”üi‘ĺăŽs—§‘‡ˆă—ĂƒZƒ“ƒ^[@ŒŒ‰t“ŕ‰ČjAŒüˆä@ŒĺAŠÔ•”ŒŤŠ°Aâ–{Œb—˜“ށA‹ŕ“‡@LA•y“cŽqAX@G•vAˆäă@Œ’AŽč“‡”Ž•ś
ŠáÇó‚ɑ΂ľÉŽq‘̐śŒŸ‚ɂčĔ­‚Ɛf’f‚ľ‚˝•@oŒ´”­ˆŤŤƒŠƒ“ƒpŽî‚Ěˆę—á.
‘ć91‰ń‹ß‹EŒŒ‰tŠw’n•ű‰ďA“ޗǁA6ŒŽ20“ú
‘Š–{Ž÷i‘ĺăŽs‘ĺEŒŒ‰tŽîᇐ§ŒäŠwjAN@G’jA•SŁ@‘ĺA‰Ş–{Gˆę˜YAŽçŒű@—–A˜a“cŒb—˘A’†ŞF•FA•‰ŞNMAŽ›“c–FŽ÷A‚@‹N—ǁAŽRŞF‹vA“ú–ě‰ë”V
“ŻŽí‘˘ŒŒŠ˛×–EˆÚAŒă‚̓ŤƒAƒfƒmƒEƒCƒ‹ƒXoŒŒŤäNă÷‰Š‚ɑ΂ˇ‚écidofovir‚Ě—L—pŤ‚ĚŒŸ“˘.
‘ć31‰ń“ú–{‘˘ŒŒ×–EˆÚAŠw‰ďAŽD–yA2ŒŽ5“úA6“ú
ÂŽR‘׍Fiś’ˇ‰ď•{’†•a‰@EŒŒ‰tŽžŠłƒZƒ“ƒ^[jA‹v‘şŠx‰›AŽsŒ´O‘PAęm’JˆŔ’ĂŽqA•Ä’J@¸A“ú–ě‰ë”V
Žq•ęŠÔ“ŻŽí‘˘ŒŒŠ˛×–EˆÚA‚đŽ{s‚ľ‚˝Œ´”­Ťƒ}ƒNƒƒOƒƒuƒŠƒ“ŒŒÇ‚Ě‚P—á.
‘ć31‰ń“ú–{‘˘ŒŒ×–EˆÚAŠw‰ďAŽD–yA2ŒŽ5“úA6“ú
ÔŕVŒ‹‹Mi‘ĺăŽs‘ĺEŒŒ‰tŽîᇐ§ŒäŠwjAŽ›“c–FŽ÷A“c’†‚ł‚â‚ŠA•SŁ@‘ĺA‘Š–{Ž÷A‰Ş–{Gˆę˜YAŽçŒű@—–A˜a“cŒb—˘AN@G’jA’†ŞF•FA•‰ŞNMA‚@‹N—ǁAŽRŞF‹vA‘ĺŕV­•FA“ú–ě‰ë”V
“ŻŽí‘˘ŒŒŠ˛×–EˆÚAŒăBKƒEƒCƒ‹ƒX‚É‚ć‚édÇ”x‰Š‚Ěˆę—á.
‘ć31‰ń“ú–{‘˘ŒŒ×–EˆÚAŠw‰ďAŽD–yA2ŒŽ5“úA6“ú
ŠâŒŠ–žŽqi‘ĺăŽs‘ĺE7ŠK•a“jAŒK–ź“ÖŽqAŽR“c˜a”üA”g•˝m”üA‹ŽRŒłŽqA’ß“c—ŒbA‹{č‹žŽqA’†ŞF•FA•‰ŞNMA“ú–ě‰ë”V
‘˘ŒŒŠ˛×–EˆÚA‚ĚŒűo”S–ŒáŠQ—\–h‚Ć‚ľ‚Ä‚ĚGFOŒoŒűŰŽć‚ĚŒř‰Ę.
‘ć31‰ń“ú–{‘˘ŒŒ×–EˆÚAŠw‰ďAŽD–yA2ŒŽ5“úA6“ú
ă–ě^—RŽqi‘ĺăŽs‘ĺE7ŠK•a“jAĄˆä—ÁA‘˝ŽĄ”䐴ŽqAŽRčm”üA‹{‰ş’ĺ”üA”g•˝m”üA‹ŽRŒłŽqA’ß“c—ŒbA‹{č‹žŽq
‘˘ŒŒŠ˛×–EˆÚA‚É‚¨‚Ż‚éADL’ቺ‚̉e‹ż—vˆö‚ĚŒŸ“˘-FIM•]‰ż‚đ—p‚˘‚Ä-.
‘ć31‰ń“ú–{‘˘ŒŒ×–EˆÚAŠw‰ďAŽD–yA2ŒŽ5“úA6“ú
‡“ŻƒVƒ“ƒ|ƒWƒEƒ€u”ńŒŒ‰PBSCT‚ÉŒü‚Ż‚āv
“ú–ě‰ë”Vi‘ĺăŽs‘ĺEŒŒ‰tŽîᇐ§ŒäŠwj
œ‘ˆÚA„iŕ’ciJMDPj‚É‚¨‚Ż‚éŽć‘g‚ĚŒťó‚ƏŤ—ˆ“W–].
‘ć31‰ń“ú–{‘˘ŒŒ×–EˆÚAŠw‰ďAŽD–yA2ŒŽ5“úA6“ú
•‰ŞNMi‘ĺăŽs‘ĺEŒŒ‰tŽîᇐ§ŒäŠwjA’†ŞF•FAN@G’jA‰Ş–{Gˆę˜YA‘Š–{Ž÷A˜a“cŒb—˘A•SŁ@‘ĺA‚@‹N—ǁAŽRŞF‹vAŽ›“c–FŽ÷A’†‘O”Ž‹vAŽçŒű@—–A”~–{—R—˘A“ú–ě‰ë”V
‰ŠúŽĄ—Ă•s‰žŤ‚Ě’°ŠÇ‹}ŤGVHD‚ɑ΂ˇ‚éƒXƒeƒƒCƒh“Ž’—Ă–@‚ĚŒŸ“˘.
‘ć31‰ń“ú–{‘˘ŒŒ×–EˆÚAŠw‰ďAŽD–yA2ŒŽ5“úA6“ú
’†ŞF•Fi‘ĺăŽs‘ĺEŒŒ‰tŽîᇐ§ŒäŠwjA•‰ŞNMA’†‘O”Ž‹vA‘Š–{Ž÷AN@G’jA•SŁ@‘ĺA‰Ş–{Gˆę˜YA˜a“cŒb—˘AŽçŒű@—–A”~–{—R—˘AŽ›“c–FŽ÷A‚@‹N—ǁAŽRŞF‹vA“ú–ě‰ë”V
‹}ŤGVHD‚ɑ΂ˇ‚鏉ŠúŽĄ—Ă‚Ć‚ľ‚Ä‚ĚƒXƒeƒƒCƒh‚¨‚ć‚Ńƒ~ƒRƒtƒFƒm[ƒ‹Ž_ƒ‚ƒtƒFƒ`ƒ‹iMMFj•š—p—Ă–@‚ĚˆŔ‘SŤ‚¨‚ć‚Ń—LŒřŤ‚ÉŠÖ‚ˇ‚錟“˘.
‘ć31‰ń“ú–{‘˘ŒŒ×–EˆÚAŠw‰ďAŽD–yA2ŒŽ5“úA6“ú
ź‰Y”üKi‘ĺăŽs‘ĺEŒŒ‰t“ŕ‰ČŠO—ˆjAŒK–ź“ÖŽqA’ß“c—ŒbA‰Í“ŕƒqƒfŽqA‹{č‹žŽq
‘˘ŒŒŠ˛×–EˆÚAŒă‚̐HŽ–‚ĚŽŔŰ‚ɂ‚˘‚Ä.
‘ć31‰ń“ú–{‘˘ŒŒ×–EˆÚAŠw‰ďAŽD–yA2ŒŽ5“úA6“ú
ŠÔ•”ŒŤŠ°iĎś‰ď’†’Ă•a‰@EŒŒ‰t“ŕ‰ČjA‹ž–{”ŽsAŽR‘ş—ş‰îA“Ą’J—m‘ž˜NAŹâ‚ł‚¨‚čA‘ž“cŒ’‰îAź“cM•FAźě“T—ǁA‘ë“cł—şA‹ŕ“‡@LAŽč“‡”Ž•śAŽçŒű@—–A“ú–ě‰ë”V
‘˘ŒŒ×–EˆÚA‘O‚ĚŒűo“ੴőŒšƒXƒNƒŠ[ƒjƒ“ƒO‚ĚŒŸ“˘.
‘ć31‰ń“ú–{‘˘ŒŒ×–EˆÚAŠw‰ďAŽD–yA2ŒŽ5“úA6“ú
ŽçŽRˆç”üi‘ĺăŽs‘ĺEŒŒ‰t“ŕ‰ČjA{ě”üKA‘şŒű—SŽqA‘ĺ“c–ƒˆßŽqAŠp@^‘ăA’ß“c—ŒbA”g•˝m”üA‹{č‹žŽq
ˆÚAŒăŠłŽŇ‚Ě•s–°Çó‚ɑ΂ˇ‚éƒAƒƒ}ƒeƒ‰ƒs[‚ĚŒř‰Ę.
‘ć31‰ń“ú–{‘˘ŒŒ×–EˆÚAŠw‰ďAŽD–yA2ŒŽ5“úA6“ú
[‘˝Ž{Ý‹¤“ŻŒ¤‹†]
•ŕVĘŽqi‘—§‚Ş‚ńƒZƒ“ƒ^[’†‰›•a‰@EŠ˛×–EˆÚA‰ČjAŽRŒű‘ń—mA‹ŕX•˝˜aAŽR‰ş‘ě–çA‰P‹nŒ›—SA–ňŽtŽ›˜aşA’|“ŕ@mA“ě’J‘אmAŽÄŽR_•FA“ú–ě‰ë”VAX“ŕK”üA˜e@–[ŽqA‹›“ˆL•FA“Ą“c_”VA‚ź@‘ׁA›Á@“úłA”öčŒhŽĄAźÎ‰péA‹Ęˆä‰ŔŽqA‹´–ě@‘A‚–ě–í“ށAź‹´‰ŔŽqA“ú‚“šOA‰i“ˆ‹M”ŽA•xŽR‡ŽĄA’r‹T˜a”ŽA‹{˜eCˆęA“ŕ“c’ź”VA_“c‘PLA•Ÿ“c—˛_
‘ćˆęŠ°‰đŠú(CR1)‹}Ťœ‘Ť”’ŒŒ•a(AML)‚ɑ΂ˇ‚é“ŻŽíˆÚA‚đŠÜ‚ß‚˝ŽĄ—Ă‚ÉŠÖ‚ˇ‚é—Տ°Œˆ’f•ŞÍi’†ŠÔ‰đÍj.
‘ć31‰ń“ú–{‘˘ŒŒ×–EˆÚAŠw‰ďAŽD–yA2ŒŽ5“úA6“ú
[‘˝Ž{Ý‹¤“ŻŒ¤‹†]
”‹Œ´›’‘ž˜YA‹ŕ@ŹŒłAŹźP•FAŒă“Ą“N–çAă“c‹ą“TAˆÉ“Ąr˜NA“ú–ě‰ë”VAŠp“ěˆę‹MA“c–ěč—˛“ńAX@Tˆę˜YAă@šLA’J–{“N–çA“c“‡ŒŚŽqA•Ÿ“cűéLA‚ă—mˆęiRISTŒ¤‹†ƒOƒ‹[ƒvj
ƒNƒ‰ƒhƒ‹ƒrƒ“‚¨‚ć‚ŃƒuƒXƒ‹ƒtƒ@ƒ“‚đ‘Oˆ’u‚Ć‚ľ‚˝HLA“K‡ŒŒ‰ŽŇŠÔƒ~ƒjˆÚA‚É‚¨‚Ż‚éGVHD—\–h‚ÉŠÖ‚ˇ‚郉ƒ“ƒ_ƒ€‰ť‘ćII‘ŠŽŽŒąFƒVƒNƒƒXƒ|ƒŠƒ“’P“Ć‘Îƒ^ƒNƒƒŠƒ€ƒX’P“ƁiRIST0301j.
‘ć31‰ń“ú–{‘˘ŒŒ×–EˆÚAŠw‰ďAŽD–yA2ŒŽ5“úA6“ú
[‘˝Ž{Ý‹¤“ŻŒ¤‹†]
ŽRčGli‹ŕ‘ň‘ĺŠwE×–EˆÚAŠwjA“ú–ě‰ë”VAŒĂě’B—YAX‰ş„‹vA‰F“s‹{äoAĄ‘ş‰ëŠ°A‹S’ː^mAV’Ă—mŽi˜YAŠ}ˆäł°A“c“ˆŽŽjA”~Œ´‹v”́A“‡čçqA’JŒűCˆęAĄ‘ş@–LA’†”öáÁ“ń
C3‚đŽw•W‚Ć‚ľ‚˝ƒVƒNƒƒXƒ|ƒŠƒ“‚É‚ć‚é‹}ŤGVHD—\–h–@‚ĚŒŸ“˘F‘źŽ{Ý‹¤“Ż—Տ°ŽŽŒą‚̐ŹŃ.
‘ć31‰ń“ú–{‘˘ŒŒ×–EˆÚAŠw‰ďAŽD–yA2ŒŽ5“úA6“ú

2008”N
‚đƒNƒŠƒbƒN‚ľ‚Ä‚˘‚˝‚ž‚­‚Ć˜a•ś´˜^‚Ş‚˛——‚˘‚˝‚ž‚Ż‚Ü‚ˇB

ŠeŠw‰ď‚É‚¨‚Ż‚鉉‘č‡˜‚Í•M“ŞŽŇ‚đŒÜ\‰š‡‚Ĺ•Ŕ‚ׂè‚č‚Ü‚ˇ

50th American Society of Hematology
San FransiscoADec 6-9
[‹¤“ŻŒ¤‹†]
1170
Randomized Phase II Trial Comparing Cyclosporine (CSP) and Tacrolimus (TAC). for Methotrexate (MTX)-Free Graft-Versus-Host Disease (GVHD) Prophylaxis after Allogeneic Transplantation from a Matched Related Donor (MRD) with a Reduced-Intensity Regimen Containing Cladribine and Busulfan

Kim SW, Fukuda T, Hagiwara S, Komatsu T, Goto T, Ueda Y, Ito T, Hino M, Sunami K, Tanosaki R, Mori S, Kami M, Tajima K, Takaue Y


‘ž“c’‰Miś’ˇ‰ď•{’†•a‰@“ŕ‰ČjA‰Ş“c@Œ’AŒĂě‰Ŕ‰›AŽsŒ´O‘PAÂŽR‘׍FA‹v‘şŠx‰›Aęm’JˆŔ’ĂŽqA“ú–ě‰ë”VA‘O‘qrŽĄ
TCRˆâ“`ŽqÄ\Ź‚đ”F‚߃Šƒ“ƒpŽî‚Ć‚ĚŠÓ•Ę‚đ—v‚ľ‚˝ś‰ş• •”Œ´”­adenocarcinoma‚Ěˆę–UŒŸ—á.
‘ć70‰ń“ú–{ŒŒ‰tŠw‰ď‘‰ď
‹ž“sA10ŒŽ10-12“ú
Źâ‚ł‚¨‚či‘ĺă•{Ďś‰ď’†’Ă•a‰@ŒŒ‰t“ŕ‰ČjA‘ž“cŒ’‰îAŽçŒű@—–A”‹Œ´Œ‰’ʁA‹v‘şŠx‰›A’†”ö‹gFAâ–{Œb—˜“ށA‰Ş–{Gˆę˜YAœAŁ’ŠśA‰Í–ěŒŞˆę˜YAÂŽR‘׍FAŽR‘ş—ş‰îA—с@—ÇŽ÷A‹ŕ“‡@LA‚@‹N—ǁAŽRŞF‹vA“ú–ě‰ë”V
LˆćRśÜ•s‰ž‚Ě”­”MŤD’†‹…Œ¸­Ç‚ɑ΂ˇ‚éŒoŒą“IŽĄ—Ă‚Ć‚ľ‚Ä‚ĚƒCƒgƒ‰ƒRƒiƒ][ƒ‹’ŽË–ň‚Ě—L—pŤ‚ɂ‚˘‚Ä.
‘ć70‰ń“ú–{ŒŒ‰tŠw‰ď‘‰ď
‹ž“sA10ŒŽ10-12“ú
â–{Œb—˜“ށi‘ĺăŽs—§‘‡ˆă—ĂƒZƒ“ƒ^[ŒŒ‰t“ŕ‰ČjA‘ž“cŒ’‰îAŽçŒű@—–AN@G’jA’†ŞF•FA•‰ŞNMAŽ›“c–FŽ÷A˜a“cŒb—˘A•SŁ@‘ĺA‘Š–{Ž÷AŹâ‚ł‚¨‚čAŽR‘ş—ş‰îAŠÔ•”ŒŤŠ°A‚@‹N—ǁAŽRŞF‹vA“ú–ě‰ë”V
‘˘ŒŒŠíŽžŠłŽĄ—Ă’†ŠłŽŇ‚Ě”­”MŤD’†‹…Œ¸­Ç‚̐f’fŽĄ—Ă‚É‚¨‚Ż‚éƒvƒƒJƒ‹ƒVƒgƒjƒ“‚Ě—L—pŤ‚ÉŠÖ‚ˇ‚錟“˘.
‘ć70‰ń“ú–{ŒŒ‰tŠw‰ď‘‰ď
‹ž“sA10ŒŽ10-12“ú
Ž›“c–FŽ÷i‘ĺăŽs—§‘ĺŠw‘ĺŠw‰@ˆăŠwŒ¤‹†‰ČŒŒ‰tŽîᇐ§ŒäŠwjA’†‘O”Ž‹vAŽçŒű@—–A‹ŕ“‡@LAâ–{Œb—˜“ށA‘Š–{Ž÷A˜a“cŒb—˘AN@G’jA’†ŞF•FA•‰ŞNMA‚@‹N—ǁAŽRŞF‹vA’†”ö‹gFAęm’JˆŔ’ĂŽqA‘ž“cŒ’‰îAŽč“‡”Ž•śA“ú–ě‰ë”V
‚Ń‚Ü‚ńŤ‘ĺ×–EŒ^B×–EŤƒŠƒ“ƒpŽî‚ĚCHOP—Ă–@‚É‚¨‚Ż‚éRelative Dose IntensityiRDIj‚Ě—\Œă‚ւ̉e‹ż.
‘ć70‰ń“ú–{ŒŒ‰tŠw‰ď‘‰ď
‹ž“sA10ŒŽ10-12“ú
’†”ö—˛•śi‘ĺăŽs—§‘ĺŠwŒŒ‰t“ŕ‰ČE‘˘ŒŒ×–EˆÚA‰ČA‘ĺăŽs—§‘ĺŠw•ŞŽq•a‘Ô–ň—ŠwjAŽRŞF‹vA•Đă”şŽqA˛Žç—F”ŽAŠâ”ö@—mA“ú–ě‰ë”V
ƒGƒNƒ\ƒ“13‚ɐV‹Kƒiƒ“ƒZƒ“ƒX•ĎˆŮiTrp499Stopj‚đ”F‚ß‚˝ƒvƒŒƒJƒŠƒNƒŒƒCƒ“Œ‡–RÇ.
‘ć70‰ń“ú–{ŒŒ‰tŠw‰ď‘‰ď
‹ž“sA10ŒŽ10-12“ú
“Ą’J—m‘ž˜Ni‘ĺăŽs—§‘‡ˆă—ĂƒZƒ“ƒ^[ŒŒ‰t“ŕ‰ČjA‹ŕ“‡@LA‹gˆä—R”üAŒüˆä@ŒĺA—с@—ÇŽ÷Aâ–{Œb—˜“ށAŽč“‡”Ž•ś
“–‰Č‚É‚¨‚Ż‚閝Ťœ‘Ť”’ŒŒ•a‚ɑ΂ˇ‚郁ƒVƒ‹Ž_ƒCƒ}ƒ`ƒjƒuŽĄ—ÐŹŃ.
‘ć70‰ń“ú–{ŒŒ‰tŠw‰ď‘‰ď
‹ž“sA10ŒŽ10-12“ú
ŠÔ•”ŒŤŠ°i‘ĺă•{Ďś‰ď’†’Ă•a‰@ŒŒ‰t“ŕ‰ČjA“Ą’J—m‘ž˜NAŹâ‚ł‚¨‚čAŽR‘ş—ş‰îA‘ž“cŒ’‰îAXě@‹MAZ’J[OAˆäă@Œ’AŽč“‡”Ž•ś
Œo‹CŠÇŽx”xśŒŸ‚ɂĐf’fŠm’č‚ľAŽŠ‰Ć––˝ŒŒŠ˛×–EˆÚA‚Ş—LŒř‚Ĺ‚ ‚Á‚˝ŒŒŠÇ“ŕ‘ĺ×–EŒ^‚a×–EƒŠƒ“ƒpŽîÇ—á.
‘ć70‰ń“ú–{ŒŒ‰tŠw‰ď‘‰ď
‹ž“sA10ŒŽ10-12“ú
ęm’JˆŔ’ĂŽqiś’ˇ‰ď•{’†•a‰@ŒŒ‰t“ŕ‰ČjAŽsŒ´O‘PAÂŽR‘׍FA‹v‘şŠx‰›AŒĂě‰Ŕ‰›A‘ž“c’‰MA‘ž“c„OA“ú–ě‰ë”VA’Jě@’A‘O‘qrŽĄA‰Ôˆä@~
‹}‘Ź‚ČƒAƒ~ƒƒCƒh[ƒVƒX‚̐is‚đ”F‚ß‚˝‘˝”­Ťœ‘Žî.
‘ć70‰ń“ú–{ŒŒ‰tŠw‰ď‘‰ď
‹ž“sA10ŒŽ10-12“ú
[‘˝Ž{Ý‹¤“ŻŒ¤‹†]
ÎˆäˆęŒciŽs—§ŠÝ˜a“cŽs–Ż•a‰@ŒŒ‰t“ŕ‰ČjAŠÔ•”ŒŤŠ°A‰Ž–Ř•q–çAŽč“‡”Ž•śA‰iâX–őÍA–Ř‘ş‰pŽkA‰YŁ•ś–žA—с@–M—YAŽÄ–ě@ŒŤA’ËŒű^’mŽqAŒj“c’B–çAęm’JˆŔ’ĂŽqA–kŽR@“™A–ě‘şšě
‚—îŽŇaggressive”ńƒzƒWƒLƒ“ƒŠƒ“ƒpŽî‚ɑ΂ˇ‚éR-VNCOP-B—Ă–@.‘ć2‘ŠŒ¤‹†.
‘ć70‰ń“ú–{ŒŒ‰tŠw‰ď‘‰ď
‹ž“sA10ŒŽ10-12“ú
[‘˝Ž{Ý‹¤“ŻŒ¤‹†]
ŠÝ–{—TŽŸiŠÖźˆă‰Č‘ĺŠw•‘Ž–‡•ű•a‰@ŒŒ‰tEŽîᇓŕ‰ČjAŽRŞF‹vA‘ž“cŒ’‰îA“Ą“c^–çA“c“ˆŒ’ˆę˜YAX@áÁˆę˜YA’†”ö—˛•śA‚@‹N—ǁA–p@‹ÎAAŹâ‚ł‚¨‚čAŽR‘ş—ş‰îA“ňě—´ˆęA“ú–ě‰ë”VA•ŸŒ´Ž‘űś
–ŤŠúCML‚É‚¨‚Ż‚éƒCƒ}ƒ`ƒjƒuŽĄ—Ă‚ĚŒťó.
‘ć70‰ń“ú–{ŒŒ‰tŠw‰ď‘‰ď
‹ž“sA10ŒŽ10-12“ú
‹{–{“Ţ’ĂŽqi‘ĺăŽs—§‘ĺŒŒ‰t“ŕ‰ČE‘˘ŒŒŠ˛×–EˆÚA‰ČjAŹě‹g•FA’†ŞF•FA˜a“c@Œb—˘AN@G’jA•‰ŞNMAŽ›“c–FŽ÷A‚@‹N—ǁAŽRŞF‹vA“ú–ě‰ë”V
“ŻŽí‘˘ŒŒŠ˛×–EˆÚAŒăA‚“x‚Ě•Ö”é‚ƓŤ• ’É‚Ĺ”­Ç‚ľ‚˝”dŽíŤ…“—‘яóáv]ƒEƒCƒ‹ƒX(VZV)Š´őÇ‚Ěˆę—á.
‘ć185‰ń“ŕ‰ČŠw‰ď‹ß‹E’n•ű‰ď
‘ĺăA6ŒŽ7“ú
‘Š–{Ž÷i‘ĺăŽs‘ĺŒŒ‰t“ŕ‰ČE‘˘ŒŒ×–EˆÚA‰ČjA’†ŞF•FAN@G’jA•‰ŞNMAÔŕVŒ‹‹MAŽçŒű@—–A˜a“cŒb—˘AŽ›“c–FŽ÷A‚@‹N—ǁAŽRŞF‹vA“ú–ě‰ë”V
’°ŠÇGVHDŽĄ—Ă’†‚ÉEBƒEƒCƒ‹ƒXŠÖ˜AˆÚAŒăƒŠƒ“ƒp‘BŤŽžŠł(PTLD)‚É‚ć‚鏬’°úE‚đ—ˆ‚ľ‚˝‹}Ťœ‘Ť”’ŒŒ•a‚Ěˆę—á.
‘ć30‰ń“ú–{‘˘ŒŒ×–EˆÚAŠw‰ď‘‰ď
‘ĺăA2ŒŽ29“ú-3ŒŽ1“ú
ŠâŒŠ–žŽqi‘ĺăŽs‘ĺŒŒ‰t“ŕ‰Č•a“ŠĹŒěŽtjAŽçŽRˆç”üA”g•˝m”üA‘OŒ´ŽpŽqA‹ŽRŒłŽqA‘Š–{Ž÷A•‰ŞNMA“ú–ě‰ë”VA’ß“c—ŒbA‹{č‹žŽq
‘˘ŒŒŠ˛×–EˆÚA‚Ě”S–ŒáŠQ‚ɑ΂ľ‚ÄGFO“Š—^‚Ş—LŒř‚Ĺ‚ ‚Á‚˝ˆę—á.
‘ć30‰ń“ú–{‘˘ŒŒ×–EˆÚAŠw‰ď‘‰ď
‘ĺăA2ŒŽ29“ú-3ŒŽ1“ú
N@G’ji‘ĺăŽs‘ĺŒŒ‰t“ŕ‰ČE‘˘ŒŒ×–EˆÚA‰ČjA‚@‹N—ǁA’†ŞF•FA•‰ŞNMAŽçŒű@—–A‘Š–{Ž÷A˜a“cŒb—˘AÔŕVŒ‹‹MAŽ›“c–FŽ÷A’†‘O”Ž‹vAŽRŞF‹vA“ú–ě‰ë”V
ƒVƒNƒƒtƒHƒXƒtƒ@ƒ~ƒhƒpƒ‹ƒX—Ă–@‚Ş’˜Œř‚ľ‚˝“ŻŽí‘˘ŒŒŠ˛×–EˆÚAŒăIdiopathic Pneumonia Syndrome‚É‚¨‚Ż‚éTh1ATh2ƒTƒCƒgƒJƒCƒ“‚ĚŒŸ“˘.
‘ć30‰ń“ú–{‘˘ŒŒ×–EˆÚAŠw‰ď‘‰ď
‘ĺăA2ŒŽ29“ú-3ŒŽ1“ú
’ß“c—Œbi‘ĺăŽs‘ĺŠw‚Ş‚ńŠĹŒěę–ĺŠĹŒěŽtjA‘OŒ´ŽpŽqA‹ŽRŒłŽqA‹{č‹žŽq
‘˘ŒŒ×–EˆÚAŠłŽŇƒTƒ|[ƒgƒ`[ƒ€‚̍\’z.
‘ć30‰ń“ú–{‘˘ŒŒ×–EˆÚAŠw‰ď‘‰ď
‘ĺăA2ŒŽ29“ú-3ŒŽ1“ú
Ž›“c–FŽ÷i‘ĺăŽs‘ĺŒŒ‰t“ŕ‰ČE‘˘ŒŒ×–EˆÚA‰ČjAŽRŞF‹vAN@G’jA’†ŞF•FA•‰ŞNMAŽçŒű@—–A‘Š–{Ž÷AÔŕVŒ‹‹MA˜a“cŒb—˘A’†‘O”Ž‹vA‚@‹N—ǁA“ú–ě‰ë”V
‘˘ŒŒŠíˆŤŤŽžŠł‚ɑ΂ˇ‚éIntravenous Busulfan 8mg/kg+Fludarabine 180mg/m2+TBI 4Gy‚É‚ć‚鍜‘”ń”j‰ó“Iä`‘ŃŒŒˆÚAiRICBTj‚ĚŒŸ“˘.
‘ć30‰ń“ú–{‘˘ŒŒ×–EˆÚAŠw‰ď‘‰ď
‘ĺăA2ŒŽ29“ú-3ŒŽ1“ú
’†ŞF•Fi‘ĺăŽs‘ĺŒŒ‰t“ŕ‰ČE‘˘ŒŒ×–EˆÚA‰ČjA’†‘O”Ž‹vA‘Š–{Ž÷Aă–{e•FAÔŕVŒ‹‹MA˜a“cŒb—˘AN@G’jA•‰ŞNMAŽ›“c–FŽ÷A‚@‹N—ǁAŽRŞF‹vA“ú–ě‰ë”V
S‹@”\’ቺ5Ç—á‚ɑ΂ˇ‚鍜‘”ń”j‰ó“I“ŻŽí‘˘ŒŒŠ˛×–EˆÚAiRISTjŒă‚̐S‹@”\‚¨‚ć‚ŃŽŠ—Ľ_Œo‹@”\‚̉đÍ.
‘ć30‰ń“ú–{‘˘ŒŒ×–EˆÚAŠw‰ď‘‰ď
‘ĺăA2ŒŽ29“ú-3ŒŽ1“ú
˜a“cŒb—˘i‘ĺăŽs‘ĺŒŒ‰t“ŕ‰ČE‘˘ŒŒ×–EˆÚA‰ČjAâ–{Œb—˜“ށAN@G’jA’†ŞF•FA•‰ŞNMAŽçŒű@—–A‘Š–{Ž÷AÔŕVŒ‹‹MAŽ›“c–FŽ÷A‚@‹N—ǁAŽRŞF‹vA“ú–ě‰ë”V
‘˘ŒŒŠ˛×–EˆÚAŒă‚ĚAMPH-BŽĄ—Ă’†‚ɐV‹K”­Ç‚ľ‚˝ƒgƒŠƒRƒXƒ|ƒƒ“ŒŒÇ‚Ě2—á.
‘ć30‰ń“ú–{‘˘ŒŒ×–EˆÚAŠw‰ď‘‰ď
‘ĺăA2ŒŽ29“ú-3ŒŽ1“ú
[‘˝Ž{Ý‹¤“ŻŒ¤‹†]
ÂŽR‘׍F(ś’ˇ‰ď•{’†•a‰@ŒŒ‰t“ŕ‰ČjA”¨’†ˆęśA•Ä’J@¸Aź–{“N˜YA‹›“ˆL•FA‰Ş–{‰ëŽiAŽR‘ş—ş‰îAěă@ŠwA‹Ę’uLĆA‰E‹ž’źĆAă“cGŽŸAŽR–{–˘‰›A’†‘ş@ŒOA”’ě—R”üŽqAź–{—R”üA“Ą‘ăŽu•ŰA‹ß“Ą^—ŽqAź“c—EŽ™A’JŠ_“ŕˆč—]A‹Ę’urŽĄ
ŒŒ‰tŽžŠłf—Ă‚ÉŒg‚í‚éˆăŽtEŠĹŒěŽt‚̐E‹ĆŤƒXƒgƒŒƒXE—}‚¤‚ÂŽÚ“x‚ĚŒť‹ľ.
‘ć30‰ń“ú–{‘˘ŒŒ×–EˆÚAŠw‰ď‘‰ď
‘ĺăA2ŒŽ29“ú-3ŒŽ1“ú
[‘˝Ž{Ý‹¤“ŻŒ¤‹†]
“‡čçqAˆęŒË’C•vA•lŒűŒł—mA“n•Ó@VAÎ“cG”VA‹gŒ´—˛•vAX–{@“NA‹›“ˆL•FA‘Ť—§‘sˆęAŒ˘Ž”ŠxŽjAŕV“c–ž‹vA‰Ş@GŽŸAˆÉ“Ą@–žA“ú–ě‰ë”VAć|“c~–çA“ŕ“c@‘ěAŹŽ›—ǏŽ
T×–E”ńœ‹ŽNIMA•sˆę’vŒŒ‰ŽŇŠÔˆÚA’ˇŠúś‘ś—á‚É‚¨‚Ż‚閝ŤGVHD‚ĚŒŸ“˘.
‘ć30‰ń“ú–{‘˘ŒŒ×–EˆÚAŠw‰ď‘‰ď
‘ĺăA2ŒŽ29“ú-3ŒŽ1“ú

2007”N
‚đƒNƒŠƒbƒN‚ľ‚Ä‚˘‚˝‚ž‚­‚Ć˜a•ś´˜^‚Ş‚˛——‚˘‚˝‚ž‚Ż‚Ü‚ˇB
ŠeŠw‰ď‚É‚¨‚Ż‚鉉‘č‡˜‚Í•M“ŞŽŇ‚đŒÜ\‰š‡‚Ĺ•Ŕ‚ׂè‚č‚Ü‚ˇ
ŽsŒ´O‘Piś’ˇ‰ď•{’†•a‰@jA‘ž“c’‰MAŒĂě‰Ŕ‰›AÂŽR‘׍FA‹v‘şŠx‰›Aęm’JˆŔ’ĂŽqA“ú–ě‰ë”V
INF-ƒŔ“Š—^ŒăˆŤŤ•nŒŒ‚đ‡•š‚ľ‚˝Ç—á.
‘ć88‰ń‹ß‹EŒŒ‰tŠw’n•ű‰ď
‹ž“sA11ŒŽ24“ú
•SŁ@‘ĺi‘ĺăŽs‘ĺŒŒ‰t“ŕ‰ČE‘˘ŒŒ×–EˆÚA‰ČjAN@G’jA’†ŞF•FA•‰ŞNMAŽçŒű@—–A‘Š–{Ž÷A˜a“cŒb—˘AÔŕVŒ‹‹MAŽ›“c–FŽ÷A‚@‹N—ǁAŽRŞF‹vA“ú–ě‰ë”V
–Ťœ‘‘BŤŽžŠł‚ɔ畆č÷—ą‹…“÷Žî‚đ‡•š‚ľ‚˝ˆę—á.
‘ć88‰ń‹ß‹EŒŒ‰tŠw’n•ű‰ď
‹ž“sA11ŒŽ24“ú
ŠÔ•”ŒŤŠ°iĎś‰ď’†’Ă•a‰@jA‰Ş–{Gˆę˜YAŹâ‚ł‚¨‚čAŽR‘ş—ş‰îA‘ž“cŒ’‰îAi“ĄŠě—\A–؉şŠěŒőA’F@—zˆęA‹ŕ“‡@LAŽč“‡”Ž•ś
ƒƒVƒ‹Ž_ƒCƒ}ƒ`ƒjƒu‘—Ę‚Ş–łŒř‚Ĺ‚ ‚Á‚˝t(9;12)Œ^–Ťœ‘Ť”’ŒŒ•a.
‘ć88‰ń‹ß‹EŒŒ‰tŠw’n•ű‰ď
‹ž“sA11ŒŽ24“ú
Koh H, Koh KR, Hagihara K, Nakane T, Takeoka Y, Kanashima H, Sakamoto H, Nakamae M, Ichihara H, Terada Y, Nakamae H, Ohta K, Yamane T, Watanabe T, Hino M
Allogeneic hematopoietic stem cell transplantation for adult T-cell leukemia: result of a single center study.
13th International Conference on Human Retrovirology HTLV and Related Viruses, Hakone, 22-25 May
Sakamoto E, Ohta K, Nishiki S, Terada Y, Moriguchi R, Nakao Y, Teshima H, Mugitani A, Hino M
Intravenous Itraconazole for empiric antifungal therapy for persistent fever in neutropenic patients with hematological malignancies in Japan.
3rd Trends in Medical Mycology, Torino, 28-31 October
Koh KR, Nakamae H, Ohta K, Li HZ, Koh H, Nakane T, Takeoka Y, Hirose A, Hagihara K, Sakamoto E, Nakamae M, Terada Y, Yamane T, Hino M
Possible involvement of ƒÁƒÂ-T cells in the development of chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.
49th Annual Meeting of the American Society of Hematology,
Atlanta, 8-11 December
Terada Y, Nakamae H, Nakane T, Koh H, Takeoka Y, Moriguchi R, Aimoto M, Akazawa Y, Wada E, Kanashima H, Sakamoto E, Koh KR, Yamane T, Ohta K, Nakao Y, Teshima H, Hino M
The impact of relative dose intensity (RDI) of CHOP on outcome of diffuse large B-cell lymphoma: results of a single center study.
49th Annual Meeting of the American Society of Hematology,
Atlanta, 8-11 December
Ichinohe TShimazaki C, Hamaguchi M, Watanabe A, Ishida H, Yoshihara T, Morimoto A, Uoshima N, Adachi S, Inukai T, Sawada A, Oka K, Itoh M, Hino M, Kanda J, Uchiyama T, KoderaY
Long-term survival after HLA-haploidentical stem cell transplantation from non-inherited maternal antigen-mismatched family donors: impact of chronic graft-versus-host-disease.
49th Annual Meeting of the American Society of Hematology,
Atlanta, 8-11 December
ÂŽR‘׍Fiś’ˇ‰ď•{’†•a‰@jA‹v‘şŠx‰›A‘ž“c’‰MAŒĂě‰Ŕ‰›Aęm’JˆŔ’ĂŽqAŽsŒ´‘POA“ú–ě‰ë”V
Žs’†•a‰@“ü‰@’†‚ĚŒŒ‰tŽžŠłŠłŽŇ‚É‚¨‚Ż‚é”­”MŤD’†‹…Œ¸­Ç‚ĚŒă•űŽ‹“I‰đÍ.
‘ć69‰ń“ú–{ŒŒ‰tŠw‰ďE‘ć49‰ń“ú–{—Տ°ŒŒ‰tŠw‰ď‡“Ż‘‰ď
‰Ą•lA10ŒŽ11“ú-13“ú
‘ž“c’‰Miś’ˇ‰ď•{’†•a‰@jAŽsŒ´‘POAŒĂě‰Ŕ‰›AÂŽR‘׍FA‹v‘şŠx‰›Aęm’JˆŔ’ĂŽqA’†‘O”Ž‹vA‚@‹N—ǁAŽRŞF‹vA“ú–ě‰ë”VAź–ě‹gG
ˆŤŤƒŠƒ“ƒpŽî‚Ć‚ĚŠÓ•Ę‚Ş˘“ď‚Ĺ‚ ‚Á‚˝‰E‘lŒa•”Œ´”­ˆŤŤŽîá‡.
‘ć69‰ń“ú–{ŒŒ‰tŠw‰ďE‘ć49‰ń“ú–{—Տ°ŒŒ‰tŠw‰ď‡“Ż‘‰ď
‰Ą•lA10ŒŽ11“ú-13“ú
‚@‹N—ǁi‘ĺăŽs‘ĺŒŒ‰t“ŕ‰ČE‘˘ŒŒ×–EˆÚA‰ČjA’†‘O”Ž‹vA‘ž“cŒ’‰îA—›@ƒÍA’†ŞF•FA•‰ŞNMAœAŁ’ŠśA”‹Œ´Œ‰’ʁA‹ŕ“‡@LAâ–{Œb—˜“ށA’†‘O”ü‰ŔAŽ›“c–FŽ÷A’†”ö‹gFAŽRŞF‹vA“ú–ě‰ë”V
–ŤGVHD”­ÇŽž‚Ě––˝ŒŒTƒŠƒ“ƒp‹…ƒTƒuƒZƒbƒgA–ԏó×–E‚¨‚ć‚ŃŒŒ´ƒTƒCƒgƒJƒCƒ“‚Ě“Ž‘Ô‰đÍ.
‘ć69‰ń“ú–{ŒŒ‰tŠw‰ďE‘ć49‰ń“ú–{—Տ°ŒŒ‰tŠw‰ď‡“Ż‘‰ď
‰Ą•lA10ŒŽ11“ú-13“ú
N@G’jii‘ĺăŽs‘ĺŒŒ‰t“ŕ‰ČE‘˘ŒŒ×–EˆÚA‰ČjAâ–{Œb—˜“ށA’†ŞF•FA•‰ŞNMAŽçŒű@—–A‘Š–{Ž÷A˜a“cŒb—˘AÔŕVŒ‹‹MAŽ›“c–FŽ÷A’†‘O”Ž‹vA‚@‹N—ǁAŽRŞF‹vA“ú–ě‰ë”V
“ŻŽí‘˘ŒŒŠ˛×–EˆÚAŒă‚Ě”ńŠ´őŤ’†•_Œo‡•šÇ‚ĚŽŠŒą—á‚ĚŒŸ“˘.
‘ć69‰ń“ú–{ŒŒ‰tŠw‰ďE‘ć49‰ń“ú–{—Տ°ŒŒ‰tŠw‰ď‡“Ż‘‰ď
‰Ą•lA10ŒŽ11“ú-13“ú
Ž›“c–FŽ÷i‘ĺăŽs‘ĺŒŒ‰t“ŕ‰ČE‘˘ŒŒ×–EˆÚA‰ČjA’†ŞF•FAN@G’jAŽçŒű@—–A‘Š–{Ž÷AÔŕVŒ‹‹MA˜a“cŒb—˘A’†‘O”Ž‹vA‚@‹N—ǁAŽRŞF‹vA’†”ö‹gFA“ú–ě‰ë”V
‚Ń‚Ü‚ńŤ‘ĺ×–EŒ^B×–EŤƒŠƒ“ƒpŽî‚ĚCHOP—Ă–@‚É‚¨‚˘‚ÄRelative Dose Intensity(RDI)‚ŞŽĄ—Ă—\Œă‚É—^‚Ś‚é‰e‹ż.
‘ć69‰ń“ú–{ŒŒ‰tŠw‰ďE‘ć49‰ń“ú–{—Տ°ŒŒ‰tŠw‰ď‡“Ż‘‰ď
‰Ą•lA10ŒŽ11“ú-13“ú
ŒĂě‰Ŕ‰›iś’ˇ‰ď•{’†•a‰@jA‘ž“c’‰MAÂŽR‘׍FA‹v‘şŠx‰›Aęm’JˆŔ’ĂŽqAŽsŒ´‘POA“ú–ě‰ë”V
ATLƒLƒƒƒŠƒAŒo‰ß’†‚É”­•a‚ľ‚˝”]Œ´”­T×–EŤƒŠƒ“ƒpŽî.
‘ć69‰ń“ú–{ŒŒ‰tŠw‰ďE‘ć49‰ń“ú–{—Տ°ŒŒ‰tŠw‰ď‡“Ż‘‰ď
‰Ą•lA10ŒŽ11“ú-13“ú
ęm’JˆŔ’ĂŽqiś’ˇ‰ď•{’†•a‰@jAÂŽR‘׍FA‹v‘şŠx‰›AŒĂě‰Ŕ‰›AŽRŞF‹vA“ú–ě‰ë”V
‘˝”­Ťœ‘Žî—á‚É‚¨‚Ż‚éƒTƒŠƒhƒ}ƒCƒh‚ĚŠłŽŇ–ž‘Ť“x.
‘ć69‰ń“ú–{ŒŒ‰tŠw‰ďE‘ć49‰ń“ú–{—Տ°ŒŒ‰tŠw‰ď‡“Ż‘‰ď
‰Ą•lA10ŒŽ11“ú-13“ú
‰Ş–{Gˆę˜YiĎś‰ď’†’Ă•a‰@jAŹâ‚ł‚¨‚čAŽR‘ş—ş‰îAŠÔ•”ŒŤŠ°A‘ž“cŒ’‰îA’†“‡‰plA‚’J‹ďŽjA“ú–ě‰ë”V
Ä”­Žž‚ɐS‘Ÿ‚É‹‘ĺŽîᎂđŒ`Ź‚ľ‚˝”ńƒzƒWƒLƒ“ƒŠƒ“ƒpŽî‚Ě1—á.
‘ć183‰ń“ú–{“ŕ‰ČŠw‰ď‹ß‹E’n•ű‰ďA_ŒËA9ŒŽ1“ú
ă–ě—m—Si‘ĺăŽs‘ĺŒŒ‰t“ŕ‰ČE‘˘ŒŒ×–EˆÚA‰ČjA•‰ŞNMA’†ŞF•FAN@G’jA‘Š–{Ž÷A˜a“cŒb—˘AÔŕVŒ‹‹MAŽ›“c–FŽ÷A“ú–ě‰ë”V
”­ÇŽž‚ɐԉ苅‚Ě’˜‚ľ‚˘Œ¸­‚đ”F‚ß‚˝”ńƒzƒWƒLƒ“ƒŠƒ“ƒpŽî‚Ě1—á.
‘ć183‰ń“ú–{“ŕ‰ČŠw‰ď‹ß‹E’n•ű‰ďA_ŒËA9ŒŽ1“ú
‰şŽR@˝i‘ĺăŽs‘ĺŒŒ‰t“ŕ‰ČE‘˘ŒŒ×–EˆÚA‰ČjAN@G’jA’†ŞF•FA•‰ŞNMAâ–{Œb—˜“ށAŽsŒ´O‘PAŽ›“c–FŽ÷A‚@‹N—ǁAŽRŞF‹vA“ú–ě‰ë”V
“ŻŽí‘˘ŒŒŠ˛×–EˆÚAŒă‚ĚIdiopathic Pneumonia Syndrome (IPS)‚É”ş‚¤dÇ‚Ń‚Ü‚ńŤ”x–EoŒŒ(DAH)‚ɑ΂ľƒVƒNƒƒtƒHƒXƒtƒ@ƒ~ƒhiCY)ƒpƒ‹ƒX—Ă–@‚Ş’˜Œř‚ľ‚˝ŹlT×–E”’ŒŒ•aƒŠƒ“ƒpŽîiATLL)‚Ě1—á.
‘ć182‰ń“ú–{“ŕ‰ČŠw‰ď‹ß‹E’n•ű‰ďA‘ĺăA5ŒŽ26“ú
‰Ş–{Gˆę˜Yi‘ĺăŽs‘ĺŒŒ‰t“ŕ‰ČE‘˘ŒŒ×–EˆÚA‰ČjAN@G’jAŽ›“c–FŽ÷A’†ŞF•FA•‰ŞNMAâ–{Œb—˜“ށA‹ŕ“‡@LAŽsŒ´O‘PA’†‘O”ü‰ŔA’†‘O”Ž‹vA‚@‹N—ǁAŽRŞF‹vA“ú–ě‰ë”V
“ŻŽí‘˘ŒŒŠ˛×–EˆÚA‘Šú‚ÉŒŒ‹…ćÐHÇŒóŒQ‚đ”­Ç‚ľ‚˝ALL‚Ě1—á.
‘ć29‰ń“ú–{‘˘ŒŒ×–EˆÚAŠw‰ďA•Ÿ‰ŞA2ŒŽ16“úA17“ú
N@G’ji‘ĺăŽs‘ĺŒŒ‰t“ŕ‰ČE‘˘ŒŒ×–EˆÚA‰ČjA”‹Œ´Œ‰’ʁA‹ŕ“‡@LA’†ŞF•FA•‰ŞNMAâ–{Œb—˜“ށA’†‘O”ü‰ŔAŽsŒ´O‘PA’†‘O”Ž‹vA‚@‹N—ǁAŽRŞF‹vA“ú–ě‰ë”V
Źl‚s×–E”’ŒŒ•a/ƒŠƒ“ƒpŽîiATL/Lj‚ɑ΂ˇ‚é“ŻŽí‘˘ŒŒŠ˛×–EˆÚAiallo-HSCTj‚ĚŒŸ“˘.
‘ć29‰ń“ú–{‘˘ŒŒ×–EˆÚAŠw‰ďA•Ÿ‰ŞA2ŒŽ16“úA17“ú
Ž›“c–FŽ÷i‘ĺăŽs‘ĺŒŒ‰t“ŕ‰ČE‘˘ŒŒ×–EˆÚA‰ČjA’†‘O”Ž‹vA’†ŞF•FAN@G’jA•‰ŞNMAâ–{Œb—˜“ށA‹ŕ“‡@LAŽsŒ´O‘PA‚@‹N—ǁAŽRŞF‹vA“ú–ě‰ë”V
isŠú”’ŒŒ•a‚ɑ΂ˇ‚éintravenous busulfan(Buslufex 8mg/kg)+CY120mg/kg+TLI 7.5Gy‚đ—p‚˘‚˝modified myeloablative conditioning‚É‚ć‚é“ŻŽí‘˘ŒŒŠ˛×–EˆÚA‚ĚŒoŒą.
‘ć29‰ń“ú–{‘˘ŒŒ×–EˆÚAŠw‰ďA•Ÿ‰ŞA2ŒŽ16“úA17“ú
’†ŞF•Fi‘ĺăŽs‘ĺŒŒ‰t“ŕ‰ČE‘˘ŒŒ×–EˆÚA‰ČjA’†‘O”Ž‹vAN@G’jAâ–{Œb—˜“ށA•‰ŞNMA‹ŕ“‡@LA’†‘O”ü‰ŔAŽsŒ´O‘PA‚@‹N—ǁAŽRŞF‹vA“ú–ě‰ë”V
“–‰Č‚É‚¨‚Ż‚é”ńTBIE”ńATG‚Ĺ‚Ěfludarabine(Flu)‚đ—p‚˘‚˝”ńŒŒ‰ŽŇŠÔœ‘”ń”j‰ó“I“ŻŽí‘˘ŒŒŠ˛×–EˆÚA(u-RIST)‚̉đÍ.
‘ć29‰ń“ú–{‘˘ŒŒ×–EˆÚAŠw‰ďA•Ÿ‰ŞA2ŒŽ16“úA17“ú
‹ŕ@ŹŒłA“ú–ě‰ë”Vi‘ĺăŽs‘ĺŒŒ‰t“ŕ‰ČE‘˘ŒŒ×–EˆÚA‰ČjA”¨’†ˆęśAă“c‹ą“TA“c–ěč—˛“ńAœAě@˝AX@Tˆę˜YA’†Łˆę‘ĽAˆÉ“Ąr˜NA“‡čçqA‰Í‡‘׈ęAŠp“ěˆę‹MA’†‘O”Ž‹vA‹Ę’urŽĄA…’J’m—˘Aă@šLA’ˇ“ĄGŽiA’JŒűCˆęA‚ă—mˆęAŒ´“cŽŔŞ
ƒNƒ‰ƒhƒ‹ƒrƒ“AƒuƒXƒ‹ƒtƒ@ƒ“ATBI 4Gy‚đ—p‚˘‚˝HLA“K‡”ńŒŒ‰ŽŇŠÔœ‘ƒ~ƒjˆÚAF‘˝Ž{Ý‹¤“Ż—Տ°‘ćI‘ŠŽŽŒąiRIST0305j.
‘ć29‰ń“ú–{‘˘ŒŒ×–EˆÚAŠw‰ďA•Ÿ‰ŞA2ŒŽ16“úA17“ú

2006”N
‚đƒNƒŠƒbƒN‚ľ‚Ä‚˘‚˝‚ž‚­‚Ć˜a•ś´˜^‚Ş‚˛——‚˘‚˝‚ž‚Ż‚Ü‚ˇB
Koh K-R,Nakamae H,Ohta K,Koh H,Nakane T,Nakamae M,Kanashima H,Hagihara K,Sakamoto E,Terada Y,Takeoka Y,Hirose A,Yamane T,Hino M
Preferential Th2 polarization at the onset of thrombotic microangiopathy (TMA): Immunoligical comparison of TMA versus acute GVHD in terms of peripheral T cell subsets, dendritic cell subsets and cytokine profiles.
48th Annual Meeting of the American Society of Hematology
Florida, 9-12 December
Nakane T,Nakamae H,Kamoi H,Koh H,Takeoka Y,Sakamoto E,Kanashima H,Ichihara H,Nakamae M,Koh K-R,Yamane T,Hino M
Decreased serum levels of surfactant protein D (SP-D) prior transplant is associated with the development of bronchiolitis obliterans (BO) and idiopathic pneumonia syndrome (IPS) following allogeneic hematopoietic stem cell transplantation.
48th Annual Meeting of the American Society of Hematology
Florida, 9-12 December
Nakamae H, Nakane T, Koh H, Takaoka Y, Sakamoto E, Kanashima H, Ichihara H, Nakamae N, Koh K-R, Yamane T, Hino M
Non-TBI, Non-ATG Containing Fludarabine-Based Regimen for Unrelated Allogeneic Reduced Intensity Transplantation.
48th Annual Meeting of the American Society of Hematology
Florida, 9-12 December
Sakamoto E, Nakamae H, Koh K-R, Yamane T, Hino M
Chronic Myeloid Leukemia in Two Patients with Gastrointestinal Stromal Tumor. Session Type
  48th Annual Meeting of the American Society of Hematology
Florida, 9-12 December
Miyawaki S,Ohtake S,Fujisawa S,Kiyoi H,Shinagawa K,Usui N,Miyamura K,Nishimura M,Miyazaki Y,Nishii K,Nagai T,Yamane T,Taniwaki M,Takahashi M,Yagasaki F,Kimura Y,Asou N,Honda S,Ohnishi K,Naoe T,Ohno R
Postremission therapy in adult acute myeloid leukemia (AML): A randomized comparison between high dose Ara-C therapy and conventional consolidation therapy (JALSG AML 201 study).
48th Annual Meeting of the American Society of Hematology
Florida, 9-12 December
Ohtake S,Miyawaki S,Fujita H,Miki H,Shinagawa K,Usui N,Miyamura K,Nishimura M,Miyazaki Y,Nishii K,Nagai T,Yamane T,Taniwaki M,Takahishi M,Yagasaki F,Kimura Y,Asou N,Honda S,Ohnishi K,Naoe T,Ohno R
Randomized clinical trial of induction therapy comparing intesified daunorubicin with idarubicin in patients with previously untreated de novo acute myeloid leukemia (JALSG AML 201 study).
48th Annual Meeting of the American Society of Hematology
Florida, 9-12 December
—с@—ÇŽ÷AŠÔ•”ŒŤŠ°AŽ›“c–FŽ÷A•˝ˆä@ŠwAŽč“‡”Ž•ś
VAD—Ă–@’†‚Évasospastic angina‚đ—ˆ‚ľ‚˝‘˝”­Ťœ‘Žî‚Ě1—á.
‘ć86‰ń‹ß‹EŒŒ‰tŠw’n•ű‰ďA˜a‰ĚŽRA11ŒŽ18“ú
ŽsŒ´O‘PAN@G’jA’†ŞF•FA•‰ŞNMAâ–{Œb—˜“ށA‹ŕ“‡@LA’†‘O”Ž‹vA‚@‹N—ǁAŽRŞF‹vA“ú–ě‰ë”V
”DP‚É‚ć‚čdÇ‰ť‚ľ‚˝“ŤITP‚ɑ΂ľ“EäB‚Ş—LŒř‚Ĺ‚ ‚Á‚˝1—á.
‘ć86‰ń‹ß‹EŒŒ‰tŠw’n•ű‰ďA˜a‰ĚŽRA11ŒŽ18“ú
â–{Œb—˜“ށAN@G’jA’†ŞF•FA•‰ŞNMA‹ŕ“‡@LA’†‘O”Ž‹vA‚@‹N—ǁAŽRŞF‹vA“ú–ě‰ë”VA‘ĺŕV­•FA•Ÿ“‡—TŽqAźě—˛”VA‘şŁ‡Ć
–Ťœ‘Ť”’ŒŒ•a‚ĆGastrointestinal stromal tumor‚đ‚Ů‚Ú“ŻŽž‚É”­Ç‚ľ‚Ä‚˘‚˝2Ç—á.
‘ć68‰ń“ú–{ŒŒ‰tŠw‰ďE‘ć48‰ń“ú–{—Տ°ŒŒ‰tŠw‰ď‘‰ďA•Ÿ‰ŞA10ŒŽ6-8“ú
’†‘O”ü‰ŔA‰Á“Ą—˛KA’†–{“N–çAâ–{Œb—˜“ށA‘“c‚ł‚ä‚čAŠ™“c‹IŽqAš“ߐ°‰›A‰H“Ą•ś•FA–kě˝ˆę
G-CSF‚É‚ć‚éD’†‹…‚̉^“Ž§Œä:MAP kinase‚Ě–đŠ„.
‘ć68‰ń“ú–{ŒŒ‰tŠw‰ďE‘ć48‰ń“ú–{—Տ°ŒŒ‰tŠw‰ď‘‰ďA•Ÿ‰ŞA10ŒŽ6-8“ú
•‰ŞNMA’†‘O”Ž‹vAŽRŞF‹vA‚@‹N—ǁA‘ž“cŒ’‰îA’†ŞF•FAN@G’jAâ–{Œb—˜“ށA”‹Œ´Œ‰’ʁA‹ŕ“‡@LA’†‘O”ü‰ŔA“ú–ě‰ë”V
ƒXƒeƒƒCƒh’ďRŤ‹}ŤGVHD‚ɑ΂ˇ‚éƒ~ƒRƒtƒFƒm[ƒ‹Ž_ƒ‚ƒtƒFƒ`ƒ‹(MMF)‚ĚŒř‰Ę‚ĚŒŸ“˘.
‘ć68‰ń“ú–{ŒŒ‰tŠw‰ďE‘ć48‰ń“ú–{—Տ°ŒŒ‰tŠw‰ď‘‰ďA•Ÿ‰ŞA10ŒŽ6-8“ú
N@G’jA’†‘O”Ž‹vA’†ŞF•FA•‰ŞNMAâ–{Œb—˜“ށA”‹Œ´Œ‰’ʁA’†‘O”ü‰ŔA‚@‹N—ǁA‘ž“cŒ’‰îA“cŒEFsAŽRŞF‹vA˜kŸş‰p‹@A“ú–ě‰ë”V
“ŻŽíœ‘ˆÚAŒă‚ɃEƒCƒ‹ƒX”x‰Š‚Ć‚ĚŠÓ•Ę‚Ş˘“ď‚Ĺ‚ ‚Á‚˝IPS‚đ”­Ç‚ľ‚˝ALL‚Ěˆę—á.
‘ć68‰ń“ú–{ŒŒ‰tŠw‰ďE‘ć48‰ń“ú–{—Տ°ŒŒ‰tŠw‰ď‘‰ďA•Ÿ‰ŞA10ŒŽ6-8“ú
ęm’JˆŔ’ĂŽqA–kŽR@“™A‹›“ˆL•FAŽč“‡”Ž•śA–ě‘şšěA’ˇ’Jě@–ŤA—с@–M—Y
‘˝”­Ťœ‘Žî•aŠú‘w•Ę‰ť‚ĚÄŒŸ“˘.
‘ć68‰ń“ú–{ŒŒ‰tŠw‰ďE‘ć48‰ń“ú–{—Տ°ŒŒ‰tŠw‰ď‘‰ďA•Ÿ‰ŞA10ŒŽ6-8“ú
ÂŽR‘׍FAŽR‘ş—ş‰îA‹v‘şŠx‰›Aęm’JˆŔ’ĂŽqA“ú–ě‰ë”VA˜a“c@—´A’†ěšŽq
”DP‘OŠú‚ɐf’f‚ł‚ęCAG—Ă–@‚É‚ÄŠ°‰đ‚ÉŽŠ‚čŒ’íŽ™‚đoŽY‚ľ“ž‚˝‹}Ťœ‘Ť”’ŒŒ•a‚Ě1Ç—á.
‘ć68‰ń“ú–{ŒŒ‰tŠw‰ďE‘ć48‰ń“ú–{—Տ°ŒŒ‰tŠw‰ď‘‰ďA•Ÿ‰ŞA10ŒŽ6-8“ú
ŠÔ•”ŒŤŠ°A•˝ˆä@ŠwA—с@—ÇŽ÷AŽ›“c–FŽ÷Aă“c@ÂA‘ĺě´FAˆäă@Œ’AŽč“‡”Ž•ś
‰ŠÇŤ’°ŽžŠł‘œ‚đ’ć‚ľ‚Ä”­Ç‚ľ‚˝CAEBV‚Ěˆę—á.
‘ć68‰ń“ú–{ŒŒ‰tŠw‰ďE‘ć48‰ń“ú–{—Տ°ŒŒ‰tŠw‰ď‘‰ďA•Ÿ‰ŞA10ŒŽ6-8“ú
‘ž“c’‰MAŒĂě‰Ŕ‰›AÂŽR‘׍FA‹v‘şŠx‰›Aęm’JˆŔ’ĂŽqA”‹Œ´Œ‰’ʁA’†‘O”Ž‹vA‚@‹N—ǁAŽRŞF‹vA“ú–ě‰ë”V
”M”­‚đŽĺ‘i‚ÉŒo‰ß‚ľdel(7)(q22q32)‚̐őF‘ĚˆŮí‚đŽŚ‚ľ‚˝”ń’čŒ^MDSÇ—á.
‘ć68‰ń“ú–{ŒŒ‰tŠw‰ďE‘ć48‰ń“ú–{—Տ°ŒŒ‰tŠw‰ď‘‰ďA•Ÿ‰ŞA10ŒŽ6-8“ú
â–{Œb—˜“ށAN@G’jA’†ŞF•FA•‰ŞNMA‹ŕ“‡@LA“ú–ě‰ë”VA–p@‹ÎAA‰Á–ǝ‰pAź@Mˆę
@–Ťœ‘‘BŤŽžŠłŽĄ—Ă’†‚Étoxic shock like syndrome‚𔺂¤‰óŽ€Ť‹Ř–Œ‰Š‚đ‡•š‚ľ‚˝1—á.
‘ć179‰ń“ú–{“ŕ‰ČŠw‹ß‹E’n•ű‰ďA_ŒËA6ŒŽ10“ú
N@G’jA’†ŞF•FA•‰ŞNMAâ–{Œb—˜“ށA”‹Œ´Œ‰’ʁA’†‘O”ü‰ŔA’†‘O”Ž‹vA‚@‹N—ǁA‘ž“cŒ’‰îA“cŒEFsAŽRŞF‹vA“ú–ě‰ë”V
@ä`‘ŃŒŒˆÚAŒă‚Éatypical RPLS(reversible posterior leukoencephalopathy syndrome)‚đ”­Ç‚ľ‚˝MDS‚Ě1—á.
‘ć28‰ń“ú–{‘˘ŒŒ×–EˆÚAŠw‰ďA“Œ‹žA2ŒŽ24“ú-25“ú
’†ŞF•FA’†‘O”Ž‹vAŠ›ˆä@”ŽA‘ž“cŒ’‰îAŽRŞF‹v@A“ú–ě‰ë”V
“ŻŽí‘˘ŒŒŠ˛×–EˆÚAŒă•ÂÇŤ‹CŠÇŽx‰ŠiBOj”­Ç—\‘ވöŽq‚Ć‚ľ‚Ä‚ĚŒŒ´SP-DASP-AAKL-6”Z“x‚Ě—L—pŤ‚ɂ‚˘‚Ä‚ĚŒŸ“˘.
‘ć28‰ń“ú–{‘˘ŒŒ×–EˆÚAŠw‰ďA“Œ‹žA2ŒŽ24“ú-25“ú
â–{Œb—˜“ށA‘ž“cŒ’‰îA’†‘O”Ž‹vAŽÄ“cĺŽqAŽ›“c–FŽ÷AŽRŞF‹vA“ú–ě‰ë”V
@‘˘ŒŒŠ˛×–EˆÚAŽžD’†‹…Œ¸­Šú‚É‚¨‚Ż‚銴őÇ‚ɑ΂ˇ‚éƒJƒ‹ƒoƒyƒlƒ€‚Ě—LŒřŤ.
‘ć28‰ń“ú–{‘˘ŒŒ×–EˆÚAŠw‰ďA“Œ‹žA2ŒŽ24“ú-25“ú
ŽRŞF‹vAœAŁ’ŠśA’†“ˆN”ŽA”‹Œ´Œ‰’ʁA’†‘O”Ž‹vA‚@‹N—ǁA‘ž“cŒ’‰îA•˝ˆä@ŠwA’†”ö‹gFAęm’JˆŔ’ĂŽqAŽč“‡”Ž•śA“ú–ě‰ë”V
@non-Hodgkin's lymphoma‚ɑ΂ˇ‚é‘ĺ—ʉťŠw—Ă–@•š—pŽŠ‰Ć––˝ŒŒŠ˛×–EˆÚA.
‘ć28‰ń“ú–{‘˘ŒŒ×–EˆÚAŠw‰ďA“Œ‹žA2ŒŽ24“ú-25“ú
‚@‹N—ǁA’†‘O”Ž‹vA‘ž“cŒ’‰îAN@G’jA’†ŞF•FA’†‘O”ü‰ŔA”‹Œ´Œ‰’ʁAâ–{Œb—˜“ށAŽ›“c–FŽ÷A•‰ŞNMAœAŁ’ŠśA“cŒEFsAŽRŞF‹vA“ú–ě‰ë”V
@“ŻŽí‘˘ŒŒŠ˛×–EˆÚAŒă‚Ě‹}ŤGVHD”­ÇŽž‚ĆTMA”­ÇŽž‚Ě––˝ŒŒTƒŠƒ“ƒp‹…ƒTƒuƒZƒbƒg‚¨‚ć‚ŃŒŒ´ƒTƒCƒgƒJƒCƒ“‚Ě“Ž‘Ô‰đÍ‚Ć—Ő°“IˆÓ‹`.
‘ć28‰ń“ú–{‘˘ŒŒ×–EˆÚAŠw‰ďA“Œ‹žA2ŒŽ24“ú-25“ú
–؉şŠěŒőA•ě‡•vAŠâ“cN”ŽAŹź‰pŽ÷A–kžŠ•q–çA‰œ@_ŽqA‹´–{@–ąA“ú–ě‰ë”V
@’ˇŠúŠÔŽ‘ą‚ľ‚˝Á‰ťŠíÇó‚𔺂¤ŸT•a‚đŠż•ű–ň‚ĆƒZƒƒgƒjƒ“ƒmƒ‹ƒAƒhƒŒƒiƒŠƒ“Ä‹zŽű‘jŠQ–ň•š—p‚ʼnü‘P‚ľ‚˝Ç—á.
‘ć10‰ń“ú–{S—Ă“ŕ‰ČŠw‰ďA“Œ‹žA1ŒŽ21-22“ú

2005”N
Nakamae R,Yamane T,Hagihara K,Takeoka Y,Sakamoto E,Nakane T,Nakamae M,Koh K-R,Ohta K,Hino M
@Risk factor analysis for thrmobotic microangiopathy after reduced intensity or myeloablative allogeneic hematopoietic stem cell transplantation.
@47th Annual Meeting of the American Society of Hematology
Atlanta, 10-13 Decmber
Miyamura K, Ohnishi K, Naoe T, Takeuchi H, Yoshiki N, Yagasaki F, Fujisawa S, Kimura Y, Motoji T, Imai K, Yamane T, Yoshida S, Miyawaki S, Saburi Y, Kitamura K, Ohno R (JALSG)
Triphasic exponential decline of BCR-ABL transcripts during imatinib therapy for chronic myelogenous leukemia.
47th Annual Meeting of the American Society of Hematology
Atlanta, 10-13 Decmber
Źâ‚ł‚¨‚čA’†”ö‹gFAœAŁ’ŠśA‹ŕ“‡@LAŽ†’J•x•vA’†‘O”Ž‹vA“ú–ě‰ë”V
@Rś•¨Žż—LŒř‚ĚŒŒ‹…ćÐHÇŒóŒQ‚ސćs‚ľ‚˝ˆŤŤƒŠƒ“ƒpŽî‚ĚˆęÇ—á.
‘ć84‰ń‹ß‹EŒŒ‰tŠw’n•ű‰ďA‘ĺ’ÁA12ŒŽ10“ú
’†ŞF•FA“cŒEFsA•‰ŞNMAâ–{Œb—˜“ށA”‹Œ´Œ‰’ʁA’†‘O”Ž‹vA‘ž“cŒ’‰îA‚@‹N—ǁAŽRŞF‹vA“ú–ě‰ë”V
@‘˝”­ßŠO•a•Ď‚đ‚Ć‚ŕ‚Č‚¤‰”­isŠúˆŤŤƒŠƒ“ƒpŽî‚Ě1—á.
‘ć84‰ń‹ß‹EŒŒ‰tŠw’n•ű‰ďA‘ĺ’ÁA12ŒŽ10“ú
’†”ö‹gFA‹ŕ“‡@LAœAŁ’ŠśAŹâ‚ł‚¨‚čAŽ†’J•x•vA“ú–ě‰ë”V
@•s–ž”M‚̊ӕʂɑ΂ˇ‚ésIL2 receptor‚Ě—L—pŤ‚ɂ‚˘‚Ä.
‘ć178‰ń“ú–{“ŕ‰ČŠw‰ď‹ß‹E’n•ű‰ďA‹ž“sA12ŒŽ3“ú
–؉şŠěŒőA“cŒEFsAź–{‹ąˆęA“ú–ě‰ë”V
@ŒŒ´’†Calprotectin‚Ě‘˘ŒŒŠíŽžŠł‚É‚¨‚Ż‚é‘Ş’čˆÓ‹`‚ĚŒŸ“˘.
‘ć25‰ń“ú–{—Տ°ŒŸ¸ˆăŠw‰ď‘‰ďE‘ć45‰ń“ú–{—Տ°‰ťŠw‰ď”N‰ď˜A‡‘ĺ‰ď
•Ÿ‰ŞA11ŒŽ17-20“ú
–؉şŠěŒőAŹź‰pŽ÷AŠâ“cN”ŽA–kžŠ•q–çA‰œ@_ŽqA‹´–{@–ą
@ŒJ‚č•Ô‚ˇšq“f‚đŒ_‹@‚Ɉݎîᇂ̐f’f‚ł‚ę‚˝ˆÝᑑ˘ÝÇ—á.
‘ć13‰ń—Ă—{•a°‹Ś‰ď‘S‘Œ¤‹†‰ďA“Œ‹žA11ŒŽ17“ú
’†”ö—˛•śAKaushansky Kenneth
@ƒgƒƒ“ƒ{ƒ|ƒGƒ`ƒ“‚Í“]ŽĘˆöŽqFOXO3a‚Ě•sŠˆŤ‰ť‚¨‚ć‚Ńp27KIP1‚Ě”­Œť—}§‚đ’Ę‚ś‚Ä‹Šj‹…‘˘ŒŒ‚𑣐i‚ˇ‚é.
‘ć67‰ń“ú–{ŒŒ‰tŠw‰ďE‘ć47‰ń“ú–{—Տ°ŒŒ‰tŠw‰ď‡“Ż‘‰ďA‰Ą•lA9ŒŽ17E18“ú
’†“ˆN”ŽA•˝ˆä@ŠwA‰Ž–Ř•q–çAŽč“‡”Ž•śAˆäă@Œ’A•˝Î—ĽŽqAˆäŒű‘ž˜YAâ–{@˜j
@“ÁˆŮ‚Č”’ŒŒ‰ť‚đŽŚ‚ľ‚˝Anaplastic large cell lymphoma‚Ěˆę—á.
‘ć67‰ń“ú–{ŒŒ‰tŠw‰ďE‘ć47‰ń“ú–{—Տ°ŒŒ‰tŠw‰ď‡“Ż‘‰ďA‰Ą•lA9ŒŽ17E18“ú
’†‘O”Ž‹vA”‹Œ´Œ‰’ʁAŽ›“c–FŽ÷Aâ–{Œb—˜“ށA•‰ŞNMA’†ŞF•FA’†‘O”ü‰ŔA‚@‹N—ǁA‘ž“cŒ’‰îAŽRŞF‹vA“ú–ě‰ë”V
@“–‰Č‚É‚¨‚Ż‚é“ŻŽíˆÚAŒăTMA‚ĚƒŠƒXƒNƒtƒ@ƒNƒ^[‚ĚŒă•űŽ‹“IŒŸ“˘.
‘ć67‰ń“ú–{ŒŒ‰tŠw‰ďE‘ć47‰ń“ú–{—Տ°ŒŒ‰tŠw‰ď‡“Ż‘‰ďA‰Ą•lA9ŒŽ17E18“ú
‘ž“c’‰MAŒĂě‰Ŕ‰›A^@çéŽőAÂŽR‘׍FAŽR‘ş—ş‰îAęm’JˆŔ’ĂŽqA’†‘O”Ž‹vA‚@‹N—ǁA‘ž“cŒ’‰îAŽRŞF‹vA“cŒEFsA“ú–ě‰ë”V
@R‚Ş‚ńÜŽĄ—ĂŒă‚Ě‘˘¸‹@”\‚̒ǐՂƓŻŽíˆÚAŒă‚Ě”DP‚ĹŒ’Ž™‚đ“ž‚˝”’ŒŒ•aÇ—á.
‘ć67‰ń“ú–{ŒŒ‰tŠw‰ďE‘ć47‰ń“ú–{—Տ°ŒŒ‰tŠw‰ď‡“Ż‘‰ďA‰Ą•lA9ŒŽ17E18“ú
ęm’JˆŔ’ĂŽqA‘ž“c’‰MAÂŽR‘׍FAŽR‘ş—ş‰îA^@çéŽőAŹâ‚ł‚¨‚čA‘ž“cŒ’‰îAŽRŞF‹vA“ú–ě‰ë”V
@‘˝”­Ťœ‘Žî‚ɑ΂ˇ‚éƒTƒŠƒhƒ}ƒCƒhŽĄ—Ă‚Ě—Ő°“IŒŸ“˘
‘ć67‰ń“ú–{ŒŒ‰tŠw‰ďE‘ć47‰ń“ú–{—Տ°ŒŒ‰tŠw‰ď‡“Ż‘‰ďA‰Ą•lA9ŒŽ17E18“ú
•Ÿ“‡—TŽqA‘ĺŕV­•FAˆäă@Œ’A“ú–ě‰ë”VAă“c^ŠěŽq
@ƒzƒWƒLƒ“ƒŠƒ“ƒpŽî‚É‚¨‚Ż‚éCyclooxygenase-2‚Ě”­Œť.
‘ć67‰ń“ú–{ŒŒ‰tŠw‰ďE‘ć47‰ń“ú–{—Տ°ŒŒ‰tŠw‰ď‡“Ż‘‰ďA‰Ą•lA9ŒŽ17E18“ú
•‰ŞNMA’†źŒ’ŽjA“ú–ě‰ë”VA’†‘O”Ž‹vA”‹Œ´Œ‰’ʁAâ–{Œb—˜“ށA’†ŞF•FAN@G’jA’†‘O”ü‰ŔA–q“c—
@ƒŠƒ“ƒpŽî—l‹u]Çilymphomatoid papulosisj‚Ěˆę—á.
‘ć67‰ń“ú–{ŒŒ‰tŠw‰ďE‘ć47‰ń“ú–{—Տ°ŒŒ‰tŠw‰ď‡“Ż‘‰ďA‰Ą•lA9ŒŽ17E18“ú
^@çéŽőA•Ä“c@ĺAÂŽR‘׍FAŽR‘ş—ş‰îAęm’JˆŔ’ĂŽqAˆŔ“ĄŒ’ŽĄA’†“ˆ‘דTA‹ŕ@Žç—Ç
@lHŒÄ‹zŠíŠÇ—’†‚Ěmidazolam“Š—^‚É‚ć‚č‹}ŤŠĚ•s‘S‚đ”­Ç‚ľ‚˝‹}ŤƒŠƒ“ƒpŤ”’ŒŒ•a‚ĚÇ—á.
‘ć177‰ń“ú–{“ŕ‰ČŠw‰ď‹ß‹E’n•ű‰ďA‘ĺăA9ŒŽ10“ú
’†ŞF•FA’†‘O”Ž‹vAâ–{Œb—˜“ށA•‰ŞNMA”‹Œ´Œ‰’ʁA‘ž“cŒ’‰îA‚@‹N—ǁA“cŒEFsAŽRŞF‹vA“ú–ě‰ë”V
@Š°‰đ“ą“ü’†‚É”]”^á‡‚đ‡•š‚ľ‚˝AML‚ɑ΂ľ“ŻŽí––˝ŒŒŠ˛×–EˆÚA‚đŽ{s‚ľ“ž‚˝1—á.
‘ć83‰ń‹ß‹EŒŒ‰tŠw’n•ű‰ďA‘ĺăA6ŒŽ11“ú
â–{Œb—˜“ށA’†ŞF•FA•‰ŞNMAœAŁ’ŠśA”‹Œ´Œ‰’ʁA’†‘O”Ž‹vA’ˇ’Jě‘ž˜YA‘ž“cŒ’‰îAŽRŞF‹vA“ú–ě‰ë”V
@L-asparaginase‚ŞˆęŽž“I‚É—LŒř‚Ĺ‚ ‚Á‚˝nasal NK/T-cell lmphoma.
‘ć176‰ń“ú–{“ŕ‰ČŠw‰ď‹ß‹E’n•ű‰ďA‘ĺăA6ŒŽ4“ú

2004”N
Źâ‚ł‚¨‚čA’†”ö‹gFAé‘şŽ“oAŽÄ“cĺŽqA‹ŕ“‡@LAŽ†’J•x•vi‚í‚Š‚ą‚¤‰ď•a‰@jAźŒűC•˝A“ú–ě‰ë”V
@ŽŠŒČ–ƉuŤŠĚ‰Š‚ĚŒo‰ß’†A‚“x‚Ě”ÄŒŒ‹…Œ¸­‚đ—ˆ‚ľ‚˝Ç—á.
‘ć175‰ń“ú–{“ŕ‰ČŠw‰ď‹ß‹E’n•ű‰ďA‹ž“sA12ŒŽ18“ú
’†ŞF•FA’†‘O”Ž‹vAŽ›“c–FŽ÷A’†‘O”ü‰ŔA”‹Œ´Œ‰’ʁA’ˇ’Jě‘ž˜YA‚@‹N—ǁA‘ž“cŒ’‰îAŽRŞF‹vA“ú–ě‰ë”V
@––˝ŒŒ‘˘ŒŒŠ˛×–EĚŽćŽž‚̍‡•šÇ—\‘ނɑ΂ˇ‚éS”“Ž‰đÍ‚Ě—Ő°“IˆÓ‹`.
‘ć27‰ń“ú–{‘˘ŒŒ×–EˆÚAŠw‰ď‘‰ďA‰ŞŽRA12ŒŽ16E17“ú
”‹Œ´Œ‰’ʁA’†‘O”Ž‹vA’ˇ’Jě‘ž˜YAŽ›“c–FŽ÷A•‰ŞNMA’†ŞF•FA‚@‹N—ǁA‘ž“cŒ’‰îAŽRŞF‹vA“ú–ě‰ë”V
@CML‚ɍ‡•š‚ľ‚˝“]ˆÚŤ‘ĺ’°Šŕ‚ɑ΂ľ‚Ää`‘ŃŒŒƒ~ƒjˆÚA‚đŽ{s‚ľ‚˝1—á.
‘ć27‰ń“ú–{‘˘ŒŒ×–EˆÚAŠw‰ď‘‰ďA‰ŞŽRA12ŒŽ16E17“ú
•‰ŞNMAœAŁ’ŠśA’†ŞF•FAâ–{Œb—˜“ށA”‹Œ´Œ‰’ʁA’†‘O”Ž‹vA’ˇ’Jě‘ž˜YAŽRŞF‹vA“ú–ě‰ë”V
@‚—î‚Ě•ƒei75Îj‚ć‚č“ŻŽíœ‘ˆÚA‚đŽ{s‚ľ‚˝PhőF‘Ě—zŤ‹}Ť”’ŒŒ•a‚Ě1—á
‘ć82‰ń‹ß‹EŒŒ‰tŠw’n•ű‰ď@‹ž“sA12ŒŽ11“ú
ÂŽR‘׍FAŽR‘ş—ş‰îA^@çéŽőA‘ž“c’‰MAęm’JˆŔ’ĂŽqi•{’†•a‰@jA“ú–ě‰ë”V
@––˝ŒŒ’†‚ÉCD10—zŤT×–E‚đ”F‚ß‚˝Angioimmunoblast T cell lymphoma
‘ć82‰ń‹ß‹EŒŒ‰tŠw’n•ű‰ď@‹ž“sA12ŒŽ11“ú
ÎˆäˆęŒcAŽR–{‹`ŽA–ě‘şšěA–kŽR@“™A—с@–M—YAęm’JˆŔ’ĂŽqA“Ą–ě—TŽqA‰Ž–Ř•q–çAŽč“‡”Ž•śAŒj“c’B–çA‰YŁ•ś–žA–k“‡O”V
@‚—îŽŇaggressive”ńƒzƒWƒLƒ“ƒŠƒ“ƒpŽî‚ɑ΂ˇ‚éVNCOP-B—Ă–@—LŒřŤ‚ĆˆŔ‘SŤ‚ÉŠÖ‚ˇ‚錟“˘‘ć2•ń
‘ć66‰ń“ú–{ŒŒ‰tŠw‘‰ďE‘ć46‰ń“ú–{—Տ°ŒŒ‰tŠw‘‰ďA‹ž“sA9ŒŽ17E18E19“ú
ÂŽR‘׍FAŽR‘ş—ş‰îA^@çéŽőA‘ž“c’‰MAęm’JˆŔ’ĂŽqA“ú–ě‰ë”V
@––˝ŒŒ’†‚ÉCD10—zŤT×–E‚đ”F‚ß‚˝Angioimmunoblastic T-cell lymphoma
‘ć66‰ń“ú–{ŒŒ‰tŠw‘‰ďE‘ć46‰ń“ú–{—Տ°ŒŒ‰tŠw‘‰ďA‹ž“sA9ŒŽ17E18E19“ú
“Ą–ě—TŽqA‘ĺŕV­•FA•˝ŽR“š•FA––•ď„‹vAFŠ™–F”üA”’ˆäLKAˆÉ‘q‹`OA“ú–ě‰ë”VAă“c^ŠěŽq
@Diffuse large B-cell lymphoma‚É‚¨‚Ż‚鉊Ç×–EZ‚Ć—\Œă‚ĚŠÖŒW
‘ć66‰ń“ú–{ŒŒ‰tŠw‘‰ďE‘ć46‰ń“ú–{—Տ°ŒŒ‰tŠw‘‰ďA‹ž“sA9ŒŽ17E18E19“ú
Źâ‚ł‚¨‚čA‰H“Ą•ś•FAŠ™“c‹IŽqAâ–{Œb—˜“ށA’ˇ’Jě‘ž˜YA–Ř‘ş˜NŽqA“ú–ě‰ë”VA–kě˝ˆę
@ƒqƒg’P‹…‚É‚¨‚˘‚Äč÷—ą‹…ƒRƒƒj[ŽhŒƒˆöŽq‚ÍLPS‚É‚ć‚éŽîᇉ󎀈öŽq‚ĚŽYś‚đSTAT3‚ĚŠˆŤ‰ť‚đ‰î‚ľ‚ЧŒä‚ˇ‚é
‘ć66‰ń“ú–{ŒŒ‰tŠw‘‰ďE‘ć46‰ń“ú–{—Տ°ŒŒ‰tŠw‘‰ďA‹ž“sA9ŒŽ17E18E19“ú
‘ž“c’‰Miś’ˇ‰ď•{’†•a‰@jA^@çéŽőAÂŽR‘׍FAŽR‘ş—ş‰îAęm’JˆŔ’ĂŽqA’ˇ’Jě‘ž˜YA’†‘O”Ž‹vA‚@‹N—ǁA‘ž“cŒ’‰îAŽRŞF‹vA“cŒEFsA“ú–ě‰ë”V
@ŽŠŒČ–ƉuŤ—nŒŒŤ•nŒŒ‚đ‡•š‚ľ‹}Ť”’ŒŒ•a‰ťŽž‚É46,XY,+9,der(9;18)(p10;q10)‚ĚŠjŒ^ˆŮí‚đŽŚ‚ľ‚˝MDSÇ—á
‘ć66‰ń“ú–{ŒŒ‰tŠw‘‰ďE‘ć46‰ń“ú–{—Տ°ŒŒ‰tŠw‘‰ďA‹ž“sA9ŒŽ17E18E19“ú
ŕ_–ŘŽěŒbAă@šOA_“c‘PLA˜a‹C@“ցAŽRŞF‹vA‹›“ˆL•FA’†ˆä–M‹vAˆŔ•”NMAă“c‹ą“TAˆäă“O–çAŒá‹˝_ŒúA“ú‚“šOA—с@FšAˆî–{ŒŤOA“’’nWˆę˜YA–L“ˆ’“żAŹ—Ń’źŽ÷Aˆ°“c—˛ŽiA”¨’†ˆęśA’†”ö^“ńA‹{˜dŽO˜YA’JŒűCˆę
@‹}ŤƒŠƒ“ƒp‹…Ť”’ŒŒ•a‚ɑ΂ˇ‚鍜‘”ń”j‰ó“IˆÚA‚Ě—LŒřŤF33—á‚Ě‘˝Ž{Ý‹¤“ŻŒă•űŽ‹“IŒ¤‹†
‘ć66‰ń“ú–{ŒŒ‰tŠw‘‰ďE‘ć46‰ń“ú–{—Տ°ŒŒ‰tŠw‘‰ďA‹ž“sA9ŒŽ17E18E19“ú
ŹźŽqA‘吟ˆęmAŽ›ŕV@•A“cŒEFsAŽRŞF‹vA“ú–ě‰ë”V
@ŠeŽíŒŒ‰tŽžŠł‚É‚¨‚Ż‚é‰Â—n‰ťŒ^RCAS1‘Ş’č‚ĚŒŸ“˘
‘ć51‰ń“ú–{—Տ°ŒŸ¸ˆăŠw‰ď‘‰ďA“Œ‹žA9ŒŽ3E4E5“ú
–؉şŠěŒőiś’ˇ‰ďˆ¤•—•a‰@jA“cŒEFsA•Ÿˆä@“OAŽRŞF‹vA“ú–ě‰ë”V
@‘˘ŒŒŠíŽžŠł‚É‚¨‚Ż‚ébiotin‘Ş’čˆÓ‹`‚̉”\Ť‚ɂ‚˘‚Ä
‘ć51‰ń“ú–{—Տ°ŒŸ¸ˆăŠw‰ď‘‰ďA“Œ‹žA9ŒŽ3E4E5“ú
‰Ž–Ř•q–çi‘ĺăŽs—§‘‡ˆă—ĂƒZƒ“ƒ^[jA’†“‡N”ŽA•˝ˆä@ŠwAŽč“‡”Ž•ś
@‰óásŤ”^”çÇ‚ɍ‡•š‚ľ‚˝MDS‚ÉŒŒ‰ŽŇŠÔ“ŻŽí––˝ŒŒˆÚA‚đŽ{s‚ľ‚˝1—á.
@‘ć81‰ń‹ß‹EŒŒ‰tŠw’n•ű‰ďA‘ĺăA7ŒŽ3“ú
Źâ‚ł‚¨‚či‚í‚Š‚ą‚¤‰ď•a‰@jA’†”ö‹gFA^@çéŽőAŽÄ“cĺŽqA‹ŕ“‡@LAŽ†’J•x•vA•‰ŞNMA“ú–ě‰ë”V
@Š°‰đ“ą“ü—Ă–@‚É‚ć‚錌Ź”ÂŒ¸­Šú‚ÉŒŒđŤĂ–Ź‰Š‚đ‚Ť‚˝‚ľ‚˝‹}Ťœ‘Ť”’ŒŒ•a‚Ě1Ç—á.
‘ć81‰ń‹ß‹EŒŒ‰tŠw’n•ű‰ďA‘ĺăA7ŒŽ3“ú
”‹Œ´Œ‰’ʁi‘ĺăŽs—§‘ĺŠwjA•‰ŞNMAœAŁ’ŠśA’†‘O”Ž‹vA’ˇ’Jě‘ž˜YA‘ž“cŒ’‰îA“cŒEFsAŽRŞF‹vA“ú–ě‰ë”VA’†”ö‹gF
@69Î‚̍‚—îAMLŠłŽŇ‚ÉŽ{s‚ľ‚˝ä`‘ŃŒŒƒ~ƒjˆÚA.
‘ć173‰ń“ú–{“ŕ‰ČŠw‰ď‹ß‹E’n•ű‰ďA‘ĺăA6ŒŽ5“ú
’Ë–{—R‰Ŕ(‘ĺăŽs—§‘‡ˆă—ĂƒZƒ“ƒ^[jA‹g‰ŞŽéAźŽR@—TAŹźŒ[•vA•‰ŞNMAŽč“‡”Ž•śA˛“Ą—˜•FA‘Oě’ź‹PAˆäă@Œ’
@Subcutaneous paniculitis-like T-cell lymphoma‚Ě1—á.
‘ć173‰ń“ú–{“ŕ‰ČŠw‰ď‹ß‹E’n•ű‰ďA‘ĺăA6ŒŽ5“ú
^@çéŽői‚í‚Š‚ą‚¤‰ď•a‰@jA’†”ö‹gFA‰Zś‹ąÍAV•Ű‹MŽmAŒ´“c”Ž‰ë
@DŽ_‹…‘‰Á‚𔺂¤ŠÔŽżŤ”x‰Š‚đ•š”­‚ľAƒXƒeƒƒCƒh‚É‚ć‚鎥—Ă‚Ş’˜Œř‚ˇ‚é‚ŕŒ¸—Ę’†‚É‹}Œƒ‚ČˆŤ‰ť‚đ”F‚ß‚˝MDS‚Ě1—á.
‘ć173‰ń“ú–{“ŕ‰ČŠw‰ď‹ß‹E’n•ű‰ďA‘ĺăA6ŒŽ5“ú
’†”ö‹gFi‚í‚Š‚ą‚¤‰ď•a‰@jAŽÄ“cĺŽqAŹâ‚ł‚¨‚čA‹ŕ“‡@LAŽ†’J•x•vA“ú–ě‰ë”V
@ŽŠ‘R‰ń•œ‚đŠm”F‚ľ“ž‚˝‚“x‚ĚŒŒŹ”ÂŒ¸­Ç‚Ě3—á.
‘ć173‰ń“ú–{“ŕ‰ČŠw‰ď‹ß‹E’n•ű‰ďA‘ĺăA6ŒŽ5“ú
ŠÔ•”ŒŤŠ°i˜aňŽs—§•a‰@jA˜@’rF•vA”gŒËŽ‹KAŹźr˛A´…‘וvA‰ÍŁ‹g—YAź‰ş°•FAź–{ł‹I
@ATG—Ă–@Œă‚ÉŒĹŒ`Šŕ‚đ”­Ç‚ľ‚˝Äś•s—ǐŤ•nŒŒ‚Ě3—á.
‘ć173‰ń“ú–{“ŕ‰ČŠw‰ď‹ß‹E’n•ű‰ďA‘ĺăA6ŒŽ5“ú
ŽÄ“cĺŽqi‘ĺăŽs—§‘ĺŠwjAâ–{Œb—˜“ށA’†‘O”Ž‹vA‘ž“cŒ’‰îAŽRŞF‹vA“ú–ě‰ë”V
@“–‰Č‚É‚¨‚Ż‚éFebrile neutropenia‚ɑ΂ˇ‚éRś•¨ŽżŽĄ—Ă‚Ě—Ő°‰đÍ.
‘ć78‰ń“ú–{Š´őÇŠw‰ď‘‰ďA“Œ‹žA4ŒŽ6“úA7“ú

2003”N
“ú–ě‰ë”VA–q“c—A‘ž“cŒ’‰îA”‹Œ´Œ‰’ʁA‘ž“c’‰MAŽRŞF‹vAęm’JˆŔ’ĂŽq
@G-CSF‚đ—p‚˘‚˝“ŻŽí––˝ŒŒŠ˛×–EˆÚAĚŽćŒă14ƒ–ŒŽ‚É‹}Ťœ‘Ť”’ŒŒ•a‚đ”­Ç‚ľ‚˝Ç—á
‘ć26‰ń“ú–{‘˘ŒŒ×–EˆÚAŠw‰ďA‰Ą•lA12ŒŽ19“ú|20“ú
Ž›“c–FŽ÷A’†‘O”Ž‹vAÔ–x”ü‰ŔAÂŽR‘׍FA’ˇ’Jě‘ž˜YAŽR‘ş—ş‰îA”‹Œ´Œ‰’ʁA’†“ˆN”ŽA‘ž“cŒ’‰îAŽRŞF‹vA“ú–ě‰ë”V
@ƒAƒ“ƒgƒ‰ƒTƒCƒNƒŠƒ“Œn–ňÜ‚É‚ć‚é‹}ŤS“ŐŤ‚ĚƒAƒ“ƒMƒIƒeƒ“ƒVƒ“IIŽó—e‘Ě‘jŠQÜiƒoƒ‹ƒTƒ‹ƒ^ƒ“j‚É‚ć‚é—\–hŒř‰Ę
‘ć26‰ń“ú–{‘˘ŒŒ×–EˆÚAŠw‰ďA‰Ą•lA12ŒŽ19“ú|20“ú
ÂŽR‘׍FA’†‘O”Ž‹vAŽR‘ş—ş‰îA’ˇ’Jě‘ž˜YAŽ›“c–FŽ÷A”‹Œ´Œ‰’ʁA’†“ˆN”ŽA‘ž“cŒ’‰îAŽRŞF‹vA“ú–ě‰ë”V
@œ‘”ń”j‰ó“I‘Oˆ’u‚đ—p‚˘‚˝”ńŒŒ‰ŽŇŠÔœ‘ˆÚA‚Ě‚SÇ—á
‘ć26‰ń“ú–{‘˘ŒŒ×–EˆÚAŠw‰ďA‰Ą•lA12ŒŽ19“ú|20“ú
ŽR‘ş—ş‰îAŽRŞF‹vAÂŽR‘׍FA^@çéŽőA“‡@‰xŽqAŽ›“c–FŽ÷A’†‘O”Ž‹vA’ˇ’Jě‘ž˜YA–q“c—A‘ž“cŒ’‰îA“ú–ě‰ë”V
@”ńŠ°‰đŠú”ńƒzƒWƒLƒ“ƒŠƒ“ƒpŽî‚ÉNST‚đŽ{s‚ľ‚˝4—á
‘ć26‰ń“ú–{‘˘ŒŒ×–EˆÚAŠw‰ďA‰Ą•lA12ŒŽ19“ú|20“ú
‹´–{‰K–¤A’†”ö‹gFA^@çéŽőAœAŁ’ŠśAŽ†’J•x•vAŽRŞF‹vA“‡@‰xŽqA‹ŕ“‡@LA“ú–ě‰ë”V
@ƒpƒ‹ƒ{ƒEƒCƒ‹ƒXB19Š´ő‚đ”­Ç‚ˇ‚é‚Ć“ŻŽžŠú‚ɍœ‘ˆŮŒ`ŹÇŒóŒQ‚Ɉڍs‚ľ‚˝Äś•s—ǐŤ•nŒŒ‚Ěˆę—á
‘ć172‰ń“ú–{“ŕ‰ČŠw‰ď‹ß‹E’n•ű‰ďA˜a‰ĚŽRA12ŒŽ20“ú
Nakamae H, Terada Y, Akahori M, Aoyama Y, Hasegawa T, Yamamura R, Ohta
K, Yamane T, Hino M
@Angiotensin II receptor blocker prevents acute cardiotoxicity following CHOP
5th Annual Meeting and Exposition of American Society of Hematology,
San Diego, 12ŒŽ6“ú|12ŒŽ9“ú
Ichinohe T, Uchiyama T, Shimazaki S, Tamaki S, Watanabe A, Hamaguchi M,
Hino M, Adachi S, Endoh M, Uoshima N, Yoshihara T, Hatanaka K, Fujii H, Kawa
K, Gondo H, Kawanishi K, Maruya E, Saji H, Kodera Y
@Outcome of non-T-cell-depleted hematopoietic stem cell transplantation
between HLA-haploidentical non-inherited natural antigen (NIMA)-mismatched
family members linked with long-term feto-maternal microchimerism
45th Annual Meeting and Exposition of American Society of Hematology,
San Diego, 12ŒŽ6“ú|12ŒŽ9“ú
Yamane t, Aoyama Y, Nakamae H, Hasegawa T, Yamamura R, Sakamoto C,
Terada Y, Koh G, Ohta K, Hino M
@Non-myeloablative hematopoietic stem cell transplantation for hematological
malignancies (abstract)
45th Annual Meeting and Exposition of American Society of Hematology,
San Diego, 12ŒŽ6“ú|12ŒŽ9“ú
Ohta K, Makita K, Mugitani A, Hagiwara K, Ohta T, Yamane T, Hino M
@Acute myelogenous leukemia in a donor after granulocyte-colony stimulating
factor primed peripheral blood stem cell harvestiabstract)
45th Annual Meeting and Exposition of American Society of Hematology,
San Diego, 12ŒŽ6“ú|12ŒŽ9“ú
‰Ž–Ř•q–çAŽRŞF‹v
@ŒŒ‰tŽžŠł‚Ě•ŞŽq•W“I—Ă–@|‚b‚l‚k‚ɑ΂ˇ‚éImatinib‚ĚŽĄ—ÐŹŃ‚𒆐S‚Ɂ|
‘ć‚W‚O‰ń‹ß‹EŒŒ‰tŠw’n•ű‰ďA_ŒËA12ŒŽ6“ú
^@çéŽőA‹´–{‰K–¤A’†”ö‹gFAœAŁ’ŠśAŽ†’J•x•v
ATL‚ĚŒo‰ß’†‚ɍזEŤ–Ɖu•s‘S‚É‚ć‚銴őÇ‚đ•š”­‚ľ‚˝‚RÇ—á
‘ć‚W‚O‰ń‹ß‹EŒŒ‰tŠw’n•ű‰ďA_ŒËA12ŒŽ6“ú
•‰ŞNMAŽč“‡”Ž•śA‰Ž–Ř•q–çA‹ŕ“‡@L
@’nŒĹ‚ß—Ă–@’†‚É‘˝”­Ť‚̉ŠÇŤŠĚ‹UŽîᇂ𐶂ś‚˝‹}Ť‘Oœ‘Ť”’ŒŒ•a
‘ć‚W‚O‰ń‹ß‹EŒŒ‰tŠw’n•ű‰ďA_ŒËA12ŒŽ6“ú
’†“ˆN”ŽA‘ž“cŒ’‰îAŽR‘ş—ş‰îAÂŽR‘׍FA’ˇ’Jě‘ž˜YA’†‘O”Ž‹vAŽ›“c–FŽ÷A”‹Œ´
Œ‰’ʁAŽRŞF‹vA“ú–ě‰ë”V
@S–Œ”X–E‚đ‡•š‚ľ‚˝–ŤŠˆ“ŽŤEBƒEƒCƒ‹ƒXŠ´őÇ‚Ě‚P—á
‘ć‚W‚O‰ń‹ß‹EŒŒ‰tŠw’n•ű‰ďA_ŒËA12ŒŽ6“ú
–؉şŠěŒőA“cŒEFsAŽRŞF‹vA“ú–ě‰ë”V
@‘˘ŒŒŠíŽîᇐŤŽžŠł‚É‚¨‚Ż‚éRP53R‘Ě‘Ş’č‚Ě—L—pŤ‚ĚŒŸ“˘
‘ć50‰ń“ú–{—Տ°ŒŸ¸ˆăŠw‰ďAL“‡A10ŒŽ29“ú-10ŒŽ31“ú
“ú–ě‰ë”VAŽRŞF‹v
@ˆÚAˆă—Ă
‘ć50‰ń“ú–{—Տ°ŒŸ¸ˆăŠw‰ďAL“‡A10ŒŽ29“ú-10ŒŽ31“ú
’†“ˆN”ŽA”‹Œ´Œ‰’ʁAŽ›“c–FŽ÷AŽR‘ş—ş‰îAÂŽR‘׍FA’†‘O”Ž‹vA’ˇ’Jě‘ž˜YA‘ž“c
Œ’‰îAŽRŞF‹vA“cŒEFsA“ú–ě‰ë”V
@Helicobacter pylori œ‹ŰŽĄ—Ă‚É‚ć‚éITPŽĄ—Ă‚É‚¨‚Ż‚é‹ť–Ą‚ ‚éÇ—á
‘ć171‰ń“ú–{“ŕ‰ČŠw‰ď‹ß‹E’n•ű‰ďA‘ĺăA9ŒŽ27“ú
–q“c—Aęm’JˆŔ’ĂŽqA”öź–rŽqA‘ž“c’‰MAź–Ř‚ł‚¨‚čA”‹Œ´Œ‰’ʁAŽRŞF‹vA“ú
–ě‰ë”V
@‘Sg‚ĚƒAƒXƒyƒ‹ƒMƒ‹ƒXÇđÇ‚đ‹N‚ą‚ľA‹}Œƒ‚ČŒo‰ß‚đ‚˝‚Ç‚Á‚˝ATL‚Ě–UŒŸ—á
‘ć65‰ń“ú–{ŒŒ‰tŠw‰ď‘‰ďE‘ć45‰ń“ú–{—Տ°ŒŒ‰tŠw‰ď‘‰ďA‘ĺăA8ŒŽ28“ú
’J–{“N–çA‰Í–ě‰Ă•śA“ú–ě‰ë”VAă@šLA‹{˜dŽO˜YA•őÎ@^A’JŒűCˆęA‰Í@Œh
˘AŒ´“cŽŔŞ
@Œ’ílƒhƒi[‚É‚¨‚Ż‚é––˝ŒŒŠ˛×–E‚ĚÄ“Žˆő
‘ć65‰ń“ú–{ŒŒ‰tŠw‰ď‘‰ďE‘ć45‰ń“ú–{—Տ°ŒŒ‰tŠw‰ď‘‰ďA‘ĺăA8ŒŽ28“ú
ęm’JˆŔ’ĂŽqA–q“c—A‘ž“c’‰MAź–Ř‚ł‚¨‚čA’†”ö‹gFA‰Ž–Ř•q–çA•‰ŞNMAœA
Ł’ŠśA”‹Œ´Œ‰’ʁAŽRŞF‹vA“ú–ě‰ë”V
@Ph—zŤALL5—á‚É‚¨‚Ż‚éSTI571‚ĚŽg—pŒoŒą
‘ć65‰ń“ú–{ŒŒ‰tŠw‰ď‘‰ďE‘ć45‰ń“ú–{—Տ°ŒŒ‰tŠw‰ď‘‰ďA‘ĺăA8ŒŽ28“ú
’ˇ’Jě@–ŤAźě­ŸA–ě‘şšěA“cŒEFsA––œA@ŒŞAź‹˝ŸNA—с@–M—YA‘q“c‹`
”V
@ITP‚ɑ΂ˇ‚éƒXƒeƒƒCƒhŽĄ—Ă‚Íœ—ʂɉe‹ż‚đ‚¨‚ć‚Ú‚ˇ‚Š
‘ć65‰ń“ú–{ŒŒ‰tŠw‰ď‘‰ďE‘ć45‰ń“ú–{—Տ°ŒŒ‰tŠw‰ď‘‰ďA‘ĺăA8ŒŽ28“ú
‘ž“c’‰MA”‹Œ´Œ‰’ʁAź–Ř‚ł‚¨‚čA–q“c—Aęm’JˆŔ’ĂŽqA’ˇ’Jě‘ž˜YA’†‘O”Ž‹vA
ÂŽR‘׍FA‘ž“cŒ’‰îAŽRŞF‹vA“cŒEFsA“ú–ě‰ë”V
@’˜–ž‚Č• ’ɁA• …’™—Ż‚É‚Ä”­Ç‚ľŒŒŹ”‘‘˝‚đŽŚ‚ľ‚˝C1ƒCƒ“ƒqƒrƒ^[ŠˆŤ’ቺ‚É‚ć
‚éAngioedema‚Ěˆę—á
‘ć65‰ń“ú–{ŒŒ‰tŠw‰ď‘‰ďE‘ć45‰ń“ú–{—Տ°ŒŒ‰tŠw‰ď‘‰ďA‘ĺăA8ŒŽ28“ú
‰H“Ą•ś•FA—é–ŘŒŤˆęA‰Á“Ą—˛KAź–Ř‚ł‚¨‚čAÔ–x”ü‰ŔAâ–{Œb—˜“ށA’ˇ’Jě‘ž˜YA
ă–{e•FAŽRŞF‹vAŹ–¸”ü’m‘ĽA“ú–ě‰ë”VA–kě˝ˆę
@G-CSF“Š—^‚É‚ć‚éƒqƒgD’†‹…‚ĚRituximabˆË‘śŤADCCŠˆŤ‚Ě‘‹­
‘ć65‰ń“ú–{ŒŒ‰tŠw‰ď‘‰ďE‘ć45‰ń“ú–{—Տ°ŒŒ‰tŠw‰ď‘‰ďA‘ĺăA8ŒŽ28“ú
ŽRŞF‹vAÂŽR‘׍FAă–{e•FA’†‘O”Ž‹vA’ˇ’Jě‘ž˜YAŽR‘ş—ş‰îA^@çéŽőAŽ›“c
–FŽ÷A‘ž“cŒ’‰îA“ú–ě‰ë”V
@‘˘ŒŒŠíˆŤŤŽîᇂɑ΂ˇ‚鍜‘”ń”j‰ó“I‘˘ŒŒŠ˛×–EˆÚA
‘ć65‰ń“ú–{ŒŒ‰tŠw‰ď‘‰ďE‘ć45‰ń“ú–{—Տ°ŒŒ‰tŠw‰ď‘‰ďA‘ĺăA8ŒŽ28“ú
‘ž“cŒ’‰îA’†‘O”Ž‹vA“‡@‰xŽqAœAŁ’ŠśA’†‰Ć´—˛AÂŽR‘׍FA’ˇ’Jě‘ž˜YAŽRŞ
F‹vA“ú–ě‰ë”V
@ƒqƒgœ‘ƒXƒgƒ[ƒ}×–E‚ɑ΂ˇ‚éAra-C‚Ě’źÚ“IŽhŒƒě—p
‘ć65‰ń“ú–{ŒŒ‰tŠw‰ď‘‰ďE‘ć45‰ń“ú–{—Տ°ŒŒ‰tŠw‰ď‘‰ďA‘ĺăA8ŒŽ28“ú
’ˇ’Jě‘ž˜YA—é–ŘŒŤˆęAă–{e•FAź–Ř‚ł‚¨‚čAÔ–x”ü‰ŔA‘ž“cŒ’‰îA“ú–ě‰ë”VA–k
ě˝ˆę
@ƒqƒgD’†‹…‚É‚¨‚Ż‚éIAP family‚Ě”­ŒťF–ŤD’†‹…Ť”’ŒŒ•a×–E‚É‚¨‚Ż‚écIAP2‚Ě
‰ßč”­Œť
‘ć65‰ń“ú–{ŒŒ‰tŠw‰ď‘‰ďE‘ć45‰ń“ú–{—Տ°ŒŒ‰tŠw‰ď‘‰ďA‘ĺăA8ŒŽ28“ú
^@çéŽőAÂŽR‘׍FAă–{e•FA’ˇ’Jě‘ž˜YA’†‘O”Ž‹vAŽ›“c–FŽ÷A‘ž“cŒ’‰îAŽRŞ
F‹vA“cŒEFsA“ú–ě‰ë”V
@”ńƒXƒeƒƒCƒhŒnÁ‰Š’Á’ɍ܂ɂć‚é‘˝”­Ť‰ş•”Á‰ťŠÇ’×á‡‚đ‡•š‚ľ‚˝‹}Ťœ‘’P‹…
Ť”’ŒŒ•a‚Ě‚P—á
‘ć79‰ń‹ß‹EŒŒ‰tŠw’n•ű‰ďA‘ĺăA7ŒŽ12“ú
’†”ö‹gFAŽ†’J•x•vA‹´–{‰KŒČA^@çéŽőAœAŁ’Šś
@STI571‚É‚ć‚č3“x–Ú‚Ě×–Eˆâ“`Šw“IŠŽ‘SŠ°‰đ‚É“ž’B‚ľ‚˝CML‚Ě1—á
‘ć79‰ń‹ß‹EŒŒ‰tŠw’n•ű‰ďA‘ĺăA7ŒŽ12“ú
Ž›“c–FŽ÷A‘ž“cŒ’‰îAÂŽR‘׍FAă–{e•FA’†‘O”Ž‹vA’ˇ’Jě‘ž˜YA^@çéŽőAŽRŞ
F‹vA“cŒEFsA“ú–ě‰ë”V
@“ŻŽí––˝ŒŒŠ˛×–EˆÚAŒă‚ÉäXE—ź‘¤t‚ÉŽîᎌ`Ź‚𔺂Á‚čĔ­‚ľ‚˝‹}Ťœ‘Ť”’
ŒŒ•a‚Ěˆę—á
‘ć170‰ń“ú–{“ŕ‰ČŠw‰ď‹ß‹E’n•ű‰ďA‘ĺăA6ŒŽ14“ú
•‰ŞNMAŽR‘ş—ş‰îA›–ěˆŔŠěAŠâč@šAX‰Ş@~
@Š°‰đ“ą“ü—Ă–@’†‚Éall-transƒŒƒ`ƒmƒCƒ“Ž_‚É‚ć‚é”]ˆł˜´i‚𐜂ś‚˝‹}Ťœ‘Ť”’ŒŒ•a
iAML M3j‚ĚˆęÇ—á
‘ć170‰ń“ú–{“ŕ‰ČŠw‰ď‹ß‹E’n•ű‰ďA‘ĺăA6ŒŽ14“ú